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Abstract
Sickle cell disease (SCD) is a group of inherited haemoglobinopathies caused by a 
mutation resulting in an abnormal haemoglobin (HbS). Sickle cell anaemia is the 
homozygous state (HbSS). Under deoxygenated conditions, the red cell acquires an 
elongated ‘sickle’ shape in association with vaso-occlusive events and haemolysis. 
Cerebrovascular disease (CVD) is a serious complication of SCD, which is one of the 
commonest causes of childhood stroke. Stroke occurs in up 8 % of young patients with 
SCD with an additional 25% having silent infarction on magnetic resonance imaging 
(MRI). Recurrent stroke occurs in up 67% of patients without regular blood transfusion, 
the currently recommended treatment.
There are few data on the natural history of CVD in SCD or abnormality in cerebral 
perfusion of these patients in relation to the clinical presentation. In addition, there has 
been a lack of scientific evaluation of the physiological effects of blood transfusion for 
patients with SCD and neurological complications and its effects on cerebral perfusion 
and CVD.
The research described in this thesis investigates, in both cross-sectional and 
longitudinal studies, the association of neurological events (coma, stroke, transient 
ischaemic attacks, seizures, headaches) with perfusion abnormality and progression of 
CVD in patients with SCD, and the effect of short- and long-term blood transfusion. 
This research has used MRI, MRA, and perfusion MRI (dynamic susceptibility contrast 
MRI), transcranial Doppler (TCD) ultrasound, and clinical, haematological, and oxygen 
saturation data.
The focus has been on studying cerebral perfusion abnormality in different neurological 
symptoms in patients with SCD and comparing perfusion MRI with other neuroimaging 
techniques; on investigating factors involved in the progression of CVD and perfusion 
abnormality over time; and on identifying predictors of recurrent neurological 
symptoms in this population. In addition, the effect of blood transfusion on cerebral 
perfusion and CVD is described and discussed.
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Chapter 1: General Introduction: Overview of Sickle 
Cell Disease
1.1. Genetics and Epidemiology of Sickle Cell Disease
Sickle cell disease (SCD) is a group of inherited haemoglobinopathies (Balias 1998) 
common among peoples of Equatorial African ancestry but not confined to that 
population (Seijeant 1997). The condition is caused by a mutation in the gene for 
globin, an essential component of the haemoglobin molecule (Hb), which is located 
inside the red blood cells and carries oxygen to every cell in the body. The pattern of 
inheritance is autosomal recessive and the homozygous state (HbSS) is known as sickle 
cell anaemia (Seijeant 1997).
Normal adult haemoglobin (Hb), HbA, consists of two a  and two p polypeptides chains 
(ot2 P2)- HbA comprises about 97% of the Hb in adults. Two other haemoglobins, Hb A2 
(ct2 6 2 ) and HbF (012 7 2 ), are found in smaller amounts (1.5 to 3% and less than 1%, 
respectively) (Murphy 1994). The mutation which produces HbS is the substitution of 
valine for glutamic acid at the sixth position of the p-globin chain (P6 Glut—>Val). 
Haemoglobin S behaves like normal haemoglobin when fully oxygenated but at low 
oxygen tension, the haemoglobin S polymerises resulting in gel formation. As a 
consequence, the red cell has an increased density and elongated sickle shape, becoming 
less pliable (Pavlakis et al 1989, Seijeant 1997, Alavi 1984) (figure 1.1). The rigid and 
deformed sickle cell is damaged by mechanical stress during the passage through the 
vasculature (especially in small blood vessels), resulting in a chronic haemolytic 
anaemia with red cell destruction (two to eight times higher than normal). The rate of 
red cell production and destruction in sickle cell anaemia is influenced by infection, 
drugs and other factors and if the balance is disturbed, anaemic crisis may result 
(Pavlakis et al 1989).
Figure 1.1. Red blood cell with the characteristic sickle shape (arrow) 
found in sickle cell anaemia. (From Embury SH, Hebbel RP, 
Mohandas N, Steinberg MH (eds): Sickle Cell Disease: Basic 
Principles and Clinical Practice. Raven Press, Ltd., New York, 1994)
Other double heterozygote variants of the SCD syndromes include SC disease 
(inheritance of one HbS with one gene for Hb C), the next in frequency after sickle cell 
anaemia. Co-inheritance of a p-thalassaemia gene with HbS causes sickle/p+- 
thalassaemia with 3-25% HbA, or sickle/p°-thalassaemia without HbA but often (not 
always) with increased HbF and normal or slightly reduced HbA2 (Balias 1998, 
Seijeant 1997, Zafeiriou et al 2004). Clinically, sickle cell anaemia (HbSS) and 
sickle/p0- thalassaemia tend to run a severe course, whereas haemoglobin SC disease 
and sickle/p+- thalassaemia have milder manifestations (Seijeant 1997).
Although this gene mutation is most common in equatorial Africa, it is also found in the 
Mediterranean regions of Europe and Turkey (Ranney 1994). The carrier state of the 
sickle cell gene (one HbS gene and a normal p globin gene) is defined as sickle cell trait 
(see Seijeant 1997) and protects against malaria, as sickle cells are a hostile enviroment 
for the parasite (Pavlakis et al 1989). In SCD, carrier frequency is between 5-40% in the 
populations where the frequency of the gene is high (Balias 1998, Seijeant 1997). The 
phenotype may be influenced by the different p-haplotypes patterns of polymorphisms 
in the p globin chain. There are three major African and African American haplotypes: 
Senegal, Benin and Bantu (or Central African Republic) (Seijeant 1997). In
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addition, there is an independent haplotype in India and Saudi Arabia (Balias 1998). 
The sickle gene is distributed worldwide as a consequence of the slave trade and 
economic migration (Nagel 1994, figure 1.2).
ARAB-
INDIA
BENIN | 
SENEGAL
BANTU
Figure 1.2. Shaded areas of this map represent progressively higher
c
frequencies (in direct proportion to darker intensity) of the p gene 
(Senegal, Benin, Bantu, and Arab-Indian haplotypes). From Nagel 
RL. Origins and dispersion of the sickle gene, in Embury SH, Hebbel 
RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease: Basic 
Principles and Clinical Practice. Raven Press, Ltd., New York, 1994, 
page 355).
1.2 Non-Neurological Problems of Sickle Cell Disease
There are a large number of complications of sickle cell disease, listed in table 1.1. 
Patients with SCD present with symptoms secondary to two main mechanisms: 
haemolytic anaemia and vaso-occlusion (Pavlakis et al 1989, Seijeant 1997). The 
leading causes of death among very young children with SCD are firstly acute anaemia 
(caused by splenic sequestration and aplastic crisis due to viral infection) and, secondly 
bacterial infection, particularly secondary to Pneumoccocal meningitis or pneumonia (as 
the spleen becomes non-functional) (Platt et al 1994). There is also substantial
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morbidity from early infancy due to vaso-occlusive events, which cause painful bone 
crisis, abdominal pain, acute chest syndrome and neurological events (Pavlakis et al 
1989). In the USA, the median age at death for males with sickle cell anaemia (HbSS) is 
42 years and for females, 48 years; survival is better for those with HbSC disease (Platt 
et al 1994). In older children and adults, death occurs secondary to pulmonary or renal 
failure (Platt et al 1994).
Organ or Tissue Effect of Sickling
Joints Aseptic necrosis of head of femur and humerus
Long bones Infarcts with pathologic fractures
Vertebral body Compression fracture; biconcave deformity
Lung Infarcts with cor pulmonale
Brain Infarcts with hemiplegia; various encephalopathies
Kidney Acute papillitis necroticans with hematuria
Gut Ulceration and infarction
Gallbladder Stones
Skin Necrosis and ulceration
Liver Focal necrosis; cirrhosis sometimes
Spleen Infarction and atrophy; splenic sequestration
Heart Myocardial infarction; heart failure; high output failure
Eye Retinal infarcts, vitreous haemorrhage, retinitis proliferans
Adrenal gland Infarction with Addison’s disease rarely
Pancreas Infarction with diabetes mellitus very rarely
Pituitary Infarction with hypopituitarism
Breast Tissue necrosis; fibroadenopathy
Ovary Infarction, infertility rarely
Penis Priapism with occasional penile fibrosis and impotence
Arteries Intermittent claudication; arterial thrombosis
Veins Phlebothrombosis; dural sinus thrombosis
Nerves Infarction with asymmetrical motor and sensory neuropathy
Spinal cord Infarction
Lymph Nodes Infarction; possible disturbance of immunological status
Uterus Infarction with ischaemia in pregnancy
Placenta Multiple infarcts; miscarriages and stillbirths
Bone Marrow Infarcts with pulmonary embolism (specially in pregnancy)
Teeth Periodontal tissue infarctions; caries
Whole blood Massive intravascular sickling with sudden death
Immune system Complement pathway, phagocytic defects; lymphoid 
hyperplasia
Table 1.1. Non- Neurological Complications in Sickle Cell Disease: 
Organ Involvement. *Adapted from Konotey-Ahulu F.D. The sickle 
cell diseases: Clinical manifestations including the ‘sickle cell crises.’ 
Arch Intern Med 1974; 133: 611-623 (From Pavlakis et al 1989).
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Samuels and colleagues (1992) found a high prevalence of snoring and sleep apnoea, 
apparently secondary to enlarged tonsils and adenoids, in children with sickle cell 
disease. In another study, 25% of sickle cell patients were reported to have oxygen 
saturation levels below 90%; oxygen saturation was lower in patients with acute chest 
crisis but not with stroke (Homi et al 1997). Hypoxia produces changes in the 
haemoglobin of the sickle cell leading to increased red and white cell and platelet 
adhesion (Inwald et al 2000, Setty et al 2003) as well as polymerization, gel formation 
and potassium efflux associated with increased cell density (Pavlakis et al 1989, 
Steinberg et al 1999).
1.3. Neurological Complications of Sickle Cell Disease
The WHO definition of stroke is a constellation of clinical symptoms lasting more than 
24 hours of vascular aetiology (WHO 1978). Hemiparesis is the typical presentation. In 
one North American study in which the overall incidence for childhood stroke was 
1.29/100,000 per year (ischaemic 0.58/100,000/y, and haemorrhagic 0.71/100,000/y), 
the commonest cause was SCD (39%), with an incidence of 285/100,000/year (Earley et 
al 1998), which is similar to that found in general populations of elderly adults. In 
patients with sickle cell disease, approximately 75% of the infarcts are ischaemic and 
the remainder are haemorrhagic (Powars et al 1978). The prevalence o f clinical stroke in 
patients with SCD younger than 19 years is 8.1% (Ohene-Frempong 1991) and in 
addition, the lifetime risk of stroke is between 25 and 30% (Ohene-Frempong 1998, 
Styles et al 2000).
Patients with prior infarction are at increased risk of haemorrhage as they age (Powars 
et al 1978). Infarction is common in mid-childhood, between 2 and 10 years of age. 
Stroke incidence decreases to a minimum between the ages of 20 to 29 years, but there 
is a further peak after the age of 35. Haemorrhage has the highest incidence in young 
adults (20-30 years) but is not uncommon in children (Ohene-Frempong 1998, figure 
1.3). Recurrence of stroke occurs in up 67% without blood transfusion therapy (Powars 
et al 1978).
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Figure 1.3. Hazard rates of infarctive and haemorrhagic stroke in SS 
patients by age (adapted from Ohene-Frempong et al 1998).
— Infarctive stroke; — haemorrhagic stroke
Cerebral infarction may be symptomatic or asymptomatic (silent or covert infarct). 
Acute neurological symptoms and signs are common in sickle cell disease and, as well 
as stroke, include headaches, coma, seizures, transient ischaemic accident (TIA), which 
lasts less than 24 hours, and reversible ischaemic neurological deficit (RIND), which 
lasts more than 24 hours but recovers completely with no permanent deficit (Adams 
1994). Other symptoms of cerebral infarction include dysphasia, difficulty with gait and 
‘soft neurological signs’ (Adams 1994, Mercuri et al 1995). Coma in SCD may be 
caused by intracranial haemorrhage (Adams 1994), although extensive middle cerebral 
artery infarction with oedema can also have a similar presentation (Millman et al 1998). 
In addition, children with SCD can present with central nervous system infections such 
as meningitis, bacterial abscess and cerebral tuberculoma. The incidence of CNS 
infections has decreased with penicillin prophylaxis and immunization (Pavlakis et al 
1989, Adams 1994). Severe headache can also be a symptom of intracranial
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haemorrhage (subdural, intraparenchymal, subarachnoid, or intraventricular) (Adams
1994). Other neurological complications described in sickle cell disease include 
recurrent seizures, chronic headaches, myelopathy and neuropathy (Pavlakis et al 1989, 
Adams 1994, Shields et al 1991, Danesi 1983, Liu et al 1994, Prengler et al 2001a, 
Prengler et al 2002a, Gregory et al 1994, Osontokun 1979). Venous sinus thrombosis 
and pseudotumor cerebri have also been reported (van Mierlo et al 2003, Henry et al 
2004, Pavlakis et al 1989, Adams 1994).
The majority of studies looking at cognitive function in SCD have found a reduction in 
IQ compared with controls (for review see Schatz et al 2002). Patients with HbSS have 
lower IQ than those with HbSC, who have lower IQ that those with HbS-thalassaemia 
(Mashayehki et al 1987). In one study, 33% of young children had an IQ in the range of 
mild mental retardation (IQ 50-70) (Steen et al 1999a). However, most studies have 
found IQ to be within the normal range in the majority o f patients, but with a mean 
lower than 100 (Watkins et al 1998, Schatz et al 2002). Performance and full scale IQ 
are more impaired in patients with sickle cell patients with severe anaemia (haematocrit 
<20%) and thrombocytosis (> 500 x 109/L) (Bemaudin et al 2000). IQ appeared to 
decrease with age in children followed longitudinally in the US Co-operative Study of 
Sickle Cell Disease (CSSCD) (Wang et al 2001a). There is therefore clinical evidence 
that SCD is associated with a chronic encephalopathy that may be progressive (Kugler 
et al 1993).
1.4. Molecular Sickling
The mechanism of molecular sickling in SCD, which is very important for the 
physiopathology of the complications, including cerebrovascular disease (CVD), is 
complex. HbSS behaves like a normal haemoglobin (HbA) when fully oxygenated, but 
at low oxygen tensions, the haemoglobin S polymerises resulting in gel (Pavlakis et al 
1989, Prengler et al 2002b). Gel formation is decreased in the presence of HbA and 
foetal haemoglobin (HbF) (Pavlakis et al 1989, Franco et al 2000). High concentration 
of HbSS results in increased sickling with hypoxia, acidosis or infection (Keidan et al 
1989, Sultana et al 1998) and the rigid cell may sludge in small blood
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vessels (Pavlakis et al 1989). In addition, the endothelial surface may be damaged and 
become more adhesive to red and white cells and platelets (Pavlakis et al 1989, French 
et al 1997, Nath et al 2000, Inwald et al 2000, Setty et al 2003), which is a candidate 
mechanism for endothelial injury and vaso-occlusion in SCD (Sultana et al 1998, 
Westerman et al 1999, Green et al 1999, Belcher et al 2000, Nath et al 2000, Wajer et al 
2000), perhaps resulting in the formation of a nidus of blood cells, and eventually 
leading to long term arterial narrowing. There is probably an important additional effect 
of infection (figure 1.4; see section 1.9) and it has been suggested that SCD should be 
seen as an inflammatory disease of the blood vessels (Belcher et al 2000).
Nitric oxide (NO), synthesised from L-arginine in endothelial cells, is a critical 
mediator of vascular integrity. NO regulates mainly vasomotor tone and has powerful 
vasodilatory functions (French et al 1997). Disturbance of endothelial function may 
reduce NO levels, allowing unopposed vasoconstriction instead of vasodilatation, which 
may contribute to the genesis of CVD in SCD (French et al 1997).
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Figure 1.4. Principal molecular, infectious, and prothrombotic 
mechanisms involved in the genesis of cerebrovascular disease in 
sickle cell disease. HbSS= sickle cell anaemia; RBC= red blood cell, 
CAMs= cell adhesion molecules (adapted from Prengler et al 2002b).
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1.5. Cerebrovascular Disease in Sickle Cell Disease
1.5.1. Pathology
Endothelial hyperplasia and thrombi in large and small vessels are associated with brain 
infarcts in autopsied patients with sickle cell disease (Bridgers 1939, Rothman et al 
1986, Koshy et al 1990). These data are compatible with those obtained in living 
patients: for example, in 6 out of 7 patients with stroke, cerebral angiography 
demonstrated large-artery occlusive disease with intimal narrowing or complete 
occlusion of the intracranial portion of the internal carotid artery and proximal middle 
cerebral and anterior cerebral arteries (Stockman et al 1972). Other studies have showed 
that between 60 and 95% of patients with SCD who underwent angiography had large 
vessel-disease (Adeloye et al 1970, Stockman et al 1972, Russell et al 1984, Borosh et 
al 1986).
1.5.2. Mechanism of Small and Large Blood Vessel Disease
There are at least two mechanisms involved in the development of cerebral infarction in 
SCD. The first mechanism is the large blood vessel disease with endothelial hyperplasia 
and risk of arterio-arterial thromboembolism. The abnormal red cells and increased 
blood flow at the level of the cerebral large vessel bifurcation in sickle patients may 
cause damage secondary to turbulence in the large vessel with thrombus formation and 
endothelial hyperplasia (Pavlakis et al 1989). The arterial narrowing may cause a 
relative hypoperfusion in vulnerable regions of the brain (Huttenlocher et al 1984) 
leading to borderzone infarcts (anterior, posterior or deep watershed (WS) infarcts) in 
the territory between branches of a central vessel (such as the internal carotid artery 
[ICA]). The borderzone between two fields is vulnerable if blood pressure decreases. 
One of the most vulnerable regions of the human brain is the anterior borderzone of the 
frontal lobe between the territories of the middle and anterior cerebral arteries (Torvik 
1984, Rodgers et al 1988). There is a parallel with non-SCD adult patients with large 
vessel disease (i.e. ICA stenosis), who suffer borderzone infarcts when suffering from 
acute haemodynamic insufficiency (such as severe heart disease, hypotension or
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syncope) (Bogousslavsky et al 1986, Pavlakis et al 1989). In addition, the risk of 
borderzone stroke in SCD patients may be increased by narrowing of the central large 
vessel or its branches, which is common in SCD (see section 1.4).
The second likely mechanism is the sludging of the dense sickle cells in the small blood 
vessels of the brain, such the small distal penetrating arteries of the cortex or 
lenticulostriates supplying the basal ganglia, although there is little direct evidence. 
Cerebral blood flow rates and red blood cell oxygen content are lower in these vessels 
(Kaul et al 1986, Pavlakis et al 1989). These conditions may lead to sickling and vaso- 
occlusion, which may explain the presence of infarcts in sickle cell patients without 
large vessel disease (figure 1.5). In any given patient with SCD, either or both 
mechanisms may play a role in the development of cerebral infarction.
The role of other mechanisms, such as venous sinus thrombosis (Oguz et al 1994, van 
Mierlo 2003), posterior leukencephalopathy (Coley et al 1999, Henderson et al 2002) 
demyelination (Lee et al 2002) or acute cerebral oedema, in the development of CNS 
pathology has not been extensively explored. These pathologies appear to be reversible 
and may be missed if patients do not receive emergency MR imaging, as exchange 
transfusion in the local hospital is usually the priority.
As the patient with SCD ages, the progressive narrowing of the large vessel may be 
associated with aneurysmal dilatation (Berry aneurysms) (Rinkel et al 1993, Diggs et al 
1993, Preul et al 1998), or the development of compensatory but fragile collaterals, 
defined as moyamoya syndrome (Vemet et al 1996, Dobson et al 2002). Both entities 
may lead to intracranial haemorrhage in young adults, and also in children.
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Figure 1.5. Proposed pathophysiology of cerebrovascular disease in 
SCD (adapted from Pavlakis et al 1989)
1.6. Parenchymal Imaging in Sickle Cell Disease: Stroke and Clinically 
Silent Disease
1.6.1. Magnetic Resonance Imaging (MRI)
There is a predilection for brain infarction in the borderzone areas of the brain 
demonstrated in several studies using T2 weighted MRI of the brain (Pavlakis et al 
1988, Kugler et al 1993, Adams 1994, Moser et al 1996, figure 1.6). Silent infarction is 
found in up 25% of sickle cell patients without clinical symptoms (Pavlakis et al 1989, 
Armstrong et al 1996, Kinney et al 1999, Bemaurdin et al 2000, Miller et al 2001, 
Saunders et al 2001, Pegelow et al 2002).
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Figure 1.6. The location of the various manifestations of 
cerebrovascular disease in sickle cell disease (large and small blood 
vessel disease). ‘Borderzone’ infarctions are common in the junctional 
areas between the middle and anterior cerebral and the middle and 
posterior cerebral arterial distributions. The small white matter lesions 
visualized on MRI may be seen in otherwise asymptomatic patients.
Cerebral infarcts in major vessel occlusion and ‘borderzone’ patterns 
are the most common, and fat embolism and venous abnormalities the 
least common lesions (From Adams RJ. Neurological complications, 
in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle 
Cell Disease: Basic Principles and Clinical Practice. Raven Press,
Ltd., New York, 1994, page 600).
The high prevalence of silent infarcts on MRI is a distinctive finding in children with 
SCD compared with children with non-sickle stroke, probably reflecting the chronicity 
of the vasculopathy in this population. Silent infarction is associated with significant 
and progressive cerebrovascular disease, such as moyamoya syndrome or cerebral 
vasculitis, in only in a small proportion of non-sickle stroke in childhood, whereas this 
is a common pattern in sickle cell disease (Prengler et al 1997).
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Patients with SCD and overt or silent infarction are more likely to have abnormal 
psychometric testing (Armstrong et al 1996, DeBaun et al 1998, Watkins et al 1998). In 
a study of 194 patients, those with normal MRI scored better on neurodevelopmental 
testing than those with silent infarction, and patients with silent infarction scored better 
than those with overt clinical stroke (Armstrong et al 1996). Deficits in executive 
function and attention (Brown et al 2000), spatial function and memory, are also 
described, especially in those with anterior lesions or diffuse stroke (Craft et al 1993, 
Watkins et al 1998). Because of the association with the presence of silent infarcts and 
progressive encephalopathy, psychometric testing may be a sensitive marker for the 
extent and progression of clinical and subclinical damage (Pavlakis et al 1989).
Quantitative T1 MRI (qTl MRI) may add sensitivity to the conventional MRI study. 
Abnormal qTl MRI is found in frontal and thalamic regions (Steen et al 1996) in 
children with SCD as young as four years of age (Steen et al 1999b). This study 
demonstrated selective damage in the grey rather than in the white matter (Steen et al 
1999b). Those with haematocrit lower than 27% (normal haematocrit for non-sickle 
children range: 34-40% for the same age [Camitta 1996]) and abnormal grey matter 
were more likely to have abnormal psychometric testing (Steen et al 1999a, Steen et al 
1999b). Chronic oxyhaemoglobin desaturation and anaemia in patients with SCD may 
compromise brain tissue in the absence of CVD.
Cerebral haemorrhage in older patients may be related to the progression of the 
cerebrovascular disease, leading to aneurysm formation and moyamoya syndrome 
(Preul et al 1998, Dobson et al 2002) or may occur secondary to venous sinus 
thrombosis (Gadian et al 2000).
1.7. Cerebral Blood Flow Studies in Sickle Cell Disease
1.7.1. Xenon Inhalation
Studies of global cerebral blood flow (CBF) have shown that neurologically 
asymptomatic patients with sickle cell disease usually have global cerebral hyperemia 
secondary to anaemia and may fail to increase CBF with hypercapnia (Prohnovik et al
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1 "X “X1989). Studies with Xenon demonstrated that cerebral blood flow (CBF) in patients 
with SCD was 68% greater than in controls (Kugler et al 1993, Prohnovik et al 1989); 
this increase was inversely related to hematocrit level (Prohnovik et al 1989). This 
suggests that the increased cerebral blood flow is secondary to adaptive vasodilatation 
and the vascular reserve capacity may be reduced (Prohnovik et al 1989). However, this 
hyperaemia may not be seen in patients with acute neurological symptoms. For 
example, a study using Xenon demonstrated diffusely decreased perfusion in patients 
with stupor, coma and seizures (Huttenlocher et al 1984).
1.7.2. Positron Emission Tomography (PET)
Studies of regional cerebral blood flow (CBF), for example using positron emission 
tomography (PET), have shown focal changes in CBF in SCD patients in addition: for 
example an increase in regional CBF (Herold et al 1987); or more extensive regional 
abnormalities than those shown on MRI (Powars et al 1999). Another PET study 
showed abnormal regional cerebral metabolic rates for glucose in the frontal lobes of 
asymptomatic sickle cell patients with normal CT scans (Rodgers et al 1988). There are 
few data on regional cerebral blood flow in acutely symptomatic patients, but the 
available studies suggest that, as expected, those with vessel occlusion have an area of 
reduced CBF distally (Huttenlocher et al 1984).
1.7.3. Perfusion MRI (DSC-MRI)
Perfusion MRI (dynamic susceptibility contrast MRI), using a contrast agent 
(gadolinium-diethylenetriamine penta-acetic acid), demonstrated perfusion deficits 
associated with central nervous system (CNS) events (such as stroke, transient 
ischaemic attack, severe headaches and coma) in symptomatic patients with sickle cell 
disease (Kirkham et al 2001b). These symptoms persisted in a significant proportion of 
patients despite transfusion therapy. Patients with transient ischaemic attack had 
abnormal perfusion when other neuroimaging modalities were normal (Kirkham et al 
2001b). Perfusion abnormalities were associated with MRA turbulence, which is a 
marker of cerebrovascular disease (Tzika et al 1993, Kirkham et al 2001b). Kirkham et 
al demonstrated that all the patients with severe turbulence or occlusion on MRA had
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perfusion abnormalities, but also, there were perfusion abnormalities in some patients 
with normal MRA and TCD (Kirkham et al 2001b). MRA abnormalities have been 
associated with abnormal TCD in sickle cell patients with stroke (Seibert et al 1998). 
TCD velocities higher than 200 cm/sec are associated with perfusion abnormality 
(Kirkham et al 2001 b) and risk of stroke (Adams et al 1992), but there is also an 
association between abnormal perfusion and moderately increased TCD velocities 
(>170 <200 cm/sec) (Kirkham et al 2001b). Another technique to measure cerebral 
blood flow is continuous arterial spin-labeling perfusion MR, which allows 
quantification of regional cerebral blood flow (CBF) by using magnetically labelled 
water molecules in arterial blood, without the need of exogenous agents. In a recent 
study with sickle cell children who had not have acute neurological events and had not 
received chronic transfusion, Oguz et al demonstrated that mean CBF values were 
significantly higher in sickle patients than in controls (non-sickle) and, in 4 patients, the 
baseline CBF was significantly decreased in territories seen as unaffected on 
conventional MR images and MRA (Oguz et al 2003).
The effect of blood transfusion therapy on cerebrovascular disease and perfusion has not 
been studied in depth, although of a series of 43 sickle patients on chronic transfusion 
therapy, 43% had moyamoya collaterals and 41% of the patients experienced recurrent 
cerebrovascular events despite transfusion (Dobson et al 2002). In one patient with 
chronic cerebrovascular disease, perfusion abnormalities had improved on a study 
performed a few days after transfusion compared with the appearances immediately 
before (Kirkham et al 2001b). Another patient with evidence of bilateral 
cerebrovascular disease, with high velocities on TCD and turbulence on MRA in 
association with a widespread perfusion abnormality throughout both hemispheres had 
completely normal MRI, MRA and perfusion MRI one year later (Kirkham et al 2001b). 
It is possible that chronic inflammation or infection is associated with progressive CVD 
and recurrence of CNS events despite a transfusion regime (Belcher et al 2000, Prengler 
et al 2000b). The effect of blood transfusion on the cerebral vasculature and cerebral 
perfusion is still uncertain.
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1.8. Vascular Studies
1.8.1. Cerebral Angiography
Cerebral angiography has been used in a relatively small proportion of patients with 
stroke and SCD, because of the risks of inducing crisis with the contrast medium, as 
well as of stroke. Studies have showed that between 60 and 95% of patients with SCD 
who underwent angiography had large vessel-disease (Adeloye et al 1970, Stockman et 
al 1972, Russell et al 1984, Borosh et al 1986). Conventional angiography is the 
required diagnostic technique to visualise aneurysms (Rinkel et al 1993, Diggs et al 
1993, Preul et al 1998).
1.8.2. Magnetic Resonance Angiography
MR angiography (MRA) abnormalities are associated with sub-clinical infarction when 
flow turbulence involves a long segment (6mm) and there is reduced distal flow 
(Gilliams et al 1998). In sickle cell disease, MRA can be up to 85% accurate when 
compared with conventional angiography (Kandeel et al 1996). MRA can detect CVD 
in very young children, as was shown in a study by Wang et al, where MRA 
abnormalities were found in 3 out of 29 patients from 7 to 48 months (Wang et al 1998). 
In patients with SCD with or without cerebral infarction, turbulence on MRA may be 
graded as mild, moderate and severe, but there are few data looking at the relationship 
with the degree o f arterial stenosis on conventional angiography (Seibert et al 1998, 
Kirkham et al 2001b).
1.8.3. Transcranial Doppler Ultrasound
Transcranial Doppler ultrasound (TCD) may be used to measure the mean arterial blood 
flow velocities. Increased TCD velocities may be associated with a reduced artery 
diameter, or increased CBF in the presence of anaemia. In sickle cell anaemia, stenosis 
on conventional arteriography may be detected when the MCA velocities are between 
140 and 190 cm/sec; velocities more than 190 cm/sec are associated with marked artery 
stenosis on angiography (Adams et al 1992). Mean MCA blood flow velocities equal or 
greater than 200 cm/sec are associated with 40 % of risk o f stroke over a three year- 
period (Adams et al 1997 and 1998). The STOP study has demonstrated that TCD is a
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useful tool for screening and detection of patients at risk of stroke in the sickle 
population. Children with TCD MCA or ICA time-averaged velocities at or over 200 
cm/sec are at risk of first stroke in three years (13% per year) if they do not receive 
blood transfusion therapy (Adams et al 1992, Adams et al 1997, Adams et al 1998). 
Those with ‘conditional’ TCD studies, i.e. with velocities between 170 and 200 cm/sec 
are also at higher risk of stroke than those with velocities <170 cm/sec (Adams et al 
2004). Since the trial ended prematurely because there was a very large advantage in 
favour of blood transfusion, screening and transfusion for those with velocities >200 
cm/sec has been recommended as standard care in the USA; recent epidemiological 
evidence suggests that has been a parallel fall in the incidence o f stroke in sickle cell 
disease (Fullerton et al 2004). TCD may detect cerebrovascular disease (CVD) at an 
earlier stage than MRA; the highest risk of stroke is in children in whom both are 
abnormal, whose CVD rarely improves without blood transfusion (Abboud et al 2004) 
and even then does not normalise completely (Minniti et al 2004). Studies have shown a 
good correlation between abnormally high TCD velocities and Xenon studies of CBF; 
hematocrit (Brass et al 1988); conventional angiography (Adams et al 1988); and MRA 
(Siegel et al 1995, Verlhac et al 1995, Seibert et al 1998). However, there are very few 
data on the natural history in patients with abnormally low velocities (Minniti et al 
2004).
1.9. Risk Factors for Stroke in Sickle Cell Disease
There are several risk factors that predispose individuals with sickle cell disease to 
develop cerebral infarction. Patients with SC disease and sickle/p+-thalassaemia are less 
likely to develop neurological symptoms, while those with homozygous sickle cell 
anaemia and sickle cell/p0 thalassaemia have a more severe course with a higher risk of 
cerebrovascular events (Seijeant 1997, Adams 1994, Ohene-Frempong et al 1998). Age 
is an important risk factor as the highest incidence of first infarctive stroke is in the first 
years of life (2-5 years) (Ohene-Frempong 1998).
Patients with clinical stroke have lower steady state haemoglobin concentrations, higher 
white cell count and higher reticulocyte counts (Balkaran et al 1992, Ohene-Frempong
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et al 1998, Miller et al 2000). Children with SCD have a reduction of protein S and C 
levels but there is little evidence that these prothombotic abnormalities predict stroke 
(Tam 1997, Liesner et al 1998). Other clinical risk factors for stroke include relative 
hypertension (Rodgers et al 1993, Pegelow et al 1997), painful crisis, infection, early 
dactylitis, and other systemic illnesses (Adams 1994, Miller et al 2000, Osuntokun 
1979). Nocturnal oxyhaemoglobin desaturation in children with SCD, secondary to 
upper airway obstruction (Sidman et al 1988, Samuels et al 1992), is associated with 
stroke and other central nervous system (CNS) events (Robertson et al 1988, Davies et 
al 1989, Kirkham et al 2001a).
The largest multicenter study to date (the Cooperative Study of Sickle Cell Disease) 
suggested that the predictors of ischaemic and hemorrhagic clinical stroke and silent 
infarction might be different. Independent risk factors for ischaemic stroke were 
previous transient ischaemic attacks, lower steady-state-haemoglobin concentrations, 
recent acute chest syndrome and higher blood pressure while those for haemorrhagic 
stroke included a low haemoglobin concentration and a high white cell count (Ohene- 
Frempong et al 1998). Risk factors for silent infarction were a low pain rate, history of 
seizures, leukocytosis and the Senegal ps-globin haplotype (Kinney et al 1999), but the 
severity of the anaemia was not independently associated.
Infection and chronic inflammation is a recurring theme in the pathophysiology of the 
neurological complications in sickle cell disease. Evidence of systemic inflammation is 
very common in sickle cell crisis with increased numbers of activated monocytes, 
platelets, endothelial cells and adhesion molecules and increased C-reactive protein 
(Swerlick et al 1993, Belcher et al 2000, Prengler et al 2000, figure 1.4). As well as the 
evidence that leukocytosis is a risk factor for stroke and silent infarction (Balkaran et al 
1992, Ohene-Frempong et al 1998, Kinney et al 1999), cerebrovascular episodes often 
appear to be precipitated by infections including Pneumococcal meningitis (De 
Montalembert et al 1993), Parvovirus aplastic anaemia (Wierenga et al 2001, Bakshi et 
al 2002) and Mycoplasma pneumoniae (Lee et al 2002). The role of chronic infection 
e.g. secondary to Chlamydia pneumoniae (Goyal et al 2004) or tonsillitis (Ajulo 1994) 
remains controversial. This group of patients is also relatively immunodeficient, in part 
secondary to splenic autoinfarction or surgical removal of the spleen.
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As well as the evidence for a possible effect of Senegal ps-globin haplotype (Kinney et 
al 1999), genetic modulators of the immune (Taylor et al 2002) and host inflammatory 
(Hoppe et al 2001, Hoppe et al 2003) responses might also be important in the 
development of cerebrovascular disease and stroke. There is evidence of human 
leukocyte antigen susceptibility (HLA- DRB1*0301 and 0302 alleles) for stroke in SCD 
(Styles et al 2000). Poor diet may also affect stroke risk, probably interacting with 
different genetic polymorphisms. For example, increased levels of homocysteine, which 
may be determined by genetic and nutritional factors, were found in patients with 
stroke, independent of folate intake (Houston et al 1997).
Neuroimaging, cerebral angiography and transcranial Doppler ultrasound (TCD) may 
help to predict stroke risk. Silent infarcts on MRI are associated with a higher risk of 
clinical stroke (14-fold) (Pegelow et al 1995, Miller et al 2001) and progressive 
infarction (Miller et al 2001). Cerebral angiography demonstrating severe arterial 
stenosis (> 75%) has been related to infarction, and moderate to severe arterial stenosis 
with deep white matter ischaemic lesions (Powars 2000, Zimmerman et al 1987). On 
MRA, blood flow turbulence may also be related to infarction (Seibert et al 1998). TCD 
studies demonstrated that in patients with SCD and MCA velocities of 200 cm/s or 
higher had a 40% stroke risk over three years unless they received regular blood 
transfusion (Adams et al 1992, Adams et al 1997, Adams et al 1998).
Hypoxia may be a risk factor for stroke by increasing haemoglobin gel formation and 
red cell adhesion, predisposing to molecular sickling and vaso-occlusion (Prengler et al 
2002b). Acute worsening of anaemia and hypoxia is associated with a higher stroke risk 
(Banka et al 1977, Ohene-Frempong et al 1998, Nath et al 2000). In addition, chest 
syndrome is a risk factor for stroke (Ohene- Frempong et al 1998), and this respiratory 
complication is associated with hypoxia and may cause CNS events. Nocturnal 
oxyhaemoglobin desaturation is common in sickle cell disease, in young children 
secondary to upper airway obstruction (Walsh et al 1983, Scharf et al 1983, Sidman et 
al 1988, Samuels et al 1992) and appears to be associated with CNS events such as 
stroke, transient ischaemic attacks and seizures (Robertson et al 1988, Davies et al 
1989, Kirkham et al 2001a). A study demonstrated the association of nocturnal
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oxyhaemoglobin desaturation and increased numbers of platelet-erythrocyte complexes 
and monocytes, which enhance molecular sickling (Inwald et al 2000) and may 
predispose to vaso-occlusion. Endothelial attraction and adhesion of white cells, 
platelets, red cells and reticulocytes through upregulation o f leukotriene B4, L-selectin, 
P-selectin and vascular cellular adhesion molecule-1 (VCAM-1) may also be increased 
in chronic oxyhaemoglobin desaturation sustained during day and night (Setty et al 
2003).
The mechanisms of sickling and increased red cell adhesion in association with hypoxia 
may be associated with red cell nidus formation and endothelial damage, leading to 
hyperplasia and arterial narrowing. The development of CVD might be associated with 
perfusion abnormalities in those patients with SCD and chronic oxyhaemoglobin 
desaturation.
1.10. Therapy for Stroke in Sickle Cell Disease
Transfusion therapy is the mainstay of treatment for stroke in sickle cell disease. The 
aim is to reduce the percentage of sickle haemoglobin and increase levels of 
haemoglobin A, thus reducing the deleterious effects of sickling whilst improving tissue 
oxygenation. For acutely sick patients, e.g. with severe chest crisis or neurological 
symptoms, treatment is usually simple or partial exchange-blood transfusion, avoiding 
rapid fluid shifts (Kirkham and DeBaun 2004). A chronic intermittent transfusion 
programme, aiming to keep the HbS below 30%, decreases the risk of stroke recurrence 
(Pavlakis et al 1989, Pegelow et al 1995, Uchida et al 1998, Prengler et al 2002b, 
Kirkham and DeBaun 2004). Without transfusion, the risk of stroke recurrence after the 
first event is up to 67% (Powars et al 1978). After stroke, blood transfusion is 
recommended for life (Balias 1998, Powars 2000); however its side effects (such as 
antibody formation, blood borne infections and iron overload) and the practical 
difficulties (time in hospital, nightly Desferrioxamine injections) make it difficult for 
patients to tolerate this therapy in the long term. Prophylactic transfusion is 
recommended for patients with SCD and elevated TCD velocities (> 200 cm/sec), as the 
Stroke Prevention Trial in Sickle Cell Anaemia (STOP) clearly showed a reduction in 
strokes in this group (Adams et al 1998).
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Studies of regional cerebral blood flow (CBF) using inhaled Xenon133 demonstrated that 
transfusion therapy reduced the cerebral hyperaemia in asymptomatic patients with SCD 
(Prohovik et al 1989), and that decreased CBF can be reversed by blood transfusion in 
patients with acute neurological problems (Huttenlocher et al 1984). The aim of an 
intensive blood transfusion regime is to keep the HbS level less than 20%-30%. 
Moderate transfusion regimes, maintaining HbS between 45% and 50%, were 
associated with a higher CBF than seen with the traditional regime, an effect apparently 
related in part to the haemoglobin and in part to the percentage of sickle haemoglobin 
(Hurlet-Jensen et al 1994). Although there were no neurological complications, the 
effect of the associated hyperemia over time is unknown (Hurlet-Jensen et al 1994). A 
study with MRA showed that blood transfusion might help to reverse CVD by 
increasing the lumen of the blood vessel (Steen et al 2001).
Hydroxyurea may be an alternative treatment for those who have a low tolerance for 
blood transfusion. The drug increases the production of foetal haemoglobin and 
decreases sickling (Goldberg et al 1990, Kaul et al 1995, Ware et al 1999). However, in 
one study, 19% of patients receiving hydroxyurea had stroke recurrence (Ware et al 
1999) and in a pilot study of young children there were also recurrent CNS events 
(Wang et al 2001b). However, recent data from a larger series with longer follow-up 
suggests that hydroxyurea is an effective alternative to blood transfusion, particularly if 
there is overlap (Ware et al 2004). Bone marrow transplantation and allogenic umbilical 
cord blood stem cell transplantation may have the potential to prevent progression of 
CVD and stroke (Walters et al 1996, Walters et al 2000, Nietert et al 2000, Gore et al 
2000, Steen et al 2001). Other therapies such as short-chain fatty acids (Kaul et al
1995), inhaled nitric oxide (Gladwin et al 1999) and arginine supplementation (Romero 
et al 2001) are currently under investigation. The blockade of endothelial a-V-P-3 
integrin or other anti-adhesion therapies (directed to platelet integrin receptors or 
intravenous y-globulin) may help to prevent vaso-occlusion (Kaul et al 2000, Harlan 
2000, Hertel et al 2001). In those patients with SCD and moyamoya syndrome, 
revascularisation techniques (encephaloduroarteriosynangiosis or extracranial- 
intracranial bypass) may help to improve cerebral blood perfusion and stabilise the 
progression of the CVD (Vemet et al 1996, Ganesan et al 2001, Fryer et al 2004).
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Finally, adentosillectomy may improve nocturnal oxyhaemoglobin desaturation in those 
with adenotonsillar hypertrophy and symptoms of upper airway obstruction (Davies et 
al 1982, Samuels et al 1992, Prengler et al 2001b), although this may not necessarily 
reduce the risk of neurological complications (Kirkham et al 2001a).
With respect to oxygen therapy in SCD, sickle cell adhesion may be transient (Sultana 
et al 1998, Wajer et al 2000) and may be reversed with hyperoxia (Nath et al 2000). One 
study showed that inhaled oxygen (50%O2) in sickle cell patients produced a significant 
reduction in the number of irreversibly sickled cells compared to those who received air. 
However, there was no reduction in the duration of the pain crisis in the oxygen treated 
patients compared to the control group (Zipursky et al 1992). Further trials are 
necessary to evaluate the benefits of oxygen therapy (Kirkham et al 2001a).
1.11. Hypotheses
The issues discussed in the background lead to a number of unanswered questions about 
the neurological complications of sickle cell disease:
a) There is uncertainty over the precise neurological diagnosis in acute events and 
chronic problems because the priority is to transfuse rather than to image the patient;
b) There are few data on the natural history of cerebrovascular disease (CVD) in SCD 
(using TCD or MRA) or abnormalities in the cerebral perfusion of these patients;
c) There has been a lack of scientific evaluation of the physiological effects of blood 
transfusion for patients with SCD and neurological complications e.g. improvement in 
the cerebral blood flow, or reversal of the vascular disease. The possibility that blood 
transfusion might have an aetiological role in the progression of the cerebrovascular 
disease has never been addressed and;
d) There is a need for further research, in order to to develop, if possible, alternative 
management strategies to blood transfusion, especially for the prevention of stroke and 
other neurological complications.
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The hypotheses to be tested are the following:
• Perfusion abnormality is associated with cerebrovascular disease and central
nervous system (CNS) events in sickle cell disease. This hypothesis is tested in a 
cross-sectional study (chapter 4).
• Perfusion abnormality is associated with progression o f  cerebrovascular 
disease and central nervous system events in sickle cell disease. This hypothesis
is tested in a longitudinal study looking at whether the area of the brain in
which perfusion abnormality may be demonstrated enlarges in sickle cell 
patients who have progression of turbulence on MR angiogram -or CVD- 
(chapter 5).
• Perfusion abnormality improves with blood transfusion therapy in the short and 
long term. This hypothesis is tested in a group of patients with SCD, who have 
had CNS events and are on blood transfusion therapy, in order to demonstrate 
whether the perfusion abnormality improves blood transfusion therapy by 
normalising the cerebral blood flow or by improving the pattern of CVD 
(chapter 6).
• The genesis o f  seizures in sickle cell disease are associated with perfusion 
abnormality, vasculopathy and cerebral ischaemia. This hypothesis is tested in 
a selected group of patients of this series who have had seizures during this 
study versus a control group (chapter 7).
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Chapter 2: Subjects of this Study
2.1. Patients
Sickle cell patients with neurological symptoms were recruited from referrals of joint 
Haematology/ Neurology clinics attended by MP and FK in six North London hospitals 
(Royal London Hospital, University College Hospital, North Middlesex Hospital, 
Whittington Hospital, Central Middlesex Hospital, Saint Mary’s Hospital). SCD 
patients without neurological symptoms came from a longitudinal cohort of patients, 
followed for more than ten years, in collaboration with Ms Alexandra Hogan, 
Neuropsychologist and PhD Student.
Sickle cell patients with and without neurological symptoms underwent magnetic 
resonance imaging (MRI), magnetic resonance angiography (MRA), diffusion weighted 
imaging (DWI) and magnetic resonance (MR) perfusion (dynamic susceptibility 
contrast MRI [DSC-MRI]), non-imaging transcranial doppler ultrasound (TCD) and 
pulse oximetry at the Great Ormond Street Hospital for Children NHS Trust (GOSH) 
and the Institute of Child Health (ICH), UCL. Ethical permission for this research was 
granted by the ethics committee of GOSH and ICH. O f a total of 73 patients with sickle 
cell disease who underwent the neuroimaging protocol, 70 patients had a successful MR 
perfusion study and constituted the patient group, which was studied prospectively and 
retrospectively (appendix, table 1).
Of the cohort of 70 sickle cell patients, 38 were male and 32 were female; the mean age 
of the patients was 13.6 years (range 1 to 28 years). Sixty-seven of the 70 patients had 
homozygous sickle cell disease (HbSS), one had sickle cell SC disease (HbSC) and two 
patients had sickle cell p° thalassaemia disease.
2.1.1. Therapy
From the clinical data obtainable to date, 19 of the 70 sickle cell patients in 
this study were on a regular blood transfusion programme, 1/19 patients
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on blood transfusion received overnight Oxygen, and a further two patients were also 
receiving antiepileptic medication. Sixteen patients had received blood transfusion 
previously but it had been discontinued. Of the 16 of 70 patients who stopped blood 
transfusion, two continued on Hydroxyurea, three received bone marrow transplantation 
and one patient underwent left indirect frontal revascularisation and continued on 
Hydroxyurea. One patient was on hydroxyurea at the start o f the study. Twelve 
patients underwent adenotonsillectomy; one patient was also on overnight CPAP 
[continuous positive airway pressure]. Three patients were only on anti epileptic therapy.
2.2. Controls
2.2.1. Controls for the Cross-Sectional Study (Chapter 4)
2.2.1.1. Trans cranial Doppler Ultrasound
Transcranial Doppler data were obtained from 37 controls subjects aged from 9 months 
to 28 years (21 males and 16 females) for the purpose of obtaining normal reference 
values for analysis of the TCD data. Twenty-one control subjects (11 males, 6 with 
sickle cell trait, 1 with alpha thalassaemia trait, and 14 without any haemoglobinopathy) 
came from a collaboration with the Neuropsychologist Dr Alexandra Hogan’s PhD 
project; their age range was from 9 months to 24 years. Sixteen controls (10 males) 
came from a study done by Dr Fenella Kirkham and Dr Charles Newton in Kiliffi, 
Kenya (Newton et al 1996); their age range was from 3 years to 28 years of age and 
they did not have any haemoglobinopathy.
The controls from Dr Hogan’s cohort included six babies who had repeated TCD 
studies at 9 and/or 12 months. Control data for the very young age group were 
necessarily sparse. Therefore, in order to increase the number of control TCD data for 
this age group (9-18months), the additional TCD studies of 3 babies at 9 and 12 months 
were included as control data, and therefore the control data for the analysis of the TCD 
data consisted of the number of studies and not of subjects (i.e.40 studies instead of 37 
subjects).
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2.2.L2. Awake Pulse Oximetry (SpO2)
Fifteen controls (6 with sickle cell trait, 1 with alpha thalassaemia trait, and 8 without 
any haemoglobinopathy) from Dr Hogan’s cohort had awake pulse oximetry for the 
purpose of obtaining normal reference values of SpC>2 . In the control group 8 subjects 
were male, 7 female; the mean age of the controls was 17.6 years (range 9 to 24 years). 
These controls subjects also had TCD and were part of the TCD control group.
2.2.2. Controls for the Study on Seizures in Sickle Cell Disease (Chapter 7)
For the study of seizures in SCD, the control group of children with homozygous sickle 
cell anemia had no evidence of neurological disease (n=29; 15 male) over a prolonged 
follow-up period but had undergone unsedated routine MRI and MRA screening (but 
not perfusion) over the age of six (median age 9.9, range 6.6-18.2 years) from within a 
clinic-based but otherwise unselected prospective cohort recruited from joint 
Haematology/ Neurology Clinics recruited by Dr Fenella Kirkham, Reader in Paediatric 
Neurology, Institute of Child Health, as a part of an ongoing study of the risk factors for 
stroke and cerebrovascular disease (CVD) in SCD.
2.3. Clinical Measurements: Data Collection
2.3.1. Blood Pressure
Forty-nine of 70 patients who underwent successful perfusion MRI studies had their 
blood pressure measured at the end of the study. In 43 patients, blood pressure was 
measured using a sphygmocardiograph from which systolic pressure (SP), diastolic 
pressure (DP) and mean arterial blood pressure (MAP) are obtained automatically; in a 
reduced group of patients (n= 6), only the SP and DP were measured manually with a 
sphygmomanometer because of technical reasons (the sphygmocardiograph was not 
available), in that case MAP was calculated from the formula: MAP= diastolic pressure 
+ 1/3 pulse pressure (where pulse pressure= systolic pressure -  diastolic pressure). 
Blood pressure was not measured in 21 patients for technical reasons or for because the
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studies were not supervised directly by MP (patients from Dr Hogan’s cohort or those 
who underwent MR studies under general anaesthesia). Control subjects did not have 
their blood pressure measured (patients from Dr Hogan’s cohort). The normal values of 
blood pressure were obtained from blood pressure tables, based on normal values 
depending on gender and age, from a reference book on Paediatrics, Nelson’s Textbook 
o f Pediatrics (Nelson et al 1996).
2.3.2. Haematological Data
The haematological data consisted of haemoglobin level, haematocrit, haemoglobin S%, 
ferritin and iron levels, reticulocytes, white cell count and platelets, which were 
obtained from the clinical records of the patients from the referring hospitals. The 
nearest blood tests to the date of the MR studies were those used for analysis. The 
normal values of the haematological data were obtained from a reference book on 
Paediatrics, Nelson’s Textbook o f  Pediatrics (Nelson et al 1996).
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Chapter 3: Methodology
3.1. Magnetic Resonance Studies
3.1.1. Introduction: Perfusion MRI Using Contrast Agents (DSC-MRI)
Perfusion is the volume of blood delivered to the capillary beds of a block of tissue in a 
given period of time (ml/lOOg/min). Perfusion is the flow at the capillary level, where 
there is an exchange between blood and tissue. Perfusion MRI requires a tracer, either 
endogenous i.e. magnetic labelled blood (arterial spin labelling techniques) or 
exogenous i.e. a contrast agent, usually gadolinium-DTPA for a technique usually 
referred to as dynamic susceptibility contrast (DSC) or informally as ‘bolus tracking’. 
After the rapid injection of gadolinium, the MRI signal loss due to spin dephasing (i.e. 
decrease in T2 and T2*) is measured during the fast passage of the tracer through tissue. 
Since the transit time of the bolus through the tissue is only a few seconds, a fast 
imaging technique, such as echo-planar imaging (EPI), is required to obtain sequential 
images during the washout and wash in of the contrast material.
The signal change (signal loss) can be related to the concentration of gadolinium, and 
by using a mathematical model, maps of cerebral blood flow (CBF), cerebral blood 
volume (CBV) and mean transit time (MTT) can be calculated (Figures 3.1, 3.2, 3.3). 
The quantification of absolute perfusion is not very reliable and maps of relative 
perfusion are usually used e.g. right compare with left, or grey matter compared with 
white matter or basal ganglia relative to cortex.
If there are delays and dispersions, the CBF, CBV and MTT maps are unreliable and it 
is essential to use summary parameters, such as time-to-peak (TTP), bolus arrival time 
(BAT), maximum peak concentration (MPC) or peak area in a semi-quantitative 
analysis. TTP gives information similar to MTT, MPC is approximately equivalent to 
CBF and peak area can be used to estimate CBV (Calamante et al 1999).
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Figure 3.1. Gadolinium-signal Intensity Time Course in Perfusion 
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Figure 3.2. Gadolinium-Concentration Time Curve in Perfusion MRI 
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Figure 3.3 (previous page). DSC-MRI in a 4 year-old child 12 h after 
a stroke associated with an infarct in the left basal ganglia (right side 
of the images). Sequential spin echo (SE) echo-planar images during 
the passage of a bolus of contrast agent (Gadolinium), together with 
the signal intensity time course (in arbitrary units) for three regions of 
interest (ROI [ROI 1: right basal ganglia, R02: left basal ganglia, ROI 
3: peripheral branch of the right MCA]). The top left and bottom right 
images correspond to t= 12 sec and 25.5 sec, respectively. The images 
show the signal intensity decrease associated with the passage of the 
bolus. Three different periods can be identified in the time course 
data: the baseline (before the arrival of the bolus), the first passage of 
the bolus, and the recircirculation period (in this case, a second 
smaller peak, more clearly seen in the arterial region [ROI 3]). Note 
that the stroke region (ROI 2) shows almost no contrast agent passage 
due to the very low CBF in that area. The images in the bottom row 
are (from left to rigtht): diffusion-weighted image, A D C av, CBF, 
MTT and CBV maps. All of them clearly show the ischaemic region 
(with permission of Dr F. Calamante, PhD, Radiology and Biophysics 
Unit, ICH and GOSH).
3.1.2. Data Acquisition
MR studies were performed on a 1.5 T Siemens Vision whole-body imaging system 
(Siemens AG, Erlangen, Germany). MR studies were performed on a 1.5 T Siemens 
Vision whole-body imaging system (Siemens AG, Erlangen, Germany).
3.1.2.1. Parenchymal Imaging
Seventy-three patients underwent neuroimaging studies. The structural MRI 
investigation included sagittal and coronal T1-weighted images (TR=570 msec, TE= 14 
msec), axial TSE T2-weighted (TR=3,458 msec, TE= 96 msec), and coronal Turbo- 
FLAIR T2- weighted images (TR= 9,999 msec, TE= 119 mesc, TI = 2,210 msec). MRI 
abnormalities were classified as overt cerebral infarction (stroke), silent or covert 
infarction (defined as an area of increased signal intensity on T2-weighted MRI without 
a history of a neurological event lasting more than 24 hours [Moran et al 1998]), and 
cerebral atrophy. MRI studies were assessed by two Neuroradiologists (DS and KC).
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3.1.2.2. Magnetic Resonance Angiography
MR Angiogram (MRA) was performed using a three-dimensional (3D) time-of-flight 
method, acquiring 3 slabs, each of 3.2 mm thickness, centred on the circle of Willis 
(TR= 35 msec, TE= 7.2 msec, flip angle -  20°).
The MR angiograms were reviewed by at least two of four neuroradiologists (WKC, 
DS, TC, MB), who examined them carefully following published criteria (Kirkham et al 
2001b) for evidence of turbulence in the terminal internal carotid (TICA), Al (anterior 
cerebral artery), A2, M l (middle cerebral artery), M2, PI (posterior cerebral artery) and 
P2 segments of the basal vessels (figures 3.4, 3.5, and 3.6). Turbulence on the MRA 
was graded as 1 (mild), 2 (moderate), 3 (severe), 4 (occlusion) and 5 (occlusion plus 
collaterals [moyamoya syndrome] figure 3.7). The presence of collaterals was also 
documented (Kirkham et al 2001b).
Figure 3.4 Anatomic diagram of the circle of Willis. 1: internal 
carotid artery (ICA); 2: horizontal (A l) anterior cerebral artery (ACA) 
segment; 3: anterior communicating artery; 4: posterior
communicating artery; 5: PI segment of posterior cerebral artery 
(PCA); 6; basilar artery bifurcation; 7: middle cerebral artery (MCA; 
not part of the circle of Willis); 8: vertebral arteries (not part of circle 
of Willis); 9: optic chiasm; 10: P2 (post-communicating) PCA
7^>
8
A
8
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segment; 11: A2 (post-communicating) AC A segment (modified from 
Davies and Jacobs 1994).
Figure 3.5. Anteroposterior anatomic drawing of the middle 
cerebral artery (MCA) and its branches. 1: internal carotid 
artery; 2: horizontal (M l) MCA segment; 3: lateral 
lenticulostriate arteries; 4: Sylvian fissure; 5: MCA bifurcation; 
6: anterior temporal artery; 7: M2 (sylvian) segments of MCA 
hemispheric branches; 8: M3 (opercular) MCA branches; 9: 
Sylvian point (from Davies and Jacobs 1994).
Figure 3.6. Anteroposterior anatomic drawing of the anterior 
cerebral artery (ACA) and its branches. 1: Internal carotid 
artery; 2: middle cerebral artery; 3: horizontal (A l) AC A 
segment; 4: anterior communicating artery (ACoA); 5: small 
ACoA branch to basal ganglia, corpus callosum genu; 6: medial 
lenticulostriate arteries; 7: recurrent artery of Heubner; 8: A2
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segment of ACA; 9: ACA bifurcation; 10: pericasollal artery; 
11: callosomarginal artery (from Davies and Jacobs 1994).
Figure 3.7. Magnetic resonance angiograms (MRAs) from four 
patients with sickle cell disease showing different grades of MRA 
turbulence. 0: normal; 1: mild; 2: moderate; 3: severe.
3.1.2.3. Diffusion Weighted Imaging
Diffusion weighted imaging (DWI) was performed using a FLAIR spin-echo EPI 
sequence, with a pair of diffusion gradients on either side of the refocusing pulse. The 
imaging parameters were TE/TR = 86/8,7000 msec, inversion time (TI) = 2,100 msec, 
128 x 128 matrix, 24 cm FOV, 5 mm slice thickness, 1 mm gap between slices. The 
diffusion parameters were: diffusion gradient duration (8) = 15 msec, time interval 
between diffusion gradients (A) = 40.2 msec, b values = 0 and 167 sec/mm2. A 
multislice reference scan was acquired for the on-line correction of B0 eddy-current 
effects (Calamante et al 1999). Maps of the apparent diffusion coefficient (ADC) were 
calculated online in three orthogonal directions, which were combined to generate
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average ADC maps (ADCav) to eliminate the confounding effects of diffusion 
anisotropy (Ulug et al 1997).
3.I.2.4. Perfusion MRI (DSC-MRI)
Seventy of 73 patients had successful perfusion MRI. Dynamic susceptibility contrast 
MRI (DSC-MRI) or perfusion MRI was performed using a multislice spin-echo EPI 
sequence to follow the passage of a bolus of gadolinium diethylenetriaminepenta-acetic 
acid (Gd-DTPA; Magnevist, Schering AG, Germany). The imaging parameters were 
TE/TR = 100/1,500 msec, 128 x 128 matrix, 24 cm FOV, 5 mm slice thickness, with a 
variable gap. Six slices were acquired, with one of the slices including the MCA to 
allow the estimation of the arterial input function (AIF). A Gd-DTPA bolus of 0.1-0.15 
mmol/kg body weight was injected intravenously (rate 2-6 ml/sec) using an MR- 
compatible power injector (Medrad Inc, Pittsburgh, PA), followed by a saline flush. The 
signal intensity time course was converted to a concentration time course, and the AIF 
was used to deconvolve the concentration time curve using singular value 
decomposition (SVD). A 3 x 3 uniform smoothing kernel was applied to the raw image 
data before deconvolution. Maps of cerebral blood flow (CBF), cerebral blood volume 
(CBV), and mean transit time (MTT) were calculated on a pixel-by-pixel basis. When 
long bolus arrival delays are present in the areas with perfusion disturbance, the 
quantification of DSC-MRI data using SVD produces very inaccurate results. In these 
cases, time-to-peak (TTP) maps were calculated on a pixel-by-pixel basis. A region was 
considered to be abnormal on DSC-MRI when at least one of the following situations 
was observed on visual inspection: focal reduction in CBF (mild [denoted as a minus
symbol: -], moderate [- -] or severe [-----]), increase in MTT (mild [denoted as a plus
symbol: +], moderate [+ +] or severe [+ + +]), reduction or increase in CBV (mild [-]
moderate [- -] or severe [---- ]), or increase in TTP (mild [+], moderate [+ +] or severe
[+ + +]; figures 3.8, 3.9 and 3.10 [Calamante et al 2001, Kirkham et al 2001b]).
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Figure 3.8. Perfusion MRI (DSC-MRI) in a patient with sickle cell 
anaemia and seizures. Normal T2-weighetd MRI; mild decrease in 
cerebral blood flow (CBF) or (-), mild increase in the mean transit 
time (MTT) or (+) in the right temporal areas. Cerebral blood volume 
(CBV) maps are similar to CBF.R: right; L: left.
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Figure 3.9. Perfusion MRI (DSC-MRI) in a patient with sickle cell 
anaemia, posterior territory TIA (double vision) and headaches. TCD 
MCA velocities were > 200 cm/sec. Normal T2-weighted MRI; 
moderate decrease in cerebral blood flow (CBF) or (- -), moderate 
increase in the mean transit time (MTT) or (+ +) in frontal parietal 
areas bilaterally. R: right; L: left. Cerebral blood volume (CBV) maps 
are similar to CBF.
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Figure 3.10. Perfusion MRI (DSC-MRI) in a patient with sickle cell 
anaemia and stroke. Left frontal infarct on T2-weighted MRI; severe
decrease in cerebral blood flow (CBF) or (---- ), severe increase in the
mean transit time (MTT) or (+ + +) in the left frontal areas. Cerebral 
blood volume (CBV) maps are similar to CBF. R; right; L: left.
3.2. Transcranial Doppler Ultrasonography
3.2.1. Introduction
The technique of transcranial Doppler ultrasound was first described by Aaslid (1982) 
and since then, it has become a very useful tool for a non-invasive diagnosis and 
screening of cerebral blood flow and vascular disease in several neurological conditions 
either acutely or follow-up (Adams et al 1992, von Reuten 1993). It is possible to use 
transcranial Doppler ultrasound (TCD) to measure mean arterial blood flow velocities in 
the distal internal carotid/proximal middle cerebral artery, the main site of the large- 
blood vessel disease, because of the small angle between vessel and probe which means 
that velocity is directly related to the Doppler shift frequency (Aaslid et al 1982, 
Padayachee et al 1986, Kirkham et al 1986, Gillard et al 1986, figure 3.11).
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Increased TCD velocities may be due to a reduction in artery diameter (Adams et al 
1992), or increased CBF in the presence of anaemia (Brass et al 1988, Adams et al 
1989). In African children with normal haemoglobin, the upper limit (+2 standard 
deviations from the mean) for MCA velocity was 142 cm/sec even when there was iron 
deficiency anaemia (Newton et al 1996), and the lower limit (-2 standard deviations 
from the mean) was 42 cm/sec (Newton et al 1996) in a study which included young 
infants in whom velocities are lower (Bode et al 1988). For children in this population 
aged 7-14 years, the mean (+/-SD) was 90 +/-20 cm/sec. In children with HbSS, the 
MCA velocity is typically between 100-130 centimeters per second (cm/sec) (Adams et 
al 1989). Although children with sickle cell disease have a 40 to 50 percent higher mean 
velocity of flow than children without anaemia, angiographic correlation has shown that 
severe stenosis is associated with TCD velocities 2 to 3 times normal (Adams et al
1992). In sickle cell anaemia, stenosis on conventional arteriography may be detected 
when the MCA velocities are between 140 and 190 cm/sec; velocities more than 190 
cm/sec are associated with marked artery stenosis on angiography (Adams et al 1992).
Figure 3.11. Transcranial Doppler ultrasound (TCD) measures mainly 
mean arterial blood flow velocities in the distal internal 
carotid/proximal middle cerebral artery (the main site of the large- 
blood vessel disease). From von Reuter and von Budingen, 1993.
Mean MCA blood flow velocities equal or greater than 200 cm/sec are associated with a 
40 % of risk of stroke over the subsequent three year-period (13% per year) if patients
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do not receive blood transfusion therapy (Adams et al 1992, 1997 and 1998). TCD 
velocities equal to or more than 170 cm/sec are considered conditional, predicting a 
stroke risk of 7% over the subsequent 3 years; on the other hand, patients with TCD 
velocities between 80 and 170 cm/sec had a 2 % risk of stroke over the same period 
(Adams et al 1997). In another series of sickle cell patients, TCD velocities > 200 
cm/sec or less than 100 cm/sec or presence of arterial occlusion (no flow) were found in 
9 out 12 patients with cerebral infarct (Siegel et al 1995).
The anterior cerebral artery (ACA) velocity is usually <80%  of the velocity of the 
MCA on TCD but velocity can exceed 120% of the MCA velocity in the presence of 
intracranial or extracranial pathology (Adams et al 1992b). Following Adams’s criteria, 
ACA or MCA stenosis is likely when there is a high ipsilateral ACA/MCA ratio equal 
or more than 1.2; the increased ACA velocity may be either associated to turbulent flow 
secondary to the same artery stenosis or secondary to increased collateral flow because 
of MCA/ ICA occlusion (Adams et al 1992b).
3.2.2. Transcranial Doppler Ultrasound Data Acquisition
A non-imaging transcranial Doppler ultrasound (TCD) (2 MHz probe, Nicolet EME, 
Germany) was used by MP to insonate the distal internal carotid (ICA), middle (MCA), 
anterior (ACA) and posterior cerebral (PCA) and basilar arteries using a previously 
described protocol (Adams et al 1992, Adams et al 1997, Kirkham et al 2001) in 68 out of 
70 patients with successful perfusion MRI and 21 control subjects. The MCA, distal ICA, 
ACA and PCA were studied with the transtemporal approach, and the basilar artery with 
the suboccipital approach. Time-averaged mean cerebral blood flow velocities were 
recorded in centimeters per second (cm/sec). Mean MCA velocity was recorded every 2 
mm at depths of 40 to 60 mm (Adams et al 1992). The maximum time averaged velocity 
towards the probe (ICA/MCA) was documented on both sides following Adams’ criteria 
(Adams et al 1997). For analysis, the higher velocity of the two sides was taken (Kirkham 
et al 2001).
TCD findings were abnormal if one or more of the following findings were present: 1) 
mean MCA velocity less than 70 cm/sec and MCA ratio (lowest: highest) velocity < 0.5;
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or an ACA: MCA mean velocity ratio greater than 1.2; 2) mean MCA velocity greater 
than 170 cm/sec and less than 200 cm/sec, deemed conditional by Adams and colleagues 
(1997); 3) a mean MCA velocity equal or greater than 200 cm/sec deemed critical and 
premonitory for stroke by Adams and colleagues (1997); 4) undetectable MCA (Bode et 
al 1988, Adams et al 1992b, Newton et al 1996, Adams et al 1997, Kirkham et al 2001, 
Zafeiriou et al. 2004, figures 3.12.1, 3.12.2, 3.12.3, 3.12.4, 3.12.5).
Figure 3.12.1. Normal transcranial Doppler ultrasound (TCD): normal 
mean middle cerebral MCA velocities (figure: MCA 83 cm/sec)
Figure 3.12.2. Conditional TCD: mean MCA velocities > 170 < 200 
cm/sec (figure: MCA 182 cm/sec).
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Figure 3.12.3. Critical MCA velocity on TCD: mean MCA velocities 
> 200 cm/sec. (figure: MCA 220 cm/sec).
cm /i
120
Figure 3.12.4. Low velocities on TCD: mean MCA velocities < 70 
cm/sec. (figure: MCA 35 cm/sec)
Figure 3.12.5. Undetectable signal on TCD: Undetectable MCA 
(signal by artifact or very low blood flow: MCA 8-10 cm/sec).
3.3. Awake Oxygen Saturation (S p 0 2): Measurement Methodology
3.3.1. Awake Pulse Oxymetry Methodology and Data Acquisition 
Daytime, awake pulse oximetry -  Sp02 and pulse rate (Minolta PulsOx 3i, Stowood 
Scientific Instruments, Oxford, England) was recorded for three minutes in 57 of 70 
patients with successful perfusion MRI and 14 of 15 controls. A baseline Sp02 of less
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than 92% was set as a cut-off for oxyhaemoglobin desaturation (Beckerman et al 1992, 
Ferber and Kryger 1995).
3.4. Neurophysiology
An electroencephalogram (EEG) was recorded in patients who had seizures, using 
standard digital EEG equipment (Nicolet ‘Bravo’), and electrode placements. EEGs 
were reported using conventional clinical methods of visual inspection (in chapter 7).
3.5. Statistical Analysis
The statistical analysis of the data varied for each study and is therefore described in 
each chapter.
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Chapter 4: Association of Perfusion Abnormality with 
Cerebrovascular Disease and Central Nervous System Events 
in Sickle Cell Disease: A Cross-Sectional Study
4.1. Introduction and Aims
4.1.1. Introduction
Cerebral perfusion has been previously studied in sickle cell disease in small groups of 
patients, with different techniques in cross-sectional studies. Previous studies assessed 
either cerebral blood flow haemodynamics in SCD or compared areas of cerebral blood 
flow (CBF) abnormality with structural imaging (MRI) in symptomatic versus 
asymptomatic patients (or control subjects) using different techniques such as inhaled 
Xenon133 (Banka et al 1977, Huttenlocher et al 1984, Prohovnik et al 1989, Kluger et al
1993), positron emission tomography -PET- (Herold et al 1986, Rodgers et al 1988, 
Powars et al 1999) and T2*-weighted MRI (Tzika et al 1999). In addition, a few 
investigators studied the effect of blood transfusion on cerebral perfusion using inhaled 
Xenon133 techniques (Prohovnik et al 1989, Venketasubramanian et al 1994, Hurlet- 
Jensen et al 1994; see chapter 6).
With the development of new MR techniques which allow the assessment of cerebral 
perfusion without exposing the patient to radioactivity, two recent cross-sectional 
studies demonstrated the sensitivity of perfusion MRI in patients with sickle cell 
disease. One study reported cerebral perfusion abnormalities in symptomatic patients 
with SCD using dynamic susceptibility contrast MRI (DSC-MRI) and compared these 
findings with other modalities such as MRI, DWI, MRA and TCD (Kirkham et al 
2001). The study found regions of abnormal perfusion which were normal on structural 
neuroimaging; moreover, in some patients, the extent of the perfusion abnormality was 
beyond the areas of the ischaemic lesions found on MRI (Kirkham et al 2001). The 
other study using continuous arterial spin- labelling perfusion MRI, which measures 
cerebral blood flow (Oguz et al 2003), demonstrated that CBF was higher in sickle cell 
patients in relation to controls and that there were cerebral perfusion abnormalities in
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sickle cell patients who had normal MRI, although some of these patients had cognitive 
symptoms.
However, although Kirkham et al reported a preliminary study comparing different 
imaging techniques and perfusion MRI (Kirkham et al 2001), the patterns of perfusion 
abnormality in relation to the neurological symptoms in patients with SCD have not 
been described in parallel with the severity of the perfusion abnormality compared with 
the grade of abnormality seen on conventional neuroimaging or on TCD. In addition, 
the effect of blood pressure and haematological parameters on cerebral perfusion in 
SCD has not been well documented, although it would be very important to determine 
whether these parameters are associated with perfusion abnormality in this population.
4.1.2. Aims of the Study
The aim of this cross-sectional study was to document the cerebral perfusion 
abnormality and compare it with the severity of cerebrovascular disease and with a 
variety of clinical central nervous system events in sickle cell disease.
The hypothesis to be tested in this cross-sectional study was that, in patients with sickle 
cell disease (SCD), there were different degrees of severity of the cerebral perfusion 
abnormality, and these were related to different neurological symptoms and the severity 
of the cerebrovascular disease.
The clinical questions arising from this hypothesis involved examining whether in 
sickle cell disease there were associations between:
1. The clinical severity of the central nervous system events and the severity of the 
cerebral perfusion abnormality in SCD
2. The clinical severity of the central nervous system events and conventional 
neuroimaging (T2-weighted MRI and MRA turbulence)
3. The severity of the cerebral perfusion abnormality and the findings on MRI and 
grade of turbulence in the intracranial vessels on MRA
68
4. Intracranial vessel cerebral blood flow velocity measured using transcranial 
Doppler ultrasound (TCD) and turbulence documented using MRA in the same 
vessels.
5. Abnormal TCD and perfusion abnormality, to examine whether TCD could be 
used as a non-invasive method of monitoring cerebral blood flow in SCD
6. Blood pressure and neurological symptoms in SCD
7. Blood pressure and cerebral infarction,
8. Blood pressure and cerebrovascular disease
9. Blood pressure and cerebral perfusion
10. Haematological parameters, such as haemoglobin, white cell count, platelets and 
haemoglobin S%, and cerebrovascular disease in SCD
11. Haematological parameters and cerebral infarction
12. Haematological parameters and cerebral perfusion abnormality
In addition to, and in part as a result of addressing all of the above questions, the over­
riding aim was to determine if it is possible to identify predictors of recurrent 
neurological symptoms from cross-sectional MRI, MRA, TCD and MRI perfusion 
studies in patients with SCD who have already experienced central nervous system 
complications.
4.2. Subjects
4.2.1. Patients
Data collection in the patients of this study has been described in chapter 2 (Appendix 
Table 1). Sickle cell patients with neurological symptoms were recruited from referrals 
of joint Haematology/ Neurology clinics attended by MP and FK in six North London 
hospitals. SCD patients without neurological symptoms came from a longitudinal study 
of a cohort of patients, followed for more than ten years, in collaboration with 
Alexandra Hogan, Neuropsychologist and PhD Student. Ethical permission was granted 
by the committee of Great Ormond Street Hospital for Children NHS Trust.
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Sickle cell patients with and without neurological symptoms underwent MRI, MRA, 
DWI and MRI perfusion, non-imaging TCD and pulse oximetry at Great Ormond Street 
Hospital for Children NHS Trust (GOSH) and the Institute of Child Health (ICH), UCL. 
Seventy (67 with neurological symptoms) of 73 patients had a successful MR perfusion 
study and constituted the patient group that was studied. Sixty-seven out o f 70 patients 
had homozygous sickle cell disease (HbSS), one had sickle cell SC disease (HbSC) and 
two patients had sickle cell P° thalassaemia disease. The series o f 70 patients with sickle 
cell disease with their clinical, neuroimaging and TCD data are shown in Appendix 
Table 2; the patients are numbered following a decreasing order of severity of their 
neurological symptoms.
O f the cohort of 70 sickle cell patients, 38 were male and 32 were female; the mean age 
of the patients was 13.6 years (range 1 to 28 years).
4.2.2. Controls
4.2.2.1. Trancranial Doppler Ultrasound
Transcranial Doppler data were obtained from 37 controls subjects aged from 9 months 
of age to 28 years (21 males and 16 females) for the purpose of obtaining normal 
reference values for comparison with the TCD data from the patients with sickle cell 
disease. Twenty-one control subjects (11 males; 6 with sickle cell trait, 1 with alpha 
thalassaemia trait, and 14 without any haemoglobinopathy) came from the collaboration 
with the Neuropsychologist Dr Alexandra Hogan; their age range was from 9 months to 
24 years. Sixteen controls (10 males) came from a study done by Dr Fenella Kirkham 
and Dr Charles Newton in Kiliffi, Kenya (Newton et al 1996); their age range was from 
3 years to 28 years of age and they did not have any haemoglobinopathy.
The controls from Dr Hogan’s cohort included six babies who had repeated TCD 
studies at 9 and/or 12 months. Control data for the very young age group were 
necessarily sparse. Therefore, in order to increase the number of control TCD data for 
this age group (9-18months), the additional TCD studies o f 3 babies at 9 and 12 months 
were included as control data, and therefore the control data for the analysis of the TCD
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data consisted of the number of studies and not of subjects (i.e. 40 studies instead of 37 
subjects).
4.2.2.2. Awake Pulse Oximetry (SpO2)
Fifteen controls (6 with sickle cell trait, 1 with alpha thalassaemia trait, and 8 without 
any haemoglobinopathy) from Dr Hogan’s cohort had awake pulse oximetry for the 
purpose of obtaining normal reference values of SpC>2 . In the control group 8 subjects 
were male, 7 female; mean age of the controls was 17.6 years (range 9 to 24 years). 
These controls subjects also had TCD and were part of the TCD control group.
4.3. Methods
4.3.1. Conventional Neuroimaging, Perfusion MRI, Transcranial Doppler 
Ultrasound, Oxygen Saturation, Blood Pressure Measurements and 
Haematological Parameters
The patients underwent MRI, MRA, DWI, and perfusion MRI studies following a 
published protocol (Kirkham et al 2001) with simultaneous 3-minute pulse oximetry, 
transcranial Doppler ultrasound and measurement of the blood pressure performed after 
the perfusion MRI. The data acquisition for these studies is described in chapter 3. In 
addition, the available haematological data and blood pressure measurements (of those 
patients who did not have the blood pressure recorded at the time of their MR studies) 
were collected from the clinical records of the patients.
As was mentioned in chapter 3, by convention at the Radiology and Physics Unit at 
ICH/GOSH, abnormal perfusion MRI was characterised by a regional increased MTT 
which was defined with a sign *+* on visual inspection (=: normal ; +: mild ; + +: 
moderate; + + +: severe increase in MTT); a regional decreased CBF and/ or CBV was
defined with a sign c-‘ (=: normal; mild decrease; - - : moderate decrease; : severe
decrease in CBF or CBV); or a regional increase in CBF and/ or CBV (=: normal; +: 
mild; + +: moderate; + + + : severe increase in CBF or CBV, Calamante et al 1999). An
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increase of MTT and/or decreased CBF or CBV is seen when there is cerebrovascular 
disease with artery stenosis or occlusion (Kirkham et al 2001) leading to slowing of the 
passage of blood flow secondary to the arterial abnormality. Two of the 70 patients 
(3%) (both female, 16 and 22 years old) had side effects secondary to the intravenous 
bolus of Gadolinium, which consisted of vomiting in one patient and nasal congestion 
and cough with mild bronchospasm in the other. The symptoms were transient and the 
patients rapidly improved, in the first case spontaneously, and in the second with nasal 
Oxygen.
4.3.2. Data Analysis
Statistical analysis was undertaken using SPSS 10 for Windows. For the study of 
association among recurrent neurological symptoms, conventional neuroimaging (MRI 
and MRA), TCD and perfusion MRI, x2 and Fisher’s exact test were used for binary 
categorical data, the Mann-Whitney test for associations between binary data and 
ordinal data, and Spearman‘s test for ordinal data. For clinical data (blood pressure, 
haematological parameters and oxygen saturations) logistic regression was used for 
association between continuous data and binary categorical data in relation to an 
outcome. One-way analysis of variance [ANOVA] was used to compare means of 
continuous data. Tukey’s test (ANOVA) was used for post-hoc analysis between mean 
values of continuous data to analyse differences in mean values by age group or by 
clinical symptoms. Wilcoxon’s test for related samples was used to compare non- 
parametric continuous data for analysis of TCD velocities within groups. Statistical 
significance was defined as p<0.05, and a trend for significance was defined as p>0.05 
and p< 0.1.
4.4. Results I: Neurological Symptoms and Clinical Parameters
4.4.1. Neurological Symptoms
4.4.1 A. Central Nervous System Events at Presentation
The clinical symptoms of the patients of this study are described in those who had a 
successful perfusion MRI study (n= 70 patients). The main neurological syndrome at 
presentation was described in every patient with the clinical data obtained to date and
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other recurrent symptoms (such as headaches, seizures and learning difficulties) 
considered as secondary features if they were not the main neurological symptom for a 
given patient (figure 4.1).
As the main neurological symptom at presentation, 4 patients (6%) had coma (2 with 
underlying stroke accompanied by coma with cerebral oedema and 2 associated with 
symptoms of posterior territory transient ischaemic attack). Fourteen patients had stroke 
(overt infarction, 20% [including the 2 patients who had coma and stroke, the overall 
stroke prevalence was 23%]), mostly presenting with focal neurological symptoms such 
as hemiparesis or visual symptoms.
Twenty-three of 70 patients (33%) had transient ischaemic attacks (TIA), 9 with 
anterior territory TIA characterized mainly by transient hemiparesis and/or 
hemiparaesthesia. The other 14 patients had posterior territory TIA; symptoms were 
characterized by headaches, visual symptoms, dizziness and confusion; in a lesser 
degree accompanying hemiparesis in one patient and seizures in another.
Seven of 70 patients (10%) presented with seizures at onset, which included blank 
spells (n=3), staring spells (n=l), generalised tonic-clinic seizures (n=2), and visual 
phenomena (n=l).
Fifteen patients (21.4%) had headaches, and 4 patients (6%) had learning difficulties as 
main symptoms at presentation. Only 3 patients (4%) did not have neurological 
symptoms but had severe SCD with recurrent crises such as chest syndrome.
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learning difficulty se izures ant TIA coma
Neurological Symptoms at Presentation in SCD Patients
Figure 4.1. Frequency of different central nervous system events at 
presentation of sickle cell patients who had successful perfusion MRI
4.4.1.2. Recurrent Neurological Symptoms
The main recurrent symptom (most severe recurrent symptom) in these patients with 
sickle cell disease included (figure 4.2): stroke in 3 patients (4%), one of whom had 
accompanying symptoms of posterior leukoencephalopathy with coma and 
hypertension; all were on chronic blood transfusion, although one of these patients 
stopped blood transfusion due to antibody formation against blood red cells. Other 
recurrent symptoms included: reversible ischaemic neurological deficit -RIND-
(defined as the persistence of focal neurological symptoms lasting more than 24 hours 
but eventually recovering completely) in one patient (1%); and TIAs in 11 ( 16% [7 
anterior and 4 posterior]). In addition, 7 patients (10%) had recurrent seizures, 31 
patients (44%) had headaches, and a further 6 (9%) had learning difficulties. Only 
eleven patients (16%) did not have any documented recurrent neurological symptoms.
O f the sickle cell patients who had recurrent symptoms, some had only one recurrent 
symptom, while other had multiple recurrent symptoms. Other recurrent neurological 
symptoms accompanying the main recurrent symptom included TIAs (n=2); seizures 
(n=l); headaches (n=15); and learning difficulties /behaviour problems in 32 patients.
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Twenty-three of 70 patients (33%) had only a main recurrent neurological symptom. 
Furthermore, 36 patients (51%) had two or more recurrent symptoms: 24 (34% of 70 
patients) with two recurrent neurological symptoms, 10 (14%) with three recurrent 
symptoms, and 2 patients (3%) with four different recurrent symptoms.
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Recurrent Neurological Symptoms in SCD Patients
Figure 4.2. Frequency of the main recurrent neurological symptoms 
of the sickle cell patients who had a successful perfusion MRI.
4.4.1.3. Inter-Observer Assessment in the Short- and Long- Term for Neurological 
Symptoms
Two paediatric neurologists who attended the joint Haematology/Neurologist clinics 
assessed the sickle cell patients of this series. Observer 1 was the author and observer 2 
was a Consultant Paediatric Neurologist (FJK). Observer 1 assessed the sickle cell 
patients over a relatively short period of time (3 years), as her observations on the 
patients’ neurological symptoms were based on notes taken during the clinics and/or 
during her supervision of the patients’ MRI perfusion studies, and/or from the referral 
letters written by the Consultant Paediatricians or Haematologists. Observer 2 was the 
Consultant Paediatric Neurologist for these patients who had followed and assessed 
them over a longer period of time (up to 14 years). Both observers completed forms that
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had a classification of neurological symptoms, highlighting the most severe 
neurological symptom at presentation and recurrence for each patient, which were used 
for the analysis of the clinical data. Whenever accurate clinical data were not available 
for a patient, the form was left blank (10 patients for observer 1).
Figures 4.3 and 4.4 show the inter-observer assessment in the short- and long-term for 
neurological symptoms at onset, which revealed that there was a high correspondence 
(82%) for stroke, whereas for the other symptoms of lesser severity, the correspondence 
was around 50%. Similarly, the inter-observer assessment in the short- and long-term 
for recurrent neurological symptoms (figures 4.5 and 4.6) had a very high 
correspondence for the most severe symptoms such as coma, stroke and RIND (100%). 
However for the other symptoms, the agreement was around 50%, the highest 
agreement was for headaches (62%) and the lowest agreement was for learning 
difficulty (36%).
It is possible to argue that long-term follow-up might be more accurate for the 
description of neurological symptoms for these patients, especially for detection of 
symptoms of lesser severity. The restriction of time during a single consultation or 
during the supervision of the patient during the MR studies may jeopardize the quality 
of clinical history taking, as could the fact that these symptoms were not always 
described in the referral letters. In addition, sickle cell patients may change their 
neurological symptoms over time (with worsening or improvement in symptomatology) 
depending on the course of their disease, and may forget previously experienced 
symptoms which have resolved completely.
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\Figure 4.3. Inter-observer assessment in the short- (observer 1) and long-term (observer 2) of the neurological symptoms at presentation of 
each sickle cell patient -  cross- sectional data. Categories of symptoms: 0= none; 1= learning difficulty (cognitive symptom); 2= 
headaches; 3= seizures; 4= posterior territory transient ischaemic attack (TIA); 5= anterior territory TIA; 6= stroke; and 7= coma.
Inter-Observer Assessment for Neurological Symptoms at Presentation
^ a  ■ a^a a^a •  a a^a
O)
♦  ♦  ♦
oc*>
700 5 10 3530 40 45 5015 20 25 55 60 65 75
SCD Patient Number
♦  Observer 1-CNS Event at Onset a Observer 2-CNS Event at Onset
77
Nu
m
be
r 
of 
SC
D 
Pa
tie
nt
s
Figure 4.4. Inter-observer assessment in the short-(observer 1) and long-term (observer 2) of the neurological symptoms at presentation of
the sickle cell patients for each symptom- cross- sectional data.
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Figure 4.5. Inter-observer assessment in the short-(observer 1) and long-term (observer 2) of recurrent neurological symptoms of each 
sickle cell patient -  cross- sectional data. Categories of symptoms: 0= none; 1= learning difficulty (cognitive symptom); 2= headaches; 3= 
seizures; 4= posterior territory transient ischaemic attack (TIA); 5= anterior territory TIA; 6= reversible ischaemic neurological deficit 
(RIND); 7= stroke; and 8= coma.
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Figure 4.6. Inter-observer short- (observer 1) and long-term (observer 2) o f recurrent neurological symptoms of the sickle cell patients for
each symptom- cross- sectional data.
Inter-Observer Assessment for Recurrent Neurological Symptoms
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Therefore, for the purpose of the analysis of the clinical data in all the chapters, the 
descriptions of the neurological symptoms at presentation and recurrent symptoms of 
these sickle cell patients by the Consultant Paediatric Neurologist (observer 2) were 
chosen as she had followed and assessed these patients for a longer period of time, was 
actively involved in the treatment of their neurological complications, and was blinded 
to the results of the MR perfusion.
4.4.2. Blood Pressure Measurements
4.4.2.1. Blood Pressure
4.4.2.1.1. Systolic Blood Pressure
Systolic blood pressure (SBP) was measured in 49 of 70 patients who had successful 
perfusion MRI, the mean SBP of these patients was 110 mmHg (range 85 to 129 
mmHg). Mean SBP values for age group were the following (figure 4.7): fo r  3 to 5 
years (n=2) 100 mmHg (75th percentile), range 95-105 mmHg (50-75th to 75-90th 
percentiles); fo r  6 to 12 years (n=20) 108 mmHg (75th-90th percentile), range 94 -128 
mmHg (<50th to >95th percentiles); fo r  13 to 17 years (n=15) 111 mmHg (50th 
percentile), range 85-129 mmHg (<50th to 90-95th percentiles); and fo r  18 to 28 years 
(n=12) was 116 mmHg (50th percentile), range 98-125 mmHg (<50th to 75-90th 
percentiles).
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Figure 4.7. Systolic blood pressure measurements in relation to age.
Systolic blood pressure measurements of the sickle cell patients in relation to their 
neurological symptoms at presentation (figure 4.8) were the following: the mean SBP 
for patients who presented with coma (n=l) was 117 mmHg; for stroke (n=13) was 110 
mmHg (range 95-128 mmHg); for anterior territory TIA (n=7) was 110 mmHg (range 
100-122 mmHg); for posterior territory TIA (n=10) was 108 mmHg (range 85-129 
mmHg); for seizures (n=3) was 107 mmHg (range 94-115 mmHg); headaches (n= ll) 
was 112 mmHg (range 97-125 mmHg); for learning difficulty (n=2) was 104 mmHg 
(range 103-104 mmHg); and for asymptomatic patients (n=2) was 110 mmHg (range 
108-112 mmHg). Table 4.1 shows the relationship between systolic blood pressure, 
neurological symptoms at presentation and SBP percentiles by age groups.
3-5 years 6 -1 2  years 13-17 years
A ge of Sickle Cell Patients
18-28 years
82
Neurological Age Group Patients Mean Mean SBP SBP SBP Percentile
Symptoms (years) (n) Systolic BP Percentile Range Range
(mmHg) for Age (mmHg)
Coma 6-12 y 1 117 75-90^ 117 75-90*
Stroke 3-5 y 1 95 50th 95 50*
6-12 y 3 108 75-90* 97-128 50- >95*
13-17 y 4 112 50th 108-121 <50 -  75*
18-28 y 5 113 50th 105-120 <50 -  75*
Anterior 6-12 y 2 105 50-75* 100-109 50-75*
TIA 13-17 y 2 119 50-75* 115-122 50-75*
18-28 y 3 108 <50* 100-113 <50- 50*
Posterior 6-12 y 3 107 50-75* 98-113 50 -90*
TIA 13-17 y 6 110 <50* 85-129 <50 -  90*
18-28 y 1 98 <50* 98 <50*
Seizures 6-12 y 2 103 50-75* 94-111 <50 -90*
18-28 y 1 115 <50* 115 <50*
Headaches 3-5 y 1 105 75-90* 105 75-90*
6-12 y 5 112 75-90* 97-120 <50-95*
13-17 y 3 107 <50* 104-110 <50*
18-28 y 2 120 50-75* 115-125 50-75*
Learning 6-12 y 2 104 50-75* 103-104 50-75*
Difficulty
Asymptomatic 6-12 y 2 110 75* 108-112 75-90*
Table 4.1. Relationship between systolic blood pressure (SBP), 
neurological symptoms at presentation and SBP percentiles by age 
groups in sickle cell patients.
Systolic blood pressure of the patients with SCD in relation to their recurrent 
neurological symptoms (figure 4.9) were the following: the mean SBP for patients who 
presented with coma (patient who presented with posterior leukoencephalopathy 
[PLKE]; n=l) was 117 mmHg; for stroke (n=2) was 114 mmHg (range 112-116 
mmHg); for reversible ischaemic neurological deficit (RIND; n= 1) was 120 mmHg; for 
anterior territory TIA (n=6) was 112 mmHg (range 97-128 mmHg); for posterior 
territory TIA (n=l) was 109 mmHg; for seizures (n=5) was 108 mmHg (range 94-115 
mmHg); headaches (n=21) was 110 mmHg (range 85-129 mmHg); for learning 
difficulty (n=5) was 104 mmHg (range 98-108 mmHg); and for asymptomatic patients 
(n=7) was 106 mmHg (range 95-115 mmHg). Table 4.2 shows the relationship between 
systolic blood pressure, recurrent neurological symptoms and SBP percentiles by age 
groups.
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Figure 4.8. Systolic blood pressure measurements in relation to 
neurological symptoms at presentation in sickle cell patients. TIA: 
transient ischaemic attack.
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Figure 4.9. Systolic blood pressure measurements in relation to 
recurrent neurological symptoms in sickle cell patients. TIA: transient 
ischaemic attack; PLKE: posterior leukoencephalopathy
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Recurrent Age Patients Mean Mean SBP SBP SBP
Neurological Group (n) Systolic BP Percentile Range Percentile
Symptoms (mmHg) for Age (mmHg) Range
Coma 6-12 y 1 117 75-90* 117 75-90*
Stroke 18-28 y 2 114 50th 112-116 50*
RIND 18-28 y 1 120 75th 120 75*
Anterior 6-12 y 3 108 75-90* 97-128 <50->95*
TIA 13-17 y 2 117 50-75* 112-122 <50-75*
18-28 y 1 113 50* 113 50*
Posterior 13-17 y 1 109 <50* 109 <50*
TIA
Seizures 6-12 y 3 106 75* 94-113 <50-90*
13-17 y 1 108 <50* 108 <50*
18-28 y 1 115 50-75* 115 50-75*
Headaches 3-5 y 1 105 75-90* 105 75-90^
6-12 y 6 112 75* 97-120 <75-90*
13-17 y 9 110 <50-50* 85-129 <50-90*
18-28 y 5 110 <50-50* 98-125 <50-75*
Learning 6-12 y 4 103 50* 98-108 <50-75*
Difficulty 13-17 y 1 108 <50* 108 <50*
Asymptomatic 3-5 y 1 95 50* 95 50*
6-12 y 3 106 50-75* 98-112 <50-90*
13-17 y 1 115 50-75* 115 50-75*
18-28 y 2 108 <50* 105-110 <50-50*
Table 4.2. Relationship between systolic blood pressure (SBP), 
recurrent neurological symptoms and systolic blood pressure 
percentiles by age groups in sickle cell patients.
4.4.2.1.2. Diastolic Blood Pressure
Diastolic blood pressure (DBP) was measured in 49 of 70 patients who had successful 
perfusion MRI. The mean DBP of these patients was 58 mmHg (range 30 to 81 mmHg). 
Mean DBP values for age group were the following (figure 4.10): fo r  3 to 5 years (n=2) 
46 mmHg (<50th percentile), range 34-57 mmHg (<50th to 50th percentile); fo r  6 to 12 
years (n=20) 59 mmHg (<50th -50 percentile), range 33-81 mmHg (<50th to >95th 
percentile); fo r  13 to 17 years (n=15) 56 mmHg (<50th percentile), range 31-76 mmHg
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(<50th to 75-90th percentile); and fo r  18 to 28 years (n=12) was 59 mmHg (<50th 
percentile), range 30-80 mmHg (<50th to 90th percentile).
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Figure 4.10. Diastolic blood pressure measurements in relation to 
age.
Diastolic blood pressure measurements of the sickle cell patients in relation to their 
neurological symptoms at presentation (figure 4.11) were the following: the mean DBP 
for patients who presented with coma (n= 1) was 55 mmHg; for stroke (n=13) was 56 
mmHg (range 31 to 80 mmHg); for anterior territory TIA (n=7) was 53 mmHg (range 
30 to 76 mmHg); for posterior territory TIA (n=10) was 62 mmHg (range 49 to 79 
mmHg); for seizures (n=3) was 68 mmHg (range 58 to 81 mmHg); headaches (n= ll) 
was 56 mmHg (range 33 to 80 mmHg); for learning difficulty (n=2) was 61 mmHg 
(range 51 to 71 mmHg); and for asymptomatic patients (n=2) was 50 mmHg (range 48 
to 50 mmHg). Table 4.3 shows the relationship between diastolic blood pressure, 
neurological symptoms at presentation and DBP percentiles by age groups.
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Figure 4.11. Diastolic blood pressure measurements in relation to 
neurological symptoms at presentation in sickle cell patients. TIA: 
transient ischaemic attack
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Recurrent Neurological Symptoms in Sickle Cell Patients
Figure 4.12. Diastolic blood pressure measurements in relation to 
recurrent neurological symptoms in sickle cell patients. TIA: transient 
ischaemic attack; PLKE: posterior leukoencephalopathy
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Neurological Age Group Patients Mean Mean DBP DBP DBP Percentile
Symptoms (n) Diastolic BP Percentile Range Range
(mmHg) for Age (mmHg)
Coma 6-12 y 1 55 <50 55 <50*
Stroke 3-5 y 1 57 50-75* 57 50-75*
6-12 y 3 53 <50* 42-61 <50-50*
13-17 y 4 52 <50* 31-75 <50 -  75*
18-28 y 5 61 <50* 47-80 <50 -  90*
Anterior 6-12 y 2 58 <50-50* 40-76 <50-90*
TIA 13-17 y 2 49 <50* 49-49 <50*
18-28 y 3 52 <50* 30-70 <50- 75*
Posterior 6-12 y 3 66 75* 49-79 <50 -95*
TIA 13-17 y 6 62 <50* 51-76 <50 -  90*
18-28 y 1 50 <50* 50 <50*
Seizures 6-12 y 2 70 75-90* 58-81 <50 - >95*
18-28 y 1 66 50* 66 50*
Headaches 3-5 y 1 34 <50* 34 <50*
6-12 y 5 59 <50* 33-80 <50->95*
13-17 y 3 53 <50* 45-61 50*
18-28 y 2 66
•so
52-79 <50-90*
Learning 6-12 y 2 61
■5O
51-71 <50-90*
Difficulty
Asymptomatic 6-12 y 2 50 <50* 48-52 <50*
Table 4.3. Relationship between diastolic blood pressure (DBP), 
neurological symptoms at presentation and DBP percentiles by age 
groups in sickle cell patients.
Diastolic blood pressure of the patients with SCD in relation to recurrent neurological 
symptoms (figure 4.12) were the following: the mean DBP for patients who presented 
with coma (patient who presented with PLKE; n=l) was 55 mmHg; for stroke (n=2) 
was 51 mmHg (range 47 to 54 mmHg); for reversible ischaemic neurological deficit 
(RIND; n=l) was 80 mmHg; for anterior territory TIA (n=6) was mmHg (range 
mmHg); for posterior territory TIA (n=l) was 76 mmHg ; for seizures (n=5) was 65 
mmHg (range 52 to 81 mmHg); headaches (n=21) was 57 mmHg (range 31 to 80 
mmHg); for learning difficulty (n=5) was 59 mmHg (range 48 to 71 mmHg); and for 
asymptomatic patients (n=7) was 58 mmHg (range 49 to 76 mmHg). Table 4.4 shows 
the relationship among diastolic blood pressure, recurrent neurological symptoms and 
DBP percentiles by age groups.
Recurrent Age Patients Mean Mean DBP DBP DBP
Neurological Group (n) Diastolic BP Percentile Range Percentile
Symptoms (mmHg) for Age (mmHg) Range
Coma 6-12 y 1 55 <50 55 <50*
Stroke 18-28 y 2 51 <50* 47-54 <50*
RIND 18-28 y 1 80 90th 80 90*
Anterior 6-12 y 3 46 <50* 40-56 <50*
TIA 13-17 y 2 62 <50* 49-75 <50-75*
18-28 y 1 30 <50* 30 <50*
Posterior 13-17 y 1 76 75-90* 76 75-90*
TIA
Seizures 6-12 y 3 69 75* 58-81 <50- 95*
13-17 y 1 52 <50* 52 <50*
18-28 y 1 66 50* 66 50*
Headaches 3-5 y 1 34 <50* 34 <50*
6-12 y 6 63 50-75* 33-80 <50-95*
13-17 y 9 53 <50* 31-64 <50-50*
18-28 y 5 61 <50* 50-79 <50-90*
Learning 6-12 y 4 58 <50-50* 48-71 <50-90*
Difficulty 13-17 y 1 62 <50* 62 <50*
Asymptomatic 3-5 y 1 57 50-75* 57 50-75*
6-12 y 3 59 <50* 49-76 <50-90*
13-17 y 1 49 <50* 49 <50*
18-28 y 2 62 <50* 57-66 <50-50*
Table 4.4. Relationship between diastolic blood pressure (DBP),
recurrent neurological symptoms and DBP percentiles by age groups 
in sickle cell patients.
4.4.2.1.3. Mean Arterial Blood Pressure
Mean arterial blood pressure (MAP) was measured in 49 of 70 patients who had 
successful perfusion MRI, and the mean MAP of these patients was 76 mmHg (range 55 
to 97 mmHg). Mean MAP values for age group were the following (figure 4.13): for 3 
to 5 years (n=2) 64 mmHg (range 58-70 mmHg); fo r  6 to 12 years (n=20) 77 mmHg 
(range 55-95 mmHg); fo r  13 to 17 years (n=15) 75 mmHg (range 61-90 mmHg); and 
fo r  18 to 28years (n=12) 77 mmHg (range 58-97 mmHg).
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Figure 4.13. Mean arterial blood pressure (MAP) pressure 
measurements in relation to the age of the sickle cell patients.
MAPs of the sickle cell patients in relation with their neurological symptoms at 
presentation (see figure 4.14) were the following: the mean MAP for patients who 
presented with coma (n=l) was 76 mmHg; for stroke (n=13) was 75 mmHg (range 61 
to 93 mmHg); for anterior territory TIA (n=7) was 73 mmHg (range 58 to 90 mmHg); 
for posterior territory TIA (n=10) was 78 mmHg (range 66 to 92 mmHg); for seizures 
(n=3) was 84 mmHg (range 72 to 95 mmHg); headaches (n= ll) was 76 mmHg (range 
55 to 97 mmHg); for learning difficulty (n=2) was 77 mmHg (range 69 to 84 mmHg); 
and for asymptomatic patients (n=2) was 71 mmHg (range 68 to 73 mmHg).
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Figure 4.14. Mean arterial pressure (MAP) in relation to the 
neurological symptoms at presentation in sickle cell patients. TIA: 
transient ischaemic attack
MAPs of the patients with SCD in relation to recurrent neurological symptoms (figure 
4.15) were the following: the mean MAP for patients who presented with coma (patient 
who presented with PLKE; n=l) was 76 mmHg; for stroke (n=2) was 71 mmHg (range 
68 to 74 mmHg); for reversible ischaemic neurological deficit (RIND; n=l) was 93 
mmHg; for anterior territory TIA (n=6) was 71 mmHg (range 58 to 90 mmHg); for 
posterior territory TIA (n=l) was 90 mmHg; for seizures (n=5) was 81 mmHg (range 72 
to 95 mmHg); headaches (n=21) was 75 mmHg (range 55 to 97 mmHg); for learning 
difficulty (n=5) was 75 mmHg (range 68 to 84 mmHg); and for asymptomatic patients 
(n=7) was 75 mmHg (range 66 to 90 mmHg).
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Figure 4.15. Mean arterial pressure (MAP) in relation to the recurrent 
neurological symptoms in sickle cell patients. TIA: transient 
ischaemic attack; PLKE: posterior leukoencephalopathy
4.4.2.1.4. Effect of Blood Pressure on Neurological Symptoms at Presentation and 
Recurrent Neurological Symptoms in Sickle Cell Patients
There were no significant associations between systolic (SP), diastolic (DP) and mean 
arterial (MAP) blood pressure values and the presence of neurological symptoms at 
presentation in sickle cell patients (p=0.9, p=0.4 and p=0.5 for SP, DP and MAP 
respectively, logistic regression). In addition, presence of neurological symptoms at 
presentation related more specifically to a vasculopathy/ischaemia cause, such as stroke, 
TIA and seizures in SCD (Adams et al 1994, Prengler et al 2002), were also not 
significantly associated with higher BP values (p=0.7, p=0.6 and p=0.7 for SP, DP and 
MAP respectively, logistic regression).
There were no significant differences in mean blood pressure values among the different 
neurological symptoms at presentation (p=0.9, p=0.7 and p=0.9 for SP, DP and MAP 
respectively, one-way ANOVA). Post-hoc tests were not performed because of the 
small number of patients for some symptoms.
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Recurrent neurological symptoms (presence or not of symptoms) were not significantly 
associated with higher blood pressure values (p=0.3, p=0.9 and p=0.9 for SP, DP and 
MAP respectively, logistic regression). Moreover, recurrent neurological symptoms 
more associated with vasculopathy/ischaemia (stroke, TIA, RIND and seizures) were 
also not significantly associated with higher blood pressure (p=0.4, p=0.8, p=0.6 for SP, 
DP and MAP respectively, logistic regression). Similarly, there were no significant 
differences between mean blood pressure values among the different recurrent 
neurological symptoms (p=0.7, p=0.3, p=0.5 for SP, DP and MAP respectively, one­
way ANOVA). Post-hoc tests were also not performed because the small number of 
patients for some symptoms.
Post-hoc analysis of the blood pressure values was done in order to examine if there 
were differences in BP depending on the age of the patients with SCD and neurological 
symptoms. There were no significant differences between the mean SP, DP and MAP 
among the age groups (p=0.3, p=0.5 and 0.4 for SP, DP and MAP respectively, Tukey’s 
test).
However, sickle cell patients studied between 6 and 12 years had higher percentiles for 
mean systolic and/or diastolic blood pressures (75-90 percentile) for some neurological 
symptoms at presentation (coma and stroke) and recurrent symptoms (seizures, 
posterior TIA) compared to other age groups (tables 4.1-4.4). Similarly, the percentile 
range was higher for this age group (up to 90th or >95th percentiles) for systolic pressure 
in some neurological symptoms at presentation (coma, stroke, posterior TIA and 
headaches) and in some recurrent symptoms (such as coma, anterior TIA and 
headaches). There were also similar very high percentile range (up to 90th or >95th 
percentiles) diastolic pressures in patients with some neurological symptoms (such as 
anterior and posterior TIA, seizures, headaches and learning difficulty), and in patients 
with some recurrent symptoms (such as seizures and headaches).
4.4.3. Haematological Parameters
The available haematological data of the patients (closest to the date of the 
investigations) was collected from clinical records. The blood tests were done with a 
mean of 5 months (range 0-2.9 years [between 2.9 years before and 1.6 years after])
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from the date of the magnetic resonance and transcranial Doppler ultrasound studies. 
The haematological data analysed were haemoglobin, haemoglobin S%, white cell 
count and platelets.
Other haematological data were also collected from clinical records such as neutrophils, 
lymphocytes, reticulocytes, foetal haemoglobin, ferritin, bilirubin, calcium and 
magnesium; however, the numbers of these data were too small for analysis, therefore 
these haematological and biochemical parameters were excluded from this study.
4.4.3.1. Haemoglobin
Haemoglobin (Hb) level: Haemoglobin level data were collected from 65 patients. 
Mean Hb level was 8.9 g/dL, with a range from 5.7 to 12.9 g/dL. Table 4.5 shows the 
Hb levels by age and their normal values (Nelson et al 1996). As shown in the table, the 
mean Hb values for sickle cell patients were all below the normal values for age.
Patients
Age
Hb (g/dL) 
Mean
Hb (g/dL) 
Range
Norm al Values 
(g/dL)
6-18 months 
(n=3)
8.7 8 .2 -9 .6 9- 14
2-5 years 
(n 1)
6.9 6.9 9- 14
6-12 years 
(n=28)
8.9 5 .7 -1 2 .9 11.5-15.5
13-17 years 
(n=20)
8.9 6 .6 -1 1 Male: 13-16 
Female: 12-16
18-28 years 
(n=13)
8.9 6.1 -  10.7 Male: 13.5-17.5 
Female: 12-16
Table 4.5. Haemoglobin level in sickle cell patients in relation to 
age groups.
In relation to haemoglobin levels, there was a trend for an association between 
haemoglobin levels and central nervous system events at presentation (p=0.1, one-way 
ANOVA; figure 4.16). As shown in table 4.6, patients without symptoms had the lower 
mean Hb levels (Hb 7.7.g/d/L), whereas the sickle cell patients with seizures, stroke and
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coma had the highest mean Hb levels (Hb 9.2.-9.1 g/dL); 13 patients with stroke and 2 
patients who presented with coma were on chronic blood transfusion, but none of the 7 
patients with seizures (only 1 of 7 seizure patients received transfusion acutely).
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Figure 4.16. Haemoglobin level in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack.
CNS Events 
(n = Patients)
Hb (g/dL) Mean Hb (g/dL) 
Range
No Symptoms (n=2) 7.7 7 .6 -7 .8
Learning Difficulty (n=3) 8.2 6 .9-10.7
Headaches (n=14) 8.6 6.7- 11.3
Seizures (n=7) 9.2 8 .2 -1 1 .6
Posterior TIA (n=14) 8.2 5.7-11
Anterior TIA (n=9) 8.7 6.1 -  10.3
Stroke (n=13) 9.7 8 .3 -1 1 .3
Coma (n=2) 9.5 9 .2 -9 .8
Table 4.6. Haemoglobin level in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack.
There was no association between the mean levels of haemoglobin and recurrent 
neurological symptoms (p=0.9, one-way ANOVA, figure 4.17 and table 4.7). Patients 
with recurrent posterior territory TIAs had the lowest mean Hb values (Hb 7.7 g.dL) 
and the patients with stroke had the highest (Hb 9.5 g/dL); again the majority were on 
chronic transfusion programmes.
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Figure 4.17. Haemoglobin level (g/dL) in relation to recurrent 
neurological symptoms. TIA= transient ischaemic attack; RIND= 
reversible ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Recurrent Symptom 
(n =Patients)
Hb (g/dL) 
Mean
Hb (g/dL) 
Range
No Symptoms (n=10) 8.8 5 .7 -1 0 .3
Learning Difficulty (n=6) 8.8 6 .9 -1 1 .3
Headaches (n=27) 8.7 6 .6 -1 1 .3
Seizures (n=8) 9.3 8.1 -  11.6
Posterior TIA (n=3) 7.7 6 .6 -9
Anterior TIA (n=6) 8.9 6.1 -  10.9
RIND (n=l) 9.3 9.3
Stroke (n=2) 9.5 8 .4 -1 0 .7
Coma (PLKE) (n=l) 9.8 9.8
Table 4.7. Haemoglobin level (g/dL) in relation to recurrent 
neurological symptoms. TIA= transient ischaemic attack; RIND= 
reversible ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Abnormal TCD was significantly associated with higher levels of Hb (p=0.019, logistic 
regression; figure 4.18). There was a trend for an association between abnormal MRI 
(presence of cerebral infarction) and higher Hb levels (p=0.1, logistic regression; figure 
4.19). There was no significant association between Hb level and abnormal MRA
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(p=0.9). Hb levels were higher in those with abnormal perfusion MRI, although this was 
not statistically significant (p=0.2, logistic regression; figure 4.20). Table 4.8 shows the 
mean and range of Hb level for each investigation.
Investigations
(n=pats)
N orm al Investigation  
M ean Hb (g/dL) 
(range)
A bnorm al Investigation  
M ean H b (g/dL) 
(range)
P value
M R I* 8.6 9.1 p=0.1
(n=64) (5.7-11.6) (6.1 -  11.3)
M R A 8.7 8.9 p=0.9
(n=63) (5 .7 -11 .6 ) (6.1 - 11.3)
TCD ** 8.7 8.9 p=0.019
(n=61) (6 .6 -11 .6 ) (5 .7 -1 1 .3 )
Perfusion M R I 8.5 9 p=0.2
(n=64) (5 .7 -11 .3 ) (6.1 -  11.6)
Table 4.8. Haemoglobin levels in relation to whether MR and TCD 
studies are normal or abnormal. *p=0.1; ** p=<0.05.
TCD
Figure 4.18. TCD (normal or abnormal) and haemoglobin level 
(p=0.019)
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Figure 4.19. MRI (abnormal^ presence of cerebral infarction) and 
haemoglobin level (p=0.1).
MRI Perfusion
Figure 4.20. Perfusion MRI (normal or abnormal perfusion) and 
haemoglobin level (p=0.2).
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4.43.2. Haemoglobin S
Haemoglobin S% (HbS%): The available haemoglobin S% level data were collected 
from 40 patients. Median HbS% level was 58%, with a range from 6 to 91%.
The relationships between the mean and range of HbS% and each of the central nervous 
system events at onset and recurrent neurological symptoms are shown in tables 4.9 and 
4.10. There was a significant difference between the means of the patients’ levels of 
HbS% and their CNS symptoms at onset (p=0.002, one-way ANOVA; figure 4.21); 
patients with anterior TIA, stroke and coma had lower mean HbS% values than the 
patients with other symptoms (patients on blood transfusion). However there was no 
significance association between the means of the patients’ HbS% and their recurrent 
neurological symptoms (p=0.2, one-way ANOVA, figure 4.22), although patients with 
the same symptoms described above also had lower HbS% values. Post-hoc analysis 
was not performed because the small numbers of patients for each symptom (at onset or 
recurrence).
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Figure 4.21. Haemoglobin S% levels in relation to central nervous 
system events at presentation. TIA= transient ischaemic attack.
CNS Events 
(n = Patients)
HbS%
M ean
HbS%
Range
No Sym ptom s (n = l) 62% 62%
Learning D ifficulty (n=2) 80% 72-89%
H eadaches (n=8) 75% 56-88%
Seizures(n=5) 68% 51-87%
Posterior TIA(n=9) 68% 15-91%
A nterior TIA (n=4) 42% 6-76%
Stroke (n=9) 32% 8-50%
Coma (n = l) 53% 53%
Table 4.9. Haemoglobin S % levels in relation to central nervous 
system events at presentation. TIA= transient ischaemic attack.
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Figure 4.22. Haemoglobin S% levels in relation to recurrent 
neurological symptoms. TIA= transient ischaemic attack; RIND= 
reversible ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Recurrent Symptom 
(n = Patients)
Hb S % 
Mean
Hb S% 
Range
No Symptoms (n=5) 45% 6 -  87%
Learning Difficulty (n=5) 57% 25 -  89%
Headaches (n=16) 66% 15-88%
Seizures (n=5) 61% 29 -76%
Posterior TIA (n=2) 88% 85-91%
Anterior TIA (n=4) 40% 8 -  76%
RIND (n=l) 33% 33%
Stroke (n=l) 36% 36%
Table 4.10. Haemoglobin S% levels in relation to recurrent 
neurological symptoms. TIA= transient ischaemic attack; RIND= 
reversible ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Decreased levels of HbS% were significantly associated with abnormal MRA (p=0.001, 
logistic regression; figure 4.23) and abnormal perfusion MRI (p=0.002; figure 4.24).
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There was a trend for an association between decreased HbS% and abnormal TCD 
(p=0.06; figure 4.25). There was no association with the presence of cerebral infarction 
on MRI (p=0.8). Table 4.11 shows the mean and range of HbS% in relation to each 
investigation.
Investigations
(n=pats)
Normal
HbS%
Mean
(Range)
Abnormal
HbS%
Mean
(Range)
P value
MRI (n=39) 60% 33% p=0.8
(6-91%) (29 -36%)
MRA (n=39) 75% 44% p=0.001**
(37 -88%) (6-91%)
TCD (n=39) 71% 53% p=0.06*
(50-89%) (6-91%)
Perfusion MRI (n=39) 73% 45% p=0.002**
(6-91%) (8-76%)
Table 4.11. HbS% levels in relation to whether MR and TCD
investigations are normal or abnormal in sickle cell patients. * Trend 
for an association; ** p<0.05.
M- 16 21
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MRA
Figure 4.23. Relationship between abnormal MRA and HbS% values
(p=0.001).
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Figure 4.24. Relationship between abnormal Perfusion MRI and 
HbS% values (p=0.06).
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Figure 4.25. Relationship between abnormal TCD and HbS% values 
(p=0.002).
4.4,3.3. White Cell Count
White Cell Count (WCC): White cell count data were collected from 61 patients.
Median WCC was 12.5 x 109/L cells, with a range from 2.3 to 51.50 x 109/L cells.
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Table 4.12 shows the WCC by age compared with the normal values (Nelson et al 
1996). There was no significant difference in the means of WCC by age group (p=0.98, 
one-way ANOVA)
Patients
Age
WCC x 109/L 
Mean
WCC x 109/L 
Range
Normal Values 
WCC x 109/L 
(not SCD)
6-18 months
(n=2)
14 9.6-18.5 6 -1 7 .5
2-5 years 
(n=l)
13.5 13.5 1-3 y: 6 -17.5 
4-7y: 5.5-15.5
6-12 years 
(n=27)
12.9 2 .3 -5 1 .5 4-7y: 5.5-15.5 
8-13y: 4.5-13.5
13-17 years
(n=18)
12.1 3 .7 -2 5 .3 14-28y: 4.5-11
18-28 years
(n=13)
11.8 7 .2 -1 5 .5 14-28y: 4.5-11
Table 4.12. White cell count in relation to age groups in sickle cell 
patients.
In relation to CNS events at presentation, the WCC mean of each symptom is shown in 
table 4.13. There was a significant difference between CNS symptoms at onset and 
WCC (p=0.009, ANOVA). Post-hoc analysis showed that patients with coma had 
significantly higher WCC count in relation to those with learning difficulty (p=0.03); 
headaches (p=0.002); seizures (p=0.01); posterior territory TIA (p=0.004); anterior 
territory TIA (p=0.003) and stroke (p=0.001; figure 4.26).
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Figure 4.26. White cell count in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack.
CNS Events 
(n =Patients)
WCC x 109/L 
Mean
WCC x 109/L 
Range
No Symptoms (n=2) 12.5 12.5- 12.5
Learning Difficulty (n=3) 12.6 12- 13.5
Headaches (n=14) 11.8 2 .3 -2 5 .3
Seizures (n=6) 12.8 7 .2 -1 8 .5
Posterior TIA (n=12) 12.5 6 .7 -2 1 .4
Anterior TIA (n=8) 11.2 7.1 -  16.6
Stroke (n=13) 10.4 3.7- 16.5
Coma (n=2) 30.5* 9.4 -51.5
Table 4.13. White cell count in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack. *p=0.009.
The means of the WCC in relation to each recurrent neurological symptom are shown in 
table 4.14. There was a significant difference between recurrent neurological symptoms 
and WCC (p<0.0001; ANOVA. The patient who had recurrent coma had significantly 
higher WCC than those patients with other recurrent symptoms. Post-hoc analysis was 
not performed because of the small numbers (figure 4.27).
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Figure 4.27. White Cell count in relation to recurrent neurological 
symptoms. TIA= transient ischaemic attack; RIND= reversible 
ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Recurrent Symptom WCC x 109/L WCC x 109/L
(n =Patients) Mean Range
No Symptoms (n=8) 11.9 6.9-18.5
Learning Difficulty (n=6) 11.9 5 .9 -1 5 .4
Headaches (n=25) 11.3 2 .3 -2 5 .3
Seizures (n=8) 12.1 6 .7 -1 6 .5
Posterior TIA (n=3) 13.7 8 .4 -2 1 .4
Anterior TIA (n=6) 10.9 6 .3 -1 6 .6
RIND (n=l) 11.7 11.7
Stroke (n=2) 13.1 11.7-14.4
Coma (PLKE) (n=l) 51.5* 51.5
Table 4.14. White Cell count in relation to recurrent neurological 
symptoms. TIA= transient ischaemic attack; RIND= reversible 
ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy. *p<0.0001
There were no significant associations between WCC and MRI (p=0.7, logistic 
regression); MRA (p=0.4); TCD (p=0.4); and perfusion MRI (p=0.8). Table 4.15
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shows the means of WCC and reference range in relation to normal or abnormal 
investigations in the sickle cell patients.
Investigations
(n=pats)
Normal 
Investigation 
WCC x 109/L 
Mean 
(Range)
Abnormal 
Investigation 
WCC x 109/L 
Mean 
(Range)
P value
MRI 12 12.8 rs ii p
(n=60) (2.3 -25.3) (3 .7 -51 .5 )
MRA 13.1 11.6 p=0.4
(n=59) (2 .3 -51 .5 ) (3 .7 -18 .5 )
TCD 11.3 12.9 n ii o 4^
(n=59) (2.3- 18.5) (3 .7 -51 .5 )
Perfusion MRI 12.1 12.6 II p 00
(n=60) (2 .3 -25 .3 ) (3 .7 -51 .5 )
Table 4.15. White cell count in relation to whether MR and TCD 
studies are normal or abnormal.
4.4.3.4. Platelets
Platelets: Platelet count data were collected from 60 patients. Median platelet count was 
372 x 109/L cells, with a range from 54 to 734 x 109/L cells (normal 150-400 x 109/L 
cells).
The mean and range for platelets in relation to the patients’ CNS events at presentation 
and recurrent neurological symptoms are shown in tables 4.16 and 4.17. There were no 
significant differences between the means for platelet count of each group of CNS 
events (p=0.9, one-way ANOVA; figure 4.28.), or between platelet count and type of 
recurrent neurological symptoms (p=0.7, ANOVA; figure 4.29).
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Figure 4.28. Platelet count in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack.
CNS Events 
(n =Patients)
Platelets x 109/L 
Mean
Platelets x 109/L 
Range
No Symptoms (n=2) 460 337 - 583
Learning Difficulty (n=3) 452 353 - 566
Headaches (n=14) 377 186-542
Seizures (n=6) 313 192 - 532
Posterior TIA (n = ll) 421 157-669
Anterior TIA (n=8) 368 155 - 594
Stroke (n=13) 341 54-734
Coma (n=2) 310 254 - 366
Table 4.16. Platelet count in relation to central nervous system 
events at presentation. TIA= transient ischaemic attack.
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Figure 4.29. Platelet count in relation to recurrent neurological 
symptoms. TIA= transient ischaemic attack; RESfD= reversible 
ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
Recurrent Symptom 
(n = Patients)
Platelets x 109/L 
Mean
Platelets x 109/L 
Range
No Symptoms(n=8) 358 155 -734
Learning Difficulty(n=6) 406 195 -583
Headaches (n=24) 391 54 - 636
Seizures (n=8) 335 192 - 532
Posterior TIA (n=3) 428 292 - 669
Anterior TIA (n=6) 337 140 - 594
RIND (n=l) 484 484
Stroke (n=2) 334 306 - 362
Coma (PLKE) (n=l) 254 254
Table 4.17. Platelet count in relation to recurrent neurological 
symptoms. TIA= transient ischaemic attack; RIND= reversible 
ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy.
There were no significant associations between platelet count and the presence 
of cerebral infarction on MRI (p=0.4; logistic regression); abnormal MRA 
(p=0.6); abnormal TCD (p=0.2); and abnormal perfusion MRI (p=0.8; table 
4.18).
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Investigations
(n=patients)
Normal 
Investigation 
Platelet x 109/L 
Mean 
(Range)
Abnormal 
Investigation 
Platelet x 109/L 
Mean 
(Range)
P Value
MRI (n=59) 379
(155-669)
371 
(54 -  734)
p=0.4
MRA (n=58) 365
(157-593)
386 
(54 -  734)
p=0.6
TCD (n=58) 392
(157-669)
349 
(54 -  734)
p=0.2
Perfusion MRI 
(n=59)
379
(155-669)
371 
(54 -  734)
00ollCu
Table 4.18. Platelet count in relation to whether MR and TCD studies 
are normal or abmomal.
4.4.4. Awake Oxygen Saturation
Awake-oxygen saturation (Sp02) was continuously recorded with a pulse oximeter for 
three minutes (see Methods, chapter 3) in 57 of 70 patients with sickle cell disease, just 
before or after the MR studies, and in 14 controls.
In sickle cell patients, the mean awake- Sp02 was 95.3 %, range 85 to 99.9%. As 
described in chapter 2, the cut-off for hypoxaemia was Sp02 < 92%; 7 of 50 patients 
had awake-Sp02 less than 92% (3 patients had Sp02 between 90 to 92% and 4 had 
awake-Sp02 between 85-90%). None of the patients had awake Sp02 less than 80%.
For the controls without sickle cell disease, the mean Sp02 was 97.8%, with a range 
from 95.4% to 99%. Sickle cell patients had significantly lower awake-Sp02 values 
than controls (p=0.004, one way- ANOVA; figure 4.30).
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Figure 4.30. Comparison of mean awake-Sp02 values between 
controls and sickle cell patients (p=0.004, one way-ANOVA).
4.4.4.1. Awake Oxygen Saturation in Relation to Sickle Cell Patients and their 
Central Nervous System Events at Presentation
In this series of patients with SCD, awake oxygen saturations were not significantly 
associated with the presence or absence of central nervous system (CNS) events at 
presentation (p=0.7, logistic regression) or with the presence or absence of neurological 
symptoms such as stroke, transient ischaemic attack (TIA) and seizures (p=0.2, logistic 
regression).
The mean and range of awake-Sp02 values among the different neurological symptoms 
at presentation were the following (figure 4.31): asymptomatic patients 94.5% (90.9 -  
98.1%); learning difficulty 94.3% (90.5-98%); headaches 94.9% (88.1- 97.8%); seizures 
96.9% (92.8- 98.7%); posterior territory TIA 94.8% (88.9- 97.8%); anterior territory 
TIA 96.5% (92.6-97.9%); stroke 95.7% (85-99.9%); and coma 94.9% (89.9-98.3%). 
There were no significant differences when comparing the means of awake-Sp02 values 
among groups (p=0.9, one way-ANOVA) and post-hoc analysis (p=0.9 Tukey’s test). In 
addition, 1 of the 2 sickle cell patients with no symptoms, 1/2 with learning difficulty,
Sickle Cell Patients
Sickle Cell Patients and Controls
111
1/14 with headaches, 1/13 with posterior territory TIA (1/13), 2/13 with stroke and 1/3 
with coma had awake-SpC>2 values less than 92%.
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Neurological Symptoms at Presentation in Sickle Cell Patients
Figure 4.31. Comparison of awake-SpC>2 values and central nervous 
system events at presentation in sickle cell patients.
4.4.4.2. Awake Oxygen Saturation in Relation to Recurrent Neurological Symptoms 
in Sickle Cell Patients
There was a trend for a significant association between mean awake-SpC>2 values and 
the presence or absence of recurrent neurological symptoms in this series of sickle cell 
patients (p=0.1, logistic regression; figure 4.32), but there was no significant association 
with the presence or absence of neurological symptoms more associated with a 
vasculopathy/ischaemia cause (stroke, reversible ischaemic neurological deficit [RIND], 
TIAs or seizures, p=0.7, logistic regression).
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Figure 4.32. Comparison of mean awake-Sp02 values between sickle 
cell patients who had recurrent neurological symptoms or remained 
symptom-free (p=0.1).
The mean and range of awake-Sp02 values among the different recurrent neurological 
symptoms were the following (figure 4.33): asymptomatic patients 96.7% (90.9-99.9%); 
learning difficulty 94% (90.5-98%); headaches 95% (88.1-98.4%); seizures 96.4% 
(91.9-98.2%); posterior territory TIA 94.4% (89.9-97.3%); anterior territory TIA 96.6% 
(92.5-97.9%); RIND 96.1 % (96.1%); stroke 88.7% (85-92.5%); and coma (posterior 
leukoencephalopathy [PLKE]) 98.3% (98.3%). The comparison of the means of awake- 
Sp02 values among groups was significant (p=0.04, one way-ANOVA).
Post-hoc analysis of the Sp02 means among groups (excluding RIND and coma as they 
were single cases) showed significant differences, with lower mean awake-Sp02 values 
in the stroke group in relation to asymptomatic patients (p=0.01), headaches (p=0.05), 
seizures (p=0.02), and anterior territory TIA (p= 0.02). There were no significant 
differences in mean awake-Sp02 values among the other groups of recurrent 
neurological symptoms (p=0.8, Tukey’s test). However, in addition to the patient who 
had recurrent stroke (1 out of 2), there were 1/10 patients with no recurrent symptoms, 
1/3 with recurrent learning difficulty, 2/25 with headaches, 1/6 with seizures and 1/4 
with posterior territory TIA who had mean awake-Sp02 values less than 92%.
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Figure 4.33. Comparison of mean awake-Sp02 values among the 
recurrent neurological symptoms in sickle cell patients (p=0.04, one 
way- ANOVA).
4.5. Results II: Neuroimaging and Transcranial Doppler Ultrasound
4.5.1. Magnetic Resonance Imaging
Seventy patients with sickle cell disease underwent structural MRI brain.
4.5.1.1. Magnetic Resonance Imaging and Central Nervous System Events at 
Presentation
Forty-two of the 70 patients with sickle cell disease had normal structural MRI scan. 
Three out of 42 patients with normal MRI did not have neurological symptoms, and 39 
patients had a main CNS event at presentation: 2 had coma, 15 had transient ischaemic 
attacks -TIA- (5 patients had anterior territory TIA and 10 posterior territory TIA), 6 
had seizures, 13 had headaches, and 4 patients had learning difficulties. One patient had 
seizures and generalised cerebral atrophy bilaterally; however, for the purposes of data 
analysis, the MRI was classified as normal in tables 4.19 to 4.25 because there was no
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focal abnormality such as infarction (therefore including this patient, the total number 
of patients with normal MRI is 43 in the tables 4.19 to 4.25).
Twenty-eight of the 70 patients had abnormal structural MRI: 16 had overt infarction 
(manifest clinically as stroke characterised by hemiparesis), 1 had cerebral atrophy (as 
the only MRI abnormality and without infarction) and 11 patients had covert (silent) 
infarction on MRI (defined as an area of increased signal intensity on T2-weighted MRI 
without a history of a neurological event lasting more than 24 hours [Moran et al 1998], 
table 4.19).
Of 16 patients with sickle cell disease and overt infarction, 11 had bilateral and 5 had 
unilateral cerebral infarction. The main neurological symptom at presentation was 
stroke (table 4.19); 2 of the 15 patients had stroke and coma.
Of the 11 patients whose scans showed covert (silent) infarcts, 8 were bilateral; the 
main neurological symptoms in this group were TIAs in 6 (4 patients had anterior 
territory TIA and 2 had posterior territory TIA); 1 patient had headaches; and 1 patient 
had no neurological symptoms but he had history of severe snoring and upper airway 
obstruction (OSA - obstructive sleep apnoea). Three patients had unilateral covert 
infarcts; 2 of these patients presented with anterior territory TIA and one with 
headaches.
Cerebral atrophy was diagnosed in 14 patients at the time of their MRI study. Eleven of 
14 patients had stroke (8 had bilateral infarcts and 3 patients had unilateral infarcts); 1 
patient had stroke and coma (bilateral infarcts); 1 patient had anterior territory TIA and 
bilateral covert infarcts. One patient had seizures and generalised cerebral atrophy 
bilaterally; however, the MRI was classified as normal in the tables 4.19 to 4.25 because 
there was no focal abnormality such as infarction (as mentioned above).
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Patients
(n)
Normal
MRI
Overt Infarct 
Unilateral
Overt Infarct 
Bilateral
Covert Infarct 
Unilateral
Covert Infarct 
Bilateral Total
No
Symptoms
2 1 3
Learning
Difficulty
4 4
Headaches 13 1 1 15
Seizures 7 \u 1] 7
Post. TIA 10 4 14
Ant. TIA 5 2 2 [a 1] 9
Stroke 5 3i 9 [a 8] 14
Coma 2 2 [a 1] 4
Total 43 5 11 3 8 70
Table 4.19. Relationship between main neurological symptoms and 
T2-weighted MRI findings in 70 patients with sickle cell disease.
[Q number of patients] = Indicates the number of patients with cerebral atrophy 
(e.g. 3 out of 5 patients with unilateral overt infarct had cerebral atrophy); for the 
purposes of data analysis, the MRI of a patient with seizures and generalised atrophy 
was classified as normal because there was no focal abnormality such as infarction 
(e.g. 1 out of 7 patients).
The grade of severity of the central nervous system events at presentation in this series 
of sickle cell patients was significantly associated with the presence or absence of 
infarcts (p<0.0001, Mann-Whitney test), with unilateral infarcts (p=0.03, Fisher’s test) 
and bilateral infarcts (p<0.0001, Fisher’s exact test).
Covert (silent) infarction was strongly associated with bilateral location in this series 
(pO.OOOl and p=0.03 respectively, Fisher’s exact test). Covert infarction was 
significantly associated with TIA and anterior territory TIA as CNS events at 
presentation (p=0.004 and p=0.03, respectively, Fisher’s exact test), but there were no 
associations with posterior territory TIA (p=0.2), seizures (p=0.6), headaches (p=l) or 
learning difficulty (p=l, Fisher’s exact test).
4.5.1.1.1. Central Nervous System Events at Presentation and Infarct Size
Infarct size (overt and covert) was divided into three categories: 1- small (diameter < 
lcm), 2- medium (l-5cm), 3-large (>5cm) (Watkins et al 1998). Thirteen patients had 
small infarcts; 8 patients had medium size infarcts; and 6 patients had large infarcts. 
The severity of central nervous system events at presentation was significantly 
associated with increasing infarct size (p<0.0001, Spearman’s test, correlation
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coefficient [CC] =0.6). Figure 4.34 and table 4.20 show the relationship between CNS
events at presentation and infarct size.
□
1
■ Infarct Size
> 5 cm -large
1 -5 cm -m oaera te
< 1 cm-small
n  no infarct
None Headaches Posterior TIA Stroke
Learning Difficulty S e iz u re s  A nterior TIA Coma
Central Nervous System Events at Presentation
Figure 4.34. Infarct size and central nervous system events at 
presentation in 70 patients with SCD. TIA: transient ischaemic attack.
CNS Normal Infarct Infarct Infarct Total
Events MRI < 1 cm- 1-5 cm- > 5 cm-
(n = Patients) small moderate Large
No Symptoms 2 1 3
Learning Difficulty 4 4
Headaches 13 2 15
Seizures 7 7
Post TIA 10 3 1 14
Ant TIA 5 3 1 9
Stroke 3 6 5 14
Coma 2 1 1 4
Total 43 13 8 6 70
Table 4.20. Infarct size and central nervous system events at 
presentation in 70 patients with SCD. TIA: transient ischaemic attack. 
For the purposes of data analysis, the MRI of a patient with seizures and generalised 
atrophy was classified as normal because there was no focal abnormality such as 
infarction.
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4.5.1.1.2. Central Nervous System Events at Presentation and Infarct Number
Infarct number was divided into four categories (1, 2, 3 and 4 or more [multiple] 
infarcts). Four patients had one infarct. Five patients had 2 infarcts, 2 with unilateral and 
3 with bilateral infarcts. One patient had three infarcts bilaterally; and 17 patients had 
multiple infarcts, 2 unilaterally, and 15 bilaterally. The severity of central nervous 
system events at presentation was significantly associated with increasing infarct 
number (p<0.0001, Spearman’s test, correlation coefficient [CC]=0.5, figure 4.35 and 
table 4.21). In addition, there was a significant association between increased infarct 
number and decreased infarct size (p<0.0001, Spearman’s test, correlation coefficient: 
0.9, table 4.22).
Infarct Number
multiple
None Headaches Posterior TIA Stroke
Learning Difficulty S e izu re s  A nterior TIA Coma
Central Nervous System Events at Presentation
Figure 4.35. Infarct number and central nervous system events at 
presentation in 70 patients with SCD. TIA: transient ischaemic attack.
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CNS 
Events 
(n = 
Patients)
Normal
MRI
1
Infarct
2
Infarcts
3
Infarcts
Multiple
Infarcts
Total
No
Symptoms
2 1 3
Learning
Difficulty
4 4
Headaches 13 1 1 15
Seizures 7 7
Post TIA 10 4 14
Ant TIA 5 1 3 9
Stroke 3 3 1 7 14
Coma 2 1 1 4
Total 43 4 5 1 17 70
Table 4.21. Infarct number and central nervous system events at 
presentation in 70 patients with SCD. TIA: transient ischaemic attack. 
For the purposes of data analysis, the MRI of a patient with seizures and generalised 
atrophy was classified as normal because there was no focal abnormality such as 
infarction.
Infarct
Size
Normal
MRI
1
Infarct
2
Infarcts
3
Infarcts
Multiple
Infarcts
Total
No
Infarct
43 43
Small
Infarct
1 1 11 13
Medium
Infarct
1 2 1 4 8
Large
Infarct
2 2 2 6
Total 43 4 5 1 17 70
Table 4.22. Relation between infarct number and infarct size in 70 
patients with SCD. TIA: transient ischaemic attack. Infarct size: small 
=<lcm; medium=l-5cm; and large=>5cm of diameter.
For the purposes of data analysis, the MRI of a patient with seizures and generalised 
atrophy was classified as normal because there was no focal abnormality such as 
infarction.
4.5.1.2. Magnetic Resonance Imaging and Recurrent Neurological Symptoms
In relation to recurrent neurological symptoms, 7 of 42 patients with normal MRI (i.e. 
excluding the single patient with cerebral atrophy [see tables 4.19 to 4.25]) were 
asymptomatic; however, 35 patients with a normal MRI study had recurrent
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neurological symptoms such as posterior territory TIA (n=3), seizures (n=6), headaches 
(n=22), and learning difficulties (n=5).
Twenty-eight of the 70 patients with recurrent neurological symptoms had abnormal 
structural MRX Sixteen patients had had overt infarction, 1 had cerebral atrophy without 
infarction (included as normal in the table [a patient with seizures]) and 11 had covert 
(silent) infarction on MRI, table 4.23)
Of 16 patients with sickle cell disease and overt infarction, 11 had bilateral and 5 had 
unilateral cerebral infarction. The recurrent neurological symptoms of this group were 
coma (with posterior leukoencephalopathy, n=l), stroke (n=2), RIND (n=l), anterior 
territory TIA (n=3), seizures (n=2), headaches (n=3) and learning difficulty (n=l); three 
patients had no symptoms.
Eleven of the 70 patients had covert (silent) infarct. Eight patients had bilateral and 3 
patients had unilateral covert infarcts; the main neurological symptoms in this group 
were anterior territory TIA (n=3), posterior territory TIA (n=l), headaches (n=4) and 
learning difficulty (n=l); two patients had no symptoms.
Cerebral atrophy on MRI was found in 12 patients with recurrent symptoms: 1 of the 
two patients with recurrent stroke (bilateral infarcts), 1 patient with stroke and coma 
(bilateral infarcts); 1 with reversible ischaemic neurological deficit - RIND - (bilateral 
infarcts), 3 patients with anterior territory TIA (1 with bilateral and 1 with unilateral 
overt infarcts; and 1 patient with covert infarcts), 3 patients with seizures (1 patient 
with cerebral atrophy without infarct [included in tables 4.19 to 4.25 as normal], 1 with 
unilateral and 1 with bilateral overt infarcts) and 1 with learning difficulty (bilateral 
overt infarcts). Two patients with bilateral overt infarcts and atrophy did not have 
recurrent symptoms (table 4.23). There was a trend for cerebral atrophy on MRI to be 
commoner in those with more severe recurrent neurological symptoms (p=0.1, Mann- 
Whitney test), with atrophy more likely in those with recurrent anterior territory TIA, 
RIND and stroke.
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Patients
(*)
Normal
MRI
Overt Infarct 
Unilateral
Overt Infarct 
Bilateral
Covert Infarct 
Unilateral
Covert Infarct 
Bilateral Total
No
Symptoms
7 3 [a 2] 1 1
12
Learning
Difficulty
5 l [ o l ] 1
7
Headaches 22 2 [u 2] l [ n l ] 1 3 29
Seizures 6 [n 1] l [ n l ] 1 [°1] 8
Post. TIA 3 1 4
Ant. TIA 1[° 1] 2 [a 1] 1 2 [a 1] 6
RIND l [ a l ] 1
Stroke 1 1 [nl] 2
Coma
(PLKE)
1 1
Total 43 5 11 3 8 70
Table 4.23. Relationship between recurrent neurological symptoms 
and structural MRI findings in 70 patients with sickle cell disease.
[B number of patients] = Indicates the number of patients with cerebral atrophy
(e.g. 2 out of 2 patients with unilateral overt infarct had cerebral atrophy); for the 
purposes of data analysis, the MRI of a patient with seizures and generalised atrophy 
was classified as normal because there was no focal abnormality such as infarction 
(e.g. 1 out of 6 patients).
The grade of severity of the recurrent neurological symptoms in this series of 
sickle cell patients was significantly associated with the presence or absence of infarcts 
(p=0.04, Mann-Whitney test). There was a trend for association between recurrent 
symptoms and bilateral infarcts, but no association for unilateral infarcts (p=0.1 and 
p=0.3, Fisher’s exact test). There were trends for association between covert infarct and 
recurrent TIA and anterior territory TIA (p=0.06 and p=0.07, respectively, Fisher’s 
exact test), but there were no associations with recurrent posterior territory TIA (p=0.5), 
seizures (p=0.3); headaches (p=l) or learning difficulty (p=l, Fisher’s exact test).
4.5.1.2.1. Recurrent Neurological Symptoms and Infarct Size
Thirteen patients with recurrent neurological symptoms had small infarcts, 8 patients 
had medium size infarcts, and 6 patients had large infarcts. There was a trend for an 
association between the severity of the recurrent neurological symptoms and increasing 
infarct size (p=0.06, Spearman’s test, correlation coefficient [CC] =0.2). Figure 4.36 
and table 4.24 show the relationship between recurrent neurological symptoms and 
infarct size.
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Figure 4.36. Infarct size and recurrent neurological symptoms in 70 
patients with SCD. TIA: transient ischaemic attack; PLKE: posterior 
leukoencephalopathy; RIND: reversible ischaemic neurological
deficit.
Recurrent 
Symptom 
(n = Patients)
Normal
MRI
Infarct 
< 1cm- 
small
Infarct 
1-5 cm- 
moderate
Infarct
> 5 cm- 
large
Total
No Symptoms 7 2 3 12
Learning Difficulty 5 1 1 7
Headaches 22 4 2 1 29
Seizures 6 1 1 8
Post TIA 3 1 4
Ant TIA 4 1 1 6
RIND 1 1
Stroke 2 2
Coma (PLKE) 1 1
Total 43 13 8 6 70
Table 4.24. Relationship between infarct size and recurrent 
neurological symptoms. TIA: transient ischaemic attack; PLKE: 
posterior leukoencephalopathy; RIND: reversible ischaemic
neurological deficit.
For the purposes of data analysis, the MRI of a patient with seizures and generalised 
atrophy was classified as normal because there was no focal abnormality such as 
infarction.
■
n
Infarct Size
* 5 cm -large 
1 1 -5 cm -m oderate 
1cm-small 
□  no infarct
1 2 2
4.5.1.2.2. Recurrent Neurological Symptoms and Infarct Number 
Four patients with recurrent neurological symptoms had one infarct; 5 patients had 2 
infarcts; 1 patient had three infarcts; and 17 patients had multiple infarcts. There was an 
inverse trend for an association between the severity of recurrent neurological 
symptoms and decreased infarct number (p=0.07, Spearman’s test, correlation 
coefficient [CC] = 0.2, figure 4.37 and table 4.25).
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Figure 4.37. Infarct number and recurrent neurological symptoms in 
70 patients with SCD. TIA: transient ischaemic attack; PLKE: 
posterior leukoencephalopathy; RIND: reversible ischaemic
neurological deficit.
infarct Number
[ l l f l  multiple
Recurrent 
Symptom 
(n = Patients)
Normal
MRI
1
Infarct
2
Infarct
s
3
Infarcts
Multiple
Infarcts
Total
No Symptoms 7 1 4 12
Learning Difficulty 5 2 7
Headaches 22 2 2 3 29
Seizures 6 1 1 8
Post TIA 3 1 4
Ant TIA 2 1 3 6
RIND 1 1
Stroke 1 1 2
Coma(PLKE) 1 1
Total 43 4 5 1 17 70
Table 4.25. Relation between infarct number and recurrent 
neurological symptoms. TIA: transient ischaemic attack; PLKE: posterior 
leukoencephalopathy; RIND: reversible ischaemic neurological deficit. For the 
purposes of data analysis, the MRI of a patient with seizures and generalised atrophy 
was classified as normal because there was no focal abnormality such as infarction.
123
4.5.1.3. Magnetic Resonance Imaging and Blood Pressure Measurements
The presence of cerebral infarction on T2-weighted MRI in this group of sickle cell 
patients (as a whole and not taking into account age differences) was significantly 
associated with lower diastolic blood pressure -  DBP - values (mean 53 mmHg [range 
30-80 mmHg]) and mean arterial blood pressure -  MAP - values (mean 72 mmHg 
[range 58-93 mmHg]) compared with those patients with SCD who did not have infarcts 
on conventional MRI and whose mean DBP was 62 mmHg - range 33-81 mmHg - with 
mean MAP 79 mmHg - range 55-97 mmHg - (p=0.01 and p=0.02, logistic regression, 
figures 4.38 and 4.39). Systolic blood pressure was not significantly associated with the 
presence of cerebral infarction (p=0.96).
n -  a  *
No Yes
C erebral Infarction on MRI (O vert an d  Covert)
Figure 4.38 Relation between diastolic arterial blood pressure and the 
presence or absence of cerebral infarcts on MRI in this series of 
patients with SCD.
124
100
50 J______________________<______________________________ p____________________
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C eretiral Infarction on MRI (O vert an d  Covert)
Figure 4.39. Relation between mean (MAP) arterial blood pressure 
and the presence or absence of cerebral infarcts on MRI in this series 
of patients with SCD.
4.5.1.4. Magnetic Resonance Imaging and Oxygen Saturation
Awake oxygen saturation measured by pulse oximetry (Sp02) was not significantly 
associated with the presence or absence of infarcts on MRI (p=0.8, logistic regression) 
in this group of sickle cell patients analysed as a whole.
4.5.1.5. MRI Patterns in Relation with CNS Events at Presentation
Following the data analysis shown in this section, the predominant MRI pattern for 
each central nervous system event at presentation in this series of patients with SCD can 
be summarised as follows (from asymptomatic to most severe neurological symptom; 
based on infarct size [figure 4.34/ table 4.20]; and infarct number [fig. 4.35/ tab. 4.21]):
- No symptoms: a large proportion of patients had a normal MRI and small 
percentage had small, multiple infarcts;
- Learning difficulty: normal MRI;
- Headaches: mostly normal MRI and a small proportion of patient had small, 
multiple infarcts;
Seizures: normal MRI;
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- Posterior territory TIA: a large proportion of patients had a normal M R I , while 
smaller proportions had small (mainly) or moderate size, multiple infarcts;
- Anterior TIA: 50% of patients had normal MRI and 50% had small (mainly) or 
moderate size, multiple (2 or more) infarcts;
- Stroke: mainly moderate or large, one or multiple infarcts and a smaller 
proportion of patients with single small infarcts;
Coma: One patient with normal MRI, and the rest with small or large, multiple 
infarcts.
4.5.1.6. MRI Patterns in Relation with Recurrent Neurological symptoms
Based on a single MRI study, the MRI pattern of this cross-sectional study for each 
recurrent neurological symptom in this series of patients with SCD can be summarised 
as follows (from asymptomatic to most severe neurological symptom, based on infarct 
size [figure 4.36/ table 4.24]; and infarct number [figure 4.37/ table 4.25]):
- No symptoms: two third of the patients had a normal MRI and one third had
small or moderate, multiple infarcts;
- Learning difficulty: mostly normal MRI and a small proportion of patients had
moderate or large, multiple infarcts;
- Headaches: mostly normal MRI and smaller proportions of patients had mainly
small, moderate, or large, single or multiple infarcts;
Seizures: mainly normal MRI, and smaller proportions of patients had moderate 
or large, single or multiple infarcts;
- Posterior territory TIA: a large proportion of patients had a normal MRI and 
smaller proportion had small, multiple infarcts;
- Anterior TIA: Two third of the patients had small and multiple infarcts, and one
third had moderate or large, multiple infarcts;
- Reversible ischaemic neurological deficit (RIND): small and multiple infarcts; 
Stroke: large, one or multiple infarcts;
Coma (posterior leukoencephalopathy): small and multiple infarcts.
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4.5.2. Diffusion Weighted Imaging (DWI)
In patients with SCD and chronic infarction (n=26), DWI was as expected with high 
diffusion; only one of the 70 patients had an abnormal signal on DWI consisted with 
reduced diffusion. This patient had stroke and had neuroimaging acutely within the first 
week of the CNS event.
4.5.3. Magnetic Resonance Angiography
Sixty-nine out of 70 patients with SCD had a successful MRA, one patient did not 
tolerate this study. Thirty seven patients had a normal and 32 patients had an abnormal 
MRA.
4.5.3,1. MRA Turbulence (Cerebrovascular Disease) and Central Nervous System 
Events at Presentation
Ordinal MRA data were defined by the presence of any grade of flow turbulence seen 
on the scan (coded in increasing grade of severity: 0= no turbulence; 1= mild; 2= 
moderate; 3= severe turbulence; 4= arterial occlusion; and 5= arterial occlusion plus 
collaterals [moyamoya syndrome]).
Thirty-seven of the 69 patients had a normal MRA; their central nervous system events 
at presentation were as follows: learning difficulty (n=4), headaches (n=10), seizures 
(n=6), posterior territory TIA (n=8), anterior territory TIA (n=4), stroke (n=l) and coma 
(n=3); 1 patient had no neurological symptoms.
Of the 32 sickle cell patients with abnormal MRA, 12 patients had mild turbulence on 
MRA (grade 1) and they presented with headaches (n=2), seizures (n=l), posterior 
territory TIA (n=4), anterior territory TIA (n=l), and stroke (n=2). Two patients were 
asymptomatic.
Five of the 32 patients with abnormal MRA had moderate turbulence (grade 2) and 
these patients had headaches (n=2), anterior territory TIA (n=2) and coma (n=l).
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Seven sickle cell patients had severe turbulence on MRA (grade 3) and their CNS 
events were the following: headaches (n=l), posterior territory TIA (n=l), anterior 
territory TIA (n=l) and stroke (n=4).
Three of 32 patients with abnormal MRA had arterial occlusion (grade 4) and all of 
them presented with stroke. Finally 5 patients with vessel occlusion and the presence of 
collaterals (grade 5) had posterior territory TIA (n=l) and stroke (n=4).
The severity of the CNS events at presentation was significantly associated with 
increasing grade of turbulence/occlusion on MRA (p<0.0001, Spearman’s test, 
correlation coefficient [CC]=0.4). Figure 4.40 and table 4.26 show the association of 
CNS events and grades of MRA turbulence in these sickle cell patients.
A Turbulence
Occlusion/Collateral 
Artery Occlusion 
Severe 
Moderate 
Mild 
Normal
None Headaches Posterior TIA Stroke
Learning Difficulty Seizures Anterior TIA Coma
Central Nervous System Events at Presentation
Figure 4.40. Association between central nervous system events at 
presentation and grades of MRA turbulence. TIA: transient ischaemic 
attack.
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CNS
Events
(n -  
Patients)
N orm al
M R A
M ild
Turbulence
G rade 1
M oderate
Turbulence
G rade 2
Severe
T urbulence
G rade 3
A rtery
O cclusion
G rade 4
O cclusion +  
C ollaterals
G rade 5
T otal
N o
S y m p to m s
1 2 3
L e a r n in g
D if f ic u lty
4 4
H e a d a c h e s 10 2 2 1 15
S e iz u r e s 6 1 7
P o st  T IA 8 4 1 1 14
A n t T IA 4 1 2 1 8
S tr o k e 1 2 4 3 4 14
C o m a 3 1 4
T o ta l 37 12 5 7 3 5 69
Table 4.26. Association between central nervous system events at 
presentation and grades of MRA turbulence. TIA: transient ischaemic 
attack.
4.53.2. MRA Turbulence and Recurrent Neurological Symptoms
Recurrent neurological symptoms in patients with normal MRA (n=37) were learning 
difficulty (n=4), headaches (n=18), seizures (n=6), posterior territory TIA (n=2), and 
coma with posterior leukoencephalopathy-PLKE- (n=l); 6 patients had no neurological 
symptoms (see figure 4.41 and table 4.27).
Thirty-two patients had abnormal MRA (figure 4.41 and table 4.27). Of 12 patients 
with mild turbulence on MRA learning difficulty (n=l), symptoms included recurrent 
headaches (n=4), seizures (n=l), and posterior territory TIA (n=2). Four patients were 
asymptomatic.
Of 5 patients with moderate turbulence, 3 had recurrent headaches and 2 had anterior 
territory TIA. Seven sickle cell patients who had severe turbulence on MRA (grade 3) 
continued to have headaches (n=2); anterior territory TIA (n=3), or reversible ischaemic 
neurological deficit (n=l). One patient remained without neurological symptoms.
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Patients with vessel occlusion (n=3) had recurrent seizures (n=l), anterior TIAs (n=l) 
and stroke (n=l). Five patients with vessel occlusion and collaterals had learning 
difficulty (n=2), recurrent headaches (n=2) and stroke (n=l; figure 4.41 and table 4.27).
The severity of the recurrent neurological symptoms in these sickle cell patients was 
associated (but with borderline significance) with increasing grade of turbulence or 
pattern of vessel occlusion on MRA (p=0.056, Spearman’s test, correlation coefficient 
[CC]=:0.2). Figure 4.41 and table 4.27 show the association between the recurrent 
neurological symptoms and grades of MRA turbulence in these sickle cell patients.
MRA Turbulence
□  Occlusion/Collatet'al 
Artery Occlusion 
Severe
|  Moderate 
|  Mild
□  Normal
IMone Headaches Posterior TIA RIMD Coma (PLKE)
Learning Difficulty Seizures Anterior TIA Stroke
Recurrent Neurological Symptoms
Figure 4.41. Association of recurrent neurological symptoms and 
grades of MRA turbulence. TIA: transient ischaemic attack, PLKE: 
posterior leukoencephalopathy
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Recurrent
Symptom
(n
=Patients)
Normal
MRA
Mild
Turbulence
Grade 1
Moderate
Turbulence
Grade 2
Severe
Turbulence
Grade 3
Artery
Occlusion
Grade 4
Occlusion
+
Collateral 
Grade 5
Total
No
Symptoms
6 4 1 11
Learning
Difficulty
4 1 2 7
Headache 18 4 3 2 2 29
Seizures 6 1 1 8
Post TIA 2 2 4
Ant TIA 2 3 1 6
RIND 1 1
Stroke 1 1 2
Coma
(PLKE)
1 1
Total 37 12 5 7 3 5 69
Table 4.27. Association of recurrent neurological symptoms and 
grades of MRA turbulence. TIA: transient ischaemic attack, PLKE: 
posterior leukoencephalopathy
4.5.3.3. MRA Turbulence and Parenchymal Imaging (MRI)
4.5.3.3.1. MRA Turbulence and Unilateral and Bilateral Cerebral Infarcts
Of the sickle cell patients who had cerebral infarction, 2 had a normal MRA study, 8 
had mild turbulence, 3 had moderate and 6 had severe turbulence on MRA, 3 had artery 
occlusion and 5 had occlusion and collaterals (figure 4.42). Severity of the grade of 
turbulence on MRA was significantly associated with the presence of infarcts 
(pO.OOOl), unilateral infarcts (pO.OOOl) and bilateral infarcts (pO.OOOl, Mann- 
Whitney test) on T2- weighted MRI.
131
40
CL 20
■
H i
Cerebral Infarction
H  Yes
I I No
Normal Moderate Artery Occlusion
Mild Severe Occlusion/Collateral
MRA Turbulence
Figure 4.42. Association of cerebral infarction on MRI and grades of 
MRA turbulence.
Unilateral infarcts on MRI in these patients with SCD were associated in a greater 
proportion with artery occlusion plus collaterals; however there were also unilateral 
infarcts with mild and severe turbulence and artery occlusion (figure 4.43).
Unilateral Infarct
A rte ry  O c c lu s io n  
Severe Occlusion/Collateral
MRA Turbulence
Figure 4.43. Association of unilateral cerebral infarction on MRI and 
grades of MRA turbulence.
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Bilateral infarcts were seen mainly in those with artery occlusion and mild, moderate 
and severe turbulence on MRA, in addition there were a few patients with normal MRA 
and bilateral infarcts (figure 4.44).
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Figure 4.44. Association of bilateral cerebral infarction on MRI and 
grades of MRA turbulence.
4.5.3.3.2. MRA Turbulence and Covert (Silent) Infarcts
Covert infarcts on MRI were found in patients with mild (n=6), moderate (n=2) and 
severe turbulence on MRA (n=2), and in one patient with artery occlusion and 
collaterals (figure 4.45). Covert infarction was significantly associated with the grade of 
MRA turbulence (p<0.0001, Mann- Whitney test).
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I H  Yes 
MRA Turbulence
Figure 4.45. Association of bilateral covert infarction on MRI and 
grades of MRA turbulence.
4.5.3.3.3. MRA Turbulence and Infarct Size and Infarct Number
Worsening of MRA turbulence or vessel occlusion was significantly associated with 
increasing infarct size (pO.OOOl, CC: 0.8) and infarct number (pO.OOOl, CC: 0.7, 
Spearman’s correlation) on MRI. Figure 4.46 and table 4.28 show the relationship 
between MRA abnormality and infarct size; and figure 4.47 and table 4.29 show the 
association between MRA grades and infarct number in this series of patients with 
sickle cell disease.
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Figure 4.46. Association of infarct size and grades of MRA 
turbulence.
M RA  
(n = Patients)
Norm al
MRI
Infarct 
< 1cm- 
small
Infarct 
1-5 cm- 
m oderate
Infarct 
> 5 cm- 
large
Total
N orm al M RA 35 2 37
M ild Turbulence 4 5 2 1 12
M oderate Turbulence 2 2 1 5
Severe Turbulence 1 4 2 7
Artery O cclusion 1 2 3
O cclusion+Collaterals 3 2 5
Total 42 13 8 6 69
Table 4.28. Relationship between infarct size and grades of MRA 
turbulence.
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Figure 4.47. Relationship between infarct number and grades of MRA 
turbulence.
M RA  
(n = Patients)
Norm al
MRI
1
Infarct
2
Infarcts
3
Infarcts
M ultiple
Infarcts
Total
Norm al
M RA
35 2 37
M ild
Turbulence
4 2 6 12
M oderate
Turbulence
2 1 2 5
Severe
Turbulence
1 2 1 3 7
Artery
O cclusion
1 1 1 3
O cclusion + 
Collaterals
1 1 3 5
Total 42 4 5 1 17 69
Table 4.29. Relationship between infarct number and grades of MRA 
turbulence.
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4.53,4. MRA Turbulence and Blood Pressure Measurements
Lower mean diastolic blood pressure (mean 54 mmHg [range 30-80 mmHg]) and mean 
arterial blood pressure (mean 73 mmHg [range 55-93 mmHg]) values were significantly 
associated with abnormal MRA in this series of patients with SCD (p=0.047 and 
p=0.055, logistic regression, figures 4.48 and 4.49), compared with those patients who 
had normal MRA (DBP mean 62 mmHg [range 45-81 mmHg]; MAP mean 79 
mmHg[range 65-97 mmHg]), but there was no association for systolic blood pressure 
(p=0.7).
Abnormal MRA in Sickle Cell P a tien ts
Figure 4.48. Relationship between diastolic blood pressure and MRA 
abnormality.
.....
A bnorm al MRA in Sickle Cell P a tien ts
Figures 4.49. Relationship between mean arterial blood pressure 
measurements and MRA abnormality.
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4.5.3.5. MRA Turbulence and Oxygen Saturation
There was no significant association between mean awake-SpC^ and presence or 
absence of abnormal MRA in this group of patients (p= 0.5, logistic regression).
4.5.3.6. MRA Patterns in Relation to CNS Events
Following the data analysis shown in this section, the MRA pattern for each central 
nervous system events at presentation in this series of patients with SCD can be 
summarised as follow (from asymptomatic to most severe neurological symptom, figure 
4.40 and table 4.26):
- No symptoms: Two thirds of the patients had mild turbulence on MRA and one 
third had normal MRA
Learning difficulty: normal MRA;
- Headaches: a large proportion of patients had normal MRA, while smaller 
proportions had mild, moderate and severe turbulence;
Seizures: mostly normal MRA; and few patients had mild turbulence;
- Posterior territory TIA: more than half of the patients had a normal MRA, one 
third had mild turbulence, and a small percentage had severe turbulence and 
artery occlusion plus collaterals ;
- Anterior TIA: 50% of patients had normal MRA, while smaller proportions had 
moderate, mild and severe turbulence;
- Stroke: one third of patients had severe turbulence and one third had artery 
occlusion plus collaterals, while smaller proportions had artery occlusion, mild 
turbulence and in few patients normal MRA;
- Coma: mainly normal MRA, with a small proportion having moderate 
turbulence.
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4.5.3.7. MRA Patterns in Relation to Recurrent Neurological Symptoms
Based on an MRA at a single time point study, the MRA pattern for each recurrent 
neurological symptom in this series of patients with SCD can be summarised as follow 
(from asymptomatic to most severe neurological symptom, figure 4.41 and table 4.27):
- No symptoms: 50% of the patients had a normal MRA, while a smaller 
proportion had turbulence, and few patients had severe turbulence;
- Learning difficulty: two third of the patients had normal MRA and a small 
proportion of patients had occlusion plus collaterals and mild turbulence; 
Headaches: two third of the patients had normal MRA, while smaller 
proportions had mild, moderate and severe turbulence and artery occlusion plus 
collaterals ;
Seizures: mainly normal MRA, and small proportions of patients with mild 
turbulence or artery occlusion plus collaterals;
- Posterior territory TIA: half of the patients had normal MRA, and half had mild 
turbulence;
- Anterior TIA: half of the patients had severe turbulence, while a smaller 
proportion of patients had moderate turbulence and few patients had artery 
occlusion;
Reversible ischaemic neurological deficit (RIND): severe turbulence;
- Stroke: half of the patients had artery occlusion and half had artery occlusion 
plus collaterals;
Coma (with posterior leukoencephalopathy): normal MRA.
4.5.4. Perfusion MRI
4.5.4.I. Perfusion Abnormality and CNS Events at Presentation
Seventy patients with SCD had a successful perfusion MRI (dynamic susceptibility 
contrast MRI or DSC-MRI). Thirty-one patients (44%) had normal perfusion MRI 
studies and 39 patients (56%) had abnormal studies. The severity of the cerebral 
perfusion abnormality in relation to central nervous system events at presentation is
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shown in figures and tables with perfusion MRI maps of cerebral blood flow -  CBF - 
(abnormal perfusion= decreased CBF) only, whereas perfusion MRI maps of CBF and 
mean transit time (MTT) of the passage of the intravenous bolus of Gadolinium 
(abnormal perfusion= increased MTT) were used for statistical analysis.
Thirty one patients had normal perfusion and the following main CNS events at 
presentation: learning difficulty (n=2), headaches (n=ll), seizures (n=3), posterior 
territory TIA (n=8), anterior territory TIA (n=3), and coma (n=2). Two were 
asymptomatic.
Of the 39 patients with abnormal perfusion MRI, 5 patients (7%) had mild cerebral 
perfusion abnormality (mildly decreased CBF); CNS events were learning difficulty in
2, headaches in 1 and posterior territory TIA in 2 patients.
Fifteen (21%) patients had moderate perfusion abnormality (moderately decreased 
CBF), and their symptoms were headaches in 2, seizures in 4, posterior territory TIA in
3, anterior territory TIA in 2, stroke in 2 and coma in 1. There were no symptoms in 1 
patient.
Finally, 19 sickle cell patients (27%) had severely abnormal perfusion (severely 
decreased CBF) and they presented with headaches (n=l), posterior territory TIA (n=l), 
anterior territory TIA (n=4), stroke (n=12) and coma (n=l). Figure 4.50 and table 4.30 
show the relationship between perfusion abnormality on DSC-MRI and CNS events at 
presentation.
The severity of the central nervous system events at presentation was significantly 
associated with worsening perfusion MRI demonstrated for both decreased CBF and 
increased MTT (pO.OOOl, coefficient correlation [CC]= 0.5, and pO.OOOl, CC= 0.5 
respectively; Spearman’s test).
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Figure 4.50. Relationship between central nervous system events at 
presentation and cerebral blood flow (CBF) maps on perfusion MRI. 
TLA= transient ischaemic attack; ant= anterior territory; post=posterior 
territory.
CNS 
Events 
(n = Patients)
Normal
Perf.
MRI
(Normal
CBF)
Mild
Decreased
CBF
(CBF-)
Moderate
Decreased
CBF
(CBF--)
Severe
Decreased
CBF
(CBF—)
Total
No Symptoms 2 1 3
Learning Difficulty 2 2 4
Headache 11 1 2 1 15
Seizures 3 4 7
Post TIA 8 2 3 1 14
Ant TIA 3 2 4 9
Stroke 2 12 14
Coma 2 1 1 4
Total 31 5 15 19 70
Table 4.30. Relationship between central nervous system events at 
presentation and cerebral blood flow (CBF) maps on perfusion MRI. 
TIA= transient ischaemic attack; ant= anterior territory; post=posterior 
territory.
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4.5.4.1.1. Extension o f Perfusion Abnormality and CNS Events at Presentation
Abnormal cerebral perfusion localised to one hemisphere was found in 11 patients, and 
was present in both hemispheres (bilateral) in 28 patients. The extent of perfusion 
abnormality was significantly associated with increasing severity of CNS event at 
presentation (p=0.007, CC= 0.3, Spearman’s test) and bilateral abnormal perfusion. 
Stroke, seizures and anterior TIA were the CNS events associated with more extensive 
perfusion abnormality involving regions of both cerebral hemispheres. However, a 
proportion of patients with all types of CNS events, and some asymptomatic patients, 
had abnormal perfusion beyond the ischaemic lesion/s found on their MRI studies or 
with normal MRI (figure 4.51).
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Abnormal Perfusion
Bilateral
Unilateral
Normal
None Headaches Posterior TIA Stroke
Learning Difficulty Seizures Anterior TIA Coma
Central Nervous System Events at Presentation
Figure 4.51. Relationship between central nervous system events at 
presentation and the extent of cerebral perfusion abnormality for each 
symptom. TIA= transient ischaemic attack. Unilateral abnormal 
perfusion= confined to one cerebral hemisphere or corresponding 
ipsilaterally to the ischaemic lesion/s on MRI. Bilateral abnormal 
perfusion= extended to regions of both cerebral hemispheres or 
contralaterally to the hemisphere with ischaemic lesion/s found on 
MRI.
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4.5.4.I.2. Perfusion Abnormality and CNS Event
The univariate analysis between each CNS event and normal/abnormal perfusion 
(decreased CBF) showed significant associations for stroke (p<0.0001, Mann-Whitney 
test, figure 4.52) and headaches (p=0.008, figure 4.53), which are the CNS events with 
the greatest and lowest proportion of perfusion abnormality respectively (figure 4.51). 
There was a trend for association with posterior territory TIA (p=0.09). There were no 
associations for anterior territory TIA (p=0.3), seizures (p=0.6) and learning difficulty 
(p=0.3). Other CNS events were not analysed because of small numbers.
Stroke
CBF- (mild) CBF- - (moderate) CBF- - - (severe)
MRI Perfusion  - C ere b ra l Blood Flow M aps
Figure 4.52. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and stroke in patients with SCD.
40
CBF- (mild) CBF- - (moderate) CBF—  (severe)
MRI Perfusion  - C ereb ral Blood Flow M aps
Figure 4.53. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and headaches in patients with SCD.
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4.5.4.2. Perfusion Abnormality and Recurrent Neurological Symptoms
Of the 31/70 patients with normal perfusion MRI, 25 patients had recurrent neurological 
symptoms ongoing including learning difficulty (n=2), headaches (n=18), seizures 
(n=2) and posterior territory TIA (n=3).
Of the 39 patients with abnormal perfusion MRI, 5 patients with mild cerebral perfusion 
abnormality (mildly decreased CBF) had ongoing learning difficulty (n=2), recurrent 
headaches (n=l), seizures (n=l) and posterior territory TIA (n=3).
Fifteen patients with moderate perfusion abnormality (moderately decreased CBF) had 
recurrent symptoms such as ongoing learning difficulty in 1 patient, headaches in 6, 
seizures in 4, anterior territory TIA in 1 and coma with posterior leukoencephalopathy 
(PLKE) in 1. Two patients were asymptomatic.
Nineteen sickle cell patients with severely abnormal perfusion (severely decreased 
CBF) had ongoing learning difficulty (n=2), recurrent headaches (n=4), seizures (n=l), 
anterior territory TIA (n=5), reversible ischaemic neurological deficit (RIND, n=l) and 
stroke (n=2). Figure 4.54 and table 4.31 show the relationship between perfusion 
abnormality on DSC-MRI and recurrent neurological symptoms in this series of patients 
with SCD.
There was a trend for an association between the severity of the recurrent neurological 
symptoms and worsening perfusion MRI demonstrated by decreased CBF (p=0.1, CC= 
0.2, Spearman’s test) but there was no association with an increased MTT (p=0.2, [the 
correlation coefficient is not included because it is not significant]).
144
40
CL 2 0
O
C/D
C erebral Blood Flow
CBF—  (severe)
CBF- - (moderate)
CBF- (mild)
Normal
None Headaches' Post TIA RIND
Learning Difficulty Seizures Ant TIA Stroke
P L K E
Recurrent Neurological Symptoms
Figure 4.54. Relationship between recurrent neurological symptoms 
and cerebral blood flow (CBF) maps on perfusion MRI. TIA= 
transient ischaemic attack; ant= anterior territory; post=posterior 
territory; RIND= reversible ischaemic neurological deficit.
Recurrent 
Symptoms 
(n = Patients)
Normal 
Perf. MRI 
(Normal 
CBF)
Mild
Decreased
CBF
(CBF-)
Moderate
Decreased
CBF
(CBF--)
Severe
Decreased
CBF
(CBF--)
Total
No Symptoms 6 2 4 12
Learning
Difficulty
2 2 1 2 7
Headache 18 1 6 4 29
Seizures 2 1 4 1 8
Post TIA 3 1 4
Ant TIA 1 5 6
RIND 1 1
Stroke 2 2
Coma (PLKE) 1 1
Total 31 5 15 19 70
Table 4.31. Relationship between central nervous system events at 
presentation and cerebral blood flow (CBF) maps on perfusion MRI. 
TIA= transient ischaemic attack; ant= anterior territory; post=posterior 
territory; RIND= reversible ischaemic neurological deficit.
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4.5.4.2.1. Extent o f Perfusion Abnormality and Recurrent Neurological Symptoms
The severity of the recurrent neurological symptoms was not associated with the extent 
of the perfusion abnormality (p=0.6, Spearman’s test). For each recurrent neurological 
symptom abnormal perfusion was seen in a proportion of patients, either unilaterally or 
bilaterally (for example, headaches; figure 4.55)
4 0
3 0  ■
Abnormal Perfusion
Bilateral
Unilateral
Normal
None Headaches Posterior TIA RIND Coma (PLKE)
Learning Difficulty Seizures Anterior TIA Stroke
R ecurrent Neurological Symptoms
Figure 4.55. Relationship between recurrent neurological symptoms 
and extension of cerebral perfusion abnormality for each symptom. 
TIA= transient ischaemic attack, RIND= reversible ischaemic 
neurological deficit; PLKE= posterior leukoencephalopathy. 
Unilateral abnormal perfusion= confined to one cerebral hemisphere 
or corresponding ipsilaterally to the ischaemic lesion/s on MRI. 
Bilateral abnormal perfusion= extended to regions of both cerebral 
hemispheres or contralaterally to the hemisphere with ischaemic 
lesion/s found on MRI.
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4.5.4.2.2. Perfusion Abnormality and Recurrent Neurological Symptom
The univariate analysis for the relationship between each recurrent neurological 
symptom and normal/abnormal perfusion (decreased CBF) showed significant 
associations for recurrent anterior territory TIA (p=0.001, Mann-Whitney’s test; figure 
4.56) and headaches (p=0.01; figure 4.57). They were the recurrent neurological 
symptoms with the most severely decreased CBF and the least severely decreased CBF 
respectively in this series. There were trends for association for recurrent stroke 
(p=0.08; figure 4.58) and posterior territory TIA (p=0.1; figure 4.59). There were no 
associations for seizures (p=0.7; figure 4.60) and learning difficulty (p=0.7; figure 
4.61). Other recurrent neurological symptoms were not analysed because of small 
numbers.
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MRI Perfusion- Cerebral Blood Flow Maps
Figure 4.56. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent anterior territory TIA in patients with 
SCD.
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Figure 4.57. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent headaches in patients with SCD.
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Figure 4.58. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent stroke in patients with SCD.
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Figure 4.59. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent posterior (post.) territory TIA in patients 
with SCD.
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Figure 4.60. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent seizures in patients with SCD.
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Figure 4.61. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and recurrent (rec.) learning difficulty (diff) in patients 
with SCD.
4.5.4.3. Perfusion Abnormality and Parenchymal Imaging (MRI)
4.5.4.3.I. Perfusion Abnormality in Relation with Infarct size and Infarct Number
Worse perfusion abnormality demonstrated by decreased CBF and increased MTT was 
significantly associated with increased infarct size (p<0.0001, CC: 0.6, for CBF and 
MTT), and increased infarct number (p<0.0001, CC: 0.5, Spearman’s correlation, for 
each CBF and MTT) on MRI. Table 4.32 shows the relationship between perfusion 
MRI abnormality by CBF and infarct size; and table 4.33 shows the association between 
abnormal perfusion MRI by CBF and infarct number in this series of patients with 
sickle cell disease.
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(n = Patients) Normal
MRI
Infarct 
< 1cm- 
small
Infarct 
1-5 cm- 
moderate
Infarct 
> 5 cm- 
large
Total
Normal Perf. MRI 
(Normal CBF)1
27 3 1 31
Mild Decreased CBF 
(CBF-)
5 5
Moderate Decreased 
CBF (CBF--)
8 6 1 15
Severe Decreased CBF 
(CBF--)
3 4 7 5 19
Total 43 13 8 6 70
Table 4.32. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and infarct size.
(n = Patients) Normal
MRA
1
Infarct
2
Infarcts
3
Infarcts
Multiple
Infarcts
Total
Normal Perf. MRI 
(Normal CBF)
27 4 31
Mild Decreased 
CBF (CBF-)
5 5
Moderate Decreased 
CBF (CBF—)
8 2 5 15
Severe Decreased 
CBF (CBF—)
3 2 5 1 8 19
Total 43 4 5 1 17 70
Table 4.33. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and infarct number.
4.5.4.3.2. Perfusion Abnormality and Unilateral and Bilateral Cerebral Infarcts
Unilateral infarct was significantly associated with very abnormal perfusion MRI 
demonstrated by a severe decreased CBF (p=0.005, Mann-Whitney test, figure 4.62) 
and an increased MTT (p=0.006), whereas bilateral infarcts were significantly 
associated with severe but also with moderate perfusion abnormality (p=0.001, for 
decreased CBF [figure 4.63]; and p=0.002 for increased MTT). However, there were 
unilateral or bilateral infarcts in some patients with normal perfusion MRI (i.e. normal 
other than in the region of the infarcts themselves).
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Figure 4.62. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and unilateral infarct.
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Figure 4.63. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and bilateral infarcts.
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4.5.4.3.3. Extent o f Perfusion Abnormality in Relation to Infarct Size and Infarct
Number
Decreased infarct size and increased infarct number were significantly associated with 
the extent of perfusion abnormality in both cerebral hemispheres (p<0.0001, CC= 0.5 
and p<0.0001, CC=0.4, Spearman’s test, respectively). As discussed in the MRI section, 
multiple and small/moderate infarcts are more commonly found bilaterally, and were 
associated with moderate to severe perfusion abnormality as explained above. In 
addition, unilateral infarcts were also accompanied by a bilateral perfusion abnormality, 
and there was a large proportion of patients with bilaterally abnormal perfusion and 
normal MRI.
Infarct Size
1 -5  cm -m oderate
no infarct
Normal MRI P erfusion  Abnormal Ipsilateral Abnormal Bilateral
MRI Perfusion Abnormality Unilateral or Bilateral Hemispheres
Figure 4.64. Relationship between infarct size and extent of cerebral 
perfusion abnormality. Unilateral abnormal perfusion= confined to 
one cerebral hemisphere or corresponding ipsilaterally to the 
ischaemic lesion/s on MRI. Bilateral abnormal perfusion= extended to 
regions of both cerebral hemispheres or contralaterally to the 
hemisphere with ischaemic lesion/s found on MRI.
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Figure 4.65. Relationship between infarct number and extent of 
cerebral perfusion abnormality. Unilateral abnormal perfusion= 
confined to one cerebral hemisphere or corresponding ipsilaterally to 
the ischaemic lesion/s on MRI. Bilateral abnormal perfusion= 
extended to regions of both cerebral hemispheres or contralaterally to 
the hemisphere with ischaemic lesion/s found on MRI.
4.5.4.3.4. Perfusion Abnormality and Covert Infarction
The severity of cerebral perfusion abnormality showed no association between the 
presence of covert (silent) infarcts on MRI and decreased CBF (p=0.6, Mann-Whitney 
test) or increased MTT (p=0.4). However, covert infarct was more common in patients 
with moderately and severely decreased CBF, and there was a small proportion of 
patients (n=4, [6%]) who had normal perfusion MRI studies and covert infarcts on MRI 
(Figure 4.66).
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Figure 4.66. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and covert infarcts.
4.S.4.4. Perfusion Abnormality and Magnetic Resonance Angiography
The severity of cerebral perfusion abnormality showed a significant correlation with 
increased grade of turbulence on MRA (p<0.0001, CC= 0.7 for decreased CBF and 
p<0.0001, CC=0.6 for increased MTT, Spearman’s test). Figure 4.67 and table 4.34 
show this association in this series of sickle cell patients. Furthermore, one third of the 
patients with normal MRA had abnormal perfusion, characterised mainly by moderately 
decreased CBF, while a smaller proportion had mildly and severely decreased CBF; 
there were similar findings in sickle cell patients who had mild turbulence on MRA.
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Cerebral Blood Flow
CBF—  (severe)
CBF- - (moderate)
CBF- (mild)
Normal
Mild
Moderate Artery Occlusion
Severe Occlusion/Collateral
MRA Turbulence
Figure 4.67. Perfusion MRI abnormality (decreased cerebral blood 
flow -CBF-) and grades of MRA turbulence.
MRA 
(n = 
Patients)
Normal
Perf.
MRI
(Normal
CBF)
Mild
Decreased
CBF
(CBF-)
Moderate
Decreased
CBF
(CBF--)
Severe
Decreased
CBF
(CBF--)
Total
Normal
MRA
25 3 7 2 37
Mild
Turbulence
5 1 5 1 12
Moderate
Turbulence
1 1 3 5
Severe
Turbulence
2 5 7
Artery
Occlusion
3 3
Occlusion + 
collaterals
5 5
Total 30 5 15 19 69
Table 4.34. Perfusion MRI abnormality (decreased cerebral blood flow 
-CBF-) and grades of MRA turbulence.
4.5.4.5. Perfusion Abnormality and Blood Pressure Measurements
Mean arterial blood pressure (mean 73.5 mmHg [range 55-95 mmHg]) was lower in 
patients with abnormal perfusion but this was of borderline significance (p=0.056, 
logistic regression; figure 4.68), and there was a trend for association for lower mean 
diastolic blood pressure (mean 55 mmHg [range 30-81 mmHg]; p=0.07, figure 4.69) in 
those with abnormal perfusion in comparison with those patients who had a normal 
perfusion MRI study (MAP mean 80 mmHg [range 65-97 mmHg] and DBP mean 62 
mmHg [range 45-80 mmHg]). There was no association between systolic blood 
pressure and perfusion abnormality (p=0.3).
MRI Perfusion  (No P atien ts)
Figure 4.68. Relationship between perfusion MRI abnormality and 
diastolic arterial blood pressure.
MRI Perfusion  (No P atien ts)
Figure 4.69. Relationship between perfusion MRI abnormality and 
mean arterial (MAP) blood pressure.
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4,5.4.6. Perfusion Abnormality and Oxygen Saturation
There was no association between awake-Sp02 and the presence or absence of abnormal 
perfusion (p=0.6, logistic regression).
4.5.4.7. Perfusion MRI Patterns in Relation to CNS Events
Following the data analysis shown in this section, the perfusion MRI pattern for each 
central nervous system events at presentation in this series of patients with SCD can be 
summarised as follows (from asymptomatic to most severe neurological symptom, 
figure 4.50 and table 4.30):
- No symptoms: two third of the patients had normal perfusion MRI and one third 
moderate perfusion abnormality;
- Learning difficulty: half of the patients had normal perfusion and half had mild 
abnormal perfusion;
- Headaches: a large proportion of patients had normal perfusion, while smaller 
proportions had moderate, mild and severe perfusion abnormality;
Seizures: more than half of patients had moderate perfusion abnormality and the 
rest had normal perfusion;
- Posterior territory TIA: more than half of the patients had a normal perfusion, 
while smaller proportions had moderate, mild and severe perfusion abnormality ;
- Anterior TIA: one third of patients had severe perfusion abnormality, while 
smaller proportions had normal perfusion and moderate perfusion abnormality;
- Stroke: mainly severe, while a smaller proportion had moderate perfusion 
abnormality;
Coma: more than half of the patients had normal study, while smaller 
proportions had moderate/severe perfusion abnormality.
4.5.3.7. Perfusion MRI Patterns in Relation to Recurrent Neurological Symptoms
The perfusion MRI pattern of this cross-sectional study for each recurrent neurological 
symptom in this series of patients with SCD can be summarised as follows (from 
asymptomatic to most severe neurological symptom; figure 4.54 and table 4.31):
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- No symptoms: half of the patients had normal perfusion MRI, one third severe 
and a small proportion moderate perfusion abnormality;
- Learning difficulty similar proportions of patients had normal perfusion, mild, 
moderate and severe perfusion abnormality;
- Headaches: two third of the patients had normal perfusion, while smaller 
proportions had moderate, severe and mild perfusion abnormality;
- Seizures: more than half of the patients had moderate perfusion abnormality, 
while smaller proportions had normal perfusion and mild and severe perfusion 
abnormality;
- Posterior territory TIA: mainly normal perfusion, while a smaller proportion had 
mild perfusion abnormality;
- Anterior TIA: mainly severe, while a smaller proportion had moderate perfusion 
abnormality;
- Reversible ischaemic neurological deficit (RIND): severe perfusion abnormality; 
Stroke: severe perfusion abnormality;
Coma (posterior leukoencephalopathy): moderate perfusion abnormality.
4.5.5. Transcranial Doppler Ultrasound
4.5.5.1. Transcranial Doppler Ultrasound: Patients and Controls
Sixty-eight patients with sickle cell disease and 37 controls (40 control studies as 
discussed in the ‘Subjects’ section of this chapter) underwent non-imaging transcranial 
Doppler ultrasound. For analysis of the TCD data, the mean maximum velocities of the 
middle cerebral artery (MCA) and the arterial cerebral artery (ACA) were analysed, 
comparing controls and patients and by age groups.
Mean maximum MCA (maxMCA) velocity in the patients’ group was 94 cm/sec (range 
0-230 cm/sec) and in controls was 64 cm/sec (range 30-120 cm/sec). Sickle cell patients 
had significantly increased mean maxMCA velocity compared to the control group 
(p<0.0001, one-way ANOVA, figure 4.70)
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Sickle Ceil Patients
Sickle Cell P atien ts  an d  C ontrols (n)
Figure 4.70. Comparison between mean maximum middle cerebral 
artery (MCA) velocities between controls and patients with SCD.
Mean maximum AC A (max AC A) velocity in the patients’ group was 59 cm/sec (range 
0-156 cm/sec) and in controls was 69 cm/sec (range 30-120 cm/sec). There was a trend 
for lower mean maxACA velocities in the sickle cell patients compared with the 
control group (p=0.1, one-way ANOVA, figure 4.71), however, the highest individual 
values of maxACA velocities were also found in patients with SCD.
200
2?  100
Sickle Cell Patients
Sickle Cell Patients and Controls (n)
Figure 4.71. Comparison between mean maximum anterior cerebral 
artery (ACA) velocities between controls and patients with SCD.
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The mean maxMCA velocities were significantly different in patients with SCD 
compared to controls in similar age groups (p=0.003, one-way ANOVA). Post-hoc 
analysis showed significantly higher TCD velocities in the 6 to 12 years old group 
compared with the group of 18 to 28 years old (p=0.002; figure 4.72 and table 4.35).
300
T
P atien ts /C on tro ls
□  Controls
□  Sickle Cell
N -  9 0 1 0  11 26 8 20 11 16
9-18 months 2-5 years 6-12 years 13-17 years 18-28 years
Sickle Cell Patients & Controls -  G roups by A ge
Figure 4.72. Comparison between mean maximum middle cerebral 
artery (MCA) velocities among age groups between controls and 
patients with SCD.
Age group Control
M ean
M ax.
M CA
(cm /sec)
Control
Range
M ax.
M C A
(cm /sec)
SCD
M ean
M ax.
M CA
(cm/sec)
SCD
Range
M ax.
M CA
(cm/sec)
9-18 months 58 3 0 -1 0 0 89 8 3-94
2-5 years 58 58 127 100-160
6-12 years 69 4 2 -1 2 0 115* 0 -2 3 9
13-17 years 67 5 1 -7 4 86 0 -1 4 9
18-28 years 62 3 8 -8 9 62 0 -1 3 6
Table 4.35. Mean maximum middle cerebral artery (MCA) velocities 
among age groups between controls and patients with SCD.*p=0.002 
compared to 18-28 year-old group.
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In addition, mean maxACA velocities were significantly higher in patients with SCD 
and controls in relation to their age groups (p=0.01, one-way ANOVA). Analysing 
separately the patients and the control subjects, both groups had significantly different 
mean maxACA velocities between age groups (p=0.01 and p=0.028 respectively, one­
way ANOVA). In sickle cell patients, post-hoc analysis showed significantly higher 
maxACA velocities in the 6 to 12 years old group in relation to the group of 13 and 17 
years old (p=0.03) and the group of 18 to 28 years old (p=0.018; figure 4.73 and table 
4.36). In controls, post-hoc analysis was not performed because of the small numbers, 
but as is shown in figure 4.55 and table 4.36, the 6-12 year-old controls had higher 
mean maxACA velocities than the 13-17 year-old and 18-28 years-old groups.
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Figure 4.73. Comparison between mean maximum anterior cerebral 
artery (ACA) velocities among age groups between controls and 
patients with SCD.
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Age group
Control
Mean
MaxACA
(cm/sec)
Control
Range
MaxACA
(cm/sec)
SCD
Mean
MaxACA
(cm/sec)
SCD
Range
MaxACA
(cm/sec)
9-18 months 76 50-95 70 60-80
2-5 years 92 92 81 0-154
6-12 years 84* 59-108 80** 0-156
13-17 years 57 40-90 45 0-102
18-28 years 59 30-120 40 0-108
Table 4.36. Mean maximum anterior cerebral artery (ACA) velocities 
among age groups between controls and patients with SCD. *p=0.028;
**p=0.01 in relation to patients of 13-17 years and 18-28 years of age 
(one-way ANOVA).
4.5.5.1.1. Comparison between Left and Right Middle Cerebral Arteries and Anterior 
Cerebral Arteries in Sickle Cell Patients and Controls
There were no significant differences between sickle cell patients and controls for the 
left mean maxMCA (p=0.2, one-way ANOVA) and left and right maxACA velocities 
(p=0.4 and p=0.2 respectively). There was a trend for higher velocities in the right MCA 
in the patients compared to the controls (p=0.1, table 4.37).
Sickle cell patients had significantly increased mean maxACA velocities in the left 
ACA (p=0.001, one way-ANOVA) and right ACA (p=<0.001) compared to the right 
and left AC As of the controls.
The comparison between the maximum velocities of right and left MCAs within 
patients showed a trend for higher right MCA velocities (median 89 [0-239] cm/sec) 
compared with the left (median 87 [0-200] cm/sec; p=0.15, Wilcoxon’s test). There 
were significantly increased left MCA velocities (median 70 [38-89] cm/sec) within 
controls, compared to the right MCA (median 65 [0-87] cm/sec); p=0.02, Wilcoxon’s 
test).
Within patients, there was no difference between the maximum velocities of the left 
(median 50 [0-154] cm/sec) and right (median 55 [0-156] cm/sec) ACAs (p=0.3, 
Wilcoxon’s test). Similarly within controls, there was no difference between the
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velocities of the left (median 42 [0-154] cm/sec) and right (median 40 [0-156] cm/sec) 
ACAs (p=0.2, Wilcoxon’s test).
Cerebral
Artery
Patients
Mean
(Median)
cm/sec
Patients
Range
cm/sec
Controls
Mean
(Median)
cm/sec
Controls
Range
cm/sec
Left MCA 83 0-200 68 38-89
(87) (70)***
Right MCA 80* 0-239 60 0-83
(89)** (63)
Left ACA 5 Y**** 0-154 42 0-61
(50) (42)
Right ACA 0-156 33 0-60
(55) (40)
Table 4.37. Comparison between the mean maximum velocities of the 
left and right middle cerebral artery (MCA) and between the mean 
maximum velocities of the left and right anterior cerebral artery 
(ACA) in the sickle cell patients of this series (n=68 for MCA and 
n=64 for ACA measurements) and controls (n=15 for MCA and n=14 
for ACA measurements). * Trend for association compared to controls 
(p=0.1); **p=0.15 compared to left MCA within patients; ***p= 0.02 
compared to right MCA within controls; **** p=0.001 (left ACA) 
and p<0.0001 (right ACA) compared to controls.
4.5.5.2. Transcranial Doppler Ultrasound and Central Nervous System Events at 
Presentation
Sixty-eight patients underwent transcranial Doppler studies following Adams’ 
methodology and using his criteria as described in chapter 3.
Twenty six (38%) of the 68 sickle cell patients had normal TCP studies, but had 
presented with the following main CNS events: learning difficulty (n=3), headaches 
(n=7), seizures (n=5), posterior territory TIA (n=4), anterior territory TIA (n=3), and 
stroke (n=3). One patient did not have any neurological symptoms.
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Of the 42 patients with abnormal TCD, 2 (3%) patients had mean maxMCA velocities 
more than 200 cm/sec and their CNS events were posterior (n=l) and anterior (n=l) 
territory TLAs.
Twenty-four patients (35%) patients had decreased mean maxMCA velocities less than 
70 cm/sec and ipsilateral MCA lowenhigher velocity ratio < 0.5 (unilaterally or 
bilaterally), and their symptoms were headaches in 5, seizures in 1, posterior territory 
TIA in 7, anterior territory TIA in 3, stroke in 4 and coma in 2. There were no 
symptoms in 2 patients.
Sixteen patients (24%) had undetectable MCA and they presented with headaches 
(n=3), seizures (n=l), posterior territory TIA (n=2), anterior territory TIA (n=2), stroke 
(n=7) and coma (n=l). Figure 4.74 and table 4.38 show the relationship between TCD 
findings and CNS events at presentation. The severity of the central nervous system 
events at presentation was significantly associated with TCD category (p=0.004, 
correlation coefficient [CC]=0.3; Spearman’s test).
TCD Categories
U ndetectab le MCA
|MCA veloc « 70 cm /s
J J m CA vel *>200 cm /se c  
[ I Normal
None Headaches Post TIA Stroke
Learning Difficulty S e iz u re s  Ant TIA Coma
Neurological Symptoms at Presentation
Figure 4.74. Relationship between TCD findings and CNS events at 
presentation. MCA=middle cerebral artery; L:H= lowest : highest 
mean ipsilateral maxMCA velocity; TIA= transient ischaemic attack; 
ant= anterior territory; post=posterior territory.
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CNS Events 
(n=patient)
Normal
TCD
MCA V 
=>200 
cm/sec
MCA V 
<70 cm/s & 
L:H ratio =<0.5
Undetectabl 
e MCA
Total
No Symptoms 1 2 3
Learning Difficulty 3 3
Headache 7 5 3 15
Seizures 5 1 1 7
Post TIA 4 1 7 2 14
Ant TIA 3 1 3 2 9
Stroke 3 4 7 14
Coma 2 1 3
Total 26 2 24 16 68
Table 4.38. Relationship between TCD findings and CNS events at 
presentation. MCA=middle cerebral artery; L:H= lowest : highest 
mean ipsilateral maxMCA velocity (V); TLA= transient ischaemic 
attack; ant= anterior territory; post=posterior territory.
For the whole group of sickle cell patients who presented with CNS events, there was a 
trend for association between symptoms and mean maxMCA velocity, independent of 
age, with lower mean maxMCA velocities (mean 92 cm/s [range 0-230]) in those with 
symptoms compared with those without symptoms (mean 135 cm/sec [range 121-143 
cm/sec], p=0.1, logistic regression; figure 4.75); however sickle cell patients with 
symptoms also had the highest mean maxMCA velocities.
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Figure 4.75. Relationship between TCD mean maxMCA velocities 
and presence or absence of CNS events. MCA=middle cerebral artery
In addition, there was a trend for an association between lower mean maxMCA 
velocities (mean 87 cm/sec [0-239]) in those sickle cell patients who had stroke, TIA or
0
o
166
seizures compared with those patients who did not have those symptoms (mean 107 
cm/sec [0-175 cm/sec], p= 0.1, logistic regression; figure 4.76), although sickle cell 
patients with more vaculopathy/ischaemia related symptoms also had the highest mean 
maxMCA velocities.
CNS ev en ts-S troke , TIA an d  S eizu res  (n= Patien ts)
Figure 4.76. Relationship between TCD mean maxMCA velocities 
and patients who had stroke, TIA and seizures. MCA=middle cerebral 
artery
For the whole group of sickle cell patients who presented with CNS events, there was a 
trend for association between mean maxACA velocity and symptoms, independent of 
age, with lower mean maxACA velocities (mean 58 cm/s [range 0-156]) in those with 
compared with those without symptoms (mean 109 cm/sec [range 100-117 cm/sec]; 
p=0.1, logistic regression; figure 4.77), but sickle cell patients with symptoms also had 
the highest mean maxACA velocities.
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Figure 4.77. Relationship between TCD mean maxACA velocities 
and presence or absence of CNS events. ACA= anterior cerebral 
artery.
Furthermore, sickle cell patients who presented with stroke, TLA and seizures had 
significantly lower mean maxACA velocities (mean 52 cm/s [range 0-156]) than those 
who did not have those symptoms (mean 74 cm/sec [range 0-154 cm/sec]; p=0.05, 
logistic regression; figure 4.78).
No (n»Patients) Yes (n-Patients)
CNS Events a t  P rese n ta tio n - S troke, TIA & S eizu res
Figure 4.78. Relationship between TCD mean maxACA velocities 
and patients who had stroke, TIA and seizures. ACA=middle cerebral 
artery
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4.5.5.3. Transcranial Doppler Ultrasound and Recurrent Neurological Symptoms
Twenty six (38%) of the 68 sickle cell patients had normal TCD studies; they presented 
with the following recurrent neurological symptoms: learning difficulty (n=3), 
headaches (n=ll), and seizures (n=5). Seven patients did not have any neurological 
symptoms.
Of the 42 patients with abnormal TCD, 2 (3%) patients had mean maxMCA velocities 
more than 200 cm/sec and their symptoms were recurrent headaches (n=l) and anterior 
territory TIA (n=T).
Twenty four patients (35%) patients had decreased mean maxMCA velocities less than 
70 cm/sec and ipsilateral MCA lowerihigher velocity ratio < 0.5 (unilaterally or 
bilaterally), and their symptoms were learning difficulty in 3, recurrent headaches in 11, 
seizures in 2, posterior territory TIA in 2, anterior territory TIA in 2, and coma with 
posterior leukoencephalopathy [PLKE] in 1. Three patients were asymptomatic.
Sixteen patients (24%) had undetectable MCA and they had recurrent headaches (n=6), 
seizures (n=l), posterior territory TIA (n=l), anterior territory TIA (n=3), reversible 
ischaemic neurological deficit [RIND] (n=l), and stroke (n=2). Two patients remained 
without symptoms. Figure 4.79 and table 4.39 show the relationship between TCD 
findings and recurrent neurological symptoms.
The severity of the recurrent neurological symptoms was significantly associated with 
the TCD category (p=0.007, CC=0.3; Spearman’s test).
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TCD Categories
H  U ndetectab le MCA
^ | m C A  veloc < 70  cm /s 
& L:H ratio =« 0 .5 ,
U m c a  vel =>200 cm /sec
I | Normal
None Headaches Post TIA RIND Coma (PLKE)
Learning Difficulty S e iz u re s  Ant TIA S troke
Recurrent Neurological Symptoms
Figure 4.79. Relationship between TCD findings and recurrent
neurological symptoms. MCA=middle cerebral artery; L:H= lowest : 
highest mean ipsilateral maxMCA velocity; TIA= transient ischaemic
attack; ant= anterior territory; post=posterior territory; RIND=
reversible ischaemic neurological deficit; PLKE= posterior
leukoencephalopathy.
Recurrent
Symptom
(n=patient)
Normal
TCD
MCA
V=>200
cm/sec
MCA V < 70 
cm/s & L:H 
ratio =< 0.5
Undetectable
MCA
Total
No Symptoms 7 3 2 12
Learning
Difficulty
3 3 6
Headache 11 1 11 6 29
Seizures 5 2 1 8
Post TIA 2 1 3
Ant TIA 1 2 3 6
RIND 1 1
Stroke 2 2
Coma (PLKE) 1 1
Total 26 2 24 16 68
Table 4.39. Relationship between TCD findings and recurrent neurological 
symptoms. MCA=middle cerebral artery; L:H= lowest : highest mean 
ipsilateral maxMCA velocity; TLA= transient ischaemic attack; ant= anterior 
territory; post=posterior territory; RIND= reversible ischaemic neurological 
deficit; PLKE= posterior leukoencephalopathy.
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There was a trend for lower mean maxMCA velocities (mean 80 cm/sec [0-239 
cm/sec]) in those sickle cell patients who had recurrent stroke, RIND, TIA and seizures 
compared with those patients who did not have those symptoms (mean 99 cm/sec [0- 
200 cm/sec], p= 0.1, logistic regression; figure 4.80), although one sickle cell patient 
with anterior TIAs had the highest mean maxMCA velocities .
No (n=Patlents) Yes (n»Palients)
Recurrent Neurological Sym ptom s-Stroke, RIND, TIA & Seizure
Figure 4.80. Relationship between TCD mean maxMCA velocities 
and patients who had recurrent stroke, TIA and seizures. 
MCA=middle cerebral artery
4.5.5.4. Transcranial Doppler Ultrasound and Magnetic Resonance Imaging
The presence or absence of infarction on MRI was significantly associated with 
increased severity of the TCD category (p=0.001, Mann-Whitney’s test). In addition, 
increased infarct size and infarct number were significantly associated with the grades 
of severity of the TCD categories (p=0.001 [CC=0.39]; and p<0.0001 [CC=0.42], 
Spearman’s test).
Patients with mean maxMCA velocities less than 70 cm/sec (with lowest: highest 
ipsilateral MCA velocity ratio <0.5) or undetectable MCA had larger or more infarcts 
than the other TCD categories (tables 4.40 and 4.41).
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TCD
(n=Patients)
Normal
MRI
Infarct 
< 1cm- 
small
Infarct 
1-5 cm- 
modera 
te
Infarct 
> 5 cm- 
large
Total
Normal 22 2 1 1 26
MCA V =>200 cm/sec 1 1 2
MCA V < 70 cm/s & 
L:H ratio =< 0.5
12 6 4 2 24
Undetectable MCA 6 4 3 3 16
Total 41 13 8 6 68
Table 4.40. Relationship between TCD findings and infarct size on 
T2-weighted MRL MCA=middle cerebral artery; L:H= lowest : 
highest mean ipsilateral maxMCA velocity
TCD
(n=Patients)
Normal
MRI
1
Infarct
2
Infarcts
3
Infarcts
Multipl
e
Total
Normal 22 2 1 1 26
MCA V =>200 
cm/sec
1 1 2
MCA V < 70 cm/s 
& L:H ratio =< 0.5
12 1 1 10 24
Undetectable MCA 6 1 2 1 6 16
Total 41 4 5 1 17 68
Table 4.41. Relationship between TCD findings and infarct number 
on T2-weighted MRL MCA=middle cerebral artery; L:H= lowest : 
highest mean ipsilateral maxMCA velocity
4.5.5.5. Transcranial Doppler Ultrasound and Magnetic Resonance Angiography
Increased transcranial Doppler ultrasound abnormality was significantly associated with 
increased turbulence on MRA (p=0.003, CC=0.4, Spearman’s test). However, a 
proportion of sickle cell patients with normal MRA had abnormal TCD studies 
(undetectable MCA or decreased MCA velocities < 70 cm/sec), perhaps associated with 
technical difficulties in obtaining an adequate ultrasound signal (thick window) or the 
age of the patient (whose skull thickness increases over time). On the other hand, a 
quarter of the patients with vessel turbulence on MRA had normal TCD (figure 4.81 and 
table 4.42)
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M oderate
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Normal MCA veloc e  70  cm/s
MCA vel =>200 c m /sec  U ndetectab le MCA
Transcranial Doppler Ultrasound Category
Figure 4.81. Relationship between TCD findings and MRA. 
MCA=middle cerebral artery; L:H= lowest : highest mean ipsilateral 
maxMCA velocity.
MRA
(n=patient)
Normal
TCD
MCA
V=>200
cm/sec
MCA V < 70 
cm/s & L:H 
ratio =< 0.5
Undetectable
MCA
Total
Normal 19 10 6 35
Mild
Turbulence
4 6 2 12
Moderate
Turbulence
1 2 2 5
Severe
Turbulence
1 2 1 3 7
Artery
Occlusion
2 1 3
Occlusion + 
Collaterals
3 2 5
Total 25 2 24 16 67
Table 4.42. Relationship between TCD findings and MRA. 
MCA=middle cerebral artery; L:H= lowest: highest mean ipsilateral 
maxMCA velocity
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4.5.5.6. Transcranial Doppler Ultrasound and Perfusion MRI
Transcranial Doppler abnormality was significantly associated with decreased cerebral 
blood flow (CBF) on perfusion MRI (p=0.03, CC=0.3, Spearman’s test) but there was 
no association with increased mean transit time (MTT, p=0.2). More than half of the 
patients with moderate or severe decrease in CBF had MCA velocities <70 cm/sec or 
undetectable MCA. By contrast, a proportion of patients had normal TCD but mildly, 
moderately or severely decreased CBF on perfusion MRI (figure 4.82 and table 4.43).
There was no significant association between severity of TCD and extent of the 
perfusion abnormality (confined to [a] region/s of one cerebral hemisphere or both 
hemispheres; p=0.5, Spearman’s test).
Cerebral Blood Flow
CBF—  (s e v e re )
CBF- - (m oderate)
n  Normal
Normal MCA veloc * 70 cm/s
MCA vel =>200 c m /sec  U ndetectab le MCA
TCD Categories
Figure 4.82. Relationship between TCD findings and Perfusion MRI. 
MCA=middle cerebral artery; L:H= lowest: highest mean ipsilateral 
maxMCA velocity; CBF: cerebral blood flow.
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TCD
(n=patients)
Normal 
Perf. MRI 
(Normal 
CBF)
Mild
Decreased
CBF
(CBF-)
Moderate
Decreased
CBF
(CBF—)
Severe
Decreased
CBF
(CBF--)
Total
Normal TCD 14 3 6 3 26
MCA V=>200 
cm/sec
1 1 2
MCA V <70 cm/s & 
L:H ratio =< 0.5
10 1 7 6 2 4
Undetectable MCA 6 1 9 16
Total 30 4 15 19 68
Table 4.43. Relationship between TCD findings and Perfusion MRI. 
MCA=middle cerebral artery; L:H= lowest: highest mean ipsilateral 
maxMCA velocity; CBF: cerebral blood flow.
4.5.5.7. Transcranial Doppler Ultrasound and Blood Pressure Measurements
There were no associations between presence or absence of abnormal TCD and systolic 
(p=0.7), diastolic (p=0.18) or mean arterial (p=0.3) blood pressure values in these sickle 
cell patients. Although not statistically significant, diastolic blood pressure values in 
patients with abnormal TCD (mean 56 mmHg [range 30-80 mmHg]) were lower in 
comparison with those sickle cell patients with a normal study (mean 61 mmHg [range 
33-81 mmHg]; figure 4.83).
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Figure 4.83. Relationship between TCD and diastolic blood pressure 
measurements.
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4.5.5.8. Transcranial Doppler Ultrasound and Oxygen Saturation
There was no association between presence or absence of abnormal TCD and awake- 
Sp02 in this series of patients (p=0.6, logistic regression).
4.5.5.9. TCD Patterns in Relation with CNS Events
As the data analysis in this section has shown, the transcranial Doppler ultrasound 
pattern for each central nervous system event at presentation in this series of patients 
with SCD can be summarised as follows (from asymptomatic to most severe 
neurological symptom, figure 4.74 and table 4.38):
- No symptoms: two third of the patients had maxMCA velocities <70 cm/sec 
(unilateral or bilateral) and one third normal TCD;
Learning difficulty: normal TCD;
- Headaches: one third of the patients had normal TCD, one third had maxMCA 
velocity <70 cm/sec, and the remainder had undetectable MCA;
Seizures: two third of the patients had normal TCD, while smaller proportions 
had maxMCA veloc.< 70 cm/sec and undetectable MCA;
Posterior territory TIA: more than half of the patients had maxMCA velocity < 
70 cm/sec, while smaller proportions had undetectable MCA and maxMCA 
veloc. >200 cm/sec;
- Anterior TIA: one third of patients had normal TCD, one third had max MCA 
velocity < 7 0  cm/sec, while smaller proportions had undetectable MCA and 
maxMCA velocity > 200 cm/sec;
- Stroke: more than half of the patients had undetectable MCA, followed by 
maxMCA velocity <70 cm/sec and normal TCD;
Coma: two third of the patients had maxMCA velocity < 70 cm/sec, while 
smaller proportions had undetectable MCA.
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4.5.5.10. TCD Patterns in Relation with Recurrent Neurological Symptoms
The TCD pattern of this cross-sectional study for each recurrent neurological symptom 
in this series of patients with SCD can be summarised as following (from asymptomatic 
to most severe neurological symptom, figure 4.79 and table 4.39):
- No symptoms: more than half of the patients had normal TCD, while smaller 
proportions had maxMCA velocity <70 cm/sec and undetectable MCA;
- Learning difficulty: half of patients had normal TCD, and half had maxMCA 
velocity <70 cm/sec;
- Headaches: one third of the patients had normal TCD, one third had maxMCA
velocity < 7 0  cm/sec, while smaller proportions had maxMCA velocity > 200
cm/sec;
Seizures: two third of the patients had normal TCD, while smaller proportions 
had maxMCA velocity <70 cm/sec and undetectable MCA;
- Posterior territory TIA: two third of the patients had maxMCA velocity < 7 0  
cm/sec, while a smaller proportion had undetectable MCA;
- Anterior TIA: half of the patients had undetectable MCA, while smaller
proportions had maxMCA velocity < 70 cm/sec and maxMCA velocity > 200
cm/sec ;
Reversible ischaemic neurological deficit (RIND): undetectable MCA;
Stroke: undetectable MCA;
Coma (posterior leukoencephalopathy): maxMCA velocity < 70 cm/sec.
4.5.6. Comparison among MRI, MRA, Perfusion MRI and TCD Studies
Comparing the different MR modalities (table 4.44), perfusion MRI was the most 
sensitive technique to detect cerebral abnormality compared to MRA and MRI (56% 
vs 46% and 40% respectively) in patients with SCD and neurological complications, 
with MRA the second most sensitive investigation (figures 4.84 and 4.85).
On the other hand, TCD ultrasound had the highest number of patients overall who 
had an abnormal study (62%). This high proportion of abnormality surpassed that of
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the MR studies; however this may in fact be an artefact of the number of TCDs that 
were abnormal due to technical difficulties (e.g. thick skull). These technical 
difficulties, inherent to TCD, might affect in some circumstances the sensitivity and 
specificity of this investigation in detecting cerebrovascular disease in this 
population.
Investigation
(n=Patients)
Normal 
Investigation 
n= Patients 
(%)
Abnormal 
Investigation 
n= Patients 
(%)
MRI 42 28
(n=70)
(60%) (40%)
MRA 37 32
(n=69)
(54%) (46%)
Perfusion MRI 31 39
(n=70)
(44%) (56%)
TCD 26 42
(n=68)
(38%) (62%)
Table 4.44. Comparison of normal and abnormal findings in MRI, 
MRA, perfusion MRI and TCD in sickle cell patients in this cross- 
sectional study.
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T2-weighted MRI MTT-Perfusion MRI CBF-Perfusion MRI
MRA & TCD
Figure 4.84. Ten-year-old patient with sickle cell anaemia, anterior 
territory TIA, seizures and headaches, on blood transfusion therapy. 
MRI: cerebral infarct (subcortical) in the anterior borderzone 
(MCA/AC A) region on the right. Perfusion M R I: severe increase in 
the mean transit time (MTT) of the passage of the Gadolinium bolus 
and decrease in the cerebral blood flow (CBF) in the right deep white 
matter (MCA/ACA territory). M RA : severe turbulence in the right 
MCA. TCD: maximum right MCA velocity: 220 cm/sec, and 
maximum left MCA velocity: 130 cm/sec.
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T2-weighted MRI Perfusion MRI- MTT Perfusion MRI-CBF
TCD: Right MCA TCD: Left MCA
Figure 4.85. Nine year-old patient with sickle cell anaemia who had 
stroke with left hemiparesis, on blood transfusion. M RL  Ischaemic 
injury in the right middle cerebral artery (MCA) territory and caudate 
nucleus. Perfusion MRL. severe increase in the mean transit time 
(MTT) and decrease in the cerebral blood flow (CBF) in the right 
MCA territory (cortical/subcortical). MRA: reduced flow in the right 
terminal carotid artery and right proximal MCA. TCD: severe 
decreased right MCA velocity ( <7 0  cm/sec) and normal left MCA 
velocity (78 cm/sec).
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4.6. Results III: Cerebral Perfusion, MRI, MRA, TCD, and CNS
Events at Onset and Recurrent Neurological Symptoms by Age Group
There were different patterns of cerebral perfusion, MRI, MRA, TCD, and central 
nervous system (CNS) events at presentation and recurrent neurological symptoms 
according to the age groups. Figures 4.86, 4.87, 4.88, 4.89, 4.90 and 4.91 compare these 
neuroimaging modalities, transcranial Doppler ultrasound and neurological symptoms 
(at onset and recurrence), which varied among the different ages of the patients of this 
cross-sectional study. The analysis of the TCD middle cerebral artery velocities by age 
was described above.
Patterns of extent of the perfusion MRI abnormality for each age group (figure 4.86) 
were the following: between 9 to 18 months, 3 patients had perfusion abnormality in 
both cerebral hemispheres or contralaterally to the hemisphere with ischaemic lesion/s 
on MRI (bilateral abnormal perfusion); between 2 to 5 years, 1 patient had normal 
perfusion MRI and 3 patients had bilateral abnormal perfusion; between 6 to 12 years, 
13 patients had normal perfusion, 5 patients had abnormal perfusion confined to one 
cerebral hemisphere or corresponding ipsilaterally to the ischaemic lesion/s on MRI 
(ipsilateral abnormal perfusion) and 9 had bilateral abnormal perfusion; between 13 and 
17 years, 11 patients had normal perfusion, 3 had ipsilateral abnormal perfusion and 6 
had bilateral abnormal perfusion; and between 18 to 28 years o f age, 6 patients had 
normal perfusion, 3 abnormal ipsilateral abnormal perfusion and 7 had abnormal 
bilateral abnormal perfusion.
There were no significant differences in the extent of the perfusion abnormality within 
the age groups of the 6 to 12 year-old, 13 to 15 year-old and 18-28 year-old sickle cell 
patients (p=0.5, p=0.2, and p=0.6 respectively; Mann-Whitney test). Younger patients 
were not analysed because of the small numbers.
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9-18 m onths 2 -5  y e a rs  6-12 y e a rs  13 -17  y e a rs  18-28  y e a rs
Groups by Age
Figure 4.86. Relationship between the ages of patients (by groups) 
and the extension of cerebral perfusion abnormality. Unilateral 
abnormal perfusion= confined to one cerebral hemisphere or 
corresponding ipsilaterally to the ischaemic lesion/s on MRI. Bilateral 
abnormal perfusion= extended to regions of both cerebral hemispheres 
or contralaterally to the hemisphere with ischaemic lesion/s found on 
MRI.
The presence or absence of cerebral infarction on MRI was related to age group as 
follows (figure 4.87): 9 to 18 months o f age, all the patients (n= 3) had normal MRI; 2 
to 5 years, 2 patients had normal MRI and 2 had infarction; 6 to 12 years, 20 patients 
had normal MRI and 7 had infarction; 13 to 17 years, 9 patients had normal MRI and 11 
had infarcts; and 18 to 28 years, 9 patients had normal MRI and 7 had infarcts.
Within each group, there were trends for a higher proportion of normal MRI studies in 
the 6 to 12 year-old patients (p=0.1; Fisher’s exact test), and for a higher proportion of 
cerebral infarction on MRI in the 13-17 year-old patients (p=0.1; Fisher’s exact test). 
There were no significant differences between the proportions of either the presence or 
absence of cerebral infarction on MRI in the 18-28 year-old group (p=0.8). Younger 
patients were not analysed because of the small numbers.
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Groups by Age
Figure 4.87. Relationship between the ages of patients (by groups) 
and the presence or absence of cerebral infarction on T2-weighted 
MRI.
Grades of turbulence on MRA abnormality for each age group (figure 4.88) were the 
following: between 9 to 18 months, 2 patients had normal MRA and 1 had mild 
turbulence; between 2 to 5 years, 2 patients had normal MRA and 2 mild turbulence; 
between 6 to 12 years, 16 patients had normal MRA, 3 mild, 1 moderate and 4 severe 
turbulence, 1 patient had vessel occlusion and 1 patient had vessel occlusion plus 
collaterals (moyamoya syndrome); between 13 and 17 years, 7 patients had normal 
MRA, 6 had mild and 3 moderate turbulence, 1 vessel occlusion and 3 vessel occlusion 
plus collaterals; and between 18 to 28 years o f age, 10 patients had normal MRA, 1 
moderate and 3 severe turbulence, 1 vessel occlusion and 1 vessel occlusion plus 
collaterals.
There was a trend for a higher number of patients with MRA turbulence in the group of 
the 13 to 17 year-old (p=0.1; Mann-Whitney test). However, the 6-12 year-old and 18- 
28 year-old groups did not show significant differences between the number of patients 
in each age group who had normal studies or turbulence on MRA (p=0.4 and 0.8 
respectively; Mann-Whitney test). Statistical analysis was not performed in patients of 
5 years of age or less because of the small numbers.
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Figure 4.88. Relationship between the ages of patients (by groups) 
and MRA.
Transcranial Doppler ultrasound finding for each age groups were as follows (figure 
4.89): 9 to 18 months o f age, all the patients (n= 3) had normal TCD; 2 to 5 years, 2 
patients had normal TCD and 1 had undetectable MCA; 6 to 12 years, 14 patients had 
normal TCD, 2 had maximum MCA (maxMCA) velocities >200 cm/sec, 10 had 
maxMCA velocities less than 70 cm/sec and lowerihigher ipsilateral MCA ratio < 0.5 
and 2 had undetectable MCA; 13 to 17 years, 10 patients had normal TCD, 10 mean 
maxMCA velocities < 70 cm/sec and 6 had undetectable MCA; and 18 to 28 years, 1 
patients had normal TCD, 8 mean maxMCA velocities < 70 cm/sec and 7 undetectable 
MCA.
Within each group, patients of 18 to 28 years of age had a significantly increased 
number of abnormal TCD studies (p=0.046; Mann-Whitney test); and there was a trend 
for an association for the 6-12 year-old (p=0.085). However, the proportion of normal 
or abnormal TCD studies was not significantly different for the 13-17 year-old patients 
(p= 0.5). Younger patients were not analysed because of the small numbers.
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Figure 4.89. Relationship between the ages of patients (by groups) 
and transcranial Doppler ultrasound. MCA^nniddle cerebral artery; 
L:H= lowest: highest mean ipsilateral maxMCA velocity.
The time of the central nervous system events (first event) was not always associated 
with the time at which the neuroimaging or TCD studies were performed in this cross- 
sectional series. Some patients had their first CNS events prior to investigation 
(especially from the group of 18-28 years) whereas other patients had their first 
neurological symptom after the data had been obtained (age groups of 9-18 months, 2-5 
years and 6-12 years). The age groups for CNS events were the following (figure 4.90): 
between 9 to 18 months, 1 patient had generalised tonic-clonic seizures and 2 anterior 
territory TIAs; between 2 to 5 years, 1 patient had learning difficulty, 1 headaches, 1 
seizures and 1 stroke; between 6 to 12 years, 3 patients had learning difficulties, 6 
headaches, 3 seizures, 4 posterior territory TIAs, 2 anterior territory TIAs, 4 stroke, 2 
coma and 3 were asymptomatic; between 13 and 17 years, 3 had headaches, 1 seizures, 
9 posterior territory TIAs, 2 anterior territory TIAs, 4 stroke and 1 coma; and between 
18 to 28 years o f age, 5 patients had headaches, 1 seizures, 1 posterior territory TIAs, 3 
anterior territory TIAs, 5 stroke and 1 had coma.
There were no significant differences in the proportion of severe CNS events at onset 
within each age group of the 6-12, 13-17 and 18-28 year-old patients (p=0.6, p=0.2,
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and p=0.3 respectively; Mann-Whitney test). Patients o f 5 years o f age or less were not
analysed because o f the small numbers.
CNS Events at Onset
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Groups dy Age
Figure 4.90. Relationship between the ages of patients (by groups) 
and central nervous system events at presentation. TIA- transient 
ischaemic attack; ant= anterior territory; post= posterior territory.
The recurrent neurological symptoms observed for each group were the following 
(figure 4.91): between 9 to 18 months, no recurrent symptoms; between 2 to 5 years, 1 
patient had learning difficulty, 1 headaches, 1 seizures and 1 was asymptomatic; 
between 6 to 12 years, 5 patients had learning difficulties, 8 headaches, 5 seizures, 1 
posterior territory TIAs, 3 anterior territory TIAs, 1 coma (posterior 
leukoencephalopathy [PLKE]) and 4 were asymptomatic; between 13 and 17 years, 1 
patient had learning difficulty, 12 headaches, 1 seizures, 3 posterior territory TIAs, 2 
anterior territory TIAs, and 1 was asymptomatic; and between 18 to 28 years o f age, 8 
patients had headaches, 1 seizures, 1 anterior territory TIAs, 1 reversible ischaemic 
neurological deficit (RIND), 2 stroke, and 3 were asymptomatic.
The proportion of severe recurrent neurological symptoms within patients of the age 
groups of the 6-12, 13-17 and 18-28 year-old patients did not reach significance
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(p=0.99, p=0.3 and p=0.5; Mann-Whitney test). Younger patients were not analysed
because of the small numbers.
Recurrent Symptoms
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Figure 4.91. Relationship between the ages of patients (by groups) 
and recurrent neurological symptoms. TIA- transient ischaemic attack; 
ant= anterior territory; post= posterior territory; PLKE= posterior 
leukoencephalopathy; RIND= reversible ischaemic neurological 
deficit.
In this series, as shown in the tables, the prevalence of cerebral infarction increased with 
age with a peak between 13-18 years, which was related to different grades of MRA 
turbulence. However, the perfusion abnormalities were more extensive (proportionally) 
in the younger groups (9-18 months and 2-5 years) in association with a normal or mild 
turbulence on MRA and with symptoms of seizures and anterior territory TIA. 
Perfusion abnormality was more localised from 6-12 years of age and onwards; nearly 
half of those patients had perfusion abnormality either in the same region or in focal 
regions of one or both cerebral hemispheres.
The age group with greatest prevalence of cerebral infarction on MRI was from 13 to 
17 years old (16%), followed by 6-12 years (10%), 18-28 years (10%) and 2-5 years 
(3%) respectively in this series of patients. However, the TCD data showed that there 
were patients with critical maxMCA velocities >200 cm/sec only between 6 and 12 
years of age, the peak ages for risk of stroke. Another critical period might be very early
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in life when some patients presenting with symptoms appear to have extensive 
perfusion abnormality without having severe cerebrovascular disease.
A higher prevalence of clinical stroke at presentation was observed in the 18 to 28 years 
age group (7%) when compared to the other age groups of 9-18 months (0%), 2-5 years 
(1%), 6-12 years (6%) and 13-17 years (6%). However, as was explained above, most of 
these older patients had their first CNS event before participating in this cross-sectional 
study, therefore their neurological symptoms at onset should be included with the 6-12 
years or 13-17 years groups. Recurrent stroke was only found in the oldest group of 
patients of this series (18-28 years); in addition, there was a predominance of recurrent 
anterior territory TIA, seizures and learning difficulty in the patients from 6 to 12 years 
but posterior territory TIA in the 13-17 year-old group. In the 13-17 and 19-28 year-old 
age groups, the most prevalent symptoms were headaches.
4.7. Results IV: Predictors of Recurrent Neurological Symptoms
Table 4.45 shows predictors of each recurrent neurological symptom in patients with 
SCD, as found in this cross-sectional study.
The most frequent finding of each neuroimaging modality, transcranial Doppler 
ultrasound, central nervous system events at presentation, and clinical parameters 
associated with each recurrent neurological symptom was selected for this table.
The severity of the central nervous system events at presentation was significantly 
associated with the severity of the recurrent neurological symptoms (p=0.003, 
correlation coefficient [CC]=0.34; Spearman’s test).
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Recurrent
Symptom
CNS  
Event at 
Onset
M RI - 
Infarct 
Size
M RA
Turbul­
ence
Perfusion
M R I
TCD Blood
Pressure
A w ake- 
S p 0 2 %
No
Symptoms
Ant. TIA Normal Normal Normal Normal NS NS
Learning
Difficulty
Learning
Difficulty
Normal Normal Normal Normal NS NS
Headache Headache Normal Normal Normal Normal ? High 
SP / DP
NS
Seizures Seizures Normal Normal CBF - - Normal ? High 
SP/ DP
NS
Post. TIA Post. TIA Normal Normal/
Mild
Normal MCA
<70
cm/sec
? High 
SP/DP
NS
Ant. TIA Ant.TIA/
Stroke
Small Severe CBF- - - Undetec­
table
MCA
? High 
SP/ DP
NS
RIND Stroke Small Severe CBF- - - Undetec­
table
MCA
NS NS
Stroke Stroke Large Occlusion
or
Occlusion
+
Collateral
CBF-- - Undetec­
table
MCA
NS ? low 
Awake- 
Sp02%
Coma
(PLKE)
Coma Small Normal CBF- - MCA
<70
cm/sec
? High SP NS
Table 4.45. The most frequent finding of each neuroimaging 
modality, transcranial Doppler ultrasound, CNS events at presentation 
and clinical parameters that was associated with each recurrent 
neurological symptom was selected for this table. TIA= transient 
ischaemic attack; ant= anterior territory; post=posterior territory; 
RIND= reversible ischaemic neurological deficit; PLKE= posterior 
leukoencephalopathy; asymp. = asymptomatic patient; CBF= cerebral 
blow flow maps; CBF- = mildly decreased; CBF- - = moderately
decreased; CBF = severely decreased; MCA= middle cerebral
artery; SP= systolic blood pressure; DP= diastolic blood pressure; 
NS= no significant association.
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4.8. Summary of Results
4.8.1. Patients and Neurological Symptoms
Central nervous system (CNS) events at presentation: 6% coma (n=4 [2/4 
patients with stroke and 2/4 with posterior territory TLA.]), 20% of sickle cell 
patients had stroke (n=14 [23% including the 2 patients who had coma and 
stroke]), 33% TIAs (n=23), 10% seizures (n=7), 21% had headaches (n=15), 6% 
learning difficulty (n=4) and 4% (n=3) had no neurological symptoms but severe 
SCD disease.
Main recurrent neurological symptoms: 3% (n=2) had recurrent stroke, 1% 
(n=l) had recurrent stroke with coma and posterior leukoencephalopaty, 1% 
(n=l) reversible ischaemic neurological deficit, 16% TIAs (n=ll), 10% seizures 
(n=7), 44% headaches (n=31), 9% learning difficulty (n=6) and 16% (n= ll) had 
no recurrent symptoms
4.8.2. Clinical Parameters: Blood Pressure Measurements, Haematological 
Parameters and Oxygen Saturation
Blood pressure was measured in 49 patients. There were no significant 
associations between the presence or absence of CNS events or recurrent 
neurological symptoms and systolic, diastolic and mean arterial blood 
pressure (BP) values in patients with SCD. However, the patients aged 6 to 
12 years had higher blood pressure percentiles.
- Haematological parameters included haemoglobin (Hb), haemoglobin S% 
(HbS%), white cell count (WCC) and platelets (PTL)
Haemoglobin: There was a trend for an association between Hb and type 
of CNS event at presentation (asymptomatic patients had the lowest 
mean Hb level [7.7 g/d/L], and patients who presented with stroke and 
coma had the highest mean Hb level [9.7 g/dL and 9.5 g/dL 
respectively]), whereas there was no significant difference among the 
mean Hb levels of each recurrent neurological symptoms of the sickle
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cell patients. Abnormal TCD was significantly associated with high 
levels of Hb; and there was a trend for an association between the 
presence of cerebral infarcts on MRI and high Hb levels. There was no 
association between Hb level and abnormal MRA. Hb was higher in 
those with abnormal perfusion but this was not statistically significant.
- Haemoglobin S%: Mean HbS% levels of each CNS at onset were 
significantly different (lower HbS% levels for anterior vascular territory 
TIA, stroke or coma); but there was no significant difference among the 
mean HbS% levels of each recurrent neurological symptoms in patients 
with SCD. Decreased HbS% was significantly associated with abnormal 
MRA and abnormal perfusion. There was a trend for an association 
between decreased HbS% and abnormal TCD, but there was no 
association between HbS% and the presence of infarction on MRI.
White Cell Count: There was no significant association between WCC 
and the presence of infarction on MRI, abnormal MRA, abnormal TCD 
and abnormal perfusion MRI. One sickle cell patient who presented with 
coma and recurrent coma (with posterior leukoencephalopathy) had 
significantly increased WCC in relation to the WCCs of the patients with 
other CNS events at onset or recurrent symptoms; however, excluding 
this patient, there were no significant differences between the mean 
WCC for the different types of CNS events, and between the mean WCC 
for each recurrent neurological symptoms.
Platelets: There were no significant differences between the patients’ 
PTL means for each type of CNS event at presentation and recurrent 
neurological symptoms. In addition, there were no associations between 
PTL count and abnormal MRI (presence of infarction), abnormal MRA, 
abnormal TCD and abnormal perfusion MRI.
Awake- pulse oximetry was measured in 57 patients and was significantly 
lower in sickle cell patients than in controls (n=14). SpC>2 was not 
significantly associated with neurological symptoms (at onset and 
recurrence); however patients with recurrent stroke had lower SpC>2 values in 
comparison with other recurrent symptoms.
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4.8.3. Magnetic Resonance Imaging
42/70 patients had normal MRI and 28 patients had an abnormal study (16 
overt infarcts, 11 covert infarcts and 1 cerebral atrophy without infarct). 
14/28 had cerebral atrophy.
The severity of the CNS events at presentation was significantly associated 
with increased infarct size and infarct number, and there was a trend for 
association between recurrent neurological symptoms and infarct size and 
number.
Covert infarction was significantly associated with bilateral location and 
anterior territory TIA at onset, and there was a trend for association with 
recurrent anterior territory TIA.
There was a trend for association between cerebral atrophy and severity of 
recurrent neurological symptoms, especially with anterior territory TIA, 
RIND and stroke.
Lower diastolic blood pressure and MAP were significantly associated with 
the presence of infarction on MRI. There were no significant associations for 
systolic BP and awake-SpCb.
4.8.4. Diffusion Weighted Imaging
In sickle cell patients with chronic infarction (n=26), DWI was as expected 
with high diffusion. Only one patient had an abnormal study DWI with 
restricted diffusion (stroke imaged acutely).
4.8.5. Magnetic Resonance Angiogram
37/69 patients had normal MRA and 32 patients had an abnormal study 
(mild turbulence in 12 patients, moderate turbulence in 5, severe turbulence 
in 7, vessel occlusion in 3 and occlusion plus collaterals in 5).
The severity of the CNS events at presentation and the recurrent neurological 
symptoms were significantly associated with increased turbulence or vessel 
occlusion on MRA.
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- Increased grades of MRA turbulence were significantly associated with the 
presence or absence of unilateral or bilateral infarcts, covert infarction and 
infarct size and number.
Lower diastolic blood pressure and MAP were significantly associated with 
abnormal MRA. There were no significant associations for systolic BP and 
awake-SpC>2 .
4.8.6. Perfusion MRI
31 of the 70 patients had normal and 39 patients had abnormal perfusion 
MRI (mildly decreased cerebral blood flow [CBF] in 5 patients, moderately 
decreased CBF in 15, severely decreased CBF in 19).
The severity of the CNS events at presentation was significantly associated 
with CBF category and with extent of perfusion abnormality.
There was a trend for association between recurrent neurological symptoms 
and the severity of decreased CBF, but not with the extent of perfusion 
abnormality.
Worsening of perfusion abnormality was significantly associated with infarct 
size and infarct number; unilateral infarct on MRI was associated with 
severely decreased CBF, whereas bilateral infarcts were seen with 
moderately and severely decreased CBF. Extent of the perfusion abnormality 
was associated with increased infarct size and number.
Increased grades of MRA turbulence were significantly associated with the 
severity of perfusion abnormality.
A lower MAP was significantly associated with the abnormal perfusion and 
there was a trend for association with lower diastolic BP. There were no 
significant associations for systolic BP and awake-SpC>2 .
4.8.7. Transcranial Doppler Ultrasound
Sickle cell patients (n=68) had significantly increased mean maximum MCA 
(maxMCA) velocities compared to controls (n=40); the group aged 6 to 12 
years had significantly higher maxMCA velocities in relation to the older 
groups.
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There was a trend for an association between lower mean maximum ACA 
(maxACA) velocities for patients with SCD compared to the control group; 
however maxACA velocities were higher when compared within groups of 
patients by age, especially those between 6 to 12 years of age.
26/68 patients had normal and 42 patients had abnormal TCD (maxMCA 
velocities > 200 cm/sec in 2; maxMCA veloc. < 70 cm/sec and lower: higher 
ratio <0.5 in 24, and undetectable MCA in 16).
The severity of the CNS events at presentation and recurrent neurological 
symptoms were significantly associated with worsening of TCD category 
following Adams’ criteria. Patients (as a whole group) who presented with 
stroke, TIA and seizures at onset had significantly lower mean maxMCA 
velocities than those patients who did not have these symptoms, and there 
was a trend for association between lower maxMCA velocities and patients 
who had recurrent stroke, RIND, TIA and seizures.
Worsening of the TCD category was significantly associated with the 
presence or absence of infarction on MRI and with infarct size and infarct 
number.
Increased grades of MRA turbulence were significantly associated with 
worsening of the TCD category.
TCD abnormality was significantly associated with worsening of CBF on 
perfusion MRI but there was no association with extension of the perfusion 
abnormality.
Diastolic BP was lower in SCD patients with abnormal TCD but not 
significantly. There were no significant associations for systolic BP, MAP 
and awake-Sp02 and abnormal perfusion.
4.8.8. Cerebral Perfusion Abnormality by Age Group
The prevalence of cerebral infarction increased with age, predominantly between 
13-17 years old.
Patterns of perfusion abnormality were more extensive in younger symptomatic 
sickle cell patients in association with a normal or mildly abnormal MRA.
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- Perfusion abnormality appeared to be more localised from the 6 to 12 year- old 
group.
Critical TCD maxMCA velocities > 200 cm/sec were found only in those in the 
6-12 years age group in this series.
4.8.9. Predictors of Recurrent Neurological Symptoms
- Predictors of recurrent neurological symptoms are summarised in table 4.45.
4.9. Discussion
This cross-sectional study showed that sickle cell patients with neurological 
complications had abnormal cerebral perfusion in more than 50% of the patients. In 
addition, the cerebral perfusion abnormality had different patterns of severity in relation 
to the severity of the central nervous system events at presentation of these patients and 
their recurrent neurological symptoms, and was significantly associated with the 
severity of the MRI, MRA and TCD abnormalities.
Perfusion MRI (DSC-MRI) appeared to be the most sensitive technique to detect 
cerebral abnormality with 56% abnormal of the 70 sickle cell patients in this series 
when compared to the other MR modalities (46% abnormal for MRA and 40% 
abnormal for MRI).
Decreased mean arterial blood pressure was significantly associated with perfusion 
abnormality, suggesting that this may be an important factor in lowering cerebral blood 
flow and contributing to the abnormal perfusion in these patients. As these patients were 
undergoing chronic blood transfusion, although haematological parameters showed a 
trend for an association between higher haemoglobin levels and abnormal perfusion, 
and a significant association between lower Hb S% and abnormal perfusion, no 
conclusions can be drawn.
Cerebral perfusion has been studied in sickle cell disease over the last two decades in 
series of small groups of patients in cross sectional studies, using different techniques 
such as Xenon133 (Prohovnik et al 1989), PET (Powars et al 1999), T2*-weighted
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(Tzica et al 1993) and perfusion MRI, either dynamic susceptibility contrast MRI -DSC- 
MRI- (Kirkham et al 2001) using intravenous bolus of Gadolinium, or continuous 
arterial spin-labelling (ASL) perfusion MRI (Oguz et al 2003).
The series using perfusion MRI had smaller samples of patients with SCD. Oguz et al 
(2003) only compared ASL perfusion with structural MRI, whereas Kirkham et al, 
using DSC-MRI, compared different MR modalities (MRI, DWI, MRA) together with 
transcranial Doppler ultrasound, highlighting the sensitivity of the perfusion MRI over 
the other investigations (Kirkham et al 2001).
This study focused on identifying patterns of cerebral perfusion abnormality, including 
its extent and severity, in relation to neurological symptoms, both at initial presentation 
and at subsequent representation with recurrent symptoms, in patients with SCD. In 
addition, this study explored the association between different grades of severity in 
cerebral perfusion abnormality (especially in terms of CBF maps) and the grades of 
abnormal MRI, MRA and TCD.
This series of patients was necessarily biased in favour of symptomatic patients, in view 
of the need for intravenous gadolinium. In relation to the central nervous system events 
at presentation, the prevalence of stroke in this series was higher (23%) compared to a 
hospital-based cohort which included only patients younger than 19 years (Ohene- 
Frempong et al 1991) and to population-based studies (Ohene-Frempong et al 1998). 
However, there were young adults in this study (age range 1 to 28 years) and, 
interestingly the stroke prevalence was comparable with those series which included 
adults with SCD reporting a life time risk for stroke between 22 -30% (Ohene- 
Frempong et al 1991, Platt et al 1994, Styles et al 2000). In addition, more than a 
quarter of the patients of this study had TIAs (predominantly anterior territory TLA); 
10% of the patients had seizures (similar prevalence to that reported by Liu et al 1994), 
and a very small proportion of the patients were asymptomatic (4%). Therefore, this 
series of patients was highly symptomatic when compared to other studies (Adams et al 
1998 and 2004, Ohene-Frempong et al 1998, Abboud et al 2004), which undoubtedly 
affects the prevalence of abnormality in the MR and TCD investigations. Although 
there are currently technical difficulties to be overcome, the use of continuous arterial 
spin-labelling (ASL) perfusion MRI (Oguz et al 2003) which does not require any
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intravenous injection, would allow a population-based study of older children, although 
it would be difficult to justify sedating asymptomatic younger children for MRI.
Thirty-five of the 70 patients were initially on blood transfusion. However only 20/35 
patients remained on chronic transfusion by the time of the investigations; nine patients 
had stopped blood transfusion therapy and the remainder (n=6) had stopped blood 
transfusion but continued with alternative treatments (such as Hydroxyurea, bone 
marrow transplant, or surgical revascularisation procedure plus Hydroxyurea).
The severity of the central nervous system events at presentation was significantly 
associated with abnormal cerebral perfusion (decreased cerebral blood flow) and the 
extent of the abnormal perfusion. Stroke was significantly associated with the worst 
perfusion (severe or moderate decrease in CBF); one third of the patients with anterior 
territory TIA had also severe perfusion abnormality, whereas headache was the 
symptom significantly associated with normal perfusion. However, smaller proportions 
of patients with headaches had mild, moderate and severe decrease in CBF. Learning 
difficulties and seizures were symptoms with around half of patients with abnormal 
perfusion (mild and moderate decrease in CBF respectively).
The extent of abnormal perfusion was also related to the severity of the CNS events at 
onset, so that bilateral (including a region/s of both cerebral hemispheres) perfusion 
abnormality was found in a higher proportion of patients who had stroke and TIAs at 
onset; on the other hand, there were also bilateral perfusion abnormalities in around a 
quarter of patients with seizures, learning difficulties or coma, and in a small proportion 
of patients without symptoms. Interestingly, 2/4 patients with coma (graded as the most 
severe symptom), who also had associated symptoms of posterior territory TIA, had 
normal perfusion MRI studies.
The presence of abnormal perfusion in patients with less severe symptoms such as 
headaches and seizures (which are not normally considered ‘at short-term risk’ of 
developing stroke) showed that, in patients with SCD, some neurological 
symptomatology (especially severe headaches or seizures) should be considered as 
‘sentinel’ symptoms (Huttenlocher et al 1984, Kirkham et al 2001, Prengler et al 2001 
and 2002). Sickle cell patients who have cerebral regions with chronic decreased
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perfusion might be at a higher risk of ischaemia (Sorensen and Reimer 2000) if the 
metabolic rate of the body and regional blood flow demands increase in situations such 
as infections or sickle cell crisis. Therefore, these patients should be monitored closely 
in order to prevent severe neurological complications such as stroke.
There was trend for an association between recurrent neurological symptoms and 
perfusion abnormality. Two patients had recurrent stroke (3%); one patient was on 
blood transfusion and another had stopped transfusion due to autoantibody formation. 
Patients with recurrent stroke, recurrent anterior territory TIA (n=6) and reversible 
ischaemic neurological deficit (n=l) had mainly severe perfusion abnormality (severe 
decrease in CBF) in their single perfusion MRI study; half of these patients were on 
blood transfusion, a quarter stopped transfusion (RIND and re-stroked) and the 
remainder (with recurrent TIA) stopped transfusion but continued with BMT or 
revascularisation procedure.
On the other hand, a patient who had recurrent coma with reversible posterior 
leukoencephalopathy in the context of a chest crisis on MRI (he had previously had 
coma and stroke at onset) and half of the patients who had recurrent seizures had 
moderate perfusion abnormality (moderate decrease in CBF). Posterior 
leukoencephalopathy in the context of a chest crisis has been reported in SCD, where an 
insufficiency of oxygen delivery may explain ‘reversible’ white matter injury 
(Henderson et al 2003); in addition leukoencephalopathy in SCD has beeen associated 
with small blood vessel disease (Steen et al 2003). In addition, recent chest crises have 
been described as risk factor for stroke (Ohene-Frempomg et al 1998). Seizures in SCD 
might be a marker for vasculopathy (small and large blood vessel disease) and silent 
infarction in this population (Adams 1994, Miller et al 1999, Prengler et al 2002).
There was a significant association between recurrent headaches and normal perfusion 
seen in two third of the sickle cell patients who had this symptom. This might suggest 
that headache is the least severe symptom in this population, compared to other less 
severe symptoms such as longstanding learning difficulty or asymptomatic patients who 
had a variety of grades of perfusion abnormality. However, one third of the patients 
with headaches had also mainly moderate and severe perfusion abnormality. The 
presence of abnormal perfusion in patients with these less severe symptoms might be
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due to the fact that most of these patients who had learning difficulty, headaches or no 
symptoms were previously symptomatic patients and were therefore on blood 
transfusion therapy, which may have prevented the development of more severe 
recurrent symptoms such as stroke. In addition, headaches have been associated with 
hyperaemia in SCD (Pavlakis et 1986) and cerebral hyperaemia over time might affect 
cerebral perfusion (Prohovnik et al 1989), therefore headaches might be associated with 
impaired cerebral perfusion over time in some patients.
Central nervous system events at presentation were significantly associated with 
increased infarct size and number and increased turbulence (or increased grade of 
severity of the cerebrovascular disease) on MR. In turn, increased perfusion abnormality 
was significantly associated with increased infarct size and number on MRI, and 
increased turbulence on MRA in patients with SCD.
This study supported previous data associating severity of neurological symptoms 
(mainly focused on stroke as an end-point) with severity of MRI (Pavlakis et al 1988, 
Zimmerman et al 1988, Pavlakis et al 1989, Kugler et al 1993, Kirkham et al 2001, 
Adams 1994, Steen et al 2004) and MRA (Seibert et al 1998, Gilliams et al 1998, Wang 
et al 1998, Kirkham et al 2002, Abboud et al 2004) abnormality; however, infarct 
number and infarct size were partially explored in relation to MRA turbulence and 
perfusion abnormality (Kirkham et al 2001) suggesting an association between the 
degree of the perfusion abnormality (which extended beyond the area of ischaemic 
lesions on MRI) and the severity of the cerebrovascular disease in SCD.
The severity of the central nervous system events at presentation was significantly 
associated with bilateral infarction, increased size of the infarct and increased number of 
infarcts. Nearly twice as many patients who presented with stroke had bilateral 
infarction. More than one third of the patients with stroke had severe turbulence, artery 
occlusion and artery occlusion plus collaterals (moyamoya syndrome), demonstrating 
the underlying large vessel disease (Pavlakis et al 1989, Stockman et al, Seibert et al 
1998). Cerebral perfusion in stroke patients was severely decreased in unilateral 
infarcts, whereas patients with multiple infarcts had moderately and severely decreased 
cerebral blood flow. The extent of the perfusion abnormality was associated with the 
infarct size and number, moreover, the perfusion abnormality extended beyond the
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ischaemic lesions seen on MRI in the majority of the sickle cell patients with stroke, 
demonstrating the presence of tissue at risk and hypoperfused in these patients which 
could contribute in the genesis of their ongoing recurrent symptoms, a finding which 
was also reported in the previous study using this technique (Kirkham et al 2001). This 
study showed that, although most of the stroke patients were on therapy (either blood 
transfusion or alternative treatments), the perfusion abnormality was still present, 
perhaps maintaining the ‘high’ risk of developing a further infarction. This extension of 
the perfusion abnormality beyond the area of the cerebral infarction, either limited to 
within a vascular territory (middle cerebral artery [MCA]) or extending to other 
neighbouring vascular territories (MCA/anterior cerebral artery [ACA]; MCA/posterior 
cerebral artery [PCA]), showed the role of the progression of the cerebrovascular 
disease which was not halted or reversed by blood transfusion or other therapies in these 
patients (Pavlakis et al 1989, Prengler et al 2002, Prengler et al 2003 and 2002).
The recurrent symptoms in the stroke patients were diverse and included recurrent 
stroke (1/2 had stopped blood transfusion), coma with posterior leukoencephalopathy on 
MRI and new small infarct on MRI, reversible deficit neurological deficit, anterior 
territory TIA, headaches and learning difficulty; only three patients remained 
asymptomatic. Except for two patients who stopped blood transfusion, the others were 
on transfusion or another type of therapy, demonstrating the extent of the damage 
beyond the original ischaemic lesion, the progression of the cerebrovascular disease and 
the extent of the perfusion abnormality, or the way that SCD manifests in each 
individual (‘individual phenotype’) may play a role in the outcome (‘individual 
prediction of outcome’) of these patients, as Weatherall (1995) suggested.
The prevalence of covert (silent) infarction on MRI in this series of sickle cell patients 
was 16%, similar to previously reported in children with sickle cell anaemia (17%, in 
Moser et al 1996) but smaller than other more recent series (older patients), which 
found a prevalence of silent infarction of around 25% (Miller et al 2001, Saunders et al 
2001). In addition silent infarction was significantly associated with TLAs, which was 
previously reported (Zimmerman et al 1987). Patient with TIAs had small or moderate 
infarct size.
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Patients with anterior and posterior vascular territory TIAs had different patterns on 
conventional neuroimaging and cerebral perfusion imaging. Anterior territory TIA was 
characteristic of half of the patients with normal MRI studies and nearly half of the 
patients with small, multiple covert infarction; MRA was normal in half of the patients, 
and the remainder had moderate (mainly), mild and severe turbulence on MRA. 
Perfusion abnormality in two third of the patients was predominantly a severe decrease 
in CBF, with a smaller proportion of patients with moderate decrease in CBF, with 
unilateral or bilateral extent of abnormal perfusion in similar proportions, whereas only 
one third of the patients had normal cerebral perfusion. In the patients with anterior 
TIAs, mild to moderate turbulence on MRA was related to multiple, small infarcts on 
MRI, whereas in patients with stroke, the most frequent finding on MRA was severe 
turbulence or artery occlusion, which was more related to one or multiple moderate- 
large infarcts; therefore anterior TIA represent symptoms which might precede stroke in 
relation to the impairment of the perfusion abnormality. The severity of this symptom 
was reflected in the treatment of this group of patients which was mainly blood 
transfusion, however one patient had stopped blood transfusion, and another patient 
stopped blood transfusion but had surgical revascularisation procedure and continued on 
Hydroxyurea. Nevertheless, patients continued having recurrent TIAs (4/9) or 
headaches (2/9); only three remained asymptomatic. Therefore, anterior TIA was a 
severe symptom, which reflected a severe perfusion abnormality and a potential risk 
factor for further stroke in SCD (Ohene-Frempong et al 1998).
By contrast, patients with posterior territory TIA had milder abnormalities on 
conventional neuroimaging than those with anterior TIA; two third of the patients had 
normal MRI, MRA and cerebral perfusion. Only one third of the patients had multiple 
small infarcts, similar mild turbulence on MRA and moderate decrease in CBF. Patients 
with posterior TIAs were mainly on blood transfusion therapy, however they continued 
having recurrent symptoms such as headaches (mainly), recurrent TIAs and seizures, 
and only one patient remained asymptomatic.
Seizures, together with posterior territory TIA, could be defined as another intermediate 
neurological symptom in relation to severity and prognosis. Patients with seizures had 
mainly normal MRI, except for one patient who had cerebral atrophy; in addition MRA 
was normal in 6 of 7 patients. However, moderate decrease in cerebral blood flow
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was found in more than the half of the patients (4/7). Six of the 7 patients who 
presented with seizures at onset were not on blood transfusion, only two were on 
anticonvulsants, and the only patient who had received blood transfusion discontinued 
this therapy. However, 5/7 patients continued having recurrent seizures, a further patient 
had recurrent headaches and another remained without symptoms, which demonstrated 
the difficulty in determining the pathophysiology of this symptom (i.e. if  the cause is 
ischaemic, epileptic or both) and in appropriately treating patients with SCD and 
seizures, as patients on anticonvulsants continued to have recurrent seizures. Four out of 
the 7 patients had perfusion abnormalities in cerebral regions (Appendix Table 1). It has 
been suggested that a vasculopathy/ischaemic underlying cause (in addition to the 
anaemia), could lead to regional cortical perfusion abnormality and seizure genesis 
(Huttenlocher et al 1984, Adams 1994, Prengler et al 2001 and 2002), and blood 
transfusion might probably help to relieve this symptom in patients with SCD (see 
chapter 7).
In this study, symptoms of lesser severity were headaches and learning difficulty. There 
has been a longstanding controversy over the importance of headaches in SCD because 
of the uncertainty over whether further investigation and treatment are needed. 
Headaches have been related to the chronic anaemia in SCD as this symptom improves 
after transfusion, and patients with SCD and headaches have found to have higher 
cerebral blood flow than patients without headaches (Pavlakis et al 1986 and 1989). In 
this study, patients with headaches had mainly normal MRI; only 2 of the 15 patients 
with headaches had covert (silent) infarction. However, one third of the patients had 
abnormal MRA with grades of mild, moderate or severe turbulence, and also, abnormal 
cerebral perfusion was found in a quarter of the patients (4/15) with mild, moderate or 
severe decrease in CBF. Eleven of 15 patients did not have treatment for SCD, one 
patient was on Hydroxyurea, and 3 patients were on blood transfusion (one discontinued 
and another stopped blood transfusion and continued on Hydroxyurea). This group of 
patients continued with recurrent headaches, only one patient remained asymptomatic. 
The continuing recurrence of headaches and the abnormal perfusion and CVD, which 
was seen in a small proportion of these patients, suggest that this symptom might be the 
first expression of an ongoing process of progression of cerebrovascular disease and 
cerebral perfusion abnormality, with an accompanying risk of ischaemia.
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Learning difficulty was associated with normal MRI and MRA. However, there were 
perfusion abnormalities, with a mild decrease in CBF, in half of the patients, whereas 
the other half had normal perfusion. Only one of the 4 patients with learning difficulty 
was initially on blood transfusion due to a SCD crisis with priapism but he discontinued 
this treatment (he also had perfusion abnormality on his perfusion MRI). It is of interest 
that priapism has been associated with cerebrovascular accidents in SCD (Siegel et al 
1993) although there are few data on any association with learning difficulty. All the 
patients in this group had ongoing learning difficulties. However, learning difficulty 
was the mildest neurological symptom in this series and was associated with the least 
severe grade of cerebral perfusion abnormality. However, learning difficulty could be a 
manfestation of underlying chronic ischemia secondary to the anaemia or/and small 
blood vessel disease as suggested by different studies in sickle cell patients with normal 
structural MRI and learning difficulties (Steen et al 1998, Steen et al 1999a and 1999b) 
or with abnormal transcranial Doppler studies (Krai et al 2003).
Finally, those patients who had severe SCD (defined as severe and/or frequent 
associated symptoms including chest syndrome, priapism or frequent and severe pain 
crisis) but no neurological symptoms had mainly normal MRI (2/3) and one patient had 
covert infarction, however two of the patients had abnormal MRA with mild turbulence 
and one had abnormal cerebral perfusion (moderate decrease in CBF); the remaining 
patient had normal MRA and perfusion. Only one of 3 patients had treatment with blood 
transfusion, which was discontinued because she received a bone marrow transplant, 
and only one patient had ongoing learning difficulty. One patient remained 
asymptomatic. This small group of patients shows that the brain may be affected in 
patients without manifesting neurological symptoms.
In relation to MRI and perfusion MRI, the majority of the patients with bilateral 
cerebral infarction on MRI had bilateral perfusion abnormalities beyond the area of the 
ischaemic lesion; however, in a small proportion of patients with unilateral infarcts, 
there were bilateral perfusion abnormalities suggesting that the disease process is 
affecting regions of both cerebral hemispheres and new areas of the brain are at risk of 
further ischaemia not seen on structural MRI (Pavlakis et al 1989, Calamante et al 1999 
(abstract), Sorensen and Reimer 2000).
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MRA and perfusion MRI, although significantly associated, was not comparable in 
terms of the grading of severity. Perfusion MRI had more severe grades of perfusion 
abnormalities in relation to the grading of MRA suggesting that the latter imaging 
technique does not provide exact information on the severity of the cerebrovascular 
disease and its effect on the cerebral perfusion. Whereas artery occlusion or moyamoya 
syndrome (artery occlusion plus collaterals) were associated with severe decrease in 
CBF; mild turbulence on MRA was related to moderate decrease in CBF; and moderate 
turbulence on MRA to severely decreased CBF in a large proportion of patients. In 
addition, a quarter of the patients with normal MRA had a moderate decrease in CBF, 
suggestive of an underlying small blood vessel disease (Pavlakis et al 1988, Pavlakis et 
al 1989). This finding adds new information about the association of MRA and cerebral 
perfusion abnormality, whereas previous studies were based on MRA and the presence 
of cerebral infarction on MRI (Zimmerman et al 1987, Gilliams et al 1998, Seibert et al 
1997, Abboud et al 2004).
There were limitations to this study for MRI, MRA and perfusion MRI which are 
similar because of the visual assessment of these investigations. In the case of MRA, an 
experienced Neuroradiologist graded the vessel turbulence or occlusion; however there 
were sometimes small discrepancies in the grading of turbulence intra-observer (when 
the Neuroradiologist assessed twice the same study). Discrepancies in the MRI 
assessment were minimal. In the case of perfusion MRI, the author, supervised by a 
Physicist experienced in this MR technique, assessed the grade of perfusion abnormality 
using the mean transit time, cerebral blood flow and cerebral blood volume maps of all 
the patients. However the grading of the CBF maps (decrease in CBF) was associated 
more significantly with neurological symptoms and the other investigations than the 
grading of the MTT maps (increase in MTT). This may be because the MTT map 
appears more highlighted on visual inspection (MTT is white and CBF is dark on the 
perfusion MRI maps), and for this reason it is more difficult to differentiate grades of 
severity on the MTT maps than on the CBF maps, which suggests that the CBF map is a 
very sensitive parameter to detect perfusion abnormality on perfusion MRI in SCD (also 
discussed in chapter 5).
In relation to transcranial Doppler ultrasound, sickle cell patients had significantly 
increased mean middle cerebral artery (MCA) and anterior cerebral artery (ACA)
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velocities compared to controls, in agreement with previous studies (Brass et al 1988, 
Prohovnik et al 1989) but there was no significant difference between left or right MCA 
or ACA within groups. The mean maximum MCA and ACA velocities were 
significantly increased in children with SCD between 6 and 12 years of age, which is a 
critical age for stroke in SCD (Ohene-Frempong et al 1991). Increased ACA velocities 
in TCD have been associated with stroke in children with SCD (Kwiatkwoski et al 
2004). In this study, there were trends for association for lower MCA or ACA velocities 
and patients who had stroke, TIA or seizures, probably because in this series severe 
cerebrovascular disease (artery occlusion) and associated lower cerebral blow flow were 
common. On the other hand, there was a wider age range in this study (from 1 year to 
28 years) which might affect the normal mean maximum velocities of the MCA and 
ACA in TCD (higher velocities in children and lower velocities in adults).
The category of the transcranial Doppler ultrasound was significantly associated with 
infarct size and infarct number, as previously reported (Siegel et al 1995). In addition, 
the grades of severity on MRA were also significantly associated with the transcranial 
Doppler ultrasound categories of severity following Adams’ criteria (Adams et al 1992, 
Adams et al 1994). The association between TCD and cerebral angiography (Adams et 
al 1988) and the association between TCD and MRA have been previously reported 
(Verlhac et al 1995, Seibert et al 1997), showing that TCD is a useful technique for 
detecting cerebrovascular disease and the presence of cerebral infarction on MRI. The 
severity of the TCD category was also significantly associated with the severity of the 
CNS events at presentation and recurrent neurological symptoms. After the Stroke 
Prevention Study in Sickle Cell Disease (STOP), the National Institutes of Health 
recommended prophylactic blood transfusion in those sickle cell patients without stroke 
who had middle cerebral artery velocities more than 200 cm/sec (Adams et al 1992, 
Adams et al 1998). Two patients in this series had mean maximum MCA velocities 
more than 200 cm/sec; one already had had stroke and the other patient presented with 
frequent headaches, TIAS and seizures, both patients were on blood transfusion therapy 
and the second patient has not developed stroke during this study, suggesting that this 
recommendation is probably beneficial (Fullerton et al 2004).
However, the association between TCD and low velocities (less than 70 cm/sec or an 
ipsilateral mean maximum MCA velocity lowest/highest ratio <0.5) and the risk of
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further stroke has been little documented until recently (Minnitti et al 2004). In this 
study, patients with low velocities in the MCA or undetectable MCA had either normal 
or different grades of turbulence on MRA (mild, moderate or severe). Patients who had 
stroke, TIA or seizures (especially stroke and TIA) had lower mean maximum MCA or 
ACA velocities, probably as an expression of an underlying severe cerebrovascular 
disease. Moreover, there was a trend for an association between lower MCA and ACA 
velocities on TCD and recurrent stroke, RIND, TIA or seizures, which showed that 
lower MCA velocities might also be predictive of recurrent stroke in patients with SCD. 
However, one third of the patients had low velocities or undetectable MCA on TCD 
with normal MRA; and also, a quarter of the patients with normal TCD had abnormal 
MRA (mainly with mild turbulence), which demonstrates that TCD has limitations as a 
diagnostic tool and could give positive false diagnoses because of the technical 
difficulties (ultrasound window, i.e. thick skull in SCD secondary to bone marrow 
changes), the experience of the TCD operator, or the difficulty in reporting an 
abnormality when the ultrasound signal from the blood vessel is not completely normal, 
but does not fit the rigorous categories of Adams’ (1992) criteria.
Those patients who had abnormal TCD (low velocities or undetectable MCA) and 
normal MRA (16/35) had recurrent neurological symptoms such as, in those patients 
with low MCA velocities (8/10): coma with posterior leukoencephalopathy on MRI 
(n=l), TIA (n=l), headaches (n=5); and, in those with undetectable MCA (5/6): 
headaches (n=4) and seizures (n=l), which suggests that these patients might have an 
underlying cerebrovascular disease not detected yet by MRA but identified by TCD 
(Minniti et al 2004, Steen et al 2004).
Transcranial Doppler was significantly associated with worse perfusion abnormality. 
More than half of the patients who had low MCA velocities or undetectable MCA had a 
moderate or severe decrease in CBF on perfusion MRI, demonstrating that an important 
proportion of patients with low MCA velocities had cerebral regions in the anterior 
vascular territory at risk of ischaemia. In addition, patients who had MCA mean 
maximum velocities more than 200 cm/sec had moderate or severe decrease in CBF, 
confirming Adams’ work suggesting that those patients are at risk of stroke (Adams et 
al 1992, Adams et al 1997). This study has demonstrated that TCD is a good monitor of 
cerebral perfusion abnormality.
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Blood pressure (BP) measurements were not significantly associated with neurological 
symptoms. Patients of 6 to 12 years had higher blood pressures values that did not reach 
statistical significance, but this age is at high risk of stroke (Ohene- Frempong et al 
1991). Furthermore, ‘relative’ hypertension in SCD, secondary to factors governing red 
cell rheology and microvascular tone, has been identified as a risk factor for stroke 
(Ohene-Frempong et al 1991, Rodgers et al 1993, Pegelow et al 1997). However, lower 
diastolic blood pressure -DBP- and mean arterial blood pressure -MAP- (analysing the 
whole group of patients, without taking account of their age) were significantly 
associated with the presence of cerebral infarction on MRI, abnormal MRA and 
abnormal perfusion MRI, and there was a trend for an association between lower 
diastolic blood pressure and abnormal TCD. A study has reported low blood pressure 
values in patients with SCD (Pegelow et al 1997); however BP varies with age, and in 
this series, the majority of the patients younger than 17 years had systolic and diastolic 
blood pressure values between the 50 and 95 percentiles. By contrast, older patients 
(18-28 years of age) had BP measurements lower than < 50 percentile. Particularly in 
this age group, lower blood pressure might be a contributing factor to impairment of 
perfusion abnormality, together with the cerebrovascular disease and this group might 
contribute to the significant association with the abnormal investigations.
There was an association between high haemoglobin levels and the presence of cerebral 
infarction on MRI and there was a trend for an association with abnormal perfusion. In 
addition, low haemoglobin S% level was associated with abnormal MRA and abnormal 
perfusion MRI. These associations are probably accounted for by those patients who 
had stroke or TIAs and were on blood transfusion therapy. However, no conclusion can 
be drawn, as these patients were on chronic blood transfusion to prevent further central 
nervous system events. In fact, the Cooperative Study of Sickle Cell Disease identified 
low steady haemoglobin level as a risk factor for ischaemic stroke in SCD (Ohene- 
Frempong et al 1998), in contrast to the findings in this study; however the data 
collection of the available haematological data was another limitation of this study, as 
many of the patients usually had their blood tests taken during post- transfusion or 
during the sickle cell crisis, and many of the pre-transfusional blood tests were not 
found during the data collection. However, the effect of increased haemoglobin level
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and red cell concentration on the cerebrovascular disease in SCD (especially on small 
blood vessels) could be explored in future studies.
Although an association between leukocytosis and other blood components involved in 
inflammation with stroke, covert infarction and cerebrovascular disease in SCD has 
been reported (Ohene-Frempong et al 1998, Kinney et al 1998, Belcher et al 2000, 
Prengler et al 2000), there were no associations in this series of patients between white 
cell count and platelet count with abnormal MRI, MRA and perfusion MRI. However a 
future study could be done exploring more specifically the association between 
neutrophils and lymphocytes with the abnormal investigations.
Awake-oxygen saturations were not significantly associated with neurological 
symptoms, abnormal MRI, MRA, TCD and perfusion MRI; however patients with 
recurrent stroke had awake SpC>2 less than 92%. Awake- SpCb < less than 90% was not 
associated with stroke risk in adults (Homi et al 1997), however nocturnal hypoxemia 
secondary to obstructive sleep apnoea has been associated with CNS events in children 
(Davies et al 1989, Kirkham et al 2001). In fact, mean overnight SpC>2 reflects daytime 
Sp02 (Setty et al 2003), although there may additional dips in SpC>2 overnight; the effect 
of daytime and nocturnal hypoxemia on the risk of recurrent symptoms could be 
explored in a future study.
Analysing the different neurological symptoms by age groups, in this study it was found 
the predominant age for cerebral infarction was between 13 to 17 years of age, in 
contrast to the Cooperative Study of Sickle Cell Disease which identified the highest 
incidence of stroke in the 2-5 years and 6-9 years of age (Ohene-Frempong et al 1998). 
However, in this study, cerebral infarction included overt and covert infarction, and 
covert infarction increases with age and in young adults is around 25% (Miller et al 
2001, Saunders et al 2001). However, the age group between 6-12 years of this series 
had increased mean MCA velocities (including the critical MCA velocities more than 
200 cm/sec), and higher blood pressure percentiles, both predictors of stroke risk. On 
the other hand, perfusion abnormalities were more extensive (bilateral) in symptomatic 
sickle cell patients less than 5 years old (the group with highest stroke incidence 
[Ohene-Frempong et al 1998]), although in this group, one patient had stroke and 
abnormal investigations, and the remaining patients had a variety of neurological
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symptoms such as TIA, seizures, headaches and learning difficulty, predominantly 
associated with normal MRI and MRA. This could suggest that the perfusion of the 
developing brain is more sensitive to the abnormal rheology of the sickle cell, especially 
at the level of the microcirculation and small blood vessels, leading to extensive 
perfusion abnormalities and more extensive areas at risk of ischaemia, whereas in the 6 
to 12 years group and beyond, the perfusion abnormality tends to be more localised. In 
this study, the highest prevalence of stroke as the CNS event at presentation was in the 
young adults, however several of these patients had had stroke before these 
investigation and should be included in the 13-17 year- old group.
Finally, severe perfusion abnormality together with stroke as the CNS event at 
presentation, severe cerebrovascular disease and undetectable MCA in TCD were 
predictors of recurrent stroke in this study. Identifying predictors of recurrent 
neurological symptoms from a single time point investigation in this study showed that 
the severity of the recurrent neurological symptoms was usually related to the severity 
of the CNS events at onset, the MR studies and TCD. However, perfusion MRI could 
detect abnormality in patients with symptoms such as seizure usually associated with 
normal conventional neuroimaging. Therefore specific CNS events at onset could be 
delineated, including seizures, posterior TIA, anterior TIA, stroke and coma, which 
were predominantly symptoms of abnormal cerebral perfusion and predicted risk of 
further ischaemia and infarction.
4.10. Conclusion
This study showed that sickle cell patients had a high prevalence of cerebral perfusion 
abnormality. In addition, a distinctive pattern of abnormal cerebral perfusion in 
association with an abnormal structural MRI and cerebrovascular disease could be 
recognised, demonstrated by MRA and transcranial Doppler ultrasound, for every 
neurological symptom in patients with SCD.
The severity of the TCD categories following Adams’ criteria was associated with the 
grades of MRA turbulence or artery occlusion and severity of the perfusion 
abnormality, which suggests that this non-invasive technique could be a good method of
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detecting and monitoring cerebrovascular disease (CVD) and perfusion abnormality in 
SCD. Moreover, TCD might detect the presence of cerebrovascular disease before MR 
angiography.
Other clinical parameters, such as low blood pressure, might affect cerebral perfusion in 
patients with SCD, in conjunction with the underlying CVD.
In this study, perfusion MRI (DSC-MRI) appears to be the most common MRI 
abnormality in sickle cell patients, in every age group and for each neurological 
symptom. In addition, perfusion MRI demonstrated that an important proportion of 
patients with SCD were at high risk of cerebral ischemia and infarction, characteristic of 
this inherited anaemia and the underlying cerebrovascular disease found in this 
condition.
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Chapter 5: Association of Perfusion Abnormality with 
Cerebrovascular Disease and Central Nervous System Events 
in Sickle Cell Disease: A Longitudinal Study
5.1. Introduction and Aims
5.1.1. Introduction
Studies in sickle cell patients have shown that there is an underlying neurological 
deterioration in a significant proportion of these patients over time. Up to 40% of 
patients with sickle cell anaemia (SCA) and stroke have recurrent central nervous 
system (CNS) events despite blood transfusion therapy (Dobson et al 2001). The 
prevalence of silent infarcts increases with age up around 25% (Miller et al 2001, 
Saunders et al 2001); and there is a progressive decrease of IQ in children with sickle 
cell disease as they age, as demonstrated longitudinally in the US Cooperative Study of 
Sickle Cell Disease (CSSCD) (Wang et al 2001a). The high prevalence of silent infarcts 
and cognitive deterioration may be markers of progression of cerebrovascular disease 
over time, which has been well described in earlier pathological studies (Stockman et al 
1972) and more recently in longitudinal studies using MRA (Seibert et al 1998). In 
addition, cognitive deterioration was also associated with chronic anaemia (Steen et al 
1999).
Whereas there have been longitudinal studies looking at recurrence of cerebral 
infarction (overt or covert) or progression of CVD using conventional neuroimaging or 
transcranial Doppler ultrasound (Adams et al 1992 and 1998), there have been no 
reports of changes in cerebral perfusion over time, although this might be an earlier and 
more sensitive marker of cerebral ischaemia in these patients. Most of the published 
series on cerebral perfusion in SCD have been cross-sectional studies using techniques 
that involve radioactivity exposure (PET, inhaled Xenon133 [Prohnovick et al 1989, 
Huttenlocher et al 1984, Powars et al 1999]). However, two recent cross-sectional 
studies using magnetic resonance techniques (dynamic susceptibility contrast MRI 
[Kirkham et al 2001] and arterial spin labelling [Oguz et al 2003]) have shown
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abnormal cerebral perfusion in children with SCD with normal T2- weighted MRI 
(Oguz et al 2003, Kirkham et al 2001) or beyond the area of cerebral infarction 
(Kirkham et al 2001). In addition, Kirkham et al (2001) demonstrated cerebral 
perfusion deficits in association with CNS events and MRA turbulence and abnormal 
TCD in symptomatic patients with sickle cell disease.
5.1.2. Aim of the Study
The aim of this study was to examine longitudinal MR perfusion imaging findings 
together with clinical, haematological and conventional MRI and MR Angiogram 
(MRA) data in patients with sickle cell disease.
The hypothesis to be tested in this study is that in patients with sickle cell disease who 
have had a central nervous system (CNS) event, there is a progression of cerebral 
perfusion abnormality associated with progression of cerebrovascular disease (CVD) 
and with the recurrence of neurological symptoms.
The clinical questions arising from this hypothesis are the following:
1) Is there a worsening of cerebral perfusion over time in patients with sickle cell 
disease and if so, is it associated with recurrent clinical symptoms?
2) If there is a worsening in cerebral perfusion, is there any correlation with new 
infarcts or atrophy on MRI?
3) Is any worsening of perfusion abnormality correlated with worsening of 
cerebrovascular disease (as evidenced by MRA turbulence) over time?
4) Are the changes of patterns of turbulence on MRA (and cerebrovascular disease) 
correlated with changes in transcranial Doppler ultrasonography over time or 
recurrent clinical symptoms?
5) Are there haematological factors, including anaemia and leukocytosis, which 
contribute to the progression of cerebrovascular disease in SCD?
6) Is it possible to identify predictors of recurrent neurological symptoms and 
future abnormality of perfusion MRI, MRA (progression of cerebrovascular 
disease) and MRI in sickle cell patients?
212
2. Subjects
5.2.1. Patients
Data collection for the patients of this study has been partly described in chapter 2 
(Appendix Table 1).
Twenty-five patients with sickle cell disease and neurological symptoms were recruited 
for this longitudinal study. Twenty-two sickle cell patients were recruited from a 
previous cross-sectional study (Kirkham et al 2001), and they had a second perfusion 
scan between 2000 and 2003. In addition, three other sickle patients with neurological 
symptoms were recruited from referrals to joint Haematology/ Neurology clinics 
attended by the author in six North London hospitals. Therefore, in total, twenty-five 
sickle cell patients underwent MR resonance and TCD initial and follow-up, and 
follow-up pulse oximetry (SpCb) and blood pressure measurements at the Great 
Ormond Street Hospital for Children NHS Trust (GOSH) and the Institute of Child 
Health (ICH), UCL. Eight of 22 patients from the previous cross-sectional study were 
studied in collaboration with Dr Alexandra Hogan, Neuropsychologist, for her PhD 
project and she supervised their perfusion MRI investigations (between 2000 and 2003). 
All the patients had sickle cell anaemia (HbSS). Two patients from the earlier cross- 
sectional study had un-analysable gadolinium perfusion maps at follow-up, and they 
were excluded from the study. The author supervised the follow-up perfusion MRI 
studies of 17 out of 23 patients.
Twenty-three patients had a successful MR perfusion study and form the basis of this 
longitudinal study. All the data analysis was performed by the author. Twelve patients 
were males and 11 females; the mean age of the patients at the initial scan was 13.4 
years (range 6.8 to 22.5 years) and at the final scan the mean age was 15.6 years (range 
7.5 to 24.8 years). The patients were followed for a mean of 2.2 years (range 8 months 
to 3.5 years).
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5.3. Methods
5.3.1. Conventional Neuroimaging, Perfusion MRI, TCD, Oxygen Saturation, 
Blood Pressure Measurements and Haematological Parameters
The patients underwent initial and follow-up MRI, MRA, DWI, and perfusion MRI 
studies following a published protocol (Kirkham et al 2001), transcranial Doppler 
ultrasound at onset (n=17) and follow-up (n=25) and follow-up pulse oximetry (Sp02, 
20/25), with a median of 3 years (range 1 to 4 years). Measurement of blood pressure 
(usually after the perfusion MRI) was done in every patient at follow-up, unless there 
were technical reasons or the perfusion study was not supervised directly by MP (Dr 
Hogan’s cohort). The data acquisition for the perfusion investigations is described in 
chapter 3. In addition, the available haematological data were collected from the clinical 
records of the patients.
5.3.2. Analysis of the Data
For the analysis of the data of the longitudinal study, the main outcome measures were 
changes shown by neuroimaging (MRI and MRA) and studies of cerebral blood flow 
(perfusion MRI and TCD) over time. These changes were defined as improvement, no 
change or worsening of the relevant parameters (see below for how these were 
categorised). The recurrence of neurological symptoms was also documented. 
Therefore, the primary data analysis focussed on changes in the patients from either 
normal or abnormal baseline studies in relation to their symptoms and cerebral 
perfusion. It was assumed that it was impossible to demonstrate improvement from 
either a normal or from an abnormal structural MRI (i.e. that evidence of infarction 
would not disappear), or from normal MRA, TCD and perfusion MRI.
Recurrent neurological symptoms were analysed in two ways, firstly as ordinal data in 
increasing order of symptom severity (0= asymptomatic; 1= cognitive problems 
[learning/behaviour]; 2= headaches; 3= seizures; 4= posterior territory TIA; 5= anterior 
territory TIA; 6= reversible ischaemic neurological deficit [RIND]; 7= stroke; and 8=
214
coma (posterior leukoencephalopathy [PLKE]), and secondly as binary data in relation 
to an outcome (recurrence or not of neurological symptoms).
The patients had a baseline MRI which was designated as either normal or abnormal. 
Abnormal baseline MRI was defined by the presence of cerebral infarcts and/or cerebral 
atrophy on MRI at the time that the patient had the first study. Worsening o f MRI over 
time was demonstrated by the presences of new infarcts and/or new atrophy or 
progression o f the baseline cerebral atrophy on MRI by the time that the patient 
underwent the follow-up scan. The analysis of the MRI data was done firstly as ordinal 
data following an increasing order of MRI severity (0= better [or improved- not 
applicable for this variable]; 1= unchanged; and 2= worse), and secondly as binary data 
in relation to an outcome (0= better/unchanged; and 1= worse).
Baseline MRA was either normal or abnormal. Abnormal baseline MRA data were 
analysed as either ordinal or binary. Ordinal MRA data were defined by the presence of 
any grade of flow turbulence seen on the scan (coded in increasing grade of severity: 0= 
no turbulence; 1= mild; 2= moderate; 3= severe turbulence; 4= arterial occlusion; and 
5= arterial occlusion plus collaterals [moyamoya syndrome]). An improvement on MRA 
over time was defined as a decrease in the grade of the flow turbulence or return to a 
normal pattern of blood flow signal. On the other hand, worsening in the MRA pattern 
of turbulence was defined by an increase on blood flow turbulence on MRA secondary 
to different grades of artery stenosis, or lack of MRA signal in the case of artery 
occlusion. As binary data, MRA turbulence was analysed in relation to an outcome (0= 
better/ unchanged [as a single category]; 1= worse).
The patients had either a normal or abnormal baseline transcranial Doppler ultrasound 
(TCD). Abnormal transcranial Doppler ultrasound was defined as the presence of an 
abnormal pattern of arterial blood flow velocities (middle and anterior cerebral arteries) 
following criteria modified from Adams (Adams et al 1992, Kirkham et al 2001). In 
these criteria the abnormal TCD patterns were classified as binary data (0= 
better/unchanged; l=worse) or as ordinal data in increasing order of severity (0=normal; 
1= middle cerebral artery (MCA) flow velocities more than 170 cm/sec and lower than 
200 cm/sec; 2= MCA velocities equal to or higher than 200 cm/sec; 3= MCA velocities 
lower than 70 cm/sec and a ratio lowest/highest of ipsilateral MCA velocities equal or
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lower than 0.5 or an anterior cerebral artery/MCA ipsilateral highest velocities more 
than 1.2 [evidence of artery stenosis]; 4= inability to record an MCA signal in the 
presence of a demonstrated ultrasound window). Pulsatility index was not considered 
for analysis (Adams et al 1992). An improvement of TCD was defined by a decrease in 
TCD category returning to a normal ultrasound pattern of blood flow or with evidence 
of better arterial blood flow. A worsening in TCD was defined as a progression of the 
abnormal ultrasound pattern of blood flow longitudinally.
Baseline perfusion MRI of the patients was defined as normal or abnormal. Abnormal 
perfusion MRI (or DSC-MRI) was characterised as the presence of a region of increased 
mean transit time (MTT) of the passage of intravenous Gadolinium bolus through the 
cerebral vasculature, or an increase or decrease of regional cerebral blood flow (CBF) or 
cerebral blood volume (CBV). An increase of MTT and/or decreased CBF or CBV is 
seen when there is cerebrovascular disease with artery stenosis or occlusion (Kirkham et 
al 2001) which leads to slow the passage of blood flow secondary to the arterial 
obstruction. An increase in CBF and/or CBV is related to hyperaemia due to adaptative 
vasodilatation secondary to anaemia (Prohnovik et al 1989). For statistical analysis, 
perfusion MRI data were used as binary data (0= unchanged/better; 1= worse), or the 
perfusion MRI parameters were used as ordinal data in increasing order of perfusion 
severity. Abnormal perfusion MRI was characterised by visual inspection of the 
relevant parameter map; e.g. a regional increase in MTT was defined with a sign ‘+ ‘ 
(=: normal ; +: mild ; + +: moderate; + + +: severe increase in MTT); a regional 
decrease in CBF and/ or CBV was defined with a sign - ‘ (=: normal; mild decrease;
- - : moderate decrease; : severe decrease in CBF or CBV). An improvement in
cerebral perfusion on perfusion MRI was defined as a change in category of two steps 
or more towards normal for MTT, CBF or CBV. Conversely, a worsening in perfusion 
MRI was defined as a change of two or more categories away from normal. These 
criteria were adopted in order to be conservative in the identification of changes 
determined on visual assessment of parameter maps.
Statistical analysis was done using SPSS 10 for Windows. For the study of association 
among recurrent neurological symptoms, conventional neuroimaging (MRI and MRA), 
TCD and perfusion MRI, x2 and Fisher’s exact test were used for binary categorical
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data, the Mann-Whitney test for associations between binary data and ordinal data, and 
Spearman's test for ordinal data. For clinical data (follow-up blood pressure and oxygen 
saturations) logistic regression was used to investigate association between continuous 
data and binary categorical data in relation to an outcome (presence of recurrent 
neurological symptoms or not); T-Test was used to compare parametric continuous data 
(initial haematological parameters), and Mann-Whitney test for non-parametric 
continuous data (follow-up haematological parameters) against an outcome (worsening 
of perfusion MRI, MRA and MRI). Level of significance was set at p<0.05 and a trend 
for significance was defined as p> 0 .05  and p< 0.1. In relation to the multiple 
comparisons issue, it is necessary to examine the level of dependence among the set of 
explanatory variables since, given a set of associated variables, the tests are not 
independent. The correlation matrix has been used for this purpose. Although 
correlation matrix calculations might usually be reserved for interval or ratio data, 
correlation matrix calculations (multivariate analyses) based on ordinal data is accepted 
in social science data analysis (Afifi and Lark, 1990). The correlation matrix provides 
an immediate visual impression of the association among the set of explanatory 
variables and avoids the complication that arises when multidimentional contingency 
tables are used for this purpose.
5.4. Results I- Neurological Symptoms and Clinical Parameters
5.4.1. Patients and Clinical Symptoms
5.4.1.1. Clinical Symptoms- Central Nervous System Events at Presentation
The clinical symptoms of the patients are described for the 23 patients included in the 
study, i.e. those who had a successful second perfusion MRI study (figure 5.1). The 
main neurological syndrome at presentation was described in every patient with the 
clinical data obtained to date, and other recurrent symptoms (such as headaches, 
seizures and learning difficulties) considered as secondary features if  they were not the 
main neurological symptom for a given patient. All patients had neurological symptoms 
initially (figure 5.1). As the main symptom at presentation, 3 patients had coma, 7 
patients had overt infarction (clinical stroke, 29%); 1 stroke patient had accompanying
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symptoms with decreased visual acuity secondary to a parietal-occipital lobe infarction. 
Six patients had transient ischaemic attacks (TIA, 26%), of whom 4 presented with 
anterior territory TIA, and 2 with posterior territory TIA. One patient had seizures, and 
6 headaches (26%).
h e a d a c h e s  s e iz u r e s  p o s t TIA an t TIA stroke com a
Main Neurological Symptom at Presentation-Longitudinal Study
Figure 5.1. Frequency of different central nervous system events at 
presentation of sickle cell patients who had a successful second 
perfusion MRI.
5.4.1.2. Clinical Symptoms- Recurrent Neurological Symptoms During Follow-up
During follow-up, the main recurrent neurological symptom, in terms of severity, was 
considered for analysis (figure 5.2). One patient presented with coma (posterior 
leukoencephalopathy-PLKE-[coma and hypertension]; 1 patient re-stroked; 7 patients 
had TIAs (30%) (6 had anterior territory TIAs [26%] and 1 had a posterior territory 
TIA); 1 patient had seizures; and 12 had recurrent headaches (52%); one patient 
maintained asymptomatic.
However, other recurrent symptoms (on one or more occasions) were manifested in the 
patients in addition to the main recurrent neurological symptom, such as TIAs in one;
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seizures in 2; headaches in 5; and cognitive symptoms (learning difficulty and 
behaviour problems) in 14 patients.
14 -------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
asymptomatic seizures ant TIA PLKE
h e a d a c h e s  p o s t TIA stroke
Main Recurrent Neurological Symptoms- Longitudinal Study
Figure 5.2. Frequency of the main recurrent neurological symptoms 
of the sickle cell patients who had a successful perfusion MRI.
Most of these patients were on therapy. Eighteen out of 23 patients were on chronic 
blood transfusion therapy. However, during follow-up, 7/18 patients stopped blood 
transfusion: 1 patient due to antibody formation against transfused red cells, 1 patient 
because she received a bone marrow transplant, 1 patient due to poor compliance with 
blood transfusion therapy, 1 patient because a decision was made that further therapy 
was unnecessary, and 3 patients who continued treatment on Hydroxyurea (1 of these 3 
patients also had a left frontal revascularisation procedure). In addition, 1 patient was on 
Hydroxyurea (without having previous blood transfusion), and 4 patients had 
adenotonsillectomy for obstructive sleep apnoea.
5.4.2. Blood Pressure Measurement and Haematological Parameters
5.4.2.1. Blood Pressure Measurements
5.4.2.1.1. Systolic Blood Pressure
Systolic blood pressure (SBP) was measured in 15 out 23 patients at follow-up.
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At the final scan, the mean SBP of the patients was 113 mmHg (range 97 to 128 
mmHg).
In relation to the effect of SBP on recurrent neurological symptoms (figure 5.3), follow- 
up systolic blood pressure measurements were done in patients who had recurrent stroke 
(n=l), coma -PLKE- (n=l), anterior territory transient ischaemic attack -TIA- (n=6), 
headaches (n=6), and in a patient who remained asymptomatic (figure 5.3). For stroke, 
the mean SBP was 112 mmHg (50-75th percentile), for coma [PLKE], the mean SBP 
was 117 mmHg (75th -90 th percentile), for anterior TIA, it was 112 mmHg (range 97- 
128 mmHg; <50-90th percentile), for headaches 113 mmHg (range 104-125 mmHg; 
<50-90lh percentile) and for the asymptomatic patient 115 mmHg (50th percentile).
asym ptom atic h e a d a c h e s  an t TIA s tro k e  PLKE
Recurrent Neurological Symptoms in Sickle Cell Disease
Figure 5.3. Systolic blood pressure measurements in relation to SCD 
patients’ recurrent neurological symptoms at follow-up.
5.4.2.1.2. Diastolic Blood Pressure
Diastolic blood pressure (DBP) was measured in a total of 15 of the 23 patients.
At the final scan, the mean DBP of the sickle cell patients was 52 mmHg (range 30 to 
79 mmHg).
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In relation to the association of DBP with recurrent neurological symptoms (figure 5.4), 
follow-up diastolic blood pressure measurements were done in patients who had 
recurrent stroke (n=l), coma -PLKE- (n=l), anterior TIA (n=6), headaches (n=6) and in 
a patient who remained asymptomatic (figure 5.4). For stroke, the mean DBP was 54 
mmHg (<50th percentile), for coma [PLKE] 55 mmHg (<50th percentile), for anterior 
TLAs 49 mmHg (range 30-75 mmHg; <50lh to 75th percentile), for headaches was 56 
mmHg (range 31-79 mmHg; <50-90th percentile) and for the asymptomatic patient was 
49 mmHg (<50th percentile).
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Figure 5.4. Diastolic blood pressure measurements in relation to SCD 
patients’ recurrent neurological symptoms at follow-up.
5.4.2.1.3. Mean Arterial Blood Pressure (MAP)
Mean arterial blood pressure (MAP) was measured in 15 of the 23 patients.
At the final scan, the mean MAP of these patients was 74 mmHg (range 58 to 97 
mmHg).
In relation to recurrent neurological symptoms (figure 5.5.), follow-up MAP 
measurements were done in patients who had recurrent stroke (n=l), coma -PLKE- 
(n=l), anterior TIA (n=6), headaches (n=6) and in a patient who remained
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asymptomatic. For stroke, the mean MAP was 74 mmHg, for coma [PLKE] it was 76 
mmHg, for anterior TIA 72 mmHg (range 58-90 mmHg), for headaches 77 mmHg ( 
range 69-97 mmHg) and for the asymptomatic patient was 72 mmHg.
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Figure 5.5. Mean arterial blood pressure (MAP) measurements in 
relation to SCD patients’ recurrent neurological symptoms at follow- 
up.
5.4.2.1.4. Effect of Blood Pressure on Recurrent Neurological Symptoms and MRL 
MRA. TCP , and Cerebral Perfusion Changes Longitudinally- Statistical Analysis
Follow-up mean systolic, diastolic and mean arterial blood pressures were not 
significantly associated with the presence of neurological symptoms in the sickle cell 
patients of this study (p=0.79, p= 0.79 and p=0.91 respectively, logistic regression). 
There were also no significant associations between follow-up mean SBP, DBP and 
MAP and worsening of MRI (p=0.48, p=0.83 and p=0.85 respectively), worsening of 
MRA (p=0.86, p=0.36 and p=0.5 respectively), and worsening of cerebral perfusion 
(p=0.63, p=0.75 and p=0.96 respectively) longitudinally. There was a trend for 
association between worsening of TCD and diastolic blood pressure (p=0.175), where 
those patients with worse TCD over time had lower DBP measurements (mean 44 
[range 30-61] mmHg) than those with better or unchanged TCD (mean 56 [range 42-74]
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mmHg); however there were no significant associations for SBP and MPA with TCD 
(p=0.67 andp=0.41 respectively).
5.4.2. Haematological Parameters
Haematological data of the patients of this study were collected from clinical records. 
For this study the nearest blood test at steady state to the neuroimaging at onset and 
follow-up were taken.
5.4.2.1. Haemoglobin Level
Haemoglobin (Hb) level at onset: Haemoglobin level data were collected from 15 
patients. Mean Hb level was 9.10 g/dL, range from 6.5 to 13.2 g/dL. Normal values for 
age are: 6-12 years: 11.5-15.5 g/dL; 12-18 years (male): 13-16 g/dL, (female): 12-16 
g/dL; 18-28 years (male): 13.5-17.5 g/dL, (female): 12-16 g/dL.
Haemoglobin (Hb) level at follow-up: Haemoglobin level data were collected from 12 
patients. Mean Hb level was 8.9 g/dL, with a range from 6.1 to 10.9 g/dL.
5.4.2.2. Haemoglobin S%
Haemoglobin S% (HbS%) at onset: No data.
Haemoglobin S% (HbS%) at follow-up: Haemoglobin S% level data were collected 
from 5 patients. Mean HbS% level was 49.12%, with a range from 17 to 90.7%.
5.4.2.3. White Cell Count
White Cell Count (WCC) at onset: White cell count data were collected from 15 
patients. Mean WCC was 11.8 x 109/L cells, with a range from 6.9 to 20.8 x 109/L cells. 
Normal values for group age are: 4-7 years: 5.5-15.5 x 109/L cells; 8-13 years: 4.5-13.5 
x 109/L cells; 14-28 years: 4.5 11.0 x 109/L cells.
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White Cell Count (WCC) at follow-up: White cell count data were collected from 12 
patients. Mean WCC was 13.2 x 109/L cells, with a range from 7.5 to 50 x 109/L cells.
5.4.2.4. Neutrophils
Neutrophils at onset: No data.
Neutrophil at follow-up: Neutrophil count data were collected from 9 patients. Mean 
neutrophil count was 11.82 x 109/L cells, with a range from 1.9 to 43.8 x 109/L cells 
(normal neutrophil ‘segs’ 3.0 -5.8 cells x 109/L).
5.4.2.5. Lymphocytes
Lymphocytes at onset: No data.
Lymphocytes at follow-up: Lymphocyte count data were collected from 9 patients. 
Mean lymphocyte count was 3.86 x 109/L cells, with a range from 1.7 to 5.7 x 109/L 
cells (normal 1.5-3.0 x 109/L cells).
5.4.2.6. Platelets
Platelets at onset: Platelet counts were collected from 15 patients. Mean platelet count 
was 311 x 109/L cells, with a range from 112 to 504 x 109/L cells (normal 150-400 x 
109/L cells).
Platelets at follow-up: Platelet count data were collected from 12 patients. Mean platelet 
count was 374 x 109/L cells, with a range from 239 to 594 x 109/L cells (normal 150- 
400 x 109/L cells).
5.4.2.11. Relation o f Haematological Parameters at Onset and Follow-up with 
Worsening Perfusion, MRI and MRA- Statistical Analysis
Worsening perfusion MRI was not significantly associated with initial haemoglobin 
level (p=0.94, T-Test), white cell count (p=0.84) and platelet count (p=0.22). However,
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there was a trend for association between worsening of cerebral perfusion over time and 
increased white cell count at follow-up (p=0.089, Mann-Whitney test, figure 5.6), but 
worsening of cerebral perfusion was not significantly associated with follow-up Hb 
levels (p=0.2), neutrophils (p=0.7), lymphocytes (p=0.8) or platelets (p=0.73)
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Figure 5.6. Relation between worsening of perfusion MRI over time 
and white cell count at follow-up.
Worsening of MRA was not associated with initial Hb level (p=0.39, T-test), on white 
cell count (p=0.4), but it was significantly associated with decreased initial platelet 
count (p=0.008, figure 5.7). In addition, worsening of MRA was not associated with 
follow-up Hb levels (p=0.47, Mann-Whitney test), white cell count (p=0.34), 
neutrophils (p=0.52), lymphocytes (p=0.44) or platelet count (p=0.94).
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Figure 5.7. Relation between worsening of MRA over time and initial 
platelet count.
There were trends for association between worsening of MRI and increased follow-up 
white cell count (p= 0.12, Mann-Whitney test, figure 5.8) and lymphocytes (p=0.14, 
figure 5.9). There were no significant associations for initial Hb level, white cell or 
platelets counts (p=0.9, p=0.46 and p=0.48, respectively, T-test) or for follow-up Hb 
level, neutrophil or platelet counts (p=0.63, p=0.71 and p=0.8, Mann-Whitney test).
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Figure 5.8. Relation between worsening of MRI over time and white 
cell count at follow-up.
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Figure 5.9. Relation between worsening of MRI over time and 
lymphocyte count at follow-up.
5.4.3. Awake Oxygen Saturation
Blood oxygen saturation (Sp02) was measured with a pulse oximeter (chapter 2) for 
three minutes in 20 out of 23 sickle cell patients, just before or after the MR studies at 
the final MR scans. Median Sp02 was 96%, range 92 to 98.4%. As described in chapter 
2, the cut-off used for hypoxaemia is Sp02 < 92, therefore these patients had day time 
oxygen saturations within the normal limits accepted by the GOSH Respiratory 
Laboratory (figure 5.10).
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Figure 5.10. Awake Oxygen Saturation in Relation to SCD Patients’ 
Recurrent Neurological Symptoms.
5.4.3.1. Effect o f  Awake Oxygen Saturations on Recurrent Neurological Symptoms 
and MRI, MRA, TCD, and Cerebral Perfusion Changes Longitudinally -  Statistical 
Analysis
Follow-up awake oxygen saturations (Sp02) of these patients were not significantly 
associated with the presence of recurrent neurological symptoms (p=0.58, logistic 
regression). There was also no significant association between awake Sp02 and 
worsening of MRI (p=0.68), worsening of MRA (p=0.94), worsening of TCD (p=0.39) 
or worsening of cerebral perfusion (p=0.96).
5.5. Results II: Recurrent Neurological Symptoms and MR and TCD 
Investigations
5.5.1. Association between MRI and Recurrent Neurological Symptoms 
Longitudinally
Twenty three sickle cell patients underwent initial and follow-up T2- weighted MRI 
scans. Seventeen patients had unchanged MRI and 6 patients had worsening of MRI 
during a follow-up of a mean of 2.2 years (range 8 months to 3.5 years, Appendix tables 
3 and 4).
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Of the patients who had longitudinally unchanged MRI, 9/17 had normal MRI 
throughout; all of these patients had headaches as the main recurrent symptom; 2/9 were 
on chronic blood transfusion therapy, which was stopped during the follow-up, 
although, one patient continued on Hydroxyurea; another patient was treated with 
Hydroxyurea only.
Eight of 17 patients had unchanged MRI with an abnormal baseline MRI. Five out of 
eight patients had anterior territory transient ischaemic attacks (TIAs); all of these sickle 
cell patients were on blood transfusion therapy but 3 of them stopped treatment during 
follow-up. MRI abnormalities consisted of small covert infarcts (unilateral in 1, 
multiple and bilateral infarcts in 2; both of the latter patients stopped blood transfusion, 
but one had a revascularisation procedure and continued on Hydroxyurea); unilateral 
multiple covert and overt infarcts in a patient who had stroke despite blood transfusion; 
and multiple covert and overt infarcts in an another patient who also had stroke but 
stopped blood transfusion and received a bone marrow transplant. Two out of eight 
patients with abnormal baseline and unchanged MRI presented with headaches; both 
patients were on blood transfusion and had a history of stroke, one had a medium sized 
unilateral infarct and the other had bilateral large infarcts and cerebral atrophy. One out 
of 8 patients, who had a history of stroke and continued with chronic blood transfusion, 
had unchanged MRI and no recurrent symptoms.
Six out of 23 patients had worsening of MRI during the follow-up. All of them were on 
blood transfusion therapy initially, but two patients stopped treatment. Five of these 6 
patients had had previous stroke, with overt infarction (4 bilateral, 1 unilateral), and 1 
patient had had a posterior territory TIA and a normal baseline MRI.
During follow-up, 3 patients (2 with history of stroke) had new infarcts (2 unilateral and 
1 bilateral) and 3 other patients had new cerebral atrophy. The recurrent neurological 
symptoms in the patients who had history of stroke were the following: coma -posterior 
leukoencephalopathy- (n=l; new unilateral infarct), re-stroked (n=l; new unilateral 
infarct; stopped blood transfusion due to antibody formation against transfused red 
cells), anterior territory TIA (n=l; new atrophy), seizures (n=l; new cerebral atrophy), 
and headaches in conjunction with decreased visual acuity (n=l; new occipital cerebral 
atrophy). One patient without history of stroke and worsening of MRI had further
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posterior territory TIAs on discontinuing blood transfusion (n=l, new bilateral 
watershed infarcts).
Only one patient with a normal baseline MRI developed new infarction (covert) and 
transient neurological symptoms (posterior territory TIA [table 5.1]). Five out of 6 
patients with worsening MRI scans had had previously abnormal baseline MRIs and all 
were on blood transfusion. Only one patient discontinued treatment and re-stroked 
(table 5.1). Patients (n=9) with normal baseline, which persisted normal through the 
study, had less severe symptoms such as headaches. However, those patients with 
abnormal baseline and unchanged MRI (all of them initially on blood transfusion) 
presented with a variety of recurrent symptom severity from being asymptomatic (only 
one patient) to TIAs (predominantly). The patients (n=2), who had the most severe 
recurrent symptoms (stroke and coma [PLKE]) had abnormal baseline and worsening 
MRI despite being on chronic blood transfusion, although one of them stopped blood 
transfusion because of antibody formation against the transfused red cells. The effect 
of blood transfusion therapy on MRI changes over time will be discussed in chapter 6.
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Change Over Time (n= 23 Sickle Cell Patients)
MRI
Recurrent
Neurological
Symptoms
(n=patients)
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Baseline
Normal
Baseline
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Baseline
Normal
Baseline
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Baseline
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(PLKE)
(n=l)
1(1 )
F
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1 ( 1 ) ,s
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A
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Table 5.1. Changes over time on MRI in relation to recurrent neurological symptoms 
and therapy in patients with sickle cell disease. Longitudinal study.
BTx: Blood transfusion therapy 
PLKE: Posterior leukoencephalopathy 
TIA: Transient ischaemic attack
HU Number of sickle cell patients on Hydroxyurea therapy 
* Number of patients who stopped blood transfusion therapy during follow-up
?Hl Number of patients who stopped blood transfusion therapy and continued with Hydroxyurea during 
follow-up
§BMT Number of patients who stopped blood transfusion therapy and had bone marrow transplant during 
follow-up
§ h u + r v  dum ber of patients who stopped blood transfusion therapy, had surgical revascularisation 
procedure and continued with Hydroxyurea during follow-up.
 ^ No data because no improvement can be demonstrated from a normal study or from a study 
showing the presence of lesions.
Patients from Appendix Tables 3 and 4 (Patient number): A: 3, 15, 17,18, 19, 20, 21, 22, 23 / B: 7,10, 12, 
13, 14 / C: 2, 5 / D 11/ E: 16/ F  1/ G 8/ H: 6 /1: 4/ J: 9
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5.5.1.1. M R I  P redictors o f  w orsen ing  M R I  a n d  R e c u rre n t N euro log ica l S y m p to m s  
over T im e
Previous stroke (overt cerebral infraction) was the main predictor of worsening of MRI 
and recurrent neurological symptoms such as coma (PLKE), stroke recurrence and 
seizures. These patients were initially on chronic blood transfusion therapy, which did 
not prevent stroke recurrence in 1/3 patients, or progression to cerebral atrophy in a 
further 2. Only one patient with previous history of stroke and on blood transfusion 
remained asymptomatic and with unchanged follow-up MRI.
Patients who had recurrent anterior territory TIAs were initially on blood transfusion 
and all had infarction on the baseline MRIs. Three out of 5 patients stopped transfusion 
and 2 of those continued with alternative treatments (table 5.2).
Patients with normal baseline MRI had mainly headaches and remained with normal 
MRI studies throughout, except for one patient who had a posterior territory TIA and 
had recurrent posterior TIA and covert infarcts on the follow-up MRI (having stopped 
blood transfusion).
5.5.1.2. C hanges Over T im e on M R I  a n d  R e c u rre n t N euro log ica l S y m p to m s  in  S C D -  
S ta tis tica l A n a ly s is
The manifestation of recurrent neurological symptoms was not significantly associated 
with worsening of MRI (p=l, Fisher’s exact test). Excluding headache, which has not 
been clearly demonstrated to be a symptom of vascular insufficiency (Pavlakis et al 
1986), symptoms such as stroke, TIAs and seizures, were selected for having been 
reported as manifestation of ischaemia or/and cerebrovascular disease in SCD (Powars 
1978, Pavlakis et al 1989, Ohene-Frempong et al 1991, Liu et al 1994, Miller et al 
1999, Prengler et al 2002). Analysis of the data showed a weak trend for patients who 
presented with stroke, seizure or TIAs to have worsening of MRI (p=0.16; Fisher’s
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exact test). Recurrent headaches and anterior TIA were significantly associated with 
unchanged MRI (p=0.002 and p=0,009; Fisher’s exact test). It was not possible to 
analyse associations between other symptoms and unchanged MRI, and between 
individual recurrent symptoms and worsening of MRI because the numbers were too 
small.
Analysing the whole group of recurrent neurological symptoms as ordinal data with 
increasing impairment, the severity of the recurrent symptoms was significantly 
associated with changes on MRI over time and infarct number (p=0.029 and p=0.001 
respectively; Spearman’s correlations, tables 5.2 and 5.3). Patients without or with less 
severe symptoms had unchanged MRI, but patients with anterior territory TIAs also 
had unchanged MRI. Patients who re-stroked and the one presenting with coma 
(PLKE) had a worse MRI at follow-up.
Changes on MRI Total
Recurrent Symptom Unchanged Worse
Asymptomatic 1 1
Headache 11 1 12
Seizures 1 1
Posterior TIA 1 1
Anterior TIA 5 1 6
Stroke 1 1
Coma (PLKE) 1 1
Total 17 6 23
Table 5.2. Severity of recurrent neurological symptoms in sickle cell 
patients and changes on MRI over time.
Patients with 2 or more infarcts at follow-up (new or old infarcts) were more likely to 
have severe recurrent neurological symptoms such as seizures, TIAS, stroke or coma 
(PLKE) (table 5.3).
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Recurrent
Symptom
Infarct Number at Follow-Up Total
No
Infarct
1
Infarct
2
Infarcts
3
Infarcts
Multiple
Infarcts
Asymptomatic 1 1
Headache 9 1 2 12
Seizures 1 1
Posterior TIA 1 1
Anterior TIA 2 1 3 6
Stroke 1 1
Coma (PLKE) 1 1
Total 9 1 4 1 8 23
Table 5.3. Recurrent neurological symptoms in sickle cell patients 
and infarct number on follow-up MRI.
There was a trend for an association between the severity of the recurrent neurological 
symptoms and infarct size (p=0.059, Spearman’s correlation, table 5.4). Patients with 
moderate to large cerebral infarcts on MRI at follow-up had recurrent seizures or stroke 
or in a fewer number TIAs. However, those with small infarcts also have 
predominantly TIAs (anterior and posterior territories) and coma (PLKE).
Recurrent
Symptom
Infarct Size Total
No
infarct
< 1cm- 
small
1-5 cm- 
moderate
> 5 cm- 
large
Asymptomatic 1 1
Headache 9 2 1 12
Seizures 1 1
Posterior TIA 1 1
Anterior TIA 4 1 1 6
Stroke 1 1
Coma (PLKE) 1 1
Total 9 6 5 3 23
Table 5.4. Recurrent neurological symptoms in sickle cell patients and 
infarct size on follow-up MRI.
5.5.2. Association of MRA and Recurrent Neurological Symptoms
Twenty three patients underwent initial and follow-up MR angiogram (MRA). Four out 
of 23 patients had an improvement in the grade of MRA turbulence, 10 patients had 
unchanged studies, and 9 patients had a worsening of the MRA turbulence on the final
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scans (table 5.5). The categorisation of MRA abnormality in terms of on flow 
turbulence/occlusion, was based on the most severe grade of MRA abnormality for each 
patient.
All four patients with an improved MRA had an abnormal baseline study, and all of 
them were initially treated with blood transfusion, although 3 patients stopped this 
treatment during follow-up. However, these patients manifested a variety of recurrent 
neurological symptoms (patients’ treatments in table 5.5). In this group of patients, 
improvement in MRA turbulence was seen in the anterior cerebral circulation (terminal 
internal carotid artery [TICA], middle cerebral artery [MCA] and anterior cerebral 
artery [ACA]). MRA improved from moderately severe (grade 2-3) to normal (grade 0) 
or mild (grade 1) turbulence. One patient had an anterior territory TIA, and another 
presented with a recurrent posterior territory TIA. The remaining two patients had 
headaches; in one the MRA improved to normal in association with blood transfusion, 
but tICA turbulence returned when he stopped treatment (patient no. 20).
Ten patients had unchanged MRA throughout the study; 7 of the 10 had a normal 
baseline MRA, and 3 had an abnormal baseline study. Six of the 7 patients with normal 
baseline MRA (which remained normal during follow-up) had predominantly 
headaches. Only one patient presented with coma and hypertension (PLKE; he had a 
previous history of stroke). Three patients had abnormal baseline MRA turbulence in 
the anterior circulation. These patients had a range of recurrent neurological symptoms, 
one patient with artery occlusion had recurrent seizures; one patient with moderate 
artery turbulence continued to have headaches; the remaining patient with mild artery 
turbulence had no recurrent symptoms during follow-up.
Nine patients had worsening of MRA at the final scan. One of the 9 patients had a 
baseline normal MRA with progression from a normal study to mild turbulence in the 
anterior circulation, and he had headaches. Eight patients had an abnormal baseline 
MRA, all of who were initially on a blood transfusion programme. One patient re­
stroked with progression from unilateral to bilateral artery occlusion, collaterals and 
severe turbulence in other vessels. Four out of the remaining 7 patients had anterior 
territory TIAs with a baseline MRA with moderate to severe turbulence, which 
progressed to artery occlusion and collaterals (n=l), collaterals (n=l), or severe
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turbulence with pre-existent collaterals (n=2). In one, new turbulent flow developed in 
previously normal vessels (n=l). Two of 8 patients had headaches; MRA changed from 
severe turbulence to occlusion and moyamoya syndrome in one; and from moyamoya 
syndrome to the addition of artery turbulence in the posterior vascular territory in the 
other. These two patients had stroke and they were on chronic blood transfusion.
As can be seen in table 5.5, only one patient with a normal baseline MRA had worse 
MRA at follow-up. Patients with stroke and anterior TIA had a baseline MRA that was 
worse at follow-up, except for one patient. Patients with headaches had predominantly 
normal baseline MRA which remained unchanged.
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Change Over Time (n=23 Sickle Cell Patients)
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Table 5.5. Changes over time on MRA in relation to recurrent neurological symptoms 
and therapy in patients with sickle cell disease.
BTx: Blood transfusion therapy 
PLKE: Posterior leukoencephalopathy 
TIA: Transient ischaemic attack
111 Number of sickle cell patients on Hydroxyurea therapy 
s Number of patients who stopped blood transfusion therapy during follow-up
*Hl Number of patients who stopped blood transfusion therapy and continued with Hydroxyurea during 
follow-up
^BM1 Number of patients who stopped blood transfusion therapy and had bone marrow transplant during 
follow-up
§ h u + r v  dumber of patients who stopped blood transfusion therapy, had surgical revascularisation 
procedure and continued with Hydroxyurea during follow-up 
I—I No data because no improvement can be demonstrated from a normal MRA
Patients from Appendix Tables 3 and 4 (Patient number): A: 12 / B: 16/ C: 18, 20/ D: ME: 3, 15, 17, 19,
21, 22 IF: 4/ G: 2/ H  11/ / :  23/7: 8 / K: 6, 7, 10, 13, 14/ L: 5, 9
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5.5.2,1, Predictors o f Recurrent Neurological Symptoms and Worsening MRA
Sickle cell patients who manifested the most severe recurrent neurological symptoms, 
such as stroke and anterior territory TIAs, had a worsening MRA pattern, as an 
indicator of progression of cerebrovascular disease (CVD), despite being on blood 
transfusion therapy. Patients with seizures, headaches or asymptomatic had unchanged 
or improved MRA pattern throughout; however, seizures could accompany other more 
severe neurological symptoms such as TIA (not included here, because the most severe 
recurrent neurological symptom was used in the analysis for each patient), and might 
also be a symptom of progression of CVD (see Chapter 7). The two patients who had 
recurrent headaches associated with worsening on MRA were patients with a previous 
history of stroke and CVD.
5.5.2.2. Changes over Time on MRA and Recurrent Neurological Symptoms in SCD- 
Statistical Analysis
Abnormal MRA at follow-up was not significantly associated with the presence of 
recurrent neurological symptoms, including headaches (p=l, Fisher’s exact test). 
However, there were trends for associations between worse MRA and recurrent 
symptoms of stroke, TIAs or seizures (p= 0.07, Fisher’s exact test) and recurrent TIAs 
(p=0.06, Fisher’s test). There was also a trend for association between recurrent 
headaches and unchanged MRA at follow-up (p= 0.06, Fisher’s test); other symptoms 
could not be analysed independently because of the small numbers.
Severity of grade of MRA turbulence at follow-up was significantly associated with 
recurrent stroke, TIAs or seizures (p=0.007, Mann-Whitney’s test, table 5.6).
Recurrent Symptom 
TIA, Stroke, or 
Seizures
MRA Turbulence at Follow-u p Total
Normal Mild Moderate Severe Occlusion Occlusion + 
Collateral
Absence 8 2 2 2 14
Presence 1 2 2 2 2 9
Total 8 3 4 2 2 4 23
Table 5.6. Relation between grade of MRA turbulence at follow-up 
and recurrence of stroke, transient ischaemic attack TIA or seizures 
(p=0.007).
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Increasing grade of MRA turbulence at follow-up was significantly associated with 
MRA changes over time (better, unchanged and worse), and there was a trend for an 
association between the severity of recurrent neurological symptoms and increase in 
MRA turbulence (p= 0.002 and p=0.05 respectively, Spearman’s correlation, tables 5.7 
and 5.8).
Changes on MRA 
over Time
MRA Turbulence at Follow-up Total
Normal Mild Moderate Severe Occlusion Occlusion + 
collaterals
Better 1 1 2 4
Unchanged 7 1 1 1 10
Worse 1 1 2 1 4 9
Total 8 3 4 2 2 4 23
Table 5.7. Relation between grade of MRA turbulence at follow-up 
and MRA change over time.
Recurrent
Symptom
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion + 
Collaterals
Asymptomatic 1 1
Headache 7 1 2 2 12
Seizures 1 1
Posterior TIA 1 1
Anterior TIA 2 2 1 1 6
Stroke 1 1
Coma (PLKE) 1 1
Total 8 3 4 2 2 4 23
Table 5.8. Relation between grade of MRA turbulence at follow-up 
and recurrent neurological symptoms.
5.5.3. Association of Transcranial Doppler Ultrasound and Recurrent Neurological 
Symptoms
Seventeen sickle cell patients underwent initial and follow-up transcranial Doppler 
ultrasound (TCD, which assessed mainly cerebral anterior circulation (MCA, AC A). 
The patient who re-stroked and the one who had coma (posterior leukoencephalopathy)
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as recurrent neurological symptoms did not have initial TCD and they were not included 
in this section. Median maximum MCA velocities (maximum velocity of both MCAs) 
were 115 cm/sec (range 30-219 cm/sec-available data-) at onset, and 91 cm/sec (range 
0-220 cm/sec) at follow-up.
Two of 17 patients had improved TCD, 8 had unchanged TCD, and 7 had worsening 
TCD at the end of the study (see table 5.9).
The two patients with improved TCDs had abnormal baseline studies. One patient had 
an anterior territory TIA, stopped blood transfusion, had a revascularisation procedure 
and continued with Hydroxyurea. This patient had initially an undetectable MCA, and 
at follow-up, a detectable MCA with decreased velocities less than 70 cm/sec (lowest: 
highest ratio <0.5). The other patient (who had headaches) had at onset decreased MCA 
velocities less than 70 cm/sec, and had normal TCD as her final study.
Eight patients had unchanged TCD. Two of the 8 patients continued to have normal 
studies and had recurrent headaches. Six of 8 patients had abnormal baseline studies, all 
of them were initially on blood transfusion: 2 patients had anterior territory TIAs and 
undetectable MCA (n=l), and low MCA flow velocities < 70 cm/sec (n=l). One patient 
had seizures (who had stroke and MCA velocities > 200 cm/sec in her first TCD before 
being included in this study), and two patients with headaches maintained MCA 
velocities <70 cm/sec throughout.
Seven patients had a worsening TCD longitudinally. Six of these patients were initially 
on blood transfusion (BTx); 4 patients stopped transfusion but 2 of those continued with 
alternative treatments. Two of the 7 patients had a normal baseline TCD (on blood 
transfusion) and had headaches; one had had stroke and from a normal TCD progressed 
to undetectable MCA; the other patient progressed to decreased MCA blood flow 
velocity less than 70 cm/sec (he stopped BTx and continued with Hydroxyurea). Five 
patients had an abnormal baseline TCD; 3 of these patients (on Btx, one stopped, 
another had a bone marrow transplant) presented with anterior territory TIAs, the TCDs 
of two of them progressed from low MCA velocities <70 cm/sec to an undetectable 
MCA, and another patient from MCA velocities > 200cm/sec (severe turbulence) to low 
MCA velocities <70 cm/sec. Of the other 2 patients with abnormal baseline TCD, one
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had a posterior TIA (stopped BTx), and the other headaches (no BTx) with low MCA 
velocities < 70 cm/sec to undetectable MCA.
As can be seen from table 5.9, only 2 patients with a normal baseline TCD had impaired 
studies at follow-up. Two third of the patients with TIAs and abnormal baseline TCD 
had worsening of their MCA blood flow. Patients with headaches had a variety of TCD 
changes, however 2/3 of these patients had unchanged or better TCD at follow-up and 
1/3 had impaired MCA flow despite blood transfusion. The asymptomatic patient (on 
BTx) maintained his TCD pattern throughout.
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Table 5.9. Changes over time on transcranial doppler ultrasound (TCD) in relation to 
recurrent neurological symptoms and therapies in patients with sickle cell disease.
No comparative data (no initial TCD)
BTx: Blood transfusion therapy 
PLKE: Posterior leukoencephalopathy 
TIA: Transient ischaemic attack
Hl Number of sickle cell patients on Hydroxyurea therapy 
* Number of patients who stopped blood transfusion therapy during follow-up
>SHL Number of patients who stopped blood transfusion therapy and continued with Hydroxyurea during 
follow-up
*BM 1 Number of patients who stopped blood transfusion therapy and had bone marrow transplant during 
follow-up
sm-m dumber of patients who stopped blood transfusion therapy, had surgical revascularisation 
procedure and continued with Hydroxyurea during follow-up
] No data because no improvement can be demonstrated from a normal TCD
Patients from Appendix Tables 3 and 4 (Patient number):
A: 14 / if; 17 / C: 18, 23 / D: 6,7 / E: 4 / F:3, 20 I G: 11 / H: 15,9 / 7:10,12,13 /J : 16 / AT: 22
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5.5.3.1. Predictors o f Recurrent Neurological Symptoms and Worsening TCD
At follow-up, fifty percent of patients with TIAs had a worse TCD despite BTx, 60% of 
patients with headaches had better or unchanged study (with and without BTx), and one 
patient with seizures remained with the same TCD flow velocities (on BTx).
5.5.3.2. Changes over Time on TCD and Recurrent Neurological Symptoms in SCD- 
Statistical Analysis
Abnormal transcranial Doppler ultrasound study at follow-up was not significantly 
related to the presence or absence of recurrent neurological symptoms, including 
headaches (p=l, Fisher’s exact test), or with patients who have only recurrent TIAs or 
seizures (p=0.63). However, there were weak trends for an association between 
recurrent TIAs and headaches and worsening TCD (p=0.14 and p= 0.14 respectively, 
Fisher’s exact test). The other recurrent symptoms could not be analysed because the 
numbers were small.
There was a trend for an association between severity of TCD category at follow-up 
(from normal to undetectable MCA) and recurrent TIAs or seizures (p=0.095, Mann- 
Whitney test, table 5.10).
Recurrent 
TIA or 
Seizures
TCD at Follow-Up Total
Normal MCA
>170
<200
cm/sec
MCA
>200
cm/sec
MCA 
veloc< 70 
cm/sec & 
ratio H:L 
=<0.5
Undetec­
table
MCA
No 3 4 2 9
Yes 4 4 8
Total 3 0 0 8 6 17
Table 5.10. Relation between transcranial Doppler ultrasound 
categories of severity at follow-up and recurrent TIA or seizures.
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There was no significant association between TCD category of severity and changes of 
TCD over time -better, unchanged, worse- (p=0.57 Spearman’s rho correlation). 
However, there were trends for associations between severity of TCD at onset and 
follow-up and recurrent neurological symptoms (p=0.07 and p=0.1, Spearman’s 
correlations, tables 5.11 and 5.12).
Recurrent
Symptom
Initial TC]0 Total
Normal MCA
>170
<200
cm/sec
MCA V 
>200 
cm/sec
MCA V 
<70 
cm/sec & 
ratio H:L 
<0.5
Undetec­
table
MCA
Asympto­
matic
1 1
Headache 4 4 8
Seizures 1 1
Post TIA 1 1
Ant TIA 1 3 2 6
Total 4 0 1 10 2 17
Table 5.11. Relation between recurrent neurological symptoms and TCD 
categories of severity at onset in sickle cell patients (p=0.07).
Recurrent
Symptom
TCD at Follow-Up Total
Normal MCA V 
> 170 < 
200 
cm/sec
MCA V 
>200 
cm/sec
MCA V 
<70 
cm/sec & 
ratio H:L 
=<0.5
Undetec­
table
MCA
Asympto­
matic
1 1
Headache 3 3 2 8
Seizures 1 1
Post TIA 1 1
Ant TIA 3 3 6
Total 3 0 0 8 6 17
Table 5.12. Relation between recurrent neurological symptoms and 
TCD categories of severity at follow-up in sickle cell patients (p=0.1).
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From tables 5.11 and 5.12, most of the patients with headaches who had had previous 
normal studies maintained their normal TCD pattern at follow-up, in contrast to patients 
with more vascular symptoms such as TIAs or seizures whose TCD studies did not 
improve despite blood transfusion. These patients maintained unchanged studies with 
decreased MCA flow velocities (very severe arterial stenosis) or undetectable MCA 
(probable artery occlusion) or progressed from an abnormal TCD baseline pattern to 
artery occlusion. One patient with MCA velocities > 200 cm/sec (severe arterial 
stenosis) progressed to decreased flow velocities (increased artery stenosis leading to 
occlusion).
5.6. Results III: Perfusion Abnormality and Recurrent Neurological 
Symptoms
5.6.1. Association of Perfusion Abnormality and Recurrent Neurological 
Symptoms
Twenty-three sickle cell patients underwent perfusion MRI (dynamic susceptibility 
contrast-MRI) with intravenous bolus of Gadolinium (Gd bolus tracking) at onset and 
they had repeat studies after a mean of 2 years (range 8 month to 3.5 years). The 
patients and their initial and follow-up perfusion MRI studies are described in Appendix 
tables 3 and 4 and 5.13 respectively.
At the end of the study (table 5.13), 6 patients had improved perfusion MRI, 9 had 
unchanged perfusion MRI and 8 patients had a worsening of their perfusion studies. 
Perfusion abnormalities consisted mainly of a region of increased mean transit time 
(MTT) of the passage of the IV Gd bolus or decreased cerebral blood flow (CBF).
The six patients with sickle cell disease who had improved perfusion MRI at follow-up, 
all had an abnormal baseline perfusion MRI and all were initially on blood transfusion 
therapy (BTx). Two patients had recurrent anterior territory TIAs: one patient had had 
stroke and had bilateral regions of perfusion abnormalities in the MCA/ACA territory,
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despite having a previous unilateral cerebral infarction; at follow-up he had a regional 
improvement bilaterally in the same vascular territory. The other patient had had 
previous TIAs and covert infarctions on MRI, and bilateral perfusion abnormalities in 
the MCA/PCA territories; he had a regional improvement in the parietal-occipital areas, 
and had undergone revascularisation. One of the 6 patients had recurrent posterior 
territory TIAs (bilateral covert infarction; stopped BTx), 1 had seizures (bilateral stroke, 
on BTx) and 1 headaches (stroke, on BTx); these 3 patients had abnormal regional 
perfusion in the MCA/PCA territory beyond the area of infarction, and they had an 
improvement in regional perfusion in the area adjacent to the infarction, which was 
previously abnormal. One patient had severe headaches with normal MRI, and had 
extensive perfusion abnormalities in the MCA territory bilaterally; this patient had a 
dramatic improvement in the abnormal regional perfusion parameters after a year on 
blood transfusion. However, after stopping treatment he had new bilateral regions of 
perfusion abnormality in the temporal-occipital areas and he continued to have less 
severe headaches (patient no. 20, Appendix tables 3 and 4).
Nine patients had unchanged perfusion MRI during follow-up. Seven out of 9 patients 
had had a normal baseline study, which persisted as normal throughout, and continued 
to have headaches; only one patient was on BTx and another on Hydroxyurea (HU) 
therapy. Two of the 9 patients had abnormal baseline MRI perfusion which remained 
unchanged, and both patients were on BTx initially. One patient had recurrent anterior 
TIAs (covert infarcts, stopped BTx) and had bilateral perfusion abnormalities in the 
frontal-parietal areas. The other patient (covert infarct, BTx) had abnormal unilateral 
perfusion in the parietal subcortical in the infarct area and beyond, and he remained 
asymptomatic (figure patient with unchanged perfusion).
Eight of 23 patients had a worsening in their perfusion MRI studies at follow-up. One 
patient had a normal baseline study, and had headaches (he stopped BTx and continued 
with HU); at follow-up he had an unilateral region of perfusion abnormality in the 
cortical temporal region.
Seven out of 8 patients with worse perfusion MRI had abnormal baseline studies and 
they were all initially on blood transfusion. One patient had coma (PLKE) and new 
cerebral infarct (on BTx, previous stroke) and another patient re-stroked (previous
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stroke, she stopped BTx due antibody formation); both patients had progression of 
perfusion abnormality, which was already beyond the infarct area, to new areas of 
abnormal regional perfusion in the MCA or MCA/PCA territories. Three patients 
presented with anterior territory TIAs, of whom 2 patients had history o f stroke and 
presented with new cerebral atrophy on MRI (one BTx, another stopped BTx and had 
bone marrow transplant) and one had previous TIAs, seizures and covert infarctions on 
MRI (BTx). All of these patients had extension of perfusion abnormality beyond the 
infarct area and also new areas of abnormal cerebral perfusion ipsilaterally (n=2) and 
contralaterally (n=l). Two other patients, who had had stroke, manifested recurrent 
headaches and were on blood transfusion, had extension in the MCA/AC A (n=l) and 
PCA/MCA (n=l) territories of the regional perfusion abnormalities beyond the infarct 
area and now in contralateral regions; the patient with abnormal PCA/MCA perfusion, 
which led to occipital cortical atrophy, also had decreased unilateral vision. In 
summary, 4 of 8 patients who had worsening of perfusion also presented with 
worsening of MRI (2 patients new infarct and 2 new cerebral atrophy).
As can be seen from inspection of Appendix tables 3 and 4, there is a general 
consistency between the anatomical location of perfusion abnormality (involving 
cortical/subcortical areas) and recurrent neurological symptoms of demonstrated 
vasculopathy/ischaemic cause (stroke, TIAs and seizures). However, there was no 
demostrated association between headaches and perfusion abnormality as the majority 
of these patients had normal perfusion studies at follow-up, with the exception of a few 
patients.
From table 5.13, only one patient with a normal baseline had a worse perfusion MRI at 
follow-up. All the patients whose perfusion status deteriorated were on blood 
transfusion initially and had an abnormal baseline perfusion MRI. The three patients 
who improved their cerebral perfusion were on blood transfusion initially, although 2 
stopped BTx and another had revascularisation and continued on HU. Fifty percent of 
patients with anterior TIAs had worse perfusion studies despite blood transfusion. 
Sixty-three percent (7/12) of patients with headaches had normal perfusion and 
continued unchanged during follow-up.
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Change Over Time (n= 2 3  Sickle Cell Patients) 
Perfusion MRI (DSC-MRI)
Recurrent
Neurological
Symptoms
(n=patients)
Better
(BTx)
Unchanged
(BTx)
Worse
(BTx)
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
Coma
(PLKE)
(n=l) 1 ( 1 ) /
Stroke
(n=l) K D ,§
j
Anterior 
Territory TIA
(n=6)
2 ( 2 )
1 § H U + R V
A
i ( i ) ,§
F
3 ( 3 )
1 § B M T
K
Posterior 
Territory TIA
(n= l)
K D 1§
B
Seizures
(n=l)
1 ( 1 )
C
Headaches
(n-12)
2 ( 2 ) ' 5 7 ( l ) lS
1 H U
1 0 )
1 § H U
2 ( 2 )
D E H L
Asymptomatic
(n=l)
1 ( 1 )
G
Table 5.13. Perfusion MRI over time and recurrent neurological symptoms in sickle 
cell patients and their treatments.
BTx: Blood transfusion therapy 
PLKE: Posterior leukoencephalopathy 
TIA: Transient ischaemic attack
HU Number of sickle cell patients on Hydroxyurea therapy 
§ Number of patients who stopped blood transfusion therapy during follow-up
§HU Number of patients who stopped blood transfusion therapy and continued with Hydroxyurea during 
follow-up
^BM 1 Number of patients who stopped blood transfusion therapy and had bone marrow transplant during 
follow-up
§ h i > r v  dumber of patients who stopped blood transfusion therapy, had surgical revascularisation 
procedure and continued with Hydroxyurea during follow-up
| No data because no improvement can be demonstrated from a normal perfusion MRI study.
Patients from Appendix Tables 3 and 4 (Patient number): A: 7, 14 IB:  16 / C: 4 ID:  2, 20 / E: 3, 
17,18,19,21,22,23 / F: 12/(7: 1 1 /H: 1 5 / / :  1 !J: 8 IK: 6,10,13 / L: 5, 9
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5.6.2. Recurrent Neurological Symptoms: Predictors of Perfusion Abnormality
Most sickle cell patients with coma (PLKE) and recurrent stroke had a worsening of 
their cerebral perfusion despite BTx (table 5.14). Most of the patients with headaches 
maintained normal perfusion throughout without BTx. Patients with recurrent seizures 
and posterior TIA had unchanged or improved cerebral perfusion on blood transfusion 
therapy, although a few of them stopped treatment. Patients with anterior TIAs had a 
range of changes in mean transit time (MTT) over time (table 5.13).
There was an association between patients’ severity of central nervous system events at 
presentation and initial perfusion abnormality as evidenced by the parameter of 
increased mean transit time (MTT) of the passage of the IV Gd bolus (table 5.14, 
p=0.007, Spearman’s correlation), and there was a trend for an association with 
decreased cerebral blood flow (CBF; p=0.07, Spearman’s correlation). As shown in 
table 5.14, patients who presented with coma, stroke or TIAs had increased MTT, 
whereas most of the patients with headaches or seizures had normal initial perfusion. 
For this analysis, 22 SCD patients were included as one patient presented with increased 
initial CBF on her perfusion MRI (the only patient of this series) and is described as a 
case report here.
CNS Events at 
Onset
Initial Perfusion MRI 
(MTT)
Total
Normal
MTT
MTT
+
MTT
++
MTT
+++
Headache 5 1 6
Seizures 1 1
Posterior TIA 1 1 2
Anterior TIA 1 1 1 3
Stroke 2 1 4 7
Coma 1 2 3
Total 10 0 4 8 22
Table 5.14. Relation between CNS events at presentation and initial 
perfusion MRI (mean transit time, MTT) in SCD patients. Regional 
M TT+: mild ; + +: moderate; + + +: severe regional increased MTT.
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Only one patient, an eight-year old girl with homozygous sickle cell anaemia (HbSS), 
had initially increased cerebral blood flow. She presented with anterior territory TIA at 
onset and, subsequently continued to have recurrent TIAs, seizures and headaches 
despite treatement with exchange transfusion programme and anticonvulsants. She had 
had covert infarcts in the right corona radiata on her first MRI which remained 
unchanged, with cerebrovascular disease (CVD) on her initial MRA (severe right 
middle cerebral artery (MCA) stenosis, which progressed to MCA occlusion plus 
collaterals; and severe turbulence in the left anterior cerebral artery, which normalised 
at follow-up) in association with persisting critical maximum MCA velocities > 200 
cm/sec in the right MCA. She showed cerebral perfusion abnormality on her first 
perfusion MRI, but, interestingly, she had a moderate regional increase in cerebral 
blood flow and cerebral blood volume in the right frontal/parietal regions with normal 
mean transit time, and greatly increased CBF, moderatly increased CBV and normal 
MTT in the right temporal areas. On her final perfusion MRI, the areas with previously 
increased CBF changed to mildly- to- moderately decreased CBF in the frontal/parietal 
regions, but MTT became moderately increased in the same regions; in contrast the 
greatly increased CBF in the right temporal region persisted throughout time but the 
MTT became abnormal (greatly increased) in this area. This regionally increased CBF 
and CBV might have been related to areas of hyperaemia secondary to compensatory 
vasodilatation in association with critical stenosis in this patient, perhaps providing 
blood flow to these areas and maintaining a normal mean transit time initially. 
However, it seems that this compensatory mechanism failed over time as CBF was 
decreased on the patient’s final perfusion MRI, although she remained on chronic blood 
transfusion. Increased CBF and/or CBV might be the first indicators of tissue at risk 
before regional CBF decreases.
5.6.3. Changes over Time on Perfusion MRI and Neurological Symptoms in SCD- 
Statistical Analysis
Abnormal perfusion at follow-up was not significantly associated with presence or 
absence of recurrent neurological symptoms and with recurrent stroke, TIA or seizures 
(p=l and p=0.65, Fisher’s exact test). Recurrent headaches were significantly 
associated with unchanged perfusion MRI at follow-up (p=0.03, Fisher’s exact test). 
Recurrent TIAs were not significantly associated with unchanged or worsening
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perfusion MRI (p=0.22, and p=l respectively, Fisher’s exact test). Other recurrent
symptoms could not be analysed statistically because of the small numbers.
Recurrent TIAs, seizures or stroke were not significantly associated with worsening 
perfusion MRI over time (p=0.73, Mann-Whitney test). Severity of recurrent 
neurological symptoms was not significantly associated with worsening of perfusion 
MRI over time (p=0.4, Spearman’s test).
There was a significant association between the severity of central nervous system 
events at presentation and initial perfusion abnormality for the parameter of increased 
mean transit time (p= 0.007, Spearman’s correlation, table 5.14), and there was a trend 
for an association with decreased cerebral blood flow (CBF, p=0.07).
5.7. Results IV: Change over Time among Magnetic Resonance Studies 
and Transcranial Doppler Ultrasound in Sickle Cell Patients
The relationship between changes over time of the different MR investigations and 
TCD at onset and follow-up are shown in table 5.15.
All the sickle cell patients with worsening MRI, MRA, TCD or Perfusion MRI had 
baseline abnormal studies. Most of the patients with worsening studies over time were 
on chronic blood transfusion therapy. Progression of abnormality over time was greatest 
for MRA, followed by perfusion MRI, and MRI and TCD in equal numbers.
Most of the patients (87 to 96% depending on the investigation) with normal baseline 
studies at onset remained normal through time. Between 60 and 66% of the patients 
with normal MRI and MRA, and 90 % of the patients with normal TCD and perfusion 
MRI who had had normal baseline studies remained normal without having received 
blood transfusion therapy.
Patients who had abnormal baseline MRI, MRA, TCD and perfusion MRI and remained 
with unchanged studies at follow-up were all on blood transfusion therapy at onset; very
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few patients stopped treatment.A small proportion of the sickle cell patients showed 
improvement in their investigations (with exception of MRI) and they were initially on 
blood transfusion therapy. At follow-up, 26% of patients who had had abnormal 
baseline perfusion MRI had improved cerebral perfusion, whereas 17% and 8% of 
patients showed better MRA and TCD respectively in their final studies. More patients 
had better cerebral perfusion (better perfusion MRI) compared with the improvement of 
the other investigations.
Change Over Time (n=Sickle Cell Patients)
Investigations
Better
(BTx)
Unchanged
(BTx)
W orse
(BTx)
Norm al
B aseline
Abnormal
B aseline
N orm al
B aseline
Abnorm al
B aseline
N orm al
B aseline
Abnormal
B aseline
MRI
(n=23)
9 ( 3 ) 2§
1HU
1§HU
8 (8 ) l§
1§HU+RV
1§BMT
i d ) 15 5 (5 )18
M RA
(n=23) 4 (3 )3§ 7 (3 )1§
1HU
1§HU
3(3) 1 8 (8 ) l§
1§BMT
1§HU+RV
TCD
(n=17) 2(1)
1§HU+RV
2 6 (6)2§ 2(2)
1§HU
5 (4 )2§
1§BMT
Perfusion MRI
(n=23) 6 (6)28
1§HU+RV
7 ( 1 ) '§
1HU
2 (2) 1§ 1(1)
1§HU
7 ( 7 ) ,§
1§BMT
Table 5.15. Change over time of MRI, MRA, transcranial Doppler Ultrasound and 
perfusion MRI in relation to recurrent neurological symptoms and therapy.
BTx: B lood  transfusion therapy 
TIA: Transient ischaem ic attack
Hu Num ber o f  sick le  ce ll patients on Hydroxyurea therapy
* Num ber o f  patients w ho stopped b lood  transfusion therapy during fo llow -up
§HU N um ber o f  patients w ho stopped b lood  transfusion therapy and continued with Hydroxyurea
*BM1 N um ber o f  patients w ho stopped b lood  transfusion therapy and had bone marrow transplant
§ h u + r v  N umber 0 f  patients w ho stopped b lood  transfusion therapy, had surgical revascularisation
procedure and continued w ith Hydroxyurea during fo llow -up
□ n o  data because no im provem ent can be dem onstrated from  a norm al study or from  an M RI study  
show ing the presence o f  lesions
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5.7.1. Perfusion Abnormality and MRI: Statistical Analysis
Changes of structural MRI and perfusion MRI over time (better, unchanged or worse) 
were not significantly associated (p=0.3, Spearman’s correlation test). Change of 
perfusion MRI over time was not significantly associated with increasing infarct size 
and infarct number at follow-up (p=0.3 and p=0.6, Spearman’s correlations).
In relation to perfusion MRI parameters, infarct number and infarct size on the sickle 
cell patients’ initial MRI studies were significantly associated with regionally decreased 
CBF (p=0.004 and p=0.012 respectively) and increased MTT (p=0.075 and p=0.05 
respectively, Spearman’s correlations) on the initial perfusion MRI scans. Follow-up 
MRI and perfusion MRI studies also showed significant associations between infarct 
size and number with decreased CBF (p<0.0001 and p=0.02 respectively) and between 
infarct size and increased MTT (p=0.027) on the final scans. There was also a weak 
trend for association between infarct number and MTT on the final scans (p=0.13, 
Spearman’s correlations).
5.7.2. Perfusion Abnormality and MRA: Statistical Analysis
Changes of MRA and perfusion MRI over time were significantly associated (p=0.03, 
Spearman’s correlation).
In relation to perfusion MRI parameters, there were significant associations between 
initial grade of MRA turbulence and decreased cerebral blood flow (p <0.0001) and 
increased MTT (p=0.02). At follow-up, grade of MRA turbulence was also 
significantly associated with final decreased CBF (p <0.0001) and increased MTT 
(p=0.003, Spearman’s correlations).
Initial MRA turbulence severity was significantly associated with initial infarct size and 
number (p=<0.0001 and p=0.006 respectively, Spearman’s correlations).
However, changes over time of MRI and MRA were not significantly associated 
(p=0.63, Spearman’s correlation).
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In addition, severity of MRA turbulence at follow-up was significantly associated with 
infarct size and infarct number on the final MRI scans (p<0.0001 and p=0.014, 
Spearman’s correlations). Final MRA studies showed that sickle cell patients who had 
at least one infarct had moderate or severe vessel turbulence or artery occlusion. 
However, patients with multiple cerebral infarcts (which include covert [silent] infarcts 
or the association of covert and overt infarcts) had a wide range of MRA turbulence 
grades (table 5.16).
Infarct 
Number at 
Follow-Up
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
No Infarct 7 1 1 9
1 Infarct 1 1
2 Infarcts 1 1 2 4
3 Infarcts 1 1
Multiple
Infarcts
1 2 2 1 1 1 8
Total 8 3 4 2 2 4 23
Table 5.16. Relation between MRA turbulence and infarct number at 
follow-up in sickle cell patients.
5.7.3. Perfusion Abnormality and Transcranial Doppler: Statistical Analysis
There was a trend for an association between changes of perfusion MRI and transcranial 
Doppler (TCD) ultrasound over time (p=0.05). There was a significant correlation 
between changes of perfusion MRI and increasing category of TCD severity in the 
initial study (p=0.01, Spearman’s correlation, table 5.17). However, there was no 
association with increasing category of TCD severity at follow-up (p=l, Spearman’s 
correlation, table 5.18).
The relation between initial TCD and follow-up cerebral perfusion demonstrated 
different natural histories for perfusion abnormality. Sickle cell patients who initially
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had mean maximum middle cerebral artery (MCA) velocities > 200 cm/sec or decreased 
mean MCA velocities < 70 cm/sec (and lowest/highest velocity ratio < 0.5) showed a 
worsening in their perfusion MRI studies at follow-up. Other patients who also had 
decreased MCA velocities < 70 cm/sec or undetectable MCA had improvement in 
cerebral perfusion or unchanged perfusion throughout (table 5.17). For the 4 patients 
with normal TCD at onset, 2 had worse perfusion and 2 were unchanged.
Initial
TCD
Changes in Cerebral 
Perfusion over Time
Total
Better Unchanged Worse
Normal 2 2 4
MCA veloc > 
170 <200 
cm/sec
0
MCA vel > 
200 cm/sec
1 1
MCA veloc< 
70 cm/sec & 
ratio H:L <0.5
3 5 2 10
Undetectable
MCA
2 2
Total 5 7 5 17
Table 5.17. Relation between change of perfusion MRI over time and 
TCD category at onset.
TCD at 
Follow-Up
Changes in Cerebral 
Perfusion over Time
Total
Better Unchanged Worse
Normal 3 3
MCA vel. > 
170 <200 
cm/sec
0
MCA vel > 
200 cm/sec
0
MCA veloc< 
70 cm/sec & 
ratio H:L<0.5
3 2 3 8
Undetectable
MCA
2 2 2 6
Total 5 7 5 17
Table 5.18. Relation between change of perfusion MRI over time and 
TCD category at follow-up.
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In relation to perfusion MRI parameters (CBF and MTT), the severity of increased 
MTT and TCD categories at onset were significantly associated (p= 0.02, Spearman’s 
correlation) and there was a trend for an association between initial decreased CBF and 
TCD (p=0.12). At follow-up, TCD severity was also significantly associated with 
increased MTT (p=0.015) and decreased CBF (p=0. 046).
5.7.3.1 R e la tion  betw een TC D  a n d  M R I
Changes over time of MRI and TCD were not significantly associated (p=0.55, 
Spearman’s correlation).
There was no association between severity of the initial TCD and infarct size (p=0.39) 
but there was a significant association between infarct number on the initial MRI and 
TCD (p=0.04, Spearman’s correlations). TCD category was also significantly associated 
with infarct size and infarct number at follow-up (p=0.04 and p=0.03 respectively, 
Spearman correlations, tables 5.19 and 5.20).
Infarct Size 
At Follow- 
Up
TCD at Follow-Up Total
Normal MCA V 
>170 < 
200 
cm/sec
MCA V >  
200 
cm/sec
MCA V 
< 70cm/sec 
& ratio 
H:L =<0.5
Undetec
-table
MCA
No Infarct 4 3 2 9
< 1cm 
(Small)
3 3 6
1-5 cm- 
(Moderate)
3 2 5
> 5 cm 
(Large)
1 2 3
Total 4 0 0 10 9 23
Table 5.19. Relation between transcranial Doppler ultrasound and 
infarct size at follow-up in sickle cell disease.
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Infarct
Number
at
Follow-
Up
TCD at Follow-Up Total
Normal MCA V 
> 170 < 
200 
cm/sec
MCA V 
>200 
cm/sec
MCA V 
<70 
cm/sec & 
ratio H:L 
<0.5
Undetec­
table
MCA
No Infarct 4 3 2 9
1 Infarct 1 1
2 Infarcts 2 2 4
3 Infarcts 1 1
Multiple
Infarcts
4 4 8
Total 4 0 0 10 9 23
Table 5.20. Relation between transcranial Doppler ultrasound and 
infarct number at follow-up in sickle cell disease.
Sickle cell patients who had abnormal TCD at follow-up with low MCA velocities or 
undetectable MCA had cerebral infarcts on their final MRI scans, with a range of infarct 
number and size at follow-up. Patients were more likely to have multiple and larger 
infarcts if they had undetectable MCA (p=0.03, Spearman’s correlation). However, 
patients without infarcts had a variety of TCD patterns, with a slight preponderance of 
normal TCD studies.
5.7.3.2. R e la tio n  betw een TC D  a n d  M R A
Change of TCD over time was not significantly associated with changes on MRA 
(p=0.78, Spearman’s correlation).
Categories of TCD severity and MRA turbulence on the initial studies were not 
significantly associated (p=0.7, Spearman’s correlation), but there was a trend for 
association between TCD and MRA turbulence at follow-up (p=0.1, Spearman’s 
correlation). Sickle cell patients with low maximum MCA velocities less than 70 cm/sec 
(and abnormal lowest/highest ipsilateral MCA velocity ^0 .5 ) or undetectable MCA had 
different grades of MRA turbulence or arterial occlusion. Only one third of the patients 
with normal MRA studies had normal TCD, possibly due to technical difficulty with the 
ultrasound window (table 5.21).
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MRA 
Turbulence 
at Follow- 
Up
TCD at Follow-Up Total
Normal MCA >170  
and < 200 
cm/sec
MCA V 
>200 
cm/sec
MCA 
veloc< 70 
cm/sec & 
ratio H:L 
=<0.5
Undetec­
table
MCA
Normal 3 3 2 8
Mild 1 1 1 3
Moderate 2 2 4
Severe 2 2
Occlusion 2 2
Occlusion + 
Collateral
2 2 4
Total 4 0 0 10 9 23
Table 5.23. Relation between MRA turbulence and TCD at follow-up 
in SCD.
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R L
M RI Perfusion M RI (M T T ) M R A  & T C D
Figure 5.11a. Initial. 11 year-old, male,SCA. Chest crisis followed by pain in right eye, severe headache and blurred 
vision. Normal M R I . Perfusion MRI: severe increased mean transit time o f the passage o f Gadolinium in the right 
MCA territory & left temporal occipital region (right » le f t ) .  MRA showed cerebrovascular disease (severe 
turbulence in middle cerbral arteries [MCA]). TCD. right MCA velocities 200 cm/sec. R: right; L: left.
R L
Perfusion MRI (M TT) M R A
Figure 5.11b. One year post-blood transfusion. Normal Perfusion MRI (normal MTT), MRI and TCD. MRA.
improved turbulence in MCAs . No symptoms, stopped blood transfusion
Left M C A
R ight M CA  
TCD M R A
R L
M RI Perfusion  M RI (M T T )
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Figure 5.11c. (figure above). Follow-up. 2 years after stopping blood transfusion. Patient with learning difficulties, 
occasional headaches. Normal T2-w MRI, MRA: new regions o f turbulence in both ICAs, Perfusion M R I: 
moderate increased mean transit time o f the passage o f IV Gadolinium bolus in the right temporal-occipital and left 
occipital bordezone regions. TCD: decreased velocities < 70 cm/sec in the left MCA (figure: TCD above) and 
normal velocities in the right MCA (figure: TCD below).
5.8. Results V: Predictors of Perfusion Abnormality, Recurrent 
Neurological Symptoms, and Conventional Neuroimaging at Follow-up
5.8.1. Predictors of Cerebral Perfusion Abnormality at Follow-up
5.8.1.1. N euro log ica l S ym p to m s a t P resen ta tion  a n d  R e c u rre n t N euro log ica l 
S ym p to m s
Central nervous system events at presentation and recurrent neurological symptoms in 
patients with SCD, especially symptoms secondary to vasculopathy/ ischaemia such as 
initial anterior territory TIA, stroke and coma at presentation, and recurrent stroke, 
coma (PLKE), anterior territory TIA and seizures during follow-up were significantly 
associated with decreased cerebral blood flow (CBF, p= 0.005 [table 5.22] and p=0.017 
[table 5.23] respectively) and increased mean transit time (MTT, p=0.002 and p=0.03 
respectively, Spearman’s correlation) of the final perfusion MRI studies. For this 
analysis, 22 SCD patients were considered, as one patient presented with increased 
initial CBF on her perfusion MRI (the only patient of this series, whose case report was 
described in another section above).
CNS Events 
at Onset
Perfusion MRI (CBF) at Fol low-up Total
Normal CBF - CBF— CBF—
Headache 5 1 6
Seizures 1 1
Posterior TIA 2 2
Anterior TIA 1 1 1 3
Stroke 7 7
Coma 1 1 1 3
Total 10 0 2 10 22
Table 5.22. Neurological symptoms at presentation in sickle cell 
patients predicting abnormal perfusion (CBF) at follow-up (p=0.005).
Regional CBF mild decrease; - moderate decrease; : severe
decrease in CBF.
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Recurrent
Symptom
Perfusion MRI (CBF) at Follow-up Total
Normal CBF - CBF— CBF—
Asymptomatic 1 1
Headache 8 4 12
Seizures 1 1
Posterior TIA 1 1
Anterior TIA 1 4 5
Stroke 1 1
Coma (PLKE) 1 1
Total 10 0 2 10 22
Table 5.23. Recurrent neurological symptoms predicting abnormal 
perfusion (CBF) at follow-up in SCD patients (p=0.017). Regional
CBF mild decrease; - moderate decrease; : severe decrease in
CBF.
5.8.1.2. M R I  A b n o rm a lity  a t O nset
Size and number of the cerebral infarct on the initial T2-weighted MRI scan were 
significantly associated with persisting abnormal perfusion MRI parameters at follow- 
up (for CBF, p<0.0001 and p=0.002 respectively; and for MTT, p=0.01 and p=0.02, 
respectively). A persisting decreased regional cerebral blood flow at follow-up was 
associated both with increasing infarct size (table 5.24), especially in patients who had 
moderate (1-5 cm diameter) or large infarcts (> 5 cm diameter) on their initial T2- 
weighted MRI scans; and also with increasing infarct number (more than 1 infarct; table 
5.25) on the patients’ initial MRI studies.
Initial Infarct 
Size
Final Perfusion MRI (<2BF) Total
Normal CBF - CBF— CBF—
No infarct 9 1 10
< lcm-Small 2 2 4
1-5 cm-Moderate 1 4 5
> 5 cm-Large 3 3
Total 10 0 2 10 22
Table 5.24. MRI predictors of final perfusion abnormality (CBF) in 
sickle cell patients. Initial infarct size on T2- weighted MRI 
(p=<0.0001). Regional CBF mild decrease; - moderate decrease; 
 : severe decrease in CBF.
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Initial
Infarct
Number
Final Perfusion MRI- CBF Total
Normal CBF - CBF— CBF—
No infarct 9 1 10
1 Infarct 1 1
2 Infarcts 3 3
3 Infarcts 1 1
Multiple
Infarcts
1 2 4 7
Total 10 0 2 10 22
Table 5.25. MRI predictors of final perfusion abnormality (CBF) in 
sickle cell patients. Initial infarct number on T2- weighted MRI 
(p=0.002). Regional CBF -: mild decreased; - moderate decreased; 
 : severe decreased CBF.
5.8.1.3. M R A  T u rb u len ce  a t O nset
Arterial blood flow turbulence on the patients’ initial MR angiogram was significantly 
associated with persisting cerebral perfusion abnormality at follow-up (for CBF, p= 
<0.0001; for MTT, p= 0.01). Patients who had an initial moderate or severe turbulence 
or arterial occlusion on MRA had severely decreased cerebral blood flow at follow-up. 
However, patients who had moderate turbulence on MRA also had normal perfusion or 
moderate decrease in CBF. Two patients with arterial occlusion and collaterals had 
severely decreased CBF at follow-up, despite having developed a compensatory 
collateral circulation. By contrast, most of the patients who had normal MRA or mild 
arterial turbulence at onset had a normal cerebral perfusion over time (table 5.26).
Initial MRA 
Turbulence
Final Perfusion MRI- CBF Total
Normal CBF - CBF— CBF—
Normal 7 1 8
Mild 1 1
Moderate 2 1 3 6
Severe 3 3
Occlusion 2 2
Occlusion + 
Collateral
2 2
Total 10 0 2 10 22
Table 5.26. MRA grade of turbulence vs perfusion abnormality at 
follow-up in SCD. Regional CBF -: mild decrease; - moderate 
decrease; : severe decrease in CBF.
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5.8.1.4. Perfusion MRI at Onset
Sickle cell patients who had normal or abnormal cerebral blood flow (CBF) initially, 
generally had the same result at follow-up. Patients with normal, or moderately or 
severely decreased CBF had a strong tendency to continue with similar parameters 
throughout time (p<0.0001, Spearman’s correlation, table 5.27). There was also a 
significant association between the initial and final perfusion MRIs for mean transit 
time (MTT), which is inversely proportional to CBF (p<0.0001, table 5.28). Initial 
cerebral blood flow (CBF) and MTT seem to be sensitive predictors of cerebral 
perfusion longitudinally.
Initial
CBF
Final CBF Total
Normal CBF - CBF-- CBF—
Normal 10 1 1 12
CBF - 0
CBF-- 1 2 3
CBF— 7 7
Total 10 0 2 10 22
Table 5.27. Predictors of perfusion abnormality in SCD: Cerebral 
blood flow (CBF) at onset on perfusion MRI. Regional C B F mild 
decreased; - - : moderate decreased;
 : severe decreased CBF.
Initial
MTT
Final MTT Total
Normal MTT + MTT ++ MTT +++
Normal 7 1 2 10
MTT + 0
MTT ++ 1 1 2 4
MTT +++ 8 8
Total 8 0 2 12 22
Table 5.28. Predictors of perfusion abnormality in SCD: Mean transit 
time (MTT) at onset on perfusion MRI. Regional M TT+: mild ; + +: 
moderate; + + +: severe regional increased MTT
5.8.1.5. TC D  a t O nset
There was a weak trend for an association between abnormal TCD at onset and 
perfusion abnormality at follow-up (for CBF, p= 0.2; and for MTT, p= 0.14, 
Spearman’s correlation). Fifty percent of the sickle patients who had had initially
263
decreased mean maximum MCA velocities < 7 0  cm/sec and lowest/highest MCA ratio 
< 0.5 or undetectable MCA had severely decreased CBF at follow-up. However, 50% of 
patients with low velocities had normal perfusion at follow-up, perhaps refelecting 
technical difficulty secondary to the ultrasound window or a reliable cut-off depth for 
age (with increasing age, the reliable ultrasound depth decreases for obtaining an 
adequate signal). The majority of the patients with initially normal TCD (3/4) had a 
normal perfusion MRI over time (table 5.29).
Initial TCD
Final CBF Total
Normal CBF - CBF— CBF—
Normal 3 1 4
MCA V >  170 
< 200 cm/sec
0
MCA V > 200 
cm/sec
0
MCA V < 70 
cm/sec & ratio 
H:L <0.5
5 5 10
Undetectable
MCA
1 1 2
Total 8 0 1 7 16
Table 5.29. Initial transcranial Doppler ultrasound vs perfusion 
abnormality at follow-up in SCD. Regional CBF mild decreased; - - 
: moderate decreased; : severe decreased CBF.
5.8.2. Predictors of Recurrent Neurological Symptoms in Sickle Cell Disease
5.8,2.1. N eu ro lo g ica l S y m p to m s  a t P resen ta tion
There was a significant correlation between the severity of the central nervous system 
events (CNS) at presentation and the severity of the recurrent neurological symptoms 
(p=0.04, Spearman’s correlation). Patients who had had stroke or transient ischaemic 
attacks (TIAs) at onset continued to have TIAs during follow-up. Fifty percent of the 
patients who had had stroke developed recurrent TIAs or seizures, and the only patients 
who re-stroked or presented in coma (posterior leukoencephalopathy [PLKE]) in this 
series had previous history of stroke. Alternatively, sickle cell patients who had only 
headaches at presentation continued with the same type of symptom during follow-up, 
rather than developing more serious ischaemic symptoms (table 5.30)
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CNS Events 
at Onset
Recurrent Neurolog ical Symptoms
Asympto­
matic
Headaches Seizures Posterior
TIA
Anterior
TIA
Stroke PLKE
Headache 6
Seizures 1
Posterior TIA 1 1
Anterior TIA 1 3
Stroke 2 1 3 1
Coma 2 1
Total 1 12 1 1 6 1 1
Table 5.30. Central nervous system events at presentation vs 
recurrent neurological symptoms in sickle cell patients at follow- 
up.
S.8.2.2. MRI at Onset
There was a significant association between the number of cerebral infarcts on the 
initial T2- weighted MRI scans and the severity of recurrent neurological symptoms 
(p=0.002, Spearman’s correlation). Increasing number of infarcts (more than 1 infarct) 
was associated with seizures, anterior territory TIAs, stroke and coma (PLKE). 
However 3/12 sickle patients who had recurrent headaches presented with 1 or more 
infarcts on the initial MRI (table 5.31).
There was a trend for association between initial infarct size and severity of recurrent 
neurological symptoms (p=0.07).
Infarct 
Number at 
Onset
Recurrent Neurological Symptoms
Asympto­
matic
Headaches Seizures Posterior
TIA
Anterior
TIA
Stroke Coma
(PLKE)
No infarct 9 1
1 Infarct 1
2 Infarcts 2 2
3 Infarcts 1
Multiple
Infarcts
1 1 3 1 1
Total 1 12 1 1 6 1 1
Table 5.31. Recurrent neurological symptoms in SCD vs initial infarct 
number on T2- weighted MRI. PLKE: posterior
leukoencephalopathy.
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5.8.2.3. MRA Turbulence at Onset
There was a trend for association between initial MRA turbulence and recurrent 
neurological symptoms (p=0.07, Spearman’s correlation). Sickle cell patients with 
recurrent symptoms such as TIAs had moderate to severe turbulence on the initial 
MRA. The patient who re-stroked had arterial occlusion in her first MRA study, and 
arterial occlusion was also observed in the patient who had recurrent seizures. In 
contrast, patients who suffered from recurrent headaches presented with a variety of 
MRA turbulence grades on the initial studies. However, 7 of 12 patients (58%) with 
headaches had a normal baseline MRA, and the one patient who remained 
asymptomatic only showed mild artery turbulence in his first MRA (he had had covert 
infarctions and was on chronic transfusion, table 5.32).
Initial
MRA
Turbulence
Recurrent Neurologica Symptoms
Asympto­
matic
Headaches Seizures Posterior
TIA
Anterior
TIA
Stroke Coma
(PLKE)
Normal 7 1
Mild 1
Moderate 3 1 2
Severe 4
Occlusion 1 1
Occlusion + 
Collateral
2
Total 1 12 1 1 6 1 1
Table 5.32. MRA turbulence vs recurrent neurological symptoms in 
SCD. PLKE: posterior leukoencephalopathy.
S.8.2.4. Perfusion MRI Abnormality at Onset
There was trend for an association between initial abnormal cerebral perfusion 
(increased MTT) and recurrent neurological symptoms (p=0.057, Spearman’s 
correlation) and for abnormal cerebral blood flow (p=0.149). Patients who had recurrent 
seizures, TIAs, stroke and coma (PLKE) had initial perfusion abnormalities with 
moderate to severe increased regional MTT. The patient who re-stroked had initially 
severe increase of the regional MTT (area of infarction and beyond); however, for those 
patients who had recurrent TIAs, 50% initially presented with moderately and 50% with
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severely increased MTT. Eight of 12 patients with recurrent headaches had normal 
perfusion MRI at onset (table 5.33).
Onset
Perfusion
MRI
(MTT)
Recurrent Neurological Symptoms
Asympto­
matic
Headache Seizures Posterior
TIA
Anterior
TIA
Stroke Coma
(PLKE)
Normal 1 8 1
MTT + 0
MTT ++ 1 2 1
MTT +++ 4 1 2 1
Total 1 12 1 1 5 1 1
Table 5.33. Perfusion MRI parameter (MTT) vs recurrent 
neurological symptoms in SCD. PLKE: posterior
leukoencephalopathy. MTT: +: mild ; + +: moderate;
+ + +: severe regional increased MTT
5.8.2.5. TCD at Onset
Increasing severity of the initial transcranial Doppler ultrasound patterns showed a trend 
for an association with severity of recurrent neurological symptoms in patients with 
SCD (p= 0.07, Spearman’s correlation). All the patients who had recurrent seizures and 
TIAs had abnormal initial TCD patterns (table 5.34). Those patients with velocities > 
200 cm/sec or undetectable MCA had further anterior TIAs during follow-up. In 
contrast, 50% of patients with recurrent headaches had normal TCD and 50% abnormal 
TCD, perhaps due to technical difficulties (ultrasound window).
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Initial TCD
Recurrent Neurological Symptoms Total
Asympto­
matic
Headaches Seizures Posterior
TIA
Anterior
TIA
Normal 4 4
MCA V >  
170< 200 
cm/sec
0
MCA V >  
200 cm/sec
1 1
MCA V <  
70 cm/sec & 
ratio L:H 
=<0.5
1 4 1 1 3 10
Undetecta­
ble MCA
2 2
Total 1 8 1 1 6 17
Table 5.34. Transcranial Doppler ultrasound patterns vs recurrent 
neurological symptoms in SCD.
5.8.3. Predictors of Recurrence of Cerebral Infarction
5.8.3.1. Neurological Symptoms at Onset
Neurological symptoms at presentation were highly associated with infarct size and 
infarct number at follow-up (p<0.0001 and p=0.007, Spearman’s correlations). 
Increasing severity of CNS events at presentations were related with increasing size and 
number of the cerebral infarct on the final MRI studies of the sickle cell patients. It is 
noteworthy that patients who had headaches as the initial symptom did not have 
cerebral infarcts during the follow-up (table 5.35 and 5.36).
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CNS 
Events at 
Onset
Iniarct Size at Follow-Up Total
No infarct < 1cm- 
Small
1-5 cm- 
Moderate
> 5 cm- 
Large
Headache 6 6
Seizures 1 1
Post TIA 1 1 2
Ant TIA 3 1 4
Stroke 1 4 2 7
Coma 1 1 1 3
Total 9 6 5 3 23
Table 5.35. Central nervous system events at presentation vs infarct 
size on T2-weighted MRI at follow-up in SCD.
CNS 
Events at 
Onset
Infarct Number at Follow-Up Total
No
Infarct
1 Infarct 2 Infarcts 3 Infarcts Multiple
Infarcts
Headache 6 6
Seizures 1 1
Post TIA 1 1 2
Ant TIA 1 3 4
Stroke 1 2 1 3 7
Coma 1 1 1 3
Total 9 1 4 1 8 23
Table 5.36. Central nervous system events at presentation predicting 
infarct number on T2-weighted MRI at follow-up in SCD.
S.8.3.2. Initial MRI Abnormality
Infarct size and infarct number on the initial T2- weighted MRI scan of the sickle cell 
patients were significantly correlated with the infarct size and number on the final scans 
(p= <0.0001 and p=<0.0001 respectively, Spearman’s correlations). From tables 5.37 
and 5.38, both parameters seems to be stable longitudinally, although one patient with a 
normal initial scan had small multiple infarcts at follow-up. However, no changes were 
seen (tables 5.37 and 5.38) for those sickle cell patients who had recurrent cerebral
269
infarction because they already had multiple cerebral infarctions at onset, therefore they 
were kept in the same category for this statistical analysis initially and at follow-up.
Initial
Infarct
Size
Inirarct Size at Follow-Up Total
No
infarct
< 1cm- 
Small
1-5 cm- 
Moderate
> 5 cm- 
Large
No infarct 9 1 10
< 1cm- 
Small
5 5
1-5 cm- 
Moderate
5 5
> 5 cm- 
Large
3 3
Total 9 6 5 3 23
Table 5.39. Relation of initial infarct size and follow-up infarct size 
on T2- weighted MRI in patients with SCD.
Initial
Infarct
Number
Infarct Number at Follow-Up Total
No
Infarct
1 Infarct 2 Infarcts 3 Infarcts Multiple
Infarcts
No infarct 9 1 10
1 Infarct 1 1
2 Infarcts 4 4
3 Infarcts 1 1
Multiple
Infarcts
7 7
Total 9 1 4 1 8 23
Table 5.40. Relation of initial infarct number and follow-up infarct 
number on T2- weighted MRI in patients with SCD.
5.8.3.3. MRA Turbulence
Severity of MRA turbulence or arterial occlusion at onset was significantly associated 
with increasing infarct size and infarct number at follow-up (p<0.0001 and p=0.007, 
Spearman’s correlations). The majority of the patients who had initial arterial turbulence 
or occlusion on MRA had infarcts of different size and number. However, all the 
patients with moderate (1-5 cm diameter) or large infarcts (>5 cm diameter), and most
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of the patients (13/14) who had 1 or more infarcts, had some grade of turbulence or 
arterial occlusion on MRA. On the other hand, most of the patients (7/8) who had 
normal MRA initially did not develop infarcts during follow-up. Patients with moderate 
and large infarcts, and with 2 or more infarcts had usually MRA grades ranging from 
moderate turbulence to artery occlusion. However, 2 patients with initial occlusion and 
collaterals had moderate, not large, infarcts and one or 2 infarcts (instead of 3 or 
multiple infarcts), which suggests that a collateral circulation might prevent further 
ischaemia and cerebral tissue damage (tables 5.39 and 5.40)
Initial
MRA
Turbulence
Infarct Size at Follow-Up Total
No
Infarct
< 1cm- 
Small
1-5 cm- 
Moderate
> 5 cm- 
Large
Normal 7 1 8
Mild 1 1
Moderate 2 2 2 6
Severe 3 1 4
Occlusion 1 1 2
Occlusion + 
collateral
2 2
Total 9 6 5 3 23
Table 5.41. MRA turbulence at presentation vs infarct size on T2- 
weighted MRI at follow-up in SCD.
Initial
MRA
Turbulence
Infarct INlumber at Follow-Up Total
No
Infarct
1 Infarct 2 Infarcts 3 Infarcts Multiple
Infarcts
Normal 7 1 8
Mild 1 1
Moderate 2 2 2 6
Severe 1 1 2 4
Occlusion 2 2
Occlusion + 
Collateral
1 1 2
Total 9 1 4 1 8 23
Table 5.42. MRA turbulence at presentation vs infarct number on T2- 
weighted MRI at follow-up in SCD.
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5.8.3.4. Perfusion MRI
Initial cerebral blood flow (CBF) reduction on perfusion MRI was significantly 
associated with increased infarct size and infarct number on the final MRI scan of the 
patients (p=0.007 and p=0.049 respectively, Spearman’s correlations, tables 5.41 and
5.42). There was also a significant association between initial abnormal (increased) 
mean transit time (MTT) and final infarct number (p=0.04, Spearman’s correlation) 
with a trend for an association between initial increased MTT and final infarct size 
(p=0.06).
There was a trend for those patients who had had moderately and severely decreased 
CBF initially to have 2 or more infarcts of a moderate or large size on their final MRI 
scans. Eight of 12 patients (67%) with normal perfusion MRI studies initially 
maintained normal perfusion throughout. Four of 12 patient maintained a normal 
cerebral perfusion but had multiple infarcts, perhaps because these lesions were too 
small (sub-cortical, deep watershed white matter lesions) to affect the perfusion MRI 
parameters, or reflecting the incomplete coverage of the brain in the perfusion MRI 
data, since only 6 slices could be acquired, and it is therefore possible that the slice 
positions from which the perfusion data were obtained did not include the small regions 
of infarction.
Initial
CBF
Ini’arct Size at Follow-Up Total
No infarct < 1cm- 
Small
1-5 cm- 
Moderate
> 5 cm- 
Large
Normal 8 2 2 12
CBF - 0
CBF— 1 1 1 3
CBF— 1 2 2 2 7
Total 9 5 5 3 22
Table 5.41. Infarct size at follow-up on T2-weighted MRI in SCD vs 
cerebral blood flow (CBF) at onset on perfusion MRI. Regional CBF - 
: mild decrease; - - : moderate decrease; : severe decrease in CBF.
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Initial
CBF
Infarct Number at Follow-Up Total
No
Infarct
1 Infarct 2 Infarcts 3 Infarcts Multiple
Infarcts
Normal 8 1 3 12
CBF - 0
CBF— 2 1 3
CBF— 1 1 1 4 7
Total 9 1 3 1 8 22
Table 5.42. Infarct number at follow-up on T2-weighted MRI in 
SCD vs cerebral blood flow (CBF) at onset on perfusion MRI. 
Regional CBF -: mild decrease;
- - : moderate decrease; : severe decrease in CBF.
5.8.3.5. TCD at onset
There was a significant association between initial severity of TCD category and 
increase in infarct number on the final MRI scans of the sickle cell patients (p= 0.02, 
Spearman’s correlation). Although patients with < 2 infarcts had several TCD patterns, 
patients with 3 or more infarcts had decreased middle cerebral artery (MCA) velocities 
< 70 cm/sec and lowest/highest ipsilateral MCA ratio < 0.5 or undetectable MCA (table
5.43).
There was no relationship between the initial TCD and follow-up infarct size on MRI 
(p=0.35).
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Initial TCD Infarct Number at Follow-Up Total
No
Infarct
2
Infarcts
3
Infarcts
Multiple
Infarcts
Normal 3 1 4
MCA V >  
170<200 
cm/sec
0
MCA vel > 
200 cm/sec
1 1
MCA veloc< 
70 cm/sec & 
ratio L:H <0.5
4 1 1 4 10
Undetectable
MCA
2 2
Total 7 3 1 6 17
Table 5.43. Transcranial Doppler ultrasound patterns vs infarct 
number on T2-weighted MRI at follow-up in SCD.
5.8.4. Predictors of MRA Turbulence
5.8.4.1. Neurological Symptoms at Presentation and Recurrent Neurological 
Symptoms
Severity of the central nervous system events at presentation significantly predicted 
severity of the MRA turbulence at follow-up (p=0.027, Spearman’s correlation). In 
particular, patients who had TIAs, stroke and coma at onset had persistent moderate to 
severe artery turbulence or occlusion at follow-up (table 5.44). Headaches and posterior 
territory TIA seem to be the most benign predictors of MRA turbulence, 4/6 patients 
maintained a normal MRA study, and 2 developed mild to moderate flow turbulence at 
follow-up. The patients with posterior territory TIA had normal or mild turbulence on 
MRA over time.
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CNS 
Events at 
Onset
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
Headache 4 1 1 6
Seizures 1 1
Post TIA 1 1 2
Ant TIA 1 2 1 4
Stroke 2 2 3 7
Coma 2 1 3
Total 8 3 4 2 2 4 23
Table 5.44. Central nervous system events at presentation vs MRA 
turbulence at follow-up in SCD.
There was a trend for an association between severity of recurrent neurological 
symptoms and MRA turbulence at follow-up (p=0.05, Spearman’s correlation). 
Similarly to the CNS at presentation, recurrent neurological symptoms such as anterior 
territory TIAs and stroke, and also seizures, had the most severe grades of turbulence or 
occlusion at follow-up, whereas 7/12 of the patients who had recurrent headaches or 
posterior territory TIAs had normal or mild turbulence. However, 5/12 of patients who 
had recurrent headaches also had moderate grades of MRA turbulence or occlusion; 
some of these patients had had stroke and cerebrovascular disease (CVD) at 
presentation, but it seems that headache as a recurrent symptom has a different 
predictive value (symptom of a stabilised condition under treatment [i.e. blood 
transfusion]) for those patients who had severe neurological symptoms at presentation 
(table 5.45).
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Recurrent
Symptom
MRA Turbulence at Fol low-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
Asymp­
tomatic
1 1
Headache 7 1 2 2 12
Seizures 1 1
Post TIA 1 1
Ant TIA 2 2 1 1 6
Stroke 1 1
Coma
(PLKE)
1 1
Total 8 3 4 2 2 4 23
Table 5.45. Recurrent neurological symptoms vs MRA turbulence at 
follow-up in SCD. PLKE: posterior leukoencephalopathy.
5.8.4.2. MRI Abnormality at Onset
There was a significant association between increasing infarct size and infarct number 
on the patients’ initial MRI scans and grade of turbulence on the final MRA scan (p 
<0.0001 and p=0.02 respectively, Spearman’s correlations) as is shown in tables 5.46 
and 5.47. Those patients who initially had more than 1 infarct and with moderate to 
large infarcts, tended to have moderate to severe turbulence or artery occlusion at 
follow-up.
Initial 
Infarct Size
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
No infarct 7 2 1 10
< lcm-Small 1 2 1 1 5
1-5 cm- 
Moderate
1 1 1 2 5
> 5 cm-Large 1 1 1 3
Total 8 3 4 2 2 4 23
Table 5.46. Initial infarct size on T2-weighted MRI vs MRA 
turbulence at follow-up in SCD.
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Initial
Infarct
Number
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
No
Infarct
7 2 1 10
1 Infarct 1 1
2 Infarcts 1 1 2 4
3 Infarcts 1 1
Multiple
Infarcts
1 1 2 1 1 1 7
Total 8 3 4 2 2 4 23
Table 5.47. Initial infarct number on T2-weighted MRI vs MRA 
turbulence at follow-up in SCD.
5.8.4.3. MRA Turbulence at Onset
Severity of MRA turbulence at onset was highly correlated with MRA turbulence at 
follow-up (p=<0.0001, Spearman’s correlation). Most of those patients who had initially 
normal MRA (7/8) maintained the normal pattern throughout; however those with 
moderate to severe turbulence progressed to severe turbulence or artery occlusion 
during the follow-up (table 5.48).
Initial MRA 
Turbulence
MRA Turbulence at Fo llow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
Normal 7 1 8
Mild 1 1
Moderate 1 1 3 1 6
Severe 1 2 1 4
Occlusion 1 1 2
Occlusion + 
Collateral
2 2
Total r 8 3 4 2 2 4 23
Table 5.48. Initial MRA turbulence vs MRA turbulence at follow-up 
in SCD.
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5.8,4.4. Perfusion MRI at Onset
Severity of the perfusion MRI abnormality at onset (reduction of regional CBF or 
increased MTT) was significantly associated with increasing of turbulence on MRA at 
follow-up (p<0.0001 for CBF and p=0.019 for MTT, Spearman’s correlations). Those 
sickle cell patients who initially had moderately to severely decreased regional CBF 
had moderately to severely turbulence or occlusion on MRA at follow-up, whereas the 
patients with initial normal perfusion (8/12) had normal cerebral vasculature 
throughout with 3 patients developing mild turbulence and only one patient with severe 
turbulence on the final MRA study (table 5.49).
Initial
CBF
MRA Turbulence at Follow-Up Total
Normal Mild Moderate Severe Occlusion Occlusion
+
Collateral
Normal 8 3 1 12
CBF- 0
CBF— 1 1 1 3
CBF— 3 1 1 2 7
Total 8 3 4 2 2 3 22
Table 5.49. MRA turbulence at follow-up vs cerebral blood flow 
(CBF) at onset on perfusion MRI. Regional CBF mild decrease; - - : 
moderate decrease; : severe decrease in CBF.
5.8 .4 .5 . T C D  a t  O n se t
TCD abnormality at onset was not a predictor of MRA turbulence at follow-up (p=0.68, 
Spearman’s correlation).
5.8.5. Multivariate Model of Statistical Analysis
Worsening of MRA was significantly associated with worsening of perfusion MRI over 
time (p= 0.017) in a univariate analysis by multiple regression in relation to an outcome 
(worse/not worse perfusion MRI at follow-up). There were trends for associations with 
the same outcome for worsening TCD (p=0.056) and worsening of MRI (p=0.07). There
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were no significant associations for the presence or not of recurrent neurological 
symptoms and for the presence of symptoms such as a stroke, seizures and TIAs against 
worsening or not of cerebral perfusion at follow-up (p=0.85 and p=0.44 respectively).
A correlation matrix was calculated to assess the level of correlation among the 
variables because this impacts on the multiple testing issue. Specifically, a common but 
naive approach to dealing with multiple testing is to control the overall (familywise) 
error rate by performing a Bonferroni adjustment. This is not always appropriate, 
however. Firstly, the correction can be conservative when applied to non-independent 
tests. Secondly, Bonferroni adjustment is not necessarily appropriate if the variables in 
question are correlated in the sense that each represents an imperfect measure of some 
underlying (latent) process or outcome. In this case a single Type I error among a set of 
significant tests is unimportant in those contexts in which all conclusions are based on 
the overall effect. In this context familywise error rate control is not called for (this 
issue is discussed at length by Benjamini and Hochberg (1995). Familywise error rate 
adjustment has not been adopted in this study, because changes in cerebral perfusion are 
expected to cause a parallel response in several of the MR observables. Correlation 
among the variables is expected; the resulting multiple tests are not, therefore, 
conceived as independent.
There was a high correlation (coefficient of > 0.5) among the following variables: 
cerebral blood flow, infarct size, infarct number and severity of MRA turbulence (table 
5.50). Furthermore, perfusion abnormality at follow-up was significantly associated 
with each of these variables (tables 5.24 to 5.32). This suggests that there is a principal 
driving disease process leading to the outcome (in this case abnormal perfusion at 
follow-up). In this context principle component analysis shows that the first principal 
component accounts for 70% of the total variance associated with the set of variables 
(dependent predictors), consistent with a major driving process. The second principal 
component accounts for an additional 15% of the total variance (table 5.51).
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Correlation Matrix
Initial MR 
Investigation
Initial
CBF
Initial
Infarct
size
Initial
Infarct
number
Initial
MRA
turbulen
ce
Initial CBF 1.000 .589 .493 .748
Initial Infarct size .589 1.000 .659 .644
Initial Infarct 
number
.493 .659 1.000 .478
Initial MRA 
turbulence
.748 .644 .478 1.000
Table 5.50. Correlation matrix of predictors of cerebral perfusion 
abnormality at follow-up.
Total Variance Explained
Initial
Eigen-values
Component Total % of Variance Cumulative %
1 2.810 70.246 70.246
2 .629 15.734 85.979
3 .328 8.199 94.178
4 .233 5.822 100.000
Table 5.51. Principle component analysis of the correlation matrix 
derived from the initial MR investigations among cerebral perfusion 
abnormality at follow-up, showing that there is a principal driving 
disease process that explains 70% of the total variance associated with 
the set of variables (dependent predictors), consistent with a major 
driving process (component 1). The second principal component 
accounts for an additional 15% of the total variance (component 2).
5.9. Summary of Results
5.9.1. Neurological Symptoms, Blood Pressure, Haematological Parameters and 
Oxygen Saturations
- Neurological symptoms at presentation consisted of: stroke in 29% (7/23) of the 
sickle cell patients, transient ischaemic attacks (TIA, including anterior and 
posterior territory TIAs) in 26% (n=6), headaches in 26% (n=6) and seizures 
(n=l).
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Main recurrent neurological symptoms consisted of: headaches in 52% (12/23), 
TIAs in 30% (n=7 [26% had anterior territory TIAs]), recurrent stroke (n=l), 
coma {posterior leukoencephalopathy) (n=l), and seizures (n=l). One patient 
remained asymptomatic. Associated recurrent symptoms were cognitive 
problems (behaviour/learning difficulties) in 14/23 patients, TIAs, headaches 
and seizures.
There were no significant associations between blood pressure measurements 
(systolic, diastolic and mean arterial pressure) at follow-up and worsening of 
MRI, MRA, TCD and perfusion MRI. There was only a trend for association 
between worsening of TCD and low diastolic blood pressure.
Haematological parameters showed a trend for association between worsening 
of perfusion and increased white cell count at follow-up. There was a significant 
association between worsening of MRA and decreased platelet count at onset. 
There were also trends for association between increased white cell and 
lymphocyte counts at follow-up and worsening of MRI.
- Day (awake) oxygen saturations measured using pulse oximetry were not 
significantly associated with the presence of recurrent neurological symptoms 
and with worsening of MRI, MRA, TCD and perfusion MRI.
5.9.2. Recurrent Neurological Symptoms and Change over Time of MRI, MRA, 
TCD and Perfusion MRI
5.9.2.1. Recurrent Neurological Symptoms and MRI Change over Time
17/23 patients had unchanged MRI: 9/17 had normal baseline and headache 
was the main recurrent symptom; 8/17 had abnormal baseline, recurrent 
symptoms were TIAs (n=5) and headaches (n=2) and one patient remained 
asymptomatic.
6/23 patients had worsening of MRI; 5/6 had abnormal baseline MRI. 
Recurrent symptoms were coma (PLKE, n=l), stroke (1), anterior (1) and 
posterior (1) territory TIA, seizures (1) and headaches with decreased visual 
acuity (1).
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There was a trend for an association for patients who had recurrent stroke, 
TIAs or seizures to have worsening of MRI. Recurrent headaches and 
anterior territory TIAs were significantly associated with unchanged MRI.
The severity of recurrent symptoms was significantly associated with MRI 
changes over time and increasing infarct number, and there was a trend for 
association with increasing infarct size.
5.9.2.2. Recurrent Neurological Symptoms and MRA Change over Time
4/23 sickle cell patients showed improved the anterior cerebral circulation on 
MRA at follow-up. Recurrent symptoms were anterior (n=l) and posterior 
(n=l) territory TIAs, and headaches (n=2).
10/23 patients had unchanged MRA. Seven out 10 patients had a normal 
baseline MRA. Neurological symptoms were predominantly headaches 
(n=6) and coma (PLKE, n=l). 3/10 had abnormal baseline MRA, symptoms 
consisted of recurrent seizures (n=l) and headaches (n=l); one patient 
remained asymptomatic.
9/23 had worsening MRA, only one patient had a normal baseline MRA 
(headaches). Recurrent symptoms of the remainding 8 patients were stroke 
(n=l), TIAs (n=5) and headaches (n=2).
There was a trend for an association between recurrent stroke, TIAs or 
seizures and worsening of MRA, and, conversely to be associated for 
headaches with unchanged MRA.
The severity of grade of MRA turbulence at follow-up was significantly 
associated with recurrent stroke, TIAs or seizures, and with changes of MRA 
over time. There was a trend for association between severity of recurrent 
neurological symptoms and increasing grade of MRA turbulence.
5.9.2.3. Recurrent Neurological Symptoms and Transcranial Doppler Ultrasound 
Change over Time
Two patients had critical mean maximum MCA velocities (> 200 cm/sec) at 
onset (one of them had also contralateral decreased MCA velocities < 7 0  
cm/sec, and because the latter is a more severe indicator, this patient was
282
considered for analysis on the basis of a velocity < 7 0  cm/sec) and these 2 
patients did not have a new cerebral infarction during follow-up but they 
were on chronic blood transfusion. Ten patients (including the patient with 
contralateral MCA velocities > 200 cm/sec) had decreased mean maximum 
MCA velocities < 70 cm/sec at onset, 1/10 patients had new infarcts (covert 
infarcts) and posterior territory TIAs and 2/10 patients had progression of 
cortical atrophy (focal) at the end of the study.
2/17 patients had an improvement of their transcranial Doppler ultrasound 
(TCD) at follow-up, one patient had recurrent anterior territory TIA and the 
other had headaches.
8/17 patients had unchanged TCD. 2/8 had a normal baseline TCD (recurrent 
headaches). 6/8 had an abnormal baseline TCD, their recurrent symptoms 
were anterior territory TIAs (n=2), seizures (1), headaches (2).
7/17 patients had a worsening of their TCD. Two patients had a normal 
baseline TCD and had headaches. Five patients had an abnormal baseline 
TCD and they presented with anterior (3) and posterior (1) territory TIAs 
and headaches (1).
There were trend for associations between worsening TCD and recurrent 
TIAs, and between worsening TCD and headaches. There was also a trend 
for association between severity of TCD category and recurrent TIAs or 
seizures, and between TCD categories and, the severity of recurrent 
neurological symptoms.
5.9 .2 .3 . R e c u r r e n t N e u ro lo g ic a l S y m p to m s  a n d  P erfu sio n  M R I  o ve r  T im e
6/23 sickle cell patients (26%) improved their perfusion MRI at follow-up. 
Recurrent neurological symptoms were anterior (n=2) and posterior (1) 
territory TIAs, seizures (1) and headaches (2).
9/23 patients (39%) had unchanged perfusion MRI. 7/9 had a normal 
perfusion MRI baseline and all patients had recurrent headaches. 2/9 had an 
abnormal baseline study, one patient had anterior territory TIAs and the 
other remained asymptomatic.
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8/23 patients (35%) had a worsening of MRI perfusion at follow-up. One 
patient had a normal baseline perfusion MRI and he had headaches. 7/8 
patients had abnormal baseline studies, and their recurrent symptoms were 
coma (PLKE, n=l), recurrent stroke (1), anterior territory TIAs (3) and 
headaches (2).
There was a good neuroanatomical correlation between regional cerebral 
perfusion abnormality and recurrent neurological symptoms such as stroke, 
TIAs and seizures.
Severity of the initial central nervous system events at presentation were 
significantly associated with an abnormal perfusion parameter (increased 
MTT) and there was a trend for decreased CBF.
There was a significant association between recurrent headaches and 
unchanged perfusion MRI at follow-up; however there were no associations 
between worsening of perfusion MRI and recurrent stroke, TIAs or 
seizures, and severity of the recurrent neurological symptoms.
5.9.3. Changes over Time of Perfusion Abnormality in Relation to Magnetic 
Resonance Studies and Transcranial Doppler Ultrasound
5.9.3.1. Perfusion MRI and T-2 Weighted MRI
- Changes of MRI and perfusion MRI over time were not significantly
associated.
- However, there were significant associations between infarct size and infarct
number on the initial and final MRI scans, and between decreased CBF and 
increased MTT at onset and follow-up respectively.
5.9.3.2. Perfusion MRI and MRA- MRA and MRI
There was a significant association between changes of MRA and perfusion 
MRI over time.
Initial grades of turbulence on MRA were significantly correlated with 
decreased CBF and increased MTT at onset. Final grades of turbulence on
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MRA were also significantly correlated with severity of the decrease in CBF 
and the increase in MTT at follow-up.
- Changes over time of MRI and MRA were not significantly associated, 
however, severity of MRA turbulence at onset and follow-up were 
significantly associated with increasing infarct size and number on the initial 
and final MRI scans respectively.
5.9 .3 .3 . P erfu s io n  M R I  a n d  T C D - T C D  a n d  M R I- T C D  a n d  M R A
There was a trend for association (nearly significant) between changes of 
TCD and perfusion MRI over time.
There was a significant correlation between changes on perfusion MRI and 
increasing category of TCD severity on the initial study.
Initial TCD severity and increased MTT were significantly associated (trend 
for initial decreased CBF). Follow-up TCD was significantly associated with 
final CBF and MTT.
Changes over time of MRI and TCD were not significantly associated. 
However, although there was not a significant association between severity 
of the initial TCD and infarct size, it was significant for infarct number on 
the initial MRI.
In addition, TCD severity at follow-up was significantly associated with 
increased infarct number and infarct size on the final MRI scans.
Change of TCD over time was not significantly associated with changes on 
MRA.
There was a trend for association between severity of TCD categories at 
follow-up and MRA turbulence grades on the final studies, but there was not 
association between initial TCD categories and MRA turbulence.
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5.9.4. Predictors of Cerebral Perfusion Abnormality, Recurrent Neurological
Symptoms and Conventional Neuroimaging at Follow-up
5.9 .4 .1 . P re d ic to rs  o f  C ereb ra l P erfu s io n  A b n o rm a lity  a t  F o llo w -u p
Severity of central nervous system (CNS) events at presentation (such as 
coma, stroke and anterior territory TIA) and recurrent neurological 
symptoms (such as recurrent stroke, coma [PLKE], anterior territory TIA 
and seizures) were significantly associated with abnormal cerebral perfusion 
parameters at follow-up characterised by decreased regional cerebral blood 
flow (CBF) and increased mean transit time (MTT).
Increasing infarct size and number on the initial T2- weighted MRI were 
significantly associated with decreased regional CBF and increased MTT at 
follow-up.
Increasing grade of MRA turbulence at onset was significantly associated 
with decreasing regional CBF and increasing MTT on the final perfusion 
MRI.
Initial decreased regional CBF and increased MTT were significantly 
associated with the same perfusion MRI parameters at follow-up. In general, 
sickle cell patients with normal, moderate or decreased CBF (or increased 
MTT) continued with similar perfusion parameters at follow-up.
There was a trend for an association between initial TCD categories and 
abnormal grades of CBF and MTT at follow-up.
The perfusion MRI parameter cerebral blood flow (CBF) seems to be a more 
sensitive parameter for prediction of abnormality over time than mean transit 
time (MTT).
5.9 .4 .2 . P re d ic to rs  o f  R e c u rre n t N e u ro lo g ic a l S y m p to m s  a t F o llo w -u p
There was significant correlations between the severity of the patients’ 
recurrent neurological symptoms and the severity of the initial CNS 
events, the number of infarcts on the initial MRI and increasing MRA 
turbulence grade at onset.
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There were trends for associations between initial regional abnormal 
cerebral perfusion (decreased CBF and increased MTT), initial TCD 
categories and severity of recurrent neurological symptoms.
5.9 .4 .3 . P re d ic to r s  o f  R e cu rren ce  o f  C ereb ra l In fa rc tio n
Severity of neurological symptoms of the patients at presentation, initial infarct 
size and infarct number, severity of MRA turbulence and initial decreased 
regional CBF on perfusion MRI were significantly associated with increasing 
infarct size and number on the final T2-weighted MRI scans.
There were also significant associations for increasing regional MTT on the 
initial perfusion MRI and initial TCD category with the final infarct number, but 
there were trends for associations for initial MTT and TCD categories with final 
infarct size.
5.9 .4 .4 . P re d ic to r s  o f  M R A  T u rb u len ce
Increasing severity of the CNS events at presentation was significantly 
associated with increasing grade on MRA turbulence at follow-up. Severity of 
recurrent neurological symptoms showed a trend for association with final MRA 
turbulence.
Initial increased infarct size and number, grade of MRA turbulence, and 
abnormal perfusion MRI (decreased CBF or increased MTT) were significantly 
associated with severity of grade of turbulence at follow-up.
TCD Doppler abnormality at onset was not a predictor of final grade of MRA 
turbulence.
5.10. Discussion
This study showed that there was progression over time of cerebral perfusion 
abnormality in more than one third of the patients with sickle cell disease. This 
progression of abnormal perfusion was associated with the severity of the patients’
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recurrent neurological symptoms and progression of cerebrovascular disease (MRA 
turbulence) and it continued in many cases despite chronic blood transfusion therapy or 
other alternative therapies.
In addition, the study demonstrated that more than a third of patients had unchanged 
cerebral perfusion during follow-up, which was associated with less severe recurrent 
neurological symptoms and mainly unchanged MRI and MRA, with or without blood 
transfusion therapy (the latter most frequent).
On the other hand, only one quarter of the sickle cell patients had an improvement in 
cerebral perfusion over time, associated with improvement on MRA turbulence or 
unchanged MRA at follow-up. These patients were on blood transfusion; they 
manifested a variety of recurrent neurological symptoms of different grade of severity, 
but none of them had recurrent stroke.
The progression of cerebral perfusion abnormality and cerebrovascular disease might be 
associated with infection in addition to the damaging effect of the sickle cell in the 
vascular endothelium, as increased white cell and thrombocytopenia were associated 
with changes of cerebral perfusion and MRA over time.
This series was composed of patients with sickle cell disease who had neurological 
symptoms. As it was highly selected, there was a high prevalence of stroke at onset 
(29%) in this patients’ group in relation to their age comparing with previous 
epidemiologic studies, where the prevalence was between 8% -11% in patients younger 
than 19 years (Ohene-Frempong et al 1991 and 1998). In this group there was also a 
high prevalence of transient ischaemic attacks (26%), especially anterior territory TIAs. 
A quarter of the patients had headaches, and one patient had seizures, but none were 
entirely asymptomatic.
Twenty out of 23 patients presented with recurrent neurological symptoms of different 
grade of severity, despite the fact that 18 out of 23 patients (78%) were initially on 
blood transfusion. Probably because a high proportion of these patients were on chronic 
blood transfusion (some of whom stopped while others continued with this therapy), 
only 3 patients (13%) had new cerebral infarctions on their final MRI studies, compared
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with the high proportion of recurrent stroke (up to 67%) in SCD without blood 
transfusion (Powars et al 1978). Two of the 3 patients had recurrent infarction (8%); one 
of the sickle cell patients manifested the cerebral infarct as clinical stroke, and another 
patient as posterior leukoencephalopathy (PLKE) with coma and hypertension. 
However, the first patient had stopped blood transfusion therapy a year before her final 
magnetic resonances studies because of the presence of antibody formation against red 
cells, whereas the second patient was on chronic blood transfusion. The third patient, 
who had recurrent posterior territory TIAs, stopped blood transfusion during the follow- 
up, and she had bilateral new infarcts on the final MRI, having had a normal scan 
previously.
Although new treatments for SCD have been advocated in recent years (Walters et al 
1996 and 2000, Ware et al 1999, Wang et al 2001, Harlan et al 2000, Vemet et al 1996, 
Ganesan et al 2001), the highest proportion of the patients of this study received the 
classical treatment of chronic blood transfusion. In spite of that, Pegelow showed that 
the protective effect of blood transfusion therapy was not complete, with a risk of 
recurrent stroke in sickle cell children receiving chronic blood transfusion up to 4.2/100 
patient-years (Pegelow et al 1995). Stroke recurrence despite blood transfusion was also 
seen in the present study (prevalence of 8%). Only 4 patients received alternative 
treatments such as Hydroxyurea, revascularisation procedure plus Hydroxyurea, and 
bone marrow transplant as only therapy (n=l) or an alternative one after stopping blood 
transfusion (n=3). In addition 4 patients stopped blood transfusion during follow-up for 
different reasons (poor compliance, autoantibody formation, etc) without receiving any 
further alternative treatment.
As stroke is the most alarming and long-term disabling complication, and occurs despite 
receiving an adequate treatment for their inherited condition (Steimberg 1999, Hoppe et 
al 1998, Balias et al 2002), this study was focused on trying to explain the cause or 
causes of recurrent neurological symptoms in SCD through changes of magnetic 
resonance (MR) technique (specifically cerebral perfusion) and clinical parameters over 
time, and to relate these changes with the recurrent symptoms. The effect of the 
different treatments, especially blood transfusion, on cerebral perfusion and other MR 
modalities will be discussed in chapter 6.
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In relation to changes over time among recurrent neurological symptoms, the different 
magnetic resonance studies, and transcranial Doppler, the study showed that there is a 
worsening of cerebral perfusion over time in more than a third of patients with sickle 
cell disease. This worsening of perfusion was associated with the severity of the 
recurrent neurological symptoms such as coma (PLKE), stroke and anterior territory 
TIAs. However the less severe symptom of headache was also associated with 
worsening of cerebral perfusion in a few patients. All these patients were on blood 
transfusion therapy. In addition, there was a strong association between the localisation 
of the regional perfusion abnormality and the clinical symptoms (see table 5.14). The 
initial severity of the symptoms showed a significant association with the degree of 
abnormal perfusion, in this case represented by the perfusion MRI parameter increased 
mean transit time (MTT). Recurrent neurological symptoms were also significantly 
associated with the abnormal perfusion parameters of decreased regional cerebral blood 
flow (CBF) and increased MTT at follow-up. Worsening of perfusion MRI occured in 
all except one of the patients who had an abnormal baseline study. In contrast, in most 
of the patients who had normal baseline perfusion MRI cerebral perfusion remained 
normal during follow-up.
Compared with conventional MRI, MR angiography (MRA) was the more sensitive 
neuroimaging modality associated with changes of perfusion. There was a significant 
association between changes of MRA and perfusion MRI over time. In addition, there 
were significant correlations between severity of cerebral perfusion abnormality (CBF 
and MTT) and grade of MRA turbulence both at onset and follow-up. This finding has 
demonstrated for the first time that there is progression of cerebrovascular disease 
associated with progression of cerebral perfusion abnormality, which could explain the 
persistence and severity of the recurrent neurological symptoms despite blood 
transfusion. Although there was a trend for association between MRA turbulence and 
the category TCD severity at follow-up (but not in the initial studies), transcranial 
Doppler ultrasound studies at onset and follow-up also had significant associations with 
initial and final perfusion MRI parameters (MTT and CBF), showing that TCD could be 
a useful technique for screening for cerebral perfusion abnormality, although it was as 
not as sensitive as MRA.
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Previous studies using neuroimaging techniques in patients with sickle cell disease 
demonstrated longitudinal changes in MRI over time from the natural history of the 
disease where up to 67% of the sickle cell patients who had a first stroke had stroke 
recurrence without blood transfusion (Powars et al 1978). The prevalence of silent 
infarcts (an important risk factor for stroke) was reported initially to be 17% between 
the ages of 6 and 16 years (Moser et al 1996), and then increased to 22% in a recent 
study of older patients by the same group of collaborators (Pegelow 2002), moreover, 
another study had reported a prevalence of silent infarcts in SCD up to 23% by 14 years 
and this proportion increased with age (Miller et al 2001). Longitudinal studies suggest 
that MRA may predict stroke (Kandeel et al 1996, Seibert et al 1998, Prengler et al 
2000). Adams et al showed that using transcranial Doppler ultrasound, critical middle 
cerebral artery velocities of more than 200 cm/sec were associated with 40% of stroke 
risk over a period of 3 years (Adams et al 1992 and 1998). Other studies supported the 
use of TCD in SCD because of its good correlation with MRA abnormality and as a 
predictor of recurrent neurological symptoms (Siegel et al 1995, Seibert et al 1997, 
Bemaudin et al 2000).
Studies of cerebral perfusion have been mainly cross-sectional in design. Techniques 
used previously include xenon inhalation (Huttenlocher 1984, Prohnovik et al 1989, 
Kugler et al 1993, Tzika et al 1993), positron emission tomography (Herold et al 1986, 
Powars et al 1999), and techniques of perfusion MRI using either IV gadolinium bolus 
tracking (dynamic susceptibility contrast MRI, Kirkham et al 2001) or continuous spin- 
labelling perfusion MRI (Oguz et al 2003), which have demonstrated abnormal 
perfusion in areas which were normal on T2-weighted MRI. Some of these studies also 
demonstrated associations between abnormal cerebral perfusion with MRA turbulence 
and TCD (Venketasubramanian et al 1994, Kirkham et al 2001). Furthermore, there 
have been a few studies on the beneficial effect of blood transfusion, shortly before and 
after treatment on cerebral perfusion (Hurlet-Jensen et al 1994, Venketasubramanian et 
al 1994, Kirkham et al 2001), but the follow-up of those patients was shorter than for 
the present study study. Another strength of the work presented here is that it has 
correlated different magnetic resonance techniques longitudinally, focusing mainly on 
perfusion MRI, instead of only different modalities of neuroimaging.
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Most of the patients who had worsening of perfusion MRI, MRI, MRA and TCD had 
abnormal baseline studies for these investigations, despite being on blood transfusion 
therapy. Although the statistical analysis of the changes over time of the different 
modalities did not reach statistical significance among themselves (except for changes 
over time between MRA and perfusion MRI), there were significant associations 
between categories of these investigations (such as infarct size and number, MRA 
turbulence, TCD severity and grades of CBF and MTT) when they were compared at 
onset and follow-up, and also in relation to the neurological symptoms (at presentation 
and recurrent), demonstrating related changes over time.
In the case of MRI, infarct number at follow-up was significantly associated with 
severity of recurrent neurological symptoms, and there were trends for associations 
between stroke, TIAs, or seizures and worsening of MRI. This finding supports 
previous studies of recurrent infarction in SCD (Moser et al 1996, Miller et al 2001). 
Furthermore, the grade of infarct size and number of infarcts were associated 
significantly with abnormal perfusion parameters (CBF and MTT) either at onset or 
follow-up.
In relation to MRA turbulence, which is an indicator of cerebrovascular disease, the 
severity of the MRA turbulence at follow-up was significantly associated with recurrent 
stroke, TIAs or seizures and with changes of MRA over time, as has been suggested in 
previous studies (Seibert et al 1998, Prengler et al 2002 and 2003). Additionally, the 
severity of the MRA turbulence was significantly associated with parameters of 
abnormal CBF and MTT, which showed the progression of the cerebrovascular disease 
and its effect on cerebral perfusion and recurrent neurological symptoms without major 
changes on T2-weighted MRI.
Transcranial Doppler ultrasound has become an important tool for screening 
cerebrovascular disease in SCD, especially for the detection of vascular disease in the 
basal arteries of the brain (MCA, ACA). Prevention of stroke in those sickle cell 
patients who have critical MCA maximum velocities (more than 200 cm/sec) and are 
therefore at high risk is possible with regular blood transfusion (Adams et al 1992 and 
1998). In this study, TCD was shown to be a good technique to detect progression of 
CVD, but it was not as sensitive as MRA. Categories of severity of TCD were weakly
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associated (but not significantly) with MRA turbulence, especially in those studies done 
at follow-up, and also with severity of the recurrent neurological symptoms. 
Associations between grade of turbulence and TCD ultrasound pattern, and between 
TCD and severity of recurrent neurological symptoms, (especially stroke) were reported 
previously (Siegel et al 1995, Verlhac et al 1997, Seibert et al 1997, Bemaurdin et al 
2000). There were also significant associations between TCD patterns of severity and 
infarct number on the initial and final studies, and with infarct size at follow-up, 
relationships which have been reported (Adams et al 1988 and 1998, Siegel et al 1995) 
but not in such extensive studies as reported here.
The association between TCD and perfusion MRI has shown interesting findings not 
reported before, as previously reports between TCD and cerebral perfusion techniques 
were based on cross-sectional studies (Kirkham et al 2001) or in relation with blood 
transfusion therapy (Venketasubramanian et al 1994).
The association between changes of TCD and perfusion MRI over time approached 
significance. Furthermore, TCD ultrasound grades of severity at onset and follow-up 
were significantly associated with initial and follow-up grades of abnormal cerebral 
perfusion (decreased CBF and increased MTT) in patients with SCD. This finding was 
also seen when comparing initial and final MRA turbulence with initial and final 
perfusion MRI. Therefore, TCD could be a very practical and non-invasive tool to 
detect and monitor over time not only cerebrovascular disease in SCD, but also 
progression of cerebral perfusion abnormality.
In this series, two patients had MCA maximum (maxMCA) velocities more than 200 
cm/sec at the onset of this study, and they did not have further overt or covert cerebral 
infarction during the follow-up period, probably because they were on chronic blood 
transfusion. One of these patients continued to have persistent maximum MCA 
velocities of more than 200 cm/sec; however her vascular disease progressed over time 
and she had decreased velocities > 7 0  cm/sec in more distal segments of the ipsilateral 
MCA. Although severely increased velocities >200 cm/sec is a well proven predictor of 
stroke recurrence (Adams et al 1998), decreased cerebral blood flow velocities could be 
related to some risk of infarction as well, especially sub-clinical or covert infarct, as has 
been demonstrated in SCD and in the elderly population (Gilliams et al 1997, Tzourio et
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al 2001, Zafeiriou et al 2004). In spite of these data, there are few data on the prediction 
of new cerebral infarcts or new cerebral atrophy in those sickle cell patients who had 
decreased blood flow velocities. In the current series, one of ten sickle cell patients 
(who had maxMCA velocities < 7 0  cm/sec and ipsilateral MCA lowest: highest ratio < 
0.5) developed a new infarct and 2 other patients had progression of focal cerebral 
atrophy, despite blood transfusion. In fact, TCD patterns of severity (where decreased 
maxMCA velocities <70 cm/sec is worse than maxMCA velocities > 200 cm/sec, 
because it is related to lower arterial blood flow secondary to very severe artery 
stenosis) were significantly associated with infarct number and size at follow-up, which 
suggests that those sickle cell patients with low TCD blood flow velocities (with a 
demonstrated ultrasound window) could be considered at risk of further cerebral 
infarction or progression of cerebral atrophy, especially if they have concomitant severe 
recurrent neurological symptoms such as TIAs and seizures as an expression of CVD 
and cerebral ischaemia (Kirkham et al 2001, Prengler et al 2002 and 2003).
The limitations of the technique of the transcranial Doppler ultrasound depend on the 
experience of the operator who performs the study, and the ultrasound window which 
can vary with age and individual (e.g. thick skull secondary to bone marrow changes). 
This very useful screening tool could give false positives (decreased MCA blood flow 
or undetectable MCA) in the presence of an inadequate ultrasound window (i.e. thick 
skull), and the TCD study should be evaluated with caution in the context of the 
patient’s symptomatology and neuroimaging. As was shown in this study, there were 
initially 7 patients with normal MRA, and only 2 of them had normal TCD following 
Adams’s criteria (Adams et al 1992). However, TCD might be a more sensitive to 
detect flow turbulence (and probable cerebrovascular disease) than MRA in sickle cell 
disease. Therefore, evidence-based guidelines for acceptable depths for the ultrasound 
window according to age of the patient and conditions which might affect skull 
thickness (as seen in SCD) should be addressed in further studies.
One quarter o f the sickle cell patients (6/23) had an improved perfusion MRI study at 
follow-up; all had had an abnormal baseline study and they were, at least initially, on 
chronic blood transfusion therapy. Nevertheless, an improvement in their cerebral 
perfusion was not accompanied with an improvement of their recurrent neurological 
symptoms, as these patients had TIAs, seizures and headaches. However, a smaller
294
number of patients had improved MRA (4/23 [13%]) and TCD (2/23 [8%]). Including 
all recurrent neurological symptoms, there does not seem to be an association with 
cerebral perfusion. In fact, these patients did not have stroke or coma [PLKE] 
recurrence, and probably the absence of these two very severe recurrent symptoms can 
be the real indicators of unchanged or improved cerebral perfusion. Transient ischaemic 
attack was a symptom found in patients with worse, unchanged, and improved 
investigations. TIAs were found, as well, in the same proportions in patients with 
improved or worse studies. However, this group of patients confirms that blood 
transfusion therapy could help to improved cerebral blood flow and vascular disease as 
has been shown in previous studies but with a shorter follow-up period (Hurlet-Jensen 
et al 1994, Venketasubramanian et al 1994, Kirkham et al 2001), although this 
improvement was seen in a smaller proportion of patients in comparison with those with 
unchanged or worse studies.
More than a third of the patients had unchanged MRI perfusion, and the majority also 
had normal baseline perfusion studies; recurrent headache was the most frequent 
symptom and was significantly associated with unchanged perfusion MRI at follow-up. 
Only one patient of 7 with a normal baseline perfusion MRI was on chronic blood 
transfusion, with one other on Hydroxyurea, whereas those patients with unchanged 
perfusion MRI who had had abnormal baseline studies were on blood transfusion 
therapy.
Most of the patients with unchanged normal perfusion MRI also had normal MRI and 
MRA studies at onset and at follow-up. TCD was the least correlated study for this 
group of patients. There was initially a small number of patients with normal TCD, 
perhaps because of technical difficulties in detecting the MCAs due to the ultrasound 
window, which could change depending on age and individual (see limitations of TCD 
explained in chapter 3 and above). This group of patients showed that most of the 
patients with normal baseline studies and less severe recurrent symptoms maintained 
normal cerebral perfusion and neuroimaging over time. In a few additional patients, 
blood transfusion may have helped to stabilise the pathology documented using 
magnetic resonance techniques.
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However, comparing MRI, MRA, TCD and perfusion MRI, it is interesting that of 
patients on chronic blood transfusion who had abnormal baseline studies, only 2 
patients had unchanged perfusion MRI, whereas there were higher numbers for MRI 
(n=8), MRA (n=6) and TCD (n=6) with unchanged studies. However the conventional 
neuroimaging and TCD could not detect particularly improvements of cerebral 
perfusion (6 patients) specifically compared with MRA (n=2), or to a lesser degree 
worsening of cerebral perfusion (n=7), especially against MRI (n=5) if we compared 
equal numbers of patients (for TCD the sample was smaller). Therefore, perfusion MRI 
is a very sensitive investigation for the evaluation of changes over time.
Regarding perfusion MRI parameters using dynamic susceptibility contrast MRI (DSC- 
MRI), cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time 
(MTT) are very sensitive indicators for identifying areas of cerebral tissue which are 
risk of ischaemia (Calamante et al 1999, Gadian et al 2000). However, a limitation of 
this study is that the assessment of cerebral perfusion abnormality is qualitative (visual 
inspection); although quantitation would provide a measure of real changes in cerebral 
blood flow, this is not technically possible using this technique at present. Visual 
inspection entails a degree of subjectivity regarding the extension and severity of the 
regional cerebral perfusion abnormality.
The main perfusion MRI parameters taken for analysis with the other modalities of 
investigation were cerebral blood flow (decreased [more frequently seen] or increased) 
and mean transit time (increased). These parameters are usually inversely related; a 
decrease in CBF is associated with an increase in MTT. The increased MTT of the 
passage of the intravenous bolus of Gadolinium occurs because there is slow passage of 
blood secondary to cerebrovascular disease (large or small blood vessel disease 
[Calamante et al 1999, Pavlakis et al 1988 and 1989, Prengler et al 2002]). Decreased or 
unchanged CBF has been shown to be a more sensitive parameter of cerebral perfusion 
abnormality than MTT in relation to clinical symptoms, neuroimaging and TCD in 
patients with SCD. Although most of the MR studies and TCD were significant for both 
parameters, CBF reached the highest level of significance when compared with MTT. 
This may be because increased MTT appears highlighted more on visual inspection than 
CBF (MTT is white and CBF is dark on the perfusion maps), and therefore for the 
observer it is more difficult to assess different grades of severity in the MTT maps than
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in the CBF maps. Because modifications in CBF have to be fairly marked in order to 
detect the differences over time on the CBF maps on visual inspection, it is possible that 
they were more correlated with the real changes (and with the other investigations) than 
MTT. In fact, for the analysis of the perfusion data over time, changes were recorded 
only when there were at least two severity grades of difference between the initial and 
final studies for both parameters CBF and MTT, to increase the robustness of the 
findings by minimising the effects of differences between independent observers.
In this series, there were some patients who had decreased CBF (usually in association 
with decreased CBV) with normal MTT initially and at follow-up. The decrease of CBF 
alone could be an early indicator of tissue at risk of ischaemia (that usually is well 
demonstrated with increased MTT). Conversely, there was only one patient in this 
series (described as a case report in a section above) who had persisting increased CBF 
(and CBV) initially with normal MTT and increased CBF (and CBV) during follow-up. 
This increase in CBF and CBV could be secondary to hyperaemia or vasodilation 
(Prohovnik et al 1989); however some regions with initial increased CBF progressed to 
decreased CBF and increased MTT in the final perfusion MRI. Therefore, it could be 
suggested that either isolated increased CBF or decreased CBF could be both indicators 
of further risk of regional cerebral ischaemia.
New perfusion MRI techniques with quantification of the CBF could help to define 
areas of decreased cerebral perfusion more accurately. A preliminary study in children 
with SCD has been published recently using continuous arterial spin- labelling (ASL) 
perfusion MRI, demonstrating that there were areas of decreased CBF (quantitative 
measurement), which were related to the symptoms of the patients (cognitive deficits) 
with normal conventional MRI scans (Oguz et al 2003). Currently, this technique is 
constrained by signal-to-noise limitations, which has prevented more widespread 
clinical application; nevertheless, research continues in this area of magnetic resonance, 
and it is likely to become more widely applied in the near future. It should also be 
noted that the assertion that the values obtained by ASL are truly quantitative is as yet 
controversial, since this technique also has a number of technical limitations. At the 
moment DSC-MRI with intravenous bolus of Gadolinium as been the most widely 
applied in clinical applications, and has shown to be a sensitive technique for diagnosis 
and monitoring sickle cell patients with neurological symptoms.
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Although many of these patients were on blood transfusion or other alternative 
treatments there was progression of cerebrovascular disease during the follow-up period 
of this study. The sickle cell can damage the endothelium not only due to its abnormal 
shape but also because it triggers a cascade of molecular factors and blood components 
that lead to the pathogenesis of cerebrovascular disease, and this process continues over 
time (Pavlakis et al 1989, Sternberg 1999, Belcher et al 2000, Franco et al 2000, 
Prengler et al 2002). The aim of blood transfusion is try to reverse this process (Pavlakis 
et al 1989, Balias 1998); however, it was demonstrated in this series that the progression 
of cerebrovascular disease continued in 26% of the patients and remained unchanged in 
another 26%, while there was not a complete reversal of the CVD.
Other clinical parameters which could affect blood vessels are blood pressure and 
haematological factors, and these were studied in these sickle cell patients in relation to 
the magnetic resonance investigations and TCD.
The effects of hypertension on the cerebral vasculature, which leads to vascular changes 
and is an important risk factor for stroke in the adult population, have been well 
documented. ‘Relative’ hypertension has been reported in sickle cell patients as 
associated with an increased risk of stroke and mortality (Rodgers et al 1993, Pegelow 
et al 1997). Increased blood pressure was also considered a risk factor for stroke in the 
Cooperative Study of Sickle Cell Disease (Ohene-Frempong et al 1998). In the series 
described in this thesis there were no significant associations between systolic, diastolic 
and mean arterial blood pressures at follow-up and worsening of MRI, MRA, TCD and 
perfusion MRI, although systolic blood pressures were above the 50th percentile for age 
but not beyond the 90th percentile. Only one patient had a hypertensive crisis in the 
context of a posterior leukoencephalopathy, and he had a new cerebral infarction at 
follow-up on his final MRI scan. Perhaps, because of the small numbers, any effect of 
blood pressure did not reach statistical significance, although there was a trend for 
association between low diastolic pressure and worsening of TCD over time, which 
could contribute to the decrease of the blood flow velocities.
Regarding haematological factors, there was a significant association between decreased 
initial platelet count and worsening of MRA. In addition, worsening of cerebral
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perfusion and worsening of MRI over time were related to increased white cells and 
lymphocytes at follow-up. There were no significant associations for haemoglobin 
levels. Blood components related to infection (i.e. white cells and neutrophils) have 
been related to the pathogenesis of CVD in sickle cell disease, and form part of the 
cascade of factors triggered either by the sickle cell itself or sepsis; this cascade also 
involves platelet activation (Sultana et al 1998, Belcher et al 2000, Inwald et al 2000). 
Sickle cell patients suffered from frequent infections, either bacterial or viral, from early 
years of life (Balias et al 1998). This study showed that there are trends for 
associations (the numbers of patients with haematological data were too small) between 
infection and perfusion abnormality and MRI, and between thrombocytopenia and 
MRA (which can be related to chronic infection). A preliminary study presented in 
abstract form showed progression of CVD in sickle cell patients who had stroke with 
increased lymphocyte counts in comparison with non-sickle children with stroke 
(Prengler et al 2000). Reducing the infection rate in these patients with environmental 
and medical measures (although they are already receiving prophylactic vaccines and 
Penicillin) may help to reduce the progression of CVD, especially in those children who 
have already had or are at risk of stroke. The effect of blood transfusion on the cerebral 
vasculature secondary to iron overload and its contribution to the progression of the 
CVD in SCD could be investigated in further studies.
Patients’ follow-up daytime awake oxygen saturations were not significantly associated 
with worsening of perfusion, MRI, MRA and TCD. Daytime awake-oxygen saturations 
were 92% or more, above the cut-off for hypoxemia (less than 92%). However, these 
normal awake-oxygen saturations did not exclude the possibility that these patients had 
nocturnal hypoxemia and obstructive sleep apnoea that have been associated with 
central nervous system events in SCD (Davies et al 1989, Kirkham et al 2001).
Finally, another aspect of this longitudinal study was to identify predictors of recurrent 
clinical symptoms and worsening of magnetic resonance studies. For worsening of 
cerebral perfusion at follow-up there were several significant associations, such as 
severity of onset and recurrent neurological symptoms, initial infarct size and number, 
grade of initial MRA turbulence and initial grade of decreased CBF or increased MTT. 
These showed that an important number of these patients maintained their initial 
symptoms and parameters throughout time without significant changes with or without
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treatment. A correlation matrix showed that there was a good correlation among initial 
infarct size, infarct number, CBF and grade of MRA turbulence. As a consequence, 
there appear to be many significant predictors in relation to worsening of perfusion 
MRI, in part because these predictors are significantly correlated among themselves. 
That means that, in this preliminary study, cerebral perfusion at follow-up could be 
predicted with one or two MR studies in addition to the initial or recurrent symptoms of 
the patient, while a number of the modalities of investigations provide only 
corraboration of these findings, without additional independent information.
Prediction of recurrent neurological symptoms, MRI and MRA changes at follow-up 
have been investigated previously (Ohene- Frempong et al 1998, Moser et al 1996, 
Miller et al 2001, Pegelow et al 2002, Seibert et al 1998). However, a number of 
additional variables different variables were analysed in the work described in this 
thesis.
Potential predictors of the severity of the recurrent neurological symptoms were severity 
of the symptoms at onset, initial number of infarcts, and grade of MRA turbulence. 
Predictors of recurrent cerebral infarction (infarct size and number on final MRI), were 
initial infarct size and number, initial MRA grade of turbulence and initial abnormal 
grade of CBF. Initial TCD ultrasound pattern was significantly associated with final 
infarct number. And finally, predictors of MRA turbulence at follow-up were severity 
of the initial neurological symptoms, initial infarct size and number, severity of 
decreased CBF or increased MTT on the initial perfusion MRI, and initial grade of 
MRA turbulence. However initial TCD was not a significant predictor for MRA 
turbulence at follow-up. A number of these significant associations were correlated 
among themselves.
However, these predictors showed that patients who had severe neurological symptoms 
at onset are more prone to have severe recurrent neurological symptoms at follow-up, 
with the exception of stroke recurrence, which might be prevented by the chronic blood 
transfusion or other alternative therapies. In addition, these predictors demonstrated that 
there are no substantial changes in the severity of MRI and MRA over time in most of 
the patients, with an exception of perfusion MRI, which showed improvement and
300
worsening of the cerebral perfusion in a higher proportion of patients than the other 
techniques.
Patients who had areas of perfusion abnormality maintained or worsened their grade of 
perfusion abnormality over time, and their perfusion MRI studies were unchanged or 
worse at follow-up. Nevertheless, those patients who improved their abnormal perfusion 
at follow-up, still had areas of persisting perfusion abnormality although in their final 
perfusion MRI, they had specific regional improvements of their cerebral perfusion.
In practice, the worst grades of CBF and MTT were chosen for statistical analysis, 
independently of whether the perfusion MRI had improved, remained unchanged or 
worsened. Because those patients whose cerebral perfusion improved still maintained 
the same initial grades of perfusion abnormality in some areas of the brain at follow-up, 
their initial and final CBF and MTT had a significant association with the other 
magnetic resonance studies and TCD (which maintained or worsened their grades of 
severity over time in a great proportion of the sickle cell patients). The same principle 
applies to MRA turbulence; while some patients had an improvement of the MRA 
turbulence, the severity of the CVD usually persisted over time.
In summary, this study demonstrated that there is not a complete reversal of CVD and 
perfusion abnormality in the majority of the patients who had abnormal baseline studies, 
and that the initial grade of severity usually persisted or impaired over time despite 
different therapies.
5.11. Conclusion
In conclusion, this study showed that there was progression of cerebral perfusion 
abnormality over time in more than one third of the patients with sickle cell disease. 
The progression of abnormal perfusion was correlated with the severity of the recurrent 
neurological symptoms and with the progression of cerebrovascular disease (MRA 
turbulence) and it continued despite chronic blood transfusion therapy or other
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alternatives therapies. In addition, more than a third of patients had unchanged cerebral 
perfusion, MRI and MRA during the follow-up.
There was a good correlation between transcranial Doppler ultrasound and MRA at 
follow-up and between TCD and perfusion MRI. TCD could be a useful tool, not only 
to monitor progression of CVD but also progression of perfusion abnormality over time. 
The progression of cerebral perfusion abnormality and cerebrovascular disease might be 
associated with infection in addition to the damaging effect of the sickle cell in the 
vascular endothelium.
Perfusion MRI seems to be the most sensitive technique to evaluate changes over time, 
and was often associated with recurrent symptoms in this population. Changes over time 
of perfusion MRI, structural MRI, MRA and TCD, and predictors of cerebral perfusion 
abnormality at follow-up, showed that there is rarely a complete reversal of the 
cerebrovascular disease, and the perfusion abnormality in those sickle cell patients who 
had abnormal baseline studies and the initial grade of severity usually persisted or 
worsened over time despite different therapies.
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Chapter 6: Effect of Blood Transfusion Therapy on Perfusion 
Abnormality in the Short and Long Term in Sickle Cell 
Disease
6.1. Introduction and Aims 
6.1.1 Introduction
Long-term blood transfusion is recommended for the prevention of recurrent stroke in 
sickle cell disease (Pavlakis et al 1989, Balias et al 2002, Kirkham and deBaun 2004). 
Without blood transfusion, recurrent stroke occurs in up 67% of patients with SCD 
(Powars et al 1978). However, in sickle cell patients on blood transfusion stroke recurs 
in up to 13%, although keeping the HbS% less than 30% in patients on chronic 
transfusion is important in reducing the recurrence risk (Pegelow et al 1995). Reported 
secondary stroke rates have been from 2.2. to 6.4 events per 100 patient-years in sickle 
cell patients on blood transfusion after their first stroke (Pegelow et al 1995, Scothom et 
al 2002). Worryingly, Dobson demonstrated that up 41% of SCD patients experienced 
recurrence o f central nervous system (CNS) events despite chronic transfusion, in 
association with a high prevalence of cerebrovascular disease (particularly moyamoya 
syndrome, with occlusion of the distal internal carotid artery and collaterals, in 43%) in 
their series (Dobson et al 2002).
1 3 3 *  *There have been few studies, which have mainly used inhaled Xenon , investigating 
the effects of blood transfusion on cerebral blood flow (CBF) before and after blood 
transfusion in patients with SCD. These studies demonstrated the beneficial effect of 
blood transfusion in normalising CBF (Prohovnik et al 1989, Hurlet-Jensen et al 1994) 
or reversing the abnormal regional perfusion in patients with acute neurological 
complications such as stroke, TIA, coma or seizures (Huttenlocher et al 1984). A recent 
cross-sectional study in patients with SCD and neurological complications (using 
perfusion MRI using intravenous bolus of Gadolinium [DSC-MRI]) showed an
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improvement of the regional perfusion abnormality in one patient, shortly after blood 
transfusion (Kirkham et al 2001).
There is increasing interest in treating children and adults with SCD with alternative 
therapies, such as Hydroxyurea (Ware et al 1995, Ware et al 1999, Ware et al 2004) and 
bone marrow transplantion (Walters et al 2000). Pilot trials of children with SCD and 
stroke treated with Hydroxyurea reported secondary stroke rates of 5.7 and 3.6 events 
per 100-patient-years (20% and 10% of the patients respectively) over a follow-up 
period of up to 42 months in children who received only Hydroxyurea and in those who 
received Hydroxyurea overlapping with blood transfusion respectively (Ware et al 
2004), a similar incidence to those treated with regular blood transfusion.
However, chronic blood transfusion currently remains the mainstay of treatment for 
SCD patients who have stroke or severe neurological complications. There have been 
no studies on the effect of long-term blood transfusion on cerebral perfusion and 
cerebrovascular disease, which could provide valuable information, as there are 
concerns about the side effects of chronic blood transfusion (i.e. iron overload, blood 
borne infections, erythrocyte autoantibody formation [Balias et al 2002]) and poor 
compliance with this treatment by a significant proportion of the patients.
6.1.2. Aims
The primary aim of this study was to examine the effect of blood transfusion on cerebral 
perfusion (imaged using magnetic resonance bolus tracking of Gadolinium) and 
cerebrovascular disease (determined using magnetic resonance angiography and 
transcranial Doppler) in both the short-term (pre- and post-blood transfusion) and in the 
long-term (post-chronic transfusion) in patients with sickle cell disease and central 
nervous system events.
Although there would be additional interest in considering the effects of other 
alternative treatments used in SCD (i.e. Hydroxyurea, bone marrow transplant and 
revascularisation procedures) on cerebral perfusion and cerebrovascular disease, 
especially in those patients who had stopped blood transfusion and continued on another
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therapy, these data were only available in three patients, and are therefore included as 
cases reports only.
6.2. Subjects
6.2.1. Short-Term Blood transfusion
Data collection for the patients of this study was described in chapter 2 (Appendix- 
Table 1). Sickle cell patients with CNS events (stroke or TIA) on blood transfusion 
therapy (BTx) were recruited from referrals to the joint Haematology/Neurology clinics 
attended by MP and FK at five North London hospitals (Central Middlesex, North 
Middlesex, University College (UCH), Royal London and Whittington Hospitals).
Nine patients with sickle cell anaemia (HbSS) who had successful magnetic resonance 
studies were originally selected for this series. One of the nine patients (patient No. 15, 
Appendix-Table 1) had successful perfusion MRI studies, but was excluded from this 
series because pre- and post-blood transfusion MR perfusion scans were in different 
positions and orientations, therefore it was difficult to conclude whether there had been 
significant changes in perfusion abnormality between the studies.
The final series consisted of eight patients with sickle cell anaemia, 4 were male and the 
mean age was 16.3 years (range 8 to 27 years).
6.2.2. Long- Term Blood transfusion
Data collection for the patients of this study was described in chapter 2 (Appendix- 
Table 1). Sickle cell patients with CNS events on chronic blood transfusion therapy 
were recruited from referrals to the joint Haematology/Neurology clinics attended by 
MP and FK at six North London hospitals (Central Middlesex, North Middlesex, 
University College (UCH), Royal London, Whittington and Saint Mary’s Hospitals).
Seventeen patients with sickle cell anaemia (HbSS) had successful initial and follow-up 
magnetic resonance studies. These patients were part of the longitudinal study described
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in chapter 5 (17/23 patients). Six of the 17 patients were included in the short-term 
blood transfusion study described above. Seven patients were male; the mean age at the 
time of their first MR studies was 12.9 years (range 6.8 to 21.9 years) and the mean age 
at the follow-up MR studies was 15.2 years (range 7.5 to 23.9 years).
6.3. Methods
6.3.1. Data Acquisistion
The methods for the acquisition of conventional neuroimaging, perfusion MRI, 
transcranial Doppler ultrasound, oxygen saturation, blood pressure measurements and 
haematological parameters have already been described in chapter 3.
For the short-term blood transfusion study, the patients (n=8) underwent magnetic 
resonance (MRI, DWI, MRA and perfusion MRI); transcranial Doppler ultrasound 
investigations (pre-BTx n=8; post-BTx n=8); blood pressure measurements, which 
included systolic, diastolic and mean arterial blood pressures (pre-BTx=7; post- 
BTxn=6); and 3 minutes’ awake-pulse oximetry [Sp02] (pre-BTx= 7; post-BTxn=7); 
with a mean of 3.9 days (range 2 to 7 days) before blood transfusion and a mean of 4.7 
days (range 0.2 to 12 days) after transfusion. Haematological parameters were collected 
from clinical records, only haemoglobin was used for analysis of this study. HbS% and 
ferritin data were also collected but the numbers were too small for analysis and 
therefore they were excluded from this study; this study did not included analysis of 
white cell and platelet counts.
For the long-term blood transfusion study, 17 patients underwent initial and follow-up 
magnetic resonance studies, and initial (n=13) and follow-up (n=17) transcranial 
Doppler ultrasound. The follow-up investigations occurred at a mean of 2.2 years (range 
8 months to 3.5 years) after the initial investigations. Initial blood pressure 
measurements (n=2) and haematological parameters were collected from clinical 
records, however only haemoglobin was used for analysis as described above; follow- 
up blood pressure measurements were recorded at the same day of the magnetic 
resonance studies in 13 patients. Analysis of the oxygen saturation (SpCh) of the
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patients was not included in the long-term blood transfusion study because there were 
no initial SpC>2 data.
6.3.2. Data Analysis
Wilcoxon test were used for comparison o f non-parametric continuous data (blood 
pressure and haemaglobin levels). Level of significance was defined as p<0.05, and a 
trend for significance was set between p >0.05 and p< 0.1.
6.4. Results I: Short-Term Blood Transfusion
6.4.1. Effect of Short-Term Blood Transfusion on Neurological Symptoms
The sickle cell patients on blood transfusion therapy had had the following central 
nervous system (CNS) events at presentation (Appendix-Table 5): stroke in 6 patients 
(one of the stroke patients presented with coma); anterior territory transient ischaemic 
(TIA) attacks in one; and posterior territory TIA (collapse and transient loss of vision) 
in one.
Of the sickle cell patients who had had stroke at onset, the majority had a history of 
recurrent neurological symptoms such as anterior territory TLAs in 2; headaches in 3; 
one patient remained asymptomatic. The patient who had initially anterior territory TIA 
became asymptomatic; and the other who presented with posterior territory TIA had 
recurrent headaches.
Shortly after blood transfusion, all of these patients experienced an improvement in 
their general symptoms caused by SCD; in 6 out of 8 patients the recurrent neurological 
symptoms diminished in frequency (n=4); 2 remained asymptomatic. Two patients 
continued having headaches (1 with stroke and another with posterior TIA at onset); 
however their generalised symptoms improved after transfusion.
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6.4.2. Effect of Short-Term Blood Transfusion on Blood Pressure
The mean of the systolic blood pressure (SBP) of the patients (n=7) before transfusion 
was 106 mmHg (range 85-121 mmHg); the diastolic blood pressure (DBP) was 52 
mmHg (range 31-75 mmHg); and the mean arterial blood pressure (MAP) was 71 
mmHg (range 61-90 mmHg).
After blood transfusion (n=6), SBP mean was 113 mmHg (rangel02-121 mmHg); DBP 
was 60 mmHg (range52-73 mmHg); and MAP was 77 mmHg (range 68-89 mmHg).
There were trends for associations between pre- and post-blood transfusion blood 
presssure measurements for a higher SBP (p=0.08, Wilcoxon test) and a higher MAP 
(p=0.1; Wilcoxon test) after transfusion. There was no association for DBP (p=0.3) 
before and after transfusion.
6.4.3. Effect of Short-Term Blood Transfusion on Oxygen Saturation
Pre-blood transfusion, the sickle cell patients had a mean awake-Oxygen saturation 
(Sp02) of 96.5 % (range 92 to 98.4%). Post-blood transfusion the awake-Sp02 mean 
was 97% (range 94-98.9%). Awake-Sp02 was significantly higher after blood 
transfusion (p=0.028; Wilcoxon test).
6.4.4. Haemoglobin
Available haemoglobin data were collected from 5 patients. The blood tests were done 
at a mean 4 days (range 0-1 months) from the neuroimaging and TCD studies. 
Haemoglobin levels pre- and post- transfusion were not available in the clinical records 
for all patients. The mean haemoglobin level was 10 g/dL (range 9.2 to 10.9 g/dL).
6.4.5. Effect of Short-Term Blood Transfusion on Magnetic Resonance Imaging
Appendix-Table 5 shows the relationship between the results from different MR 
investigations and transcranial Doppler ultrasound (TCD) in the patients included in this 
study. Of the 6 patients who presented with stroke at onset, 1/6 had an unilateral
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cerebral infarct in the anterior cerebral artery (ACA)/ middle cerebral artery (MCA) 
territories on T2-weighted MRI; the remaining 5 patients had bilateral infarcts, in the 
ACA/MCA territory in 3 patients (1/3 with cerebral atrophy), and in the posterior 
cerebral artery (PCA)/MCA territories in 2 patients (both had cerebral atrophy).
The sickle cell patient who had anterior territory TLAs had unilateral deep watershed 
white matter infarcts and the patient who presented with posterior territory TIAs both 
had bilateral deep watershed infarcts in the MCA/ACA territories.
None of the patients had any change on T2-weighted MRI after short-term blood 
transfusion.
6.4.6. Effect of Short-Term Blood Transfusion on Magnetic Resonance 
Angiography
The maximum grade of turbulence for each patient is described in Appendix Table 5. 
Before blood transfusion 1 patient had a normal and 7 had abnormal MRA studies.
Of the six patients who had stroke at onset, 3 patients presented with artery occlusion 
(ACA-A1 [n=2]; MCA-M1 [n=l, plus moyamoya collaterals]); 1 had moderate 
turbulence (terminal internal carotid artery [TICAJ/MCA/ACA) and 2 patients had 
severe turbulence on MRA (TICA, n= l; MCA-M1, n=l). The patient who had initially 
anterior territory TIAs had a normal MRA, and the other with posterior territory TIAs 
had mild turbulence on MRA (ACA-A1).
After blood transfusion, MRA was unchanged in 4 patients (2 stroke patients with artery 
occlusion, 1 stroke patient with moderate turbulence and a patient with posterior TIAs 
with previously mild turbulence). MRA improved bilaterally in one patient with stroke 
(the severe turbulence in the TICA remained but other segments normalised from mild 
to moderate turbulence i.e. MCA-M2, ACA-A1 and PCA-P1). Three patients had a 
worse MRA after blood transfusion unilaterally; one stroke with artery occlusion 
(MCA) and moyamoya collaterals (mild turbulence to artery occlusion of the PCAs), 
another stroke patient with initial severe turbulence on MRA on the TICA (this segment 
remained unchanged but other MCA/ACA segments progressed to moderate and severe
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turbulence), and the patient who had had anterior TIAs and normal initial MRA, who 
had mild turbulence in the MCA after transfusion.
In summary, 4/8 o f the patients had unchanged, 3/8 worse (unilaterally), and 1/8 had an 
improved (bilaterally) MRA studies shortly after blood transfusion.
6.4.7. Effect of Short-Term Blood Transfusion on Perfusion MRI (DSC-MRI)
Appendix-Table 5 and Appendix-Table 6 present the regions of cerebral perfusion 
abnormalities on DSC-MRI and changes of cerebral perfusion after blood transfusion. 
Initial perfusion MRI was normal in 1 and abnormal in 7 of these 8 sickle cell patients.
Before blood transfusion, one patient had a normal perfusion study (anterior territory 
TIA), 2 stroke patients had unilateral abnormal perfusion confined to a region or regions 
of a cerebral hemisphere (MCA/ACA territories); and 5 patients (4 stroke; 1 posterior 
TIAs) had bilateral perfusion abnormalities in the ACA/MCA territories (n=3) and in 
the MCA/PCA territories (n=2).
After blood transfusion, 3 patients had unchanged perfusion MRI; in one patient with a 
previous normal study, and in 2 stroke patients who had had bilateral perfusion 
abnormalities in the ACA/MCA (n=l) and MCA/PCA (n=l) territories.
However, five patients showed improved perfusion after transfusion in at least one 
cerebral region; the improvement in cerebral perfusion abnormality was characterised 
by a decrease in the mean transit time (MTT; n=2); an increase in the cerebral blood 
flow and cerebral blood volume (CBF and CBV; n=l), an increase in CBV only (n=l) 
and a decrease in MTT with an increase in CBF and CBV (n=l). One patient (posterior 
TLA) with previous bilateral abnormal perfusion improved in regions of one hemisphere 
(ACA/MCA). For the 4 remaining patients (stroke), 2 patients who had had initial 
bilateral abnormal perfusion improved in both hemispheres in the MCA/AC A (n=l) and 
PCA/MCA (n=l) territories; and two patients with previous unilateral perfusion 
improved in some regions of the MCA territory (n=l) and in a localised region of the 
ACA territory (n=l, pat. 2, Appendix-Table 5). However, there was not a complete 
reversal of the perfusion abnormality for any of these patients after blood transfusion.
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In summary, 3 of 8 sickle cell patients had unchanged perfusion MRI studies and 5 out 
of 8 had a partial improvement (either unilateral or bilaterally) of their perfusion 
abnormality shortly after blood transfusion.
6.4.8. Effect of Short-Term Blood Transfusion on Transcranial Doppler 
Ultrasound
Before blood transfusion, one patient had a normal TCD (stroke; normal MCA 
velocities, but decreased PCA velocities) and 7 patients had abnormal TCD, according 
to Adams’ criteria (Adams et al 1992 and 1998).
Of the patients who had initially abnormal TCD, 5 patients (3 stroke, 1 anterior and 1 
posterior territory TIAs) had mean maximum MCA (maxMCA) velocities less than 70 
cm/sec and lowest: highest ipsilateral MCA ratio <0.5; 2 of the stroke patients had 
undetectable MCA.
Shortly after blood transfusion 6 patients had unchanged TCD studies including the 
patient with previously normal TCD, and there was an improvement in 2 patients who 
normalised their TCDs in one MCA (1 posterior territory TIA and 1 stroke).
In summary, 6/8 of the patients had unchanged and 2/8 had improved TCD shortly after 
blood transfusion (figures 6.1 and 6.2). Table 6.1 shows the relationship between the 
different studies before and after blood transfusion in this series of sickle cell patients.
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Investigations
Better
Post-BTx
Unchanged
Post-BTx
Worse
Post-BTx
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
MRI
(n=8)
8
MRA
(n=8)
1 4 1 2
TCD
(n=8) 2 1 5
Perfusion MRI
(n=8) 5
. . .
1 2
Table 6.1. Relationship between results of the different investigations 
after blood transfusion in this series o f sickle cell patients. BTx= blood 
transfusion.
□ No data because no improvement can be demonstrated from a normal study or from a study showing the presence o f lesions.
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R L
MRI Perfusion MRI
Figure 6.1. Short-term blood transfusion. Pre-Blood transfusion. 15-year old female, SCD (HbSS), stroke 
at 12 years of age. Recurrent headaches. T2-w MRI. Mature left middle cerebral artery (MCA) infarct, 
left caudate nucleus infarct and atrophy. Perfusion MRI: Abnormal perfusion MRI. Increased mean 
transit time of the passage o f IV contrast bolus in the left MCA territory, including the left frontal region. 
MRA. Stenosis o f the left MCA and Left A l (anterior cerebral artery), collateral vessels. TCD: decreased 
left MCA blood flow velocities and turbulent left ACA flow. R: right; L: left.
R L
MRI Perfusion MRI MRA
Figure 6.2. Short- term blood transfusion (same patient). Post-Blood transfusion (six days post- 
transfusion). T2-w MRI. Unchanged MRI. Improved Perfusion M RI.Decreased (compared to pre- 
transfusion) mean transit time o f the passage of IV contrast bolus (and increased cerebral blood flow) in 
the left frontal region and, in some degree, in the left MCA territory. MRA. Unchanged for the left MCA 
& ACA. Slight improvement in the visibility of distal vessels. TCD: slight increased of the left MCA 
blood flow velocities and less turbulent flow in the left ACA. R: right; L: left.
MRA
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6.5. Results II: Long-Term Blood Transfusion
6.5.1. Long-Term Blood Transfusion and Recurrent Neurological Symptoms
The 17 sickle cell patients involved in this study had had the following central nervous 
system events at presentation (Appendix-table 3 [patients 1-16 and 20] and Appendix- 
Table 7): coma with stroke in 2 out of the 17 patients; coma and posterior territory TIA 
in 1; stroke in 7; anterior territory TIAs in 4; posterior territory TIAs in 2 and headaches 
in 1.
All 17 patients were initially on blood transfusion therapy; however during follow-up, 
only 9 out of the 17 remained on chronic blood transfusion, whereas 5 patients stopped 
blood transfusion (one due to autoantibody formation; patient 8, Appendix- table 3 ); 1 
patient stopped and continued on Hydroxyurea; 1 patient stopped transfusion and 
received a bone marrow transplant; and another stopped transfusion and had subsequent 
surgical revascularisation and continued on Hydroxyurea.
During the follow-up period, the patients had the following recurrent neurological 
symptoms: 1 patient had coma (with posterior leukoencephalopathy on MRI [this 
patient appears in the figures as ‘PLKE’]); 1 had stroke; 6 headaches; 1 seizures; 6 
anterior and 1 posterior territory TIAs; and one remained asymptomatic. The 
relationship between recurrent neurological symptoms and therapies are shown in table 
6.2 and figure 6.3.
From table 6.2 and figure 6.3, a patient who stopped blood transfusion had recurrent 
stroke, whereas all but one o f the patients who were on chronic blood transfusion 
continued to have recurrent neurological symptoms. Patients who had stopped blood 
transfusion or who were on alternative treatments for SCD, also presented with 
recurrent symptoms, in the majority of the cases, in relation to their baseline CNS event 
at onset (Appendix - table 3).
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Recurrent
Symptom
(n=Pats)
BTx BTx
Stopped
BTx
Stopped
HU
BTx
Stopped
BMT
BTx
Stopped
RV+HU
None 1
Headache 3 2 1
Seizures 1
Post. TIA 1
Ant TIA 3 1 1 1
Stroke 1
Coma
(PLK E)
1
Total 9 5 1 1 1
Table 6.2. Recurrent neurological symptoms in patients with sickle 
cell disease and their different therapies. BTx= blood transfusion; 
HU= Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure; PLKE= posterior leukoencephalopathy
7
Therapy
|BTx Stopped-RV-HU
|BTx Stopped-BMT
[BTx Stopped-HU
|BTx Stopped
M one S e iz iire - s  A n t TIA PLKE
Headaches Post TIA Stroke
Recurrent Neurological Symptoms
Figure 6.3. Recurrent neurological symptoms in patients with sickle 
cell disease and their different therapies. BTx= blood transfusion; 
HU= Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure; PLKE= posterior leukoencephalopathy
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6.5.2. Blood Pressure Measurements
The mean of the systolic blood pressure (SBP) of the patients (n=2) at the time of the 
initial investigations was 120 mmHg (range 120-120 mmHg); the mean diastolic blood 
pressure (DBP) was 55 mmHg (range 50-60 mmHg); and the mean arterial blood 
pressure (MAP) was 77 mmHg (range 73-80 mmHg).
Blood pressure measurements were done in 13 patients at follow-up, SBP mean was 
112 mmHg (range 97-128 mmHg); DBP was 49 mmHg (range 30-75 mmHg); and 
MAP was 70 mmHg (range 58-90 mmHg).
There were no significant associations for initial and final SBP, DBP and MAP (p=0.7, 
p=0.2 and p=0.3 respectively; Wilcoxon test), however the number of patients was very 
small (n=2).
6.5.3. Haemoglobin
Initial and final haemoglobin (Hb) data were obtained from 13 patients. Initial mean Hb 
level was 8.9 g/dL (6.5-10.6 g/dL), and follow-up mean Hb level was 9.1 g/dL (range 
6.1-10.9 g/dL). There was a trend for a higher Hb level at follow-up (p=0.07; Wilcoxon 
test).
6.5.4. Effect of Long-Term Blood Transfusion on Magnetic Resonance Imaging
Initial structural T2-weighted MRI scans of the patients were normal in 4 of the 17; 
there were unilateral (in one or several regions of a cerebral hemisphere) infarcts in 3 
patients; and cerebral infarcts in both hemispheres (bilateral) in 10 patients.
At the end o f the follow- up, 11 patients (65%) had unchanged and 6 (35%) had a 
worsening of their MRI studies. Table 6.3 and figure 6.4 relate changes of MRI over 
time and the different therapy modalities in these patients.
From table 6.3 and figure 6.4, two thirds of the patients on blood transfusion had worse 
MRI; another third had stopped blood transfusion. Whereas for those patients with
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unchanged MRI, half were on blood transfusion, a quarter of the patients had stopped 
blood transfusion and the remainder were on alternative therapies.
MRI Changes 
over Time 
(n=Pats)
BTx BTx
Stopped
BTx
Stopped
HU
BTx
Stopped
BMT
BTx
Stopped
RV+HU
Unchanged 5 3 1 1 1
Worse 4 2
Total 9 5 1 1 1
Table 6.3. Changes on MRI over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
12
T h e ra py
I BTx Stopped-RV-HU
I BTx Stopped-BMT
| BTx Stopped-HU
|BTx Stopped
U n ch an ged  W orse
MRI Changes over Time
Figure 6.4. Changes on MRI over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
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6.5.5. Effect of Long-Term Blood Transfusion on Magnetic Resonance
Angiography
The sickle cell patients had the following grades of MRA abnormality initially, 
considering the worse grade of turbulence in each patient: normal MRA in 3 out of 17 
patients; mild turbulence in 1; moderate turbulence in 5; severe turbulence in 4; artery 
occlusion in 2; and artery occlusion and collaterals in 2.
At the end o f the follow- up, 6 patients (35%) had unchanged, 3 (8%) had improved, 
and 8 (47%) had worse MRA studies. Table 6.4 and figure 6.5 relate MRA changes 
over time and the different treatments in these patients.
From table 6.4 and figure 6.5, two third of the patients with worse MRA were on blood 
transfusion, whereas the remainder were on alternative therapies for SCD and on patient 
had had stopped transfusion. Of the patients who had unchanged MRA at follow-up, 
two third were on blood transfusion, and the remaining 2 had stopped transfusion but 1 / 
2 continued on Hydroxyurea. Finally, patients who improved their MRA studies had 
stopped blood transfusion.
MRA 
Changes 
over Time 
(n=Pats)
BTx BTx
Stopped
BTx
Stopped
HU
BTx
Stopped
BMT
BTx
Stopped
RV+HU
U nchan­
ged
4 1 1
Im proved 3
W orse 5 1 1 1
Total 9 5 1 1 1
Table 6.4. Changes on MRA over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
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MRA Changes over Time
Figure 6.5. Changes on MRA over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
6.5.6. E ffect o f  Long-Term  Blood Transfusion on Trancranial Doppler Ultrasound
Initial transcranial Doppler studies (TCD; table 6.4) demonstrated that the patients had 
the following categories (taking into account the worst category following Adams’ 
criteria [Adams et al 1992 and 1998]): normal in 3 of the 13 patients; mean maximum 
MCA (maxMCA) velocities > 200 cm/sec in 1; mean maxMCA velocities < 70 cm/sec 
and ipsilateral lowest : highest mean maxMCA ratio <0.5 in 7; and undetectable MCA 
in 2 patients. There were no initial TCD data in 4 patients.
In the final TCD study, 6 patients (46%) had unchanged, 1 (8%) had improved, and 6 
(46%) had worse TCD. Table 6.5 and figure 6.6 show changes over time of TCD and 
the different therapies in these patients.
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Table 6.5 and figure 6.6 show that those patients who had worse TCD at follow-up, one 
third of them were on blood transfusion, one third had stopped blood transfusion, and 
the remainder were on alternative treatments. For those patients who had unchanged 
TCD, two third were on blood transfusion and one third had stopped blood transfusion. 
The patient who had an improved TCD had had revascularisation and continued on 
Hydroxyurea.
TCD changes 
over Time (n=Pats)
BTx BTx
Stopped
BTx
Stopped
HU
BTx
Stopped
BMT
BTx
Stopped
RV+HU
Unchanged 4 2
Improved 1
Worse 2 2 1 1
Total 6 4 1 1 1
Table 6.5. Changes on TCD over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
Therapy
|BTx Stopped-RV-HU
|BTx Stopped-BMT
|BTx Stopped-HU
|BTx Stopped
Improved Unchanged W orse
TCD Changes over Time
Figure 6.6. Changes on TCD over time and blood transfusion 
treatments in patients with SCD. BTx= blood transfusion; HU= 
Hydroxyurea; BMT= bone marrow transplant; RV= surgical 
revascularisation procedure.
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6.5.7. Effect of Long-Term Blood Transfusion on Cerebral Perfusion
Perfusion MRI studies at onset (Appendix-Table 3 [patients 1-16 and 20] and 
Appendix-Table 7) showed that three of the 17 patients with SCD had normal perfusion, 
whereas 6 had perfusion abnormalities confined to a region or regions of one cerebral 
hemisphere in the ACA, MCA, and /or PCA territories; and 8 patients had perfusion 
abnormalities in a region or regions of both hemispheres.
Follow-up perfusion MRI demonstrated that 3 patients (8%) had unchanged, 6 (35%) 
had improved, and 8 (47%) had a worse perfusion. Table 6.6 and figure 6.7 summarise 
the changes over time of perfusion MRI and the treatments of these patients.
From table 6.6 and figure 6.7, two thirds of the patients with worse perfusion were on 
blood transfusion therapy, whereas the remainder had stopped transfusion or had 
alternative treatments (bone marrow transplant or Hydroxyurea). Of three sickle cell 
patients with unchanged perfusion, one remained on blood transfusion and two had 
stopped transfusion, one of whom had had a revascularisation procedure and continued 
with Hydroxyurea. Finally, of the patients with improved perfusion MRI studies, more 
than half of them remained on blood transfusion.
Perfusion MRI 
Changes 
over Time 
(n=Pats)
BTx BTx
Stopped
BTx
Stopped
HU
BTx
Stopped
BMT
BTx
Stopped
RV+HU
Unchanged 1 2
Improved 3 2 1
W orse 5 1 1 1
Total 9 5 1 1 1
Table 6.6. Changes on Perfusion MRI over time and blood 
transfusion treatments in patients with SCD. BTx= blood
transfusion; HU= Hydroxyurea; BMT= bone marrow transplant; 
RV= surgical revascularisation procedure.
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T h e ra p y  
I IF M bTx Stopped-RV-HU
| BTx Stopped-BMT
|BTx Stopped-HU
Improved U nchanged W orse
Perfusion MRI Changes over Time
Figure 6.7. Changes on Perfusion MRI over time and blood 
transfusion treatments in patients with SCD. BTx= blood 
transfusion; HU= Hydroxyurea; BMT= bone marrow transplant;
RV= surgical revascularisation procedure.
6.5.8. Com parison between Cerebral Perfusion and Conventional Neuroimaging 
and TCD in Long-Term  Blood Transfusion
Worsening of the cerebral perfusion abnormality on perfusion MRI in 8 sickle cell 
patients who were on chronic blood transfusion was associated with worsening of MRI 
in 6, worsening of MRA in 8, and a worse TCD in 6 sickle cell patients (table 6.7). 
However, of 6 patients who improved their perfusion abnormality, only 3 had an 
improved MRA; and 1 patient had a better TCD. Only 3 patients had unchanged 
perfusion and 6 patients had unchanged MRA, whereas 11 patients had unchanged MRI 
and 6 unchanged TCD at follow-up (figures 6.8 and 6.9).
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C hange O ver Tim e (n=Sickle Cell Patients)
Investigations
Better Unchanged Worse
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
Normal
Baseline
Abnormal
Baseline
MRI
(n=17)
4 2 §
1 § H U
7 1§
1 § H U + R V
1 § B M T
1 I§ 5 is
MRA
(n=17) 3 3§ 3 1§
1 § H U
3 8 1§ 
1 § B M T
1 § H U + R V
TCD
(n=13) 1
1 § H U + R V
- 6 2§ 2
1 § H U
4 2 §  
1 § B M T
Perfusion MRI
(n-17) 6 2§
1 § H U + R V
1 ,§ 2 1§ 1
1 § H U
? .§
1 § B M T
Table 6.7. Changes over time of MRI, MRA, transcranial Doppler ultrasound and 
perfusion MRI in relation to recurrent neurological symptoms in sickle cell patients on 
long term blood transfusion therapy.
BTx: Blood transfusion therapy; TIA: Transient ischaemic attack.
HU: Number of sickle cell patients on Hydroxyurea therapy;
* Number of patients who stopped blood transfusion therapy during follow-up
*BMT Number of patients who stopped blood transfusion therapy and had bone marrow transplant during 
follow-up
§ h u + r v  Number of patients who stopped blood transfusion therapy, had surgical revascularisation 
procedure and continued with Hydroxyurea during follow-up
I No data because no improvement can be demonstrated from a normal study or MRI
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6.5.9. Alternative Therapies in SCD and their Effect on Magnetic Resonance 
Studies and TCD
6.5 .9 .1 . B lo o d  T ra n sfu sio n  D isc o n tin u e d  F o llo w e d  b y  H y d ro x y u re a
A male patient with sickle cell anaemia (table 6.1, No. 15) presented with posterior 
territory TLAs at 15 years of age, his initial investigations (MRI, MRA, perfusion MRI 
and TCD) were all normal and he was initially on blood transfusion, which was 
discontinued as he was asymptomatic and he started on Hydroxyurea. He had recurrent 
headaches. Four years later, follow-up investigations showed abnormal perfusion in the 
right temporal areas (increased MTT and decreased CBF), and abnormal TCD with 
decreased velocities < 70 cm/sec in the right middle cerebral artery, but he had 
unchanged MRI and MRA.
6.5 .9 .2 . B lo o d  T ra n sfu sio n  D isc o n tin u e d  F o llo w e d  b y  R eva sc u la r isa tio n  P ro c e d u re  
a n d  H y d ro x y u re a
This patient, a 12-year-old boy with sickle cell anaemia (Table 6.1, pat No. 14), 
presented with anterior territory TIAs (transient right hemiparesis), headaches and 
learning difficulties. His initial investigations showed multiple small watershed infarcts 
bilaterally on MRI, moderate turbulence in the anterior circulation (MCAs/ACAs), 
bilateral perfusion abnormalities (increased MTT and decreased CBF) in watershed 
regions (ACA/MCA/PCA territories), and abnormal TCD (right MCA). The patient was 
initially on blood transfusion, however, because of his recurrent severe symptoms, he 
underwent a left indirect frontal revascularisation procedure, stopped blood transfusion 
and continued on Hydroxyurea. Afterwards, he had recurrent headaches and ongoing 
learning difficulties but not TIAs. After 3 years, follow-up investigations showed an 
improvement (mainly) in his cerebral perfusion in some areas bilaterally, although there 
were two regions on the left hemisphere with impaired perfusion, but his MRI was 
unchanged. Follow-up MRA showed improvement in the turbulence of the left Ml 
segment (the same side of the revascularisation procedure), however his cerebrovascular 
disease was worse on the right. However, the patient improved his cerebral perfusion 
and his symptoms.
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6.5.9.3. Blood Transfusion Discontinued -  Bone Marrow Transplant
This 10-year-old girl with sickle cell anaemia, presented with stroke (right hemiparesis 
and aphasia). Her initial investigations showed a left frontal parietal infarct and on the 
right, deep watershed infarcts. She had cerebrovascular disease with severe turbulence 
(internal carotid artery, MCA) and collaterals bilaterally, abnormal TCD with low 
velocities (<70 cm/sec) bilaterally and abnormal bilateral perfusion in the MCA 
territory (increased MTT and decrease in CBF). She started blood transfusion but 
continued to have recurrent anterior territory TIAs. Two years later, blood transfusion 
was stopped and she received a bone marrow transplant and her symptoms improved. In 
the follow-up investigations, after 3 years from the initial studies, she had a worse 
perfusion MRI with more extended perfusion abnormality bilaterally in the MCA 
territories, however her MRI was unchanged. There was progression of the 
cerebrovascular disease with more collaterals bilaterally, and she had undetectable 
MCA in both sides on TCD.
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R L
MRI Perfusion MRI MRA
Figure 6.8. Long-Term blood transfusion. 21-year old female, severe SCD ( HbSS), bilateral MCA 
stroke, leg ulcers,on chronic blood transfusion. T2-w M R I . Middle cerebral artery (MCA) infarction 
bilaterally (left >right). Abnormal Perfusion MRI. Increased mean transit time of the passage of IV 
contrast bolus in the MCA territories bilaterally more on the left than the right. MRA. Occlusion of the 
right MCA & anterior cerebral artery (ACA), severe turbulence in the left MCA and moyamoya 
collaterals. R: right; L: left.
R L
MRI Perfusion MRI
Figure 6.9. Long-term blood transfusion, after 2 years (the patient stopped blood transfusion a year 
before due to erythrocyte antibody formation). T2-w MRI. Bilateral infarctions, patchy white matter 
ischaemic lesions, bilateral basal ganglia infarcts & generalised atrophy. Impaired Perfusion MRI. 
Increased mean transit time o f the passage of IV contrast bolus in the MCA territories bilaterally 
(cortical and subcortical regions) with impaired cerebral perfusion on the cerebral perfusion on the 
right MCA region. : MRA ._Both proximal MCAs and left terminal ICA are narrowed, moyamoya 
collaterals. Transcranial Doppler ultrasound (TCD): decreased MCA blood flow velocities bilaterally.
MRA
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6.6. Summary of Results
6.6.1. Short-Term Blood Transfusion
Neurological symptoms of the sickle cell patients on chronic blood transfusion 
(n=8) were as follows: 6 had stroke (1/6 presented with coma), 1 anterior 
territory TIA, and one posterior territory TIA.
There were trends for associations for higher values of systolic blood pressure 
(SBP) and mean arterial blood pressure (MAP) in the patients after blood 
transfusion. There was no association for diastolic blood pressure (DBP).
Post- transfusion awake-oxygen saturations were significantly higher after blood 
transfusion.
The mean haemoglobin level was 10 g/dL (from the nearest blood test to the 
investigations).
All the patients had cerebral infarction on their MRI, which remained unchanged 
after blood transfusion.
Seven out of 8 patients had abnormal and one patient had normal MRA. After 
blood transfusion, 4/8 patients had unchanged, 3/8 had worse and 1/8 improved 
MRA.
7 of the 8 patients had abnormal and one patient had normal perfusion MRI 
initially. After blood transfusion, there was an improvement of the perfusion 
abnormality in at least a cerebral region in 5 patients, but there was not a 
complete reversal of the abnormal perfusion. Three patients remained with 
unchanged perfusion.
Seven patients had abnormal, and one patient had a normal pre-transfusion TCD. 
After transfusion, 6/8 patients remained with unchanged, and 2 patients had 
improved TCD.
6.6.2. Long-Term Blood Transfusion
The neurological symptoms at presentation in the 17 patients of this cohort were 
as follows: 2 had coma with stroke, 1 coma with posterior territory TIA, 7 
stroke, 4 anterior territory TIAs, 2 posterior territory TIAs, and 1 headaches.
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The recurrent neurological symptoms were as follows: 1 patient had coma (with 
posterior leukoencephalopathy on MRI), 1 had stroke, 6 headaches, 1 seizures, 6 
anterior and 1 posterior territory TIA, and one patient did not have further 
symptoms.
Seventeen patients were initially on blood transfusion; during follow-up, 9 
patients remained on blood transfusion, 5 stopped blood transfusion, 3 patients 
stopped blood transfusion but continued on Hydroxyurea (n=l), had 
revascularisation and continued on Hydroxyurea (n=l), and one patient 
underwent bone marrow transplantation.
There were no significant differences between the initial and follow-up SBP, 
DBP and MAP.
There was a trend for higher haemoglobin levels at follow-up (initial mean Hb 
8.9 [6.5-10.6] g/d/L; final mean Hb 9.1 [6.1- 10.9] g/dL).
Initial MRI was normal in 4/17 patients, and abnormal in 13 patients. At follow- 
up 11 patients had unchanged, and 6 patients had worse MRI.
Initial MRA was normal in 3 and abnormal in 14 patients. In the final study, 6 
patients had unchanged, 3 improved and 8 patients had worse MRA.
Initial TCD was normal in 3/13 patients and abnormal in 10. At follow-up 6 
patients had unchanged, 1 improved, and 6 patients had worse TCD.
Perfusion MRI studies were initially normal in 3/17 patients and abnormal in 14 
patients. Final perfusion MRI showed unchanged perfusion in 3 patients, 
improved in 6, and 8 patients had worse perfusion.
6.7. Discussion
This study showed two different effects of the blood transfusion therapy on cerebral 
perfusion in relation to the timing. Whereas in the short- term there was an 
improvement of the cerebral perfusion (in at least one cerebral region) shortly after 
blood transfusion in more than half of the patients, in the long-term, perfusion 
abnormality and MRA was worse or unchanged in two third of the sickle cell patients 
on chronic transfusion, with a worsening of the structural MRI in a further third of these 
patients (35%). However, there was a very low prevalence of recurrence of severe 
neurological complications such as stroke in only one patient (6%) and coma in another
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one (6%) in the long-term study, showing the beneficial effect of blood transfusion in 
reducing the risk of recurrent stroke (but not infarction) in this population, but there was 
no reversal of the perfusion abnormality and the cerebrovascular disease.
In this study, there was an improvement of the regional abnormal perfusion in 5/8 of 
the sickle cell patients shortly after blood transfusion but not a complete reversal of the 
perfusion abnormality. The regional improvement on perfusion MRI maps was seen in 
the decrease in the mean transit time (MTT) or in an increase in cerebral blood flow 
(CBF) and/or cerebral blood volume (CBV) in very localised areas of the brain. This 
improvement of the cerebral blow flow was reported previously (Prohovnik et al 1989, 
Hurlet- Jensen et al 1994, Kirkham et al 2001) demonstrating the immediate beneficial 
effects of the cerebral vasculature of the blood transfusion by improving the rheology of 
the red cells in this inherited anaemia (Balias et al 2002) and the cerebral perfusion. In 
addition, blood pressure and oxygen saturations were higher after transfusion, which 
might contribute to the improvement of the cerebral blood flow and tissue oxygenation.
On the other hand, MRA and TCD were only improved in a small proportion of 
patients, and there were no changes on MRI, demonstrating that perfusion was the most 
sensitive modality of investigation to monitor changes which may be useful to guide 
management in individual patients (Kirkham et al 2001). Blood transfusion might 
affect blood vessels, especially in those patients with underlying cerebrovascular 
disease by increasing the turbulence in some arterial segments as was shown in this 
study, however these patients did not have a worsening in their perfusion abnormality. 
On the other hand, there was extensive cerebrovascular disease in a proportion of these 
patients and some of those appeared to have improvement or worsening of the 
turbulence in different vessels on the same MRA; therefore pre- and post- transfusion 
MRA may be misleading in terms of the real effect of blood transfusion on cerebral 
perfusion in these patients.
Long-term blood transfusion was beneficial in reducing stroke recurrence, and blood 
transfusion is the mainstay of treatment for prevention of recurrent stroke (Ohene- 
Frempong et al 1991, Seijeant 1997, Balias et al 2002, Kirkham and deBaun 2004), but 
blood transfusion did not stop the progression of cerebrovascular disease and the 
perfusion abnormality in these patients in an important proportion of these patients
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(47%). However, the only patient who had recurrent stroke had had stopped the 
transfusion therapy due to erythrocyte antibody formation. In addition, 16 of the 17 
patients continued having recurrent neurological symptoms, probably as an expression 
of the perfusion abnormality and cerebrovascular disease.
Only nine of the 17 sickle cell patients in this study continued on chronic blood 
transfusion, and the remainder stopped blood transfusion or continued with alternative 
therapies. Nevertheless, more than half of the patients on blood transfusion (5/9 
patients) still had a worsening of their cerebral perfusion and cerebrovascular disease. 
Although a previous study showed an improvement of the cerebrovascular disease after 
chronic transfusion (Russell et al 1984), this study showed that there is progression of 
cerebrovascular disease and blood transfusion could have a damaging effect on the 
cerebral blood vessels secondary to the chronic iron overload, in addition to 
infectious/inflammatory mechanisms (Belcher et al 2000) secondary to the frequent 
infections and sickle crisis that these patients usually suffer from (Russell et al 1984).
Iron overload has been associated to induced vascular dysfunction by accelerating 
thrombus formation after arterial injury, by increasing vascular oxidative stress and by 
impairing vasoreactivity in animal models (Day et al 2003). In addition, iron injury in 
blood vessels has been associated with carotid atherosclerosis (Schmitz 2003), as iron 
might be toxic to the endothelium by participating in the generation of powerful oxidant 
species such as hydroxyl radicals and in lipid peroxidation (Shah and Alam 2003). Iron 
has found to cause vasocontriction in animal models (Kuang et al 2003). However the 
susceptibility o f an individual for iron-related endothelial injury might be more 
important than the overall iron body status (Shah and Alam 2003), as this study showed 
a proportion of patients on blood tranfusion had unchanged or improved MRA at 
follow-up. In addition there was an increase in the haemoglobin levels of these patients 
at follow-up, which might contribute to the increase of free iron molecules secondary to 
red cell destruction and possible iron-related endothelial damage. The relationship 
between increased haemoglobin level and cerebrovascular disease in SCD could be 
explored in further studies.
Transcranial Doppler ultrasound was unchanged in 6 patients and worse in other 6 out 
of 13 patients at follow-up, similar proportions that were found for MRA,
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demonstrating that TCD is an adequate technique to monitor cerebrovascular disease in 
patients on chronic transfusion or with alternative treatments in the long term.
Patients who stopped blood transfusion had a variety of recurrent neurological 
symptoms, mainly headaches and TIAs, in addition to the patient who had recuurent 
stroke. In addition, these patients had unchanged or worse MRI in similar proportions, 
however those who stopped blood transfusion had improved MRA at follow-up, which 
might support the hypothesis of the iron endothelial injury (Shah and Alam 2003), or 
that these patients were less exposed to infections or SCD crisis during the follow-up or 
may reflect a selection bias. There were also smaller proportions of patients with 
unchanged or worse MRA, and two third of the patients had improved or unchanged 
perfusion MRI at follow-up. This finding demonstrates the individual variability of 
SCD in relation to the phenotypical expression of this condition (Weatherall et al 1995) 
and its treatment. However, most of the patients who stopped blood transfusion had 
milder baseline investigations and symptoms (severity and frequency) in relation to 
other patients, and blood transfusion therapy was discontinued (only in two patients had 
poor compliance or erythrocyte antibody formation).
The small number of patients who had alternative treatments did not have stroke 
recurrence or new infarction (covert) on MRI. The patient who had revascularisation 
and continued on Hydroxyurea had progression of the cerebrovascular disease (CVD), 
especially on the other side of the revascularisation, but he had improved cerebral 
perfusion and was asymptomatic, demonstrating that this therapy could be an alternative 
to those patients with poor compliance to blood transfusion, severe CVD and severe 
recurrent neurological symptoms (Vemet et al 1996, Ganesan et al 2001, Fryer et al 
2004). On the other hand, the patient who had bone marrow transplant (BMT) had a 
worse MRA and cerebral perfusion but did not have recurrent stroke or cerebral 
infarction on MRI. This therapy is considered curative for SCD (Walters et al 2000), 
and, although there was a study showing reversal of the CVD on MRA in patients who 
had received a BMT (Steen et al 2001), the effectiveness of this treatment on improving 
cerebral perfusion in the long term is uncertain. Finally, one patient on Hydroxyurea, 
after discontinuing blood transfusion, had preserved structural neuroimaging but his 
cerebral perfusion (previously normal) and TCD were worse at follow-up. Although 
there is an ongoing trial on Hydroxyurea for prevention of secondary stroke as
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alternative treatment of blood transfusion for children with SCD and neurological 
complications (Ware et al 2004), the protective effect of this drug to halt 
cerebrovascular disease and cerebral perfusion abnormality in patients with SCD in the 
long term requires further exploration.
6.8. Conclusion
This study showed that, in the short term, blood transfusion improved cerebral perfusion 
in more than half of the patients with sickle cell disease and neurological complications. 
However, in the long-term, although blood transfusion therapy was effective in 
preventing stroke recurrence, it was rarely associated with reversal of cerebrovascular 
disease and cerebral perfusion abnormality. The effect of the blood transfusion and iron 
overload on the cerebral vasculature together with infectious/inflammatory mechanisms 
might contribute to the progression of the CVD in these patients, however future 
research will be needed to study this association.
Alternative therapies in patients with SCD prevented stroke recurrence in this study; 
however bone marrow transplantation or Hydroxyurea did not halt the progression of 
cerebrovascular disease and perfusion abnormality in two patients. Surgical 
revascularisation in conjunction with Hydroxyurea improved cerebral perfusion in one 
patient, and this alternative treatment could benefit those sickle cell patients who have 
severe recurrent neurological symptoms and irreversible and severe cerebrovascular 
disease, particularly if  they are poorly compliant with blood transfusion therapy.
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Chapter 7: Seizures in Sickle Cell Disease: Perfusion 
Abnormality, Vasculopathy and Ischemia
7.1. Introduction and Aims
7.1.1. Introduction
Partial or generalized seizures affect 12-14% of patients with sickle cell disease (SCD), 
herald stroke in 10-33% (Liu et al 1994, Adams 1994) and are associated with silent 
infarction (Miller et al 1999). Triggers include central nervous system infections 
(Danesi et al 1983), chest syndrome (Henderson et al 2003), nephrotic syndrome (Coley 
et al 1999, Horton et al 1995), trauma (Danesi et al 1983), hypertension (Hamdan et al 
1984), Parvovirus infection (Wierenga et al 2001), drugs used in parenteral pain relief 
(Liu et al 1994, Nadvi et al 1999, Zolezzi et al 2001), blood transfusion (Royal et al 
1978, Siegel 1993) and bone marrow transplantation (Abboud et al 1996). However, 
the pathophysiology is poorly understood. Studies of cerebral blood flow with Xenon 
inhalation have shown that encephalopathic patients with sickle cell disease and 
seizures have areas of regional hypoperfusion, some of which may resolve at follow-up 
(Huttenlocher et al 1984). More recently, emergency MR in patients with sickle cell 
disease and acute seizures has shown sinovenous thrombosis (van Mierlo et al 2003) or 
changes on fluid-attenuated inversion recovery (FLAIR) or diffusion MR compatible 
with acute breakdown of the blood-brain barrier (Henderson et al 2003, Coley et al 
1999). There are few data in conscious patients with active acute or chronic epilepsy, 
however, and vascular imaging is rarely performed.
In a previous cross-sectional study using Gadolinium MRI to image perfusion in 48 
SCD patients with central nervous system involvement (Kirkham et al 2001), of six 
with a history of seizures, two had brain infarction, both with associated perfusion 
abnormality, one of which was beyond the area of infarction. However, some of the 
patients had had remote seizures several years before.
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7.1.2. Aims
The aim of this study was to examine the prevalence of cerebral vasculopathy in SCD 
patients with and without seizures and of MR perfusion abnormality in those with recent 
seizures.
7.2. Subjects
7.2.1. Seizure Patients
Forty-seven SCD patients were recruited from joint Haematology/Neurology clinics 
described in chapter 2. Forty-one patients with SCD were all neurologically 
symptomatic (with seizures [n=6]; and without seizures [n=35]), and an additional six 
patients, who had abnormal transcranial Doppler (TCD) ultrasound study and had 
suspected cerebrovascular disease were recruited. Of the 47 patients, 44 had sickle cell 
anaemia [HbSS], 2 had haemoglobin SC disease [HbSC], and one had sickle cell p° 
thalassaemia. The median age was 12 years (range 1.7-27 years, 23 males). Data on 
clinical presentation were obtained from the clinics or from the patients’ medical 
records.
7.2.2. Controls
The control group of children with homozygous sickle cell anemia had no evidence of 
neurological disease (n=29; 15 male) over a prolonged follow-up period but had 
undergone unsedated routine MRI and MRA screening (but not perfusion) over the 
age of six (median age 9.9, range 6.6-18.2 years) from within a clinic-based but 
otherwise unselected prospective cohort recruited from joint Haematology/ Neurology 
Clinics recruited by Dr Fenella Kirkham, Reader in Paediatric Neurology, Institute of 
Child Health, as a part of an ongoing study of the risk factors for stroke and 
cerebrovascular disease (CVD) in SCD.
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7.4. Methods
7.4.1. Conventional Neuroimaging, Perfusion MRI, Transcranial Doppler 
Ultrasound, Oxygen Saturation, Blood Pressure Measurements and 
Haematological Parameters
The methods were described in chapter 3. The patients with neurological symptoms or 
abnormal TCD (n=47; seizure, non-seizure and abnormal TCD) underwent magnetic 
resonance (MRI, DWI, MRA and perfusion MRI); transcranial Doppler ultrasound 
investigations; blood pressure measurements, and 3 minutes’ awake-pulse oximetry 
[Sp02]. Data on haematology (haemoglobin level) were obtained from the patients’ 
medical records as close as possible to the scan.
The control group (n=29) had undergone unsedated routine MRI and MRA screening 
over the age of seven and transcranial Doppler ultrasound but these group did not have 
pulse oximetry or perfusion MRI.
For this study the TCD findings were considered abnormal if  one or more of the 
following findings were present: 1) an MCA ratio (lowest: highest) velocity < 0.5; 2) an 
ACA: MCA mean velocity ratio greater than 1.2; 3) mean MCA velocity greater than 170 
cm/sec and less than 200 cm/sec, deemed conditional by Adams and colleagues (Adams et 
al 1997); 4) a mean MCA velocity equal or greater than 200 cm/sec deemed critical and 
premonitory for stroke by Adams and colleagues (Adams et al 1997); 5) a mean MCA 
velocity less than 50 cm/sec (Adams et al 1997, Kirkham et al 2001a, Zafeiriou et al 
2004).
7.4.2. Neurophysiology
An electroencephalogram (EEG) was recorded in patients who had seizures, using 
standard digital EEG equipment (Nicolet ‘Bravo’), and electrode placements. EEGs 
were reported using conventional clinical methods of visual inspection.
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7.4.3. Statistical Analysis
The data were analysed using SPSS for Windows version 10.0. One-way ANOVA was 
used to examine the association of continuous (parametric) and categorical data, and the 
Kruskal Wallis test to examine associations of non-parametric continuous data and 
categorical data between seizure, non-seizure and control groups. Binary logistic 
regression was used to examine the association of continuous and categorical data in 
relation to a binary outcome (seizure versus non-seizure group). Chi square test and 
Cramer’s V statistics were used as measures of strength of the relationship between 
categorical variables and groups of patients (seizure and non-seizure group 
[neurologically symptomatic but without seizures]) and controls. Level of significance 
was set at p< 0.05 and a trend for significance was defined as p >0.05 and p< 0.1.
SCD patients were placed into one of three groups for the purposes of analysis: 1. 
seizure, 2. non-seizure (neurologically symptomatic but without seizures), and 3. 
control (neurologically asymptomatic).
7.5. Results
7.5.1. Patients: Neurological Symptoms and Seizure Type
The neurological problems in this group of sickle cell patients (n=47) included: stroke 
(n=9), transient ischemic attack (TIA; n=8); seizures (n=6), headaches (n=9), and 
behavioural and/or learning difficulties (n=9); six patients had abnormal transcranial 
Doppler (TCD) ultrasound study and had suspected cerebrovascular disease. The 
controls (29 SCD patients) did not have neurological signs or symptoms), but one was 
known to have an abnormal TCD.
Of the 6/47 (13%) neurologically symptomatic patients with seizures, five had HbSS, 
and one had sickle cell p° thalassaemia. One also had overt cerebral infarction (stroke) 
and another also had recurrent TIAs. The median age of the seizure patients was 10.1 
years (range 1.7-20.3 years); two were male. Two had clinically generalized seizures, 
one with staring spells and the other with a non-febrile generalized tonic-clonic seizure.
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The other four patients had seizures suggestive of focal onset. One had a hemiparesis 
and focal facial twitching at presentation; during follow-up she developed staring spells. 
A patient who had cerebral infarction had hallucinations and visual phenomena; one 
with recurrent TIAs and headaches had tonic or jerking seizures of the right arm and 
leg; and one had staring spells and nocturnal seizures with right sided twitching.
7.5.2. Neurophysiology
An electroencephalogram (EEG) was recorded in all seizure patients at a median of 8.5 
days (range 4-210 days) after the last seizure and a median of 4 (range 0-56) days after 
the neuroimaging in five patients, and 64 days before the neuroimaging in one patient. 
EEG was initially abnormal in 4/6 patients (table 7.2), showing (a) left temporal focal 
slow activity and isolated sharp waves (patient 5); (b) an excess of left focal slow 
activity with further slowing following over-breathing (patient 1); (c) minor focal 
abnormalities over the right central region (patient 3); and (d) interictal runs of focal 
spikes over the right Sylvian area (patient 4). Two patients had a normal EEG. At 
follow up after one year in two patients, one (patient 1), who had had an EEG showing 
focal slow activity exacerbated by over-breathing, developed sharp and spike wave 
activity over the same region; the other patient (patient 2), who had had a previously 
normal EEG, developed bilateral spike activity.
7.5.3. Transcranial Doppler Ultrasound
Mean MCA velocity was significantly different between the children with seizures, 
those with other neurological symptoms and the asymptomatic controls (table 7.1). 
Post-hoc analysis of the three groups showed a trend for increased velocities in the 
seizure group and controls in relation to the non-seizure group (p=0.1 and p=0.06, 
respectively) but no difference between the seizure and the control groups (p=0.7).
Following Adams’ criteria, seizure patients had more abnormal TCD studies than the 
non-seizure and control groups (table 7.1). Two patients with seizures had TCD mean 
MCA velocities higher than 200 cm/sec, defined as critical (Adams et al 1997), both 
ipsilateral to EEG focal findings, whereas no non-seizure patient in this sample did. 
Two seizure patients had decreased mean MCA velocities less than 50 cm/sec
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unilaterally and one patient had turbulent signal in one MCA but blood flow velocities 
within the normal range, hi the seizure group there were more TCD studies which were 
at least conditional (mean MCA maximum velocity equal or more than 170 cm/sec) 
than in the non-seizure patients and controls (table 7.1). There was no difference 
between seizure, non-seizure and control groups for the proportion with mean 
maximum MCA velocity less than 50 cm/sec, which is associated with arterial 
occlusion or severe stenosis (p= 0.5, X2 test). During follow-up of those with seizures 
and a MCA velocity more than 200 cm/sec, one continued to have a MCA velocity 
over 200 cm/sec, and the other progressed to a pattern of artery occlusion or severe 
artery stenosis, with decreased mean MCA velocities (<50 cm/sec) in the affected 
cerebral blood vessel.
7.5.4. MRI, MRA and Diffusion Weighted Imaging
In the seizure group, three patients had normal MRI, one had silent infarction, one had 
an overt infarct and old deep white matter silent infarcts, and one patient had cerebral 
atrophy. Of the 41 non-seizure neurologically symptomatic patients, T2-weighted MRI 
was normal in 24 patients, 8 had overt infarction, 8 had silent infarction in 8 and one 
had cerebral atrophy. O f the neurologically asymptomatic group, 10 of 29 patients had 
silent infarction.
Turbulence on MRA was found in 4/6 seizure patients, in 19/40 non-seizure patients, 
and 20/29 controls. There were no abnormal DWI studies in any patient. Abnormal 
MRI and MRA were not more common in those with seizures compared to the non­
seizure and control group (table 7.1). Silent infarct on MRI was not more common in 
the seizure group compared to those without seizures and controls (table 7.1).
7.5.5. Perfusion MRI (Dynamic Susceptibility Contrast -M RI [DSC-MRI]
Perfusion MRI (DSC-MRI), reported only for the seizure group, was performed at a 
median of 30 days (range 0-365 days) from the last seizure. Two of six with seizures 
were on a monthly blood transfusion programme and perfusion MRI was done at a 
mean of 29 days after the last transfusion (one day prior to transfusion in both patients).
338
All six seizure patients had abnormal perfusion (figures 7.1 and 7.2), characterised by 
cerebral regions of increased mean transit time (MTT) and decreased cerebral blood 
flow (CBF) in five, or an increase in time to peak (TTP) in one. In five patients, 
perfusion abnormalities corresponded to the side of the abnormal EEG, and one patient 
had a region of abnormal perfusion in the right temporal region with a normal EEG 
(table 7.2).
7.5.6. Blood Pressure Measurements, Haematological Parameters and Pulse 
Oximetry
Median systolic, diastolic and MAP blood pressures in the seizure group were slightly 
higher in comparison with the non-seizure group (table 7.1). There was a trend for 
seizure patients to have higher mean haemoglobin levels than the non-seizures patients 
and controls (table 7.1). There was a trend for a higher SpC>2 in the seizure compared 
with the non-seizure group (table 7.1).
7.5.7. Management
The treament o f seizures in our patients with SCD and vasculopathy proved difficult. 
Five of the six patients had seizure recurrence despite either anticonvulsant therapy 
(three patients) or blood transfusion (one patient) or both (one patient). Only one child, 
who had a single generalized seizure, had no treatment; she had had no recurrence at the 
time of follow-up.
7.6. Discussion
It is well-recognised that seizures are more common in SCD than in the general 
population (Adams et al 1994, Prengler et al 2002). For example, in a Nigerian 
population, 10% had seizures and epilepsy was associated with a higher mortality 
(Adamolekum et al 1993). Liu and colleagues found 21/152 SCD (14%) patients had 
seizures; more than 50% were generalized (Liu et al 1994). Forty-five percent of seizure 
patients had abnormal neuroimaging and almost half had an abnormal EEG. Seizures 
are a strong predictor of stroke in elderly adults in the general population (Cleary et al
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2004). However, although sickle cell disease is the commonest cause of stroke in 
children (Earley et al 1998), any association between seizures and intracranial 
vasculopathy or focal ischaemia in this condition has received relatively little attention.
In this study, this study demonstrated that the patients with recent SCD associated 
seizures had abnormal perfusion MRI ipsilateral to any EEG abnormality. Three 
patients had abnormal regional perfusion with decreased CBF and increased MTT 
despite normal T2-weighted MRI, two had abnormal regional perfusion within the same 
territory as T2-weighted MRI abnormalities and one patient had decreased perfusion in 
association with generalised cerebral atrophy. Perfusion abnormalities involved cortical 
and subcortical areas and probably represent areas of relative ischemia which may be 
the anatomical source of seizure discharges. TCD studies showed both higher mean 
velocities in the seizure group and more abnormal individual TCD studies (5/6 in those 
with seizures who also had perfusion abnormalities on MRI). In 3, abnormal TCD (2 
had critical velocities > 200) coincided with abnormal ipsilateral abnormal MRA. 
Vascular insufficiency appears to be more common in those with compared with those 
without seizures based on the TCD group comparisons.
Seizures may be the presenting symptom of overt stroke or relative vascular 
insufficiency. In a study of very young SCD children, seizures were documented in 
3/39 patients between 7 to 48 months of age; all had cerebral infarction (Wang et al
1998). In the Cooperative Study of Sickle Cell Disease, seizures were an independent 
risk factor for silent infarction (Miller et al 1999). However, in our previous series of 
children undergoing MR, only 2/6 of those with seizures had T2-weighted abnormality 
and of the current prospective cohort, 3/6 had normal scans. Seizures may also be 
associated with large vessel disease, although our data from this and the previous series 
(Kirkham et al 2001) suggest that MRA be normal even when TCD is abnormal. Recent 
data from the STOP study suggests that TCD may pick up large vessel abnormality of 
haemodynamic importance before MRA (Abboud et al 2004) and our data would be in 
line with that. It is possible that some of these TCD abnormalities, particularly those 
associated with normal MRA, represent reversible vasospasm in response to an 
environmental trigger, rather than fixed stenosis.
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The pathophysiology of SCD associated seizures has not previously been studied in 
detail. Neurologically asymptomatic SCD patients have global cerebral hyperemia 
secondary to anaemia (Prohovnik et al 1989) and may fail to increase CBF with 
hypercapnia (Prohovnik et al 1989) suggesting that the increased cerebral blood flow is 
secondary to adaptive vasodilatation and the vascular reserve capacity may be reduced. 
However, Huttenlocher and colleagues found significantly reduced mean CBF in 
children with stupor and seizures, with additional regional reductions despite normal 
cerebral angiography (Huttenlocher et al 1984) At follow-up, mean CBF was within 
normal limits, but some of the regional abnormalities persisted, particularly in the 
parietal regions. In a previous MR perfusion study, two patients with seizures had 
perfusion abnormalities despite normal MRA (Kirkham et al 2001). In this study of 
children with active seizures, although two children had normal MRA, the majority of 
patients had MRA evidence of vasculopathy and all had abnormal MR perfusion 
ipsilateral to any EEG abnormality. Seizures in young children often occur during 
situations which increase metabolic demands, particularly infections or stress. Our data 
suggest that the vascular insufficiency may play a direct role.
One SCD patient with seizures had a perfusion study performed ictally which showed 
decreased perfusion ipsilateral to a focal seizure and ipsilateral to the hemisphere with 
silent infarction in the deep white matter. It is possible that CBF is unable to increase 
focally to meet increased metabolic demand in a maximally vasodilated cerebral 
circulation, as has been shown in Sturge-Weber syndrome, for example (Aylett et al
1999). An alternative explanation is that the deep white matter containing the areas of 
silent infarction is deafferented. In an animal model, surgical cortical deafferentation in 
a hemisphere led to an increase of asynchronic electrical activity, with generation of 
seizures in intact regions and delayed paroxysmal activity in the deafferented 
hemisphere. This study showed that deafferented neurons needed more time to reach a 
firing threshold as the time lag in the propagation of electrical activity between the 
intact and undercut areas was increased (Topolnik et al 2003). We speculate that chronic 
ischaemia in the deep white matter could produce chronic axonal damage similar to a 
’cortical deafferentation’, where, in some cases, the seizure activity could be generated 
in the normal hemisphere, and not in the hemisphere with abnormal perfusion and risk 
of white matter ischaemia.
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Treatment of seizures in SCD is not evidence-based. The presence of cerebrovascular 
disease and anaemia in this population may be a reason to consider alternative therapies 
beside antiepileptic drugs (AED). In animal models, some AEDs may have 
neuroprotective effects in brain ischaemia by decreasing excitatory transmission or 
enhancing neuronal inhibition either through receptors (e.g Felbamate) or ion channels 
(e.g carbamazepine, valproate, lamotrigine [Calabresi et al 2003]), but there are few 
data in humans. Some patients might need a short term blood transfusion programme in 
addition to the AED in order to improve oxygen delivery to poorly perfused tissue, 
although seizures may be precipitated by transfusion in certain contexts (Royal et al 
1978, Siegel 1993) e.g. for priapism. More data is needed about the risks and benefits.
7.7. Conclusion
This study suggests that a complex mechanism of large and small vessel disease, 
hypoperfusion and perhaps chronic hypoxemia (Kirkham et al 2001a) may play a role in 
the genesis of seizures. In this study, daytime oxyhaemoglobin saturation was >96% in 
the majority of patients with seizures, but we did not have measurements from the time 
of the index seizures or overnight studies in this cohort or any comparison with the 
asymptomatic patients. However, it may be of interest that haemoglobin levels were 
higher in the seizures group than in the non-seizure symptomatic and the asymptomatic 
patients, although relative anemia is a risk factor for stroke in this population (Kirkham 
et al 2001a, Balkaran et al 1992).
SCD may serve as a model for hypoxia/ischaemia associated seizures, which might 
perhaps occur secondary to ion channel dysfunction during acute hypoxia in subjects 
who are poorly preconditioned (Stenzel-Poore et al 2003). This situation may be more 
common in young children than previously recognised, particularly in those exposed to 
anemic and hypoxic hypoxia, as in sickle cell disease. Further research will be 
necessary to study whether other genetic or environmental factors in addition to cerebral 
insufficiency, predispose to seizures in this population.
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Figure 7.1. Seven-year old girl (HbSS). Seizures (facial twitching and 
blank spells) + stroke), TCD > 200 cm/sec, abnormal MRI (left 
precentral cortex infarct), MRA (reduced bloo^flow in the left middle 
cerebral artery), abnormal EEG (epileptic activity mainly over the left 
central-temporal regions [black arrows]) and Perfusion MRI 
(extensive cortical and sub-cortical perfusion abnormalities in the left 
frontal, parietal and temporal regions with severe decrease in 
cerebral blood flow, and increase in the mean transit time of the 
passage of Gadolinium bolus). R: right; L: left.
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Figure 7.2. 12-year-old boy with sickle cell p° thalassaemia. ‘Petit mal 
epilepsy’. Normal MRI/MRA/TCD, abnormal EEG (runs of focal 
spikes over the right Sylvian area [black arrows]) and Perfusion MRI 
(mild decrease in cerebral blood flow and increase in the mean transit 
time over the right sylvian and posterior temporal areas on MRI 
perfusion [yellow arrows]). R: right; L
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Table 7.1. Comparison between sickle cell patients with seizures, non-seizure neurological symptoms and no symptoms.
SCD patients with 
seizures 
n=6
Non-seizure 
neurologically 
symptomatic SCD 
patients 
n=41
Neurologically 
asymptomatic controls 
with SCD 
N=29
P for difference
Abnormal MRI 3 (50%) 17(41%) 10 (34%) 0.72, x2 test
Silent Infarct 2 (33%) 8 (19%) 10 (34%) 0.34, Fisher’s exact test
Abnormal MRA 4 (67%) 19/40 (47%) 20 (69%) 0.18, x2 test
Abnormal DWI 0 0 0
Abnormal TCD 5/6 11/29 5/24 0.005,
X2 and Cramer’s V tests
TCD mean maximum 
MCA velocities (range)
135 cm/sec 
(59-250)
96 cm/sec 
(<50-175)
120 cm/sec 
(66-176)
0.025,
One way-ANOVA
Abnormal/Conditional
TCD
(M ean M x M C A  velocity  
>. 170 cm /sec)
2
(both >200 cm/sec)
1
(175 cm/sec)
1
(176 cm/sec)
0.006,
X2 and Cramer’s V tests
Table 7.1. Comparison between sickle cell patients with seizures, non-seizure neurological symptoms and no symptoms (cont.).
SCD patients with 
seizures 
n=6
Non-seizure 
neurologically 
symptomatic SCD 
patients 
n=41
Neurologically 
asymptomatic controls 
with SCD 
N=29
P for difference
Median systolic blood 
pressure (range) 
(mmHg)
113(100-115) 109 (94-129) 0.89
Median diastolic blood 
pressure (range) 
(mmHg)
66 (40-69) 55 (30-76) 0.64
Median mean arterial 
pressure (range) 
(mmHg)
84 (61-84) 73 (55-90) 0.59
Hemoglobin g/dL 9.3 (8.1-10.3) 8.7 (6.1- 10.4) 8.6 (7-14) 0.09, 
Kruskal-Wallis test
Oxyhemoglobin 
saturation (%)
97.2 (95.8 - 98.5) 95.4 (88.1 -99.9) 0.1
SCD- sickle cell disease; TCD= transcranial Doppler ultrasound; MCA= middle cerebral artery; Mx: maximum
Table 7.2. Associations between focal EEG and neuroimaging / TCD findings in the sickle cell patients with seizures.
Time from last
EEG/ No, Sex, Seizure EEG TCD seizure (last blood MRI MRA Perfusion MRI Therapy and
Neuro- Age Type (Max MCAV) transfusion) to outcome
Imaging DSC-MRI (days)
Relation
Pat 1, F, Right focal 1st EEG (2 mo after R: 137 cm/sec 7 days Left precentral cortex Reduced flow in No Perfusion Blood
7 y HbSS, seizure at stroke stroke): Excess of slow L: 250 cm/sec (29 days after and 1 infarct, further areas the proximal left transfusion
seizures, onset. activity over the left day before blood of high T2 signal in MCA
stroke hemisphere. transfusion) the peritri-gonal
(right regions.
hemi) Follow-up:
2nd EEG (1 y  after stroke):
After 1 year, Seizure
facial twitching After 1 year. After 1 year, no new After 1 year. Extensive perfusion recurrence
Left
Focus
and staring spells Isolated brief runs of sharp R: 121 cm/sec infarcts. Cortical L.MCA narrow, abnormalities in
(atypical and spike wave over the L : <50 cm/sec atrophy left MCA poor distal flow, cortical/subcortical left
absences) left centro-temporal 
regions; occasional sharp 
waves over the right.
territory collaterals frontal, parietal and 
temporal regions.
3rd EEG (18 mo after 
stroke): normal.
Time from last
EEG/ No, Sex, Seizure EEG TCD seizure (last blood MRI MRA Perfusion MRI Therapy and
Neuro- Age, Type (Max MCAV) transfusion) to outcome
Imaging Diag. DSC-MRI (days)
Relation
Right
Focus
Pat 2, F, 
3y, 
HbSS, 
seizure
Non-febrile 
generalised tonic 
seizure (one 
event)
151 EEG : No abnormality 1a TCD:
R: 83 cm/sec
2nd EEG {after 1 year):
Frequent isolated spikes 
over the mid-parietal 
region over the right>left L: 90 cm/sec 
parietal and occipital areas.
L: 80 cm/sec
2nd TCD (after 1 
) ’)■
R: 91 cm/sec
365 days
No blood transfusion
Not done
After 1 y: 
Normal
Not done
After 1 y: 
Turbulent flow in 
the right M 1 and 
A1 segments
After 1 year: Extensive 
perfusion abnormality in 
cortical/subcortical 
frontal-parietal regions 
bilaterally, 
cortical/subcortical 
temporal-occipital 
regions right>left and 
L. cerebellum.
None
No seizure 
recurrence
Right
Focus
Pat 3, F,
12 y
HbSS,
TIAs,
seizures,
headaches
Right sided tonic 
or jerking 
seizures of the 
arm and leg
Minor irregularities over 
the right central region.
R: 218 cm/sec 
L: 130 cm/sec
After I year: 
R: 214 cm/sec 
L: 100 cm/sec
0 day
(29 days after and 1 
day before blood 
transfusion)
Tiny foci of 
abnormal signal in 
the deep white matter 
mainly on the right 
hemisphere.
Right proximal 
MCA stenosis
During R tonic seizure: 
Perfusion abnormalities 
in the right parietal -  
temporal deep white 
matter and right cortical 
/subcortical temporal 
region.
Blood
transfusion + 
Carbamazepine 
(then changed 
to Lamotrigine 
due to cardiac 
arrythmia)
Seizure
recurrence
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Time from last
EEG/ No, Sex, Seizure EEG TCD seizure (last blood MRI MRA Perfusion MRI Therapy and
Neuro- Age Type (Max MCAV) transfusion) to outcome
Imaging DSC-MRI (days)
Relation
Right
Focus
Pat 4, M, 
12 y,
Sickle cell 
P° thal, 
seizures
Staring spells Runs of focal spikes over R: 100 cm/sec 
the right sylvian area L: 108
(Decreased 
R MCA 
velocities < 50 
cm/sec below 4.4 
cm depth)
30 days
No blood transfusion
Normal Normal Perfusion abnormalities 
over the right sylvian 
area and posterior 
temporal lobe
Sodium
Valproate
Seizure
recurrence
Left and
Right
Focuses
Pat 5, F, 
21 y, 
HbSS, 
Seizures, 
stroke
Hallucinations,
Visual
phenomena
Excess of slow activity 
over the left temporal 
region with isolated sharp 
waves
R: <50cm/sec 7 days Prominence of
L: 59 cm/sec cortical sulci,
No blood transfusion cerebral atrophy
Poorer flow in the Abnormal perfusion in Sodium
right MCA the parietal- temporal 
deep white matter, 
right>left
Valproate
Seizure
recurrence
No
Focus
Pat 6, M,
12 y
HbSS,
severe
SCD,
seizures,
behaviour
problems,
headaches
Atypical 
absences, right 
sided twitching, 
nocturnal
Normal R: 78 cm/sec 
L: 90 cm/sec
(Turbulent blood 
flow US signal 
from R MCA)
210 days
No blood transfusion
Normal Normal Perfusion abnormality 
in the right cortical/ 
subcortical temporal 
region
Sodium
Valproate,
Changed for 
Lamotrigine
Seizure
recurrence
Table 7.2. Abbreviations: Pat = patient; BP = blood pressure; Dx = diagnoses; F = female; Hb = haemoglobin level (g/dL); HbSS = homozygous 
sickle cell anaemia; L = left; M = male; MAP= mean arterial pressure; Max MCAv = maximum mean middle cerebral artery velocities; Mo = 
months; MRI/GA = MRI under general anaesthesia; No = patient number; R = right; SCD = sickle cell disease; TCD = transcranial Doppler 
Ultrasound; TLA = transient ischaemic attack; Tx = blood transfusion; y = year
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Chapter 8: General Discussion
8.1. Cerebral Perfusion Abnormality in Sickle Cell Disease
This study has shown that an important proportion of patients with sickle cell disease 
and neurological complications had cerebral perfusion abnormalities. The abnormal 
perfusion may not change or may deteriorate over time despite blood transfusion or 
alternative therapies in an a significant number of sickle cell patients with central 
nervous system events, and the perfusion abnormality improved in only a small number 
of patients. Perfusion abnormality in these patients with sickle cell disease was 
significantly associated with abnormal magnetic resonance angiography (MRA), 
showing that the presence and progression of cerebrovascular disease (CVD) is a risk 
factor for cerebral ischaemia in this population. In addition, there was no reversal of the 
CVD in the majority of the patients who were on blood transfusion therapy. Blood 
transfusion does not appear to improve cerebral perfusion.
The aim of the cross-sectional study was to determine patterns of cerebral perfusion 
abnormality in relation to neurological symptoms in patients with SCD. The study 
showed that a large proportion of the patients with neurological complications had 
perfusion abnormalities. The patterns of the perfusion abnormality, including the 
severity and the extension of the abnormal perfusion, were associated with the severity 
of the central nervous system events at presentation and the recurrent neurological 
symptoms of the patients.
In addition, this cross-sectional study showed that, although there was a good 
association between the severity of the abnormal perfusion and the abnormalities found 
in MRI, MRA and transcranial Doppler ultrasound, perfusion MRI (dynamic 
susceptibility contrast MRI [DSC-MRI]) was the most sensitive technique to detect 
cerebral abnormality (means by abnormal perfusion) in 56% of the 70 patients with 
SCD of this study compared to MRA (46%) and MRI (40%).
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In relation to previous cross-sectional studies using perfusion MR techniques such as 
DSC-MRI (Kirkham et al 2001) or continuous arterial spin labelling (ASL, Oguz et al 
2003), this study focused on identifying patterns of cerebral perfusion abnormality in 
relation to neurological symptoms in patients with SCD and any association between 
grades of abnormality and conventional neuroimaging (MRI and MRA) or transcranial 
Doppler ultrasound studies (chapter 7 is a detailed study of one neurological symptom, 
seizures in SCD, and its association with cerebrovascular disease and cerebral perfusion 
abnormality). In addition, predictors of recurrent neurological symptoms were identified 
from a single time study. The sensitivity of perfusion MRI may give useful information 
to the clinician for those patients with SCD who are at serious risk of ischaemia and 
further stroke (overt infarct) or covert infarction, two neurological complications which 
can increase, in the different grades of severity, the disability of the patient.
Cerebral perfusion abnormality in relation to age groups showed that abnormal 
perfusion was more extensive (bilateral) in symptomatic patients less than 5 years old 
who had predominantly normal MRI and MRA. This finding might suggest that the 
developing brain is most sensitive at the level of small blood vessels or microcirculation 
to the abnormal rheology of the sickle cell probably triggered by infections or decreased 
Oxygen saturations (e.g. respiratory infections, obstructive sleep apnoea [Kirkham et al 
2001a, Hogan et al 2003]). A recent study in babies with SCD showed an association 
between abnormal Oxygen saturations, TCD and cognitive development (Hogan et al
2003). The finding presented in this thesis of widespread abnormal perfusion in patients 
with neurological symptoms in this age group confirms that SCD may cause cerebral 
pathology in very young children, as has been reported previously in a small series 
investigated only with MRI and MRA studies (Wang et al 1998). Therefore the 
presence of abnormal perfusion in sickle cell children of this age may guide the 
development of early preventive treatment for very young patients with SCD who are at 
risk of cerebral ischaemia, in order to avoid more severe complications over time. On 
the other hand, cerebral perfusion abnormality was more localised from 6 years of age 
and beyond, and the abnormal perfusion was related to the vascular territory involved 
by the cerebrovascular disease. Further studies could explore the adaptable changes of 
the cerebral microcirculation over time and in relation to brain development in SCD.
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The longitudinal study demonstrated than more than a third of the patients had 
progression of the perfusion abnormality over time, and this progression continued, in 
many cases, despite chronic blood transfusion. This progression of the abnormal 
cerebral perfusion was associated with progression of cerebrovascular disease, and the 
severity of the perfusion abnormality over time was related to the severity of the 
recurrent neurological symptoms of the patients. On the other side, another third of the 
patients had unchanged cerebral perfusion, with mainly unchanged MRI and MRA, with 
or without blood transfusion therapy. Only a small proportion of patients had an 
improvement of the cerebral perfusion over time. This is the first study of changes in 
cerebral perfusion over time in patients with SCD and neurological complications with 
long-term follow-up. Previous studies have only reported longitudinally changes using 
only MRI and/or MRA investigations in patients with SCD (Moser et al 1996, Kandeel 
et al 1996, Seibert et al 1998, Miller et al 2001, Pegelow et al 2002), or short-term (pre- 
and post-blood transfusion) studies using techniques which measure cerebral blood flow 
(Hurlet-Jensen et al 1994, Venketasubramanian et al 1994, Kirkham et al 2001b). 
Perfusion MRI was the most sensitive technique to evaluate cerebral abnormality in 
relation to neurological symptoms in this study and changes over time, in association 
with MRA abnormalities.
The longitudinal study could also identify predictors of recurrent neurological 
symptoms and abnormal MRI, MRA and perfusion abnormalities at follow-up by 
comparing initial and final investigations. There was a good correlation among initial 
infarct size, infarct number, perfusion abnormality (CBF) and grade of MRA 
turbulence; and the severity of the worsening of the cerebral perfusion at follow-up was 
related to the severity of the initial neurological symptoms at presentation and the 
abnormality of the initial investigations. Because there is a good correlation between the 
initial investigations, cerebral perfusion at follow-up could be predicted with one or two 
MR studies in addition to the neurological symptoms of the patients, and to identify 
predictors could give additional information to the clinician for the future management 
of the patient depending on his grade of risk of further cerebral ischaemia.
The study of the effect of blood transfusion therapy on the cerebral perfusion showed 
that in the short-term (pre- and post-blood transfusion) there was an improvement on the 
cerebral perfusion in more than half of the patients after blood transfusion, with
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unchanged MRI and mainly unchanged or worse MRA. This study demonstrated that 
blood transfusion might increase turbulence in the cerebral blood vessels in some 
patients with extensive (or not) cerebrovascular disease without worsening of the 
perfusion abnormality; therefore MRA was not a sensitive technique for evaluating 
perfusion changes after transfusion in these patients with SCD. However, this study 
agreed with previous series using cerebral blood flow techniques (Hurlet-Jensen et al 
1994, Venketasubramanian et al 1994, Kirkham et al 2001b), that short-term blood 
transfusion can be beneficial for improving perfusion abnormality.
In the long term, although blood transfusion helped to reduce recurrence of stroke in 
these patients (in only one patient had stroke recurrence out of the 17), it did not stop 
the progression of cerebrovascular disease and the perfusion abnormality in nearly half 
of the patients. However, serial haemoglobin S% levels were not available for the 
longitudinal study or blood transfusion studies (for example, at the time of the first or 
final scans or before the blood transfusion started). This issue should be addressed in 
future work. In addition most of the patients continued to have recurrent neurological 
symptoms, including those with unchanged or improved perfusion abnormality. This 
study showed that blood transfusion is effective in preventing recurrence of severe 
neurological complications in patients with SCD but this therapy was not effective for 
reversal of cerebrovascular disease and cerebral perfusion abnormality in the long term, 
therefore these sickle cell patients continued to be at risk of further cerebral ischaemia 
and infarction. The direct effect of blood transfusion, such as iron overload and iron 
toxicity, on the cerebral vasculature has been reported (Day et al 2003, Schmitz 2003, 
Shah and Alam 2003, Kuang et al 2003). Alternative therapies could be considered of 
benefit for selected patients, especially those patients with poor compliance for the 
blood transfusion regime or those who had iron overload, in addition with an underlying 
cerebrovascular disease. Perfusion MRI (DSC-MRI) can be used to study alternative 
therapies such as Hydroxyurea, bone marrow transplantation and revascularisation 
procedures and their effect on cerebral perfusion. One patient of this study, who had an 
indirect revascularisation, showed an improvement in the cerebral perfusion. 
Revascularisation could be considered in those patients with SCD and severe and 
irreversible cerebrovascular disease and severe recurrent neurological symptoms.
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The categories of severity of the transcranial Doppler ultrasound study, following a 
modification of Adams’ criteria (Adams et al 1992, Kirkham et al 2001b) were 
associated with grades of abnormal perfusion, MRA abnormality and infarct size and 
infarct number on MRI in this study, demonstrating the importance of this non-invasive 
technique as a tool for monitoring not only cerebrovascular disease in patients with 
SCD (Adams et al 1997, Adams et al 1998, Adams et al 2004) but also to monitor 
cerebral perfusion, and probably to detect early cerebrovascular disease (Minniti et al
2004) before it appears on MRA. In addition, TCD could help to predict recurrent 
neurological symptoms in sickle cell patients, because its association with MRI, MRA 
and perfusion abnormalities.
In regard to clinical parameters, lower diastolic blood pressure and mean arterial blood 
pressure (MAP) were associated with the presence of cerebral infarction on MRI, 
abnormal MRA and abnormal perfusion in the cross- sectional study. In the longitudinal 
study, there was a trend for an association between lower diastolic blood pressure and 
worsening of the transcranial Doppler ultrasound over time. Although ‘relative’ 
hypertension has been considered a risk factor for stroke in SCD (Ohene-Frempong et al 
1991, Rodger et al 1993), and low blood pressure values have been reported in patients 
with SCD (Pegelow et al 1997), the association of low diastolic pressure and MAP with 
perfusion abnormality in this study suggests that a decrease in blood pressure and, 
probably, blood flow to the brain, might be a contributing factor to impairment of 
perfusion, especially in older patients.
In the longitudinal study, there were trends for association between worsening of 
cerebral perfusion over time and worsening of MRI with increased white cell count and 
lymphocytes over time. In addition there was an association between decreased initial 
platelet count and worsening of MRA over time. These findings suggest the 
involvement of infection in the progression of cerebrovascular disease and the 
worsening of the cerebral perfusion over time. The damaging effect of 
infectious/inflammatory mechanisms in blood vessels was reported in previous studies 
(Sultana et al 198, Belcher et al 2000, Inwald et al 2000).
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8.2. Limitations of the Study
The timing of the investigations was a limitation in this study because the majority of 
the patients were studied as outpatients and not acutely, with the exception of a few 
cases. Therefore the real extent and the severity of the perfusion abnormality (or the 
presence of perfusion abnormality) in relation to the neurological symptoms at 
presentation were difficult to assess. In fact, some older patients had had stroke years 
before to this study, however, the neurological event at presentation was taken in 
account because of the persistence of the abnormal perfusion in the territory of the 
ischaemic lesion, the presence of cerebrovascular disease and recurrent neurological 
symptoms, which were related to the initial infarct on MRI perfusion abnormality 
present in a proportion of the patients of those age groups (13-17 years and 18-28 
years).
In this study, there were limitations in the analysis of MRI, MRA and perfusion MRI, 
because of the visual assessment of these investigations. As was mentioned in chapter 4 
and chapter 5 (in the ‘Discussion’ section), there were, in a very few occasions, small 
discrepancies in the assessment of the grade of turbulence on MRA by the same 
Neuroradiologist (intra-observer), when the MRA study was assessed twice by the same 
specialist. On the other hand, discrepancies on the assessment of MRI studies were 
minimal.
Dynamic susceptibility contrast (DSC) perfusion MRI was a sensitive technique to 
detect cerebral abnormality, however it also had limitations. Firstly, it was not a 
quantitative technique, so it was not possible to measure cerebral blood flow and to 
assess real changes of cerebral blood flow volume over time, or to quantify the severity 
of the perfusion abnormality in a cerebral region. Another perfusion technique used in 
patients with SCD, continuous arterial spin labelling (ASL), which does not need an 
intravenous bolus injection of Gadolinium, is able to quantify cerebral blood flow 
(Oguz et al 2003), however this technique is still under development and there are 
technical limitations for the exact measurement of CBF. On the other hand, the 
assessment of perfusion MRI is visual (Calamante et al 1999) and therefore the data for
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analysis were qualitative (ordinal data) based on a grading or categories of perfusion 
abnormality of increasing severity (either for an increase in the mean transit time (MTT) 
of the passage of the intravenous bolus of the contrast through the cerebral vasculature, 
or for a decrease in the CBF). The author, supervised by a Physicist experienced in this 
MR technique, assessed the MR perfusion maps (MTT, CBF, and cerebral blood 
volume [CBV]) of all the patients (n=70). As was mentioned in chapter 4 and 5, the 
grading of the CBF maps (mild, moderate, or severe decrease in CBF) presented a more 
significant association with neurological symptoms and other investigations 
(neuroimaging and TCD) than the grade of severity of MTT (mild, moderate or severe 
increase in MTT). This may happen because the MTT appears more highlighted on the 
visual inspection as MTT is white and CBF appears dark on the perfusion MRI maps, 
therefore it was more difficult on the visual assessment to differentiate grades of 
severity on the MTT maps than on the CBF. From this study CBF maps were the most 
sensitive parameter to assess perfusion abnormality.
Transcranial Doppler ultrasound (TCD) was a very useful non- invasive technique in 
this study, in agreement with previous studies (Adams et al 1992, Adams et al 1998). In 
addition categories of severity of the TCD (following a modification of Adams’criteria, 
Adams et al 1992, Kirkham et al 2001b) had a good correlation with grades of abnormal 
MRA and abnormal perfusion. However this technique had a limitation in this study in 
relation to the sensitivity to detect cerebrovascular disease based especially on the 
ultrasound window (e.g. thick skull secondary to bone marrow changes), which affected 
mainly the older age group of patients (mainly 18-28 years of age, and a smaller 
proportion of patients of 13-17 years of age) giving rise to false positive results 
(abnormal TCD with normal MRA). In fact, in this case, TCD might be more sensitive 
than MRA to detect early cerebrovascular disease (Minniti et al 2004), as some of these 
patients continued having recurrent neurological symptoms and abnormal perfusion. 
Another limitation was the TCD operator; although the author had experience in this 
technique, on some occasions the TCD study was more difficult to do in one patient 
than in another.
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The limitation of the haematological data was the availability to find blood tests taken 
to the patients near to their neuroimaging study in their clinical records, and the 
availability to find the patients’ clinical records. In addition, steady haemoglobin levels 
were not easy to find, as usually the patients had their blood test taken on the ward more 
than as out- patients, when they had sickle cell crises, sometimes complicated by 
infections of different grade of severity, or the blood test were taken before or after 
transfusion (pre-transfusional blood test were difficult to find usually) in those patients 
on chronic blood transfusions. In the extension of this study and in future studies, the 
documentation of haemoglobin S% level at the time of the neuroimaging and any other 
central nervous system event will be crucial.
In this study, only awake-Oxygen saturation (SpC>2) was measured and it did not have 
association with neurological symptoms and other investigations. Nocturnal hypoxemia 
was associated with central nervous system events in SCD (Davies et al 1989, Kirkham 
et al 2001a), and awake- SpC>2 was not a good measure of disease severity in this study, 
probably because the small numbers of patients who had recurrent stroke in this series, 
these patients had SpC>2 < 92% defined as hypoxemia for this study. Awake- Sp02 < 
90% was not associated with stroke risk in a previous series of patients with SCD 
(Homi et al 1997). Nocturnal hypoxemia and nocturnal SpC>2 measurements might be 
better predictors of neurological symptoms and abnormal investigations in SCD as was 
reported before (Kirkham et al 2001a).
8.3. Future Directions
This study showed that perfusion MRI (DSC-MRI) was the most sensitive technique to 
detect cerebral abnormality in patients with sickle cell disease, giving information about 
perfusion abnormality and therefore perhaps about the risk of cerebral ischaemia in an 
individual. However, data from more patients with longer follow-up will be needed to 
determine whether MR perfusion is more useful than clinical criteria for predicting 
recurrence. This technique was well tolerated by the majority of the patients and few 
patients (3% [2/70 patients]) had side effects, which were mild and transient. Perfusion 
MRI could help to guide and monitor the management of a patient, especially in those
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patient who have severe recurrent neurological symptoms or poor compliance with the 
blood transfusion therapy.
In addition a single study of perfusion MRI, together with conventional neuroimaging 
(MRI and MRA) and TCD, could help to predict in a patient with SCD who had an 
initial central nervous system event, recurrent neurological symptoms and perfusion 
abnormality at follow-up, leading to individually tailored management to prevent 
cerebral ischaemia and further disability.
Perfusion MRI could also be used to assess the benefit of new treatments for patients 
with SCD and neurological complications on cerebral perfusion and to monitor these 
new therapies over time (i.e. Hydroxyurea).
In addition, perfusion MRI may be combined with other novel non-invasive MR 
techniques, such as BOLD hyperoxia (Kennan et al 2004) to investigate the 
pathophysiology of CNS events in sickle cell disease. The author has undertaken a pilot 
demonstrating that this is feasible. As central nervous system events have been 
associated with nocturnal hypoxemia (Kirkham et al 2001a) perfusion and BOLD MRI 
could be used to assess the effect of nocturnal low oxygen saturations on cerebral 
perfusion in patients with SCD and to monitor the effect of treatments under 
investigation in the setting of randomised controlled trials, such as overnight oxygen 
supplementation in patients with nocturnal oxyhaemoglobin desaturation.
In summary, although perfusion MRI is a semiquantitative technique, it has 
considerable potential, in combination with other neuroimaging techniques, to shed 
light on the natural history and pathophysiology of the cerebral complications of sickle 
cell disease.
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Appendix
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Table 1. Chapter 2: Sickle cell patients of this study (n=70). S= stroke; Z=seizures; 
N=none; C=coma; H=headaches; L= learning difficulty; AT= anterior territory TIA; 
PT=posterior TIA; R=reversible ischaemic neurological deficit (RIND); T= transient 
ischaemic attack (TIA), presymp= neurological symptom at presentation; recsymp= 
recurrent neurological symptom; TCD=transcranial Doppler ultrasound; perf.= 
perfusion MRI; datprvpf= date of previous perfusion MRI study; mrifup= MRI at 
follow-up; Txdate= date of blood transfusion; perfptx= perfusion MRI for the pre-and 
post-transfusion study; postday= date of post-transfusion MRI.
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PAT SEX AGE PRESYMP RECSYMP DATETCD DATEMR1 DW1
1 F 4 S,Z N 21-Jan-2003 22-Jan-2003 Yes
2 M 12 S,C,H,L PL 11-Jul-2002 Yes
3 F 7 S,Z,L Z,L 12-Sep-2001 12-Jun-2003 Yes
4 F 28 S N 23-Nov-2001 23-Nov-2001 Yes
5 F 16 S,AT,H,L H,L 12-0ct-2001 12-0ct-2001 Yes
6 M 16 S,C,H,L L, H 15-Aug-2001 Yes
7 F 19 s ,r ,a t ,p t ,h ,l T, H, L 04-Jul-2002 04-Jul-2002
8 F 16 S,AT,Z,H,L T, Z, H, L 17-Jun-2002 19-Jun-2002 Yes
9 F 27 S N 12-Mar-2002 12-Mar-2002 Yes
10 F 15 S,Z,H,L Z, H, L 19-0ct-2001 Yes
11 M 8 S,AT,H,L T, H, L 06-Dec-2001 06-Dec-2001 Yes
12 F 24 S,AT,H,L T ,H, L 15-Nov-2001 15-Nov-2001 Yes
13 M 16 S,PT,H T, H 14-Mar-2002 14-Mar-2002 Yes
14 F 10 S,L L 28-Feb-2003 28-Feb-2003 Yes
15 M 22 S,Z,H,L S, Z, L 10-Apr-2003 10-Jul-2003 Yes
16 M 13 S T 11-Jul-2001 11-Jul-2001 Yes
17 F 1 AT N 29-Jan-2003 09-Dec-2002 Yes
18 M 16 AT N 13-Dec-2001 13-Dec-2001 Yes
19 F 25 AT,H,L T, H, L 07-Dec-2001 Yes
20 F 11 AT,Z,H T, Z, H 31-Aug-2001 03-Sep-2001 Yes
21 M 9 AT T 23-Nov-2001 26-Nov-2001 Yes
22 M 15 AT,H,L T,H,L 29-Aug-2002 29-Aug-2002 Yes
23 M 18 AT,H H 18-Jul-2002 Yes
24 F 22 AT,H H 23-Jan-2003 Yes
25 M 1 AT N 06-Mar-2003 07-Mar-2003 Yes
26 M 16 PT,H H 14-Nov-2001 14-Nov-2001 Yes
27 M 15 PT,H,L H, L 13-Feb-2002 13-Feb-2002 Yes
28 M 16 PT,H T, H 23-Aug-2001 23-Aug-2001 Yes
MRA PERF DATPRVPF MRIFUP TXDATE PERFPTX
Yes Yes
Yes Yes 30-Nov-1999
Yes Yes 12-Sep-2002 12-Jun-2003 No
Yes Yes
Yes Yes 18-Dec-1998 10-Jul-2003 19/10/01 Yes
Yes Yes 25-Aug-1999 i 22/06/01 Yes
Yes Yes 12-Feb-2002 06-Sep-2002
Yes Yes 29-Jun-1999 20/06/02 Yes
Yes Yes 12/04/02 Yes
Yes Yes 26/10/01 Yes
Yes Yes 06-Mar-2003 30/11/01
Yes Yes 18-Jun-1999
Yes Yes 17-Sep-1999 16/03/02 Yes
Yes Yes
Yes Yes 11/04/03 Yes
Yes Yes 02-Jul-1999
Yes Yes
Yes Yes 25-Jul-2003 15/12/01 Yes
Yes Yes 23-Nov-1999
Yes Yes 30-Nov-1999 19-Jun-2003 03/01/02 Yes
Yes Yes
Yes Yes 18-Jun-1999
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes 18-Jun-1999
Yes Yes
AY
25/10/01
04/07/01
24/06/02
12/04/02
02/ 11/01
17/04/03
04/01/02
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PAT SEX AGE PRESYMP RECSYMP DATETCD DATEMRI DWI
29 M 19 PT,H H 04-Feb-2002 04-Feb-2002 Yes
30 M 15 PT,H H 24-Mar-2003 24-Mar-2003 Yes
31 F 19 PT,C,Z H 19-Jun-2001 19-Jun-2001 Yes
32 F 16 PT,L L 19-0ct-2001 Yes
33 M 10 PT,H,L H, L 29-Nov-2001 29-Nov-2001 Yes
34 F 6 PT,H,L H,L 07-Nov-2002 Yes
35 M 10 PT N 07-Mar-2002 07-Mar-2002 Yes
36 F 16 PT,H H, L 08-Nov-2001 08-Nov-2001 Yes
37 M 12 PT,Z,H,L Z, H, L 21-Feb-2002 Yes
38 F 13 PT,H,L T, H, L 12-Nov-2001 12-Nov-2001 Yes
39 M 13 PT,H,L H, L 26-Sep-2002 Yes
40 M 16 PT,H T, H 15-Feb-2002 Yes
41 M 11 PT,C,H,L T, H, L 07-Dec-2000 Yes
42 F 21 Z,L Z, L 24-Jan-2002 24-Jan-2002 Yes
43 M 7 Z,L L, Z 31-Oct-2002 31-Oct-2002 Yes
44 F 2 Z N 14-Mar-2002 14-Feb-2003 Yes
45 M 13 Z Z 17-Aug-2001 17-Aug-2001 Yes
46 M 4 Z,L Z, L Yes
47 1 17 Z H 03-Jul-2001 03-Jul-2001 Yes
48 0 12 Z,H,L Z, FI, L 26-Oct-2001 26-Oct-2001 Yes
49 1 11 H,L H,L 07-Mar-2002 07-Mar-2002 Yes
50 0 24 H H 07-Nov-2001 07-Nov-2001 Yes
51 0 5 H H 31-Oct-2002 05-Feb-2003 Yes
52 0 15 H,L T, H, L 29-Aug-2002 #NULL! Yes
53 0 22 H, L H,L 22-Oct-2001 22-Oct-2001 Yes
54 1 16 H.L H, L 10-0ct-2001 #NULL! Yes
55 0 9 H,L H, L 14-Feb-2002 14-Feb-2002 Yes
56 0 21 H N 13-Jul-1979 13-Jul-2001 Yes
MRA PERF DATPRVPF
Yes Yes 30-Jul-1999
Yes Yes
Yes Yes 24-Mar-1999
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes 30-Jul-1999
Yes Yes
Yes Yes
Yes Yes
Yes Yes 01-May-2001
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes 01-Sep-1999
Yes Yes
Yes Yes 17-Jun-1999
Yes Yes 24-Mar-2000
Yes Yes
Yes Yes 24-Feb-1999
Yes Yes
Yes Yes 06-Jul-1999
Yes Yes
Yes Yes
MRIFUP TXDATE PERFPTX POSTXD
AY
26/03/2002 Yes 27/03/2003
26/10/01 Yes 02/11/01
14-Feb-2003
18/02/02 Yes- 21/02/02 
movement-
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SEX AGE PRESYMP RECSYMP DATETCD DATEMRI DWI
57 0 11 H,L H,L 20-Jul-2001 20-Jul-2001 Yes
58 1 24 H H, L 09-Nov-2001 09-Nov-2001 Yes
59 0 9 H H 21-Sep-2001 21-Sep-2001 Yes
60 1 9 H, L H, L 12-Jul-2002 Yes
61 1 14 H H 08-Feb-2002 08-Feb-2002 Yes
62 1 11 H,L H, L 07-Feb-2002 07-Feb-2002 Yes
63 0 20 H H 01 -Oct-2001 01-Oct-2001 Yes
64 0 11 L L 19-Aug-2002 Yes
65 0 4 L L Yes
66 1 10 L L 05-Sep-2002 Yes
67 0 13 L L 08-Nov-2001 08-Nov-2001 Yes
68 1 8 N N 31-Aug-2001 03-Sep-2001 Yes
69 1 10 N L 05-Dec-2002 05-Dec-2002 Yes
70 1 8 N N 15-Mar-2002 Yes
MRA PERF DATPRVPF MRIFUP TXDATE PERFPTX POSTXD
AY
Yes Yes 30-Jun-1999
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes 02-Jul-1999
Yes Yes
Yes yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
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Table 2: Chapter 4
Table 2. Cross-sectional study (n=70 patients). Association between patients, diagnosis, 
haemoglobin level, awake-Oxygen saturation, neurological symptoms, MR studies and 
TCD. (chapter 4).
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No, Sex, Age, 
Diagnosis, 
Haemoglobin 
(g/dl), S p 0 2
Problem
and
Recurrent
Symptoms
Main
Symptoms at 
Onset
Rx
R
TCD
R
MRA
R
M RI
R
Perf.
L
TCD
L
MRA
L
MRI
L
Perf.
l.M,12 y, SS, 
9.8, 98.3%
C, S
Coma 
(PLKE) + 
S, H
Coma + R. 
hemi Tx 0 0 FPT
(DWM)
p**p**y** 3 0 FP
(DWM)
p**
p**
2.M, 16y, SS, 
9.2, no Sp02
c , s
H, L
Coma, bilateral 
stroke, ICP
Tx
SxD
4
?win-
dow
2 FPT p + p+y* 4
?win-
dow
2 F N
3.F, 19y, SS, 
no Hb, 96.7 %
C,PT
H
Coma, H, 
dizzy, blurred 
vision
0 0 N N 3 0 N N
4.M, 13y, SS, 
no Hb,
89.9 %
C,PT
T, H, L
C, T (facial 
weakness) Tx
No
data 0 N N
No
data 0 N N
5.F, 4y, SS, 
no Hb, 98%
S, Sz 
A
R hemi + 
hemianop + R 
focal Sz
Tx 0 1
FP
(+
DWM)
p**p**Q** 4 1 FPT
p**
p**
y * *
6. F, 7y, SS, 
9.7, 97%
S, Sz
Sz, L
R hemi + R 
focal Sz Tx 0 0 FPT
(DWM)
P**P**'P** 3 4 FPT
p**
p+*
y**
7. F, 27y, SC, 
no Hb, 99.9%
S
A
R hemi or ?MS 
attack 0 0 FPT
(SC)
J**
(SC)
0 0 FPT
(SC)
y*
(SC)
8.F, 16y, SS, 
no Hb, 98.3%
S, H
H, L
R hemi +H
Tx 3 1 N N 3 4 FPT
p**
p**
y**
9. F, 19y, SS, 
9.3, 96%
S
R, T, H, L
L hemi
Tx
stopped
4 3 F
(+
DWM)
p+*p **-]-** 3 2 FP
(DWM)
p**
p+*
y**
(SC)
10.F, 16y, SS, 
no Hb, 97%
S, Sz
AT, H, L
R hemi+ 
Sz+Aphasia Tx 3 1 T p** 3 4 FPT
p**
p*
y * *
1 I F, 27y, SS, 
9.3, 97%
S
A
Sz, collapse
Tx 0 1 PO p**0* 0 3 PO p*Q*
12.F, 14y, SS, 
8.8,91.9%
S
H, L
Learning
Difficulty Tx 0 1 N o** 0 1
FP
(+
DWM)
p**
p**
y * *
0**
13.F, 7y, SS, 
10.9, 97.5%
S
AT, H, L
L hemip
Tx 4 3 FPT
(DWM)
3 2 F
(DWM)
N
14.F, 24y, SS, 
8.4, 92.5%
S
S, T, H, L
R & L hemi, 
dysphasia Tx
stopped
4 5
MM
FPTO
(DWM)
F**p**'p«*
0*
4 3
MM
FPTO
p*p*
y**
0*
15.M, 16y, SS, 
10.1,97%
S, H
H
H, collapse, R 
hemianop Tx 4 5
MM
FPT p**-p*Q** 3 5
MM
0
T(BG)
p**
0**
16.F, l ly ,  SS, 
no Hb, no 
Sp02
S
L
Multiple 
strokes, R & L 
hemi
Tx
stopped
BMT
3 5
MM
F
(+
DWM)
F**p**p** 3 5
MM
FP
(+
DWM)
p**
p*#
y * *
17.M, 22y, SS, 
no Hb, 85%
S
S, H, L
Onset L. hemi, 
recurrent L. 
hemi + Sz
Tx
AED 4 4 FPT p*p**y** 4 0 N N
18.M, lOy, SS, 
no Hb, 97%
S
A T
R hemi + 
Aphasia
Tx
Stopped-
BMT
3 3 FP
(DWM)
p*p*y*Q** 3 3 FP
p*p*
y * *
Q**
19.F, 9m, SS, 
no Hb,no 
Sp02
AT
A
?Transient 
L.leg paresis 
Dactylitis
ATB 0 0 N p**y**Q** 0 0 N
p**
y * *
o**
20.M, 15y, SS, 
no Hb, 97%
AT
A
TIAs,
intracranial
anerysms
Tx 3 1 N N 3 N FP
(DWM)
N
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No, Sex, Age, 
Diagnosis, 
Haemoglobin 
(g/dl), S p 0 2
Problem
Main
Symptoms at 
Onset
Rx
R
TCD
R
MRA
R
MRI
R
Perf.
L
TCD
L
MRA
L
MRI
L
Perf.
21.F, 25y, SS, 
6.1,97.9%
AT
AT, H, L
Transient 
hemip + H
Tx
stopped 4 2
FT
(DWM
+BG)
p*p**T*
(SC) 4 1
FPT 
(DWM 
+ BG)
P*
•p**
(SC)
22.F, 9y, SS, 
8.1,92.5%
AT
AT, Sz, H
Transient L & 
R hemi, R Sz, 
H, MCA veloc. 
>200 cm/s
Tx
AED 2 5
MM
FPT
(DWM)
0 2 N N
23.M, 8y, SS, 
8.7, 97.6%
AT
A T TIA 0
Not
done N N 0
Not
done N N
24.M, 15y, SS, 
7.8, no SpC>2
AT
AT, H, L
Transient R 
hemip + H
Tx
stopped
LRV+HU
0 2 FPTO
(BDZ)
p**p **p**
O**
3 1 FPT
(BDZ)
p**
p**
p**
0**
25.M, 18y, SS, 
no Hb, 97%
AT
H
R paraesthesia
+
R sided H
3 0 N N 4 0 N N
26.F, 22y, SS, 
no Hb, no 
S p 0 2
AT, H
H
H +L sided
paraesthesia
(pain)
3 0 N p** 0 0 N N
27.M ,llm ,SS, 
9.6, no S p 0 2
AT
A
Transient 
L hemi Tx 0 0 N p+^p^+j** 
0** +
cerebellum
0 0 N
p**
p**
j* *
0**+
cereb.
28.M, 15y, SS, 
no Hb, 95.5%
PT
H
Transient L 
hemi + 
unconscious­
ness + H
4 0 N N 3 0 N N
29.M, 16y, SS, 
6.6, 88.9%
PT
H, L
Headaches + 
Hallucinations
Tx
stopped 0 0 N N 0 0 N N
30.M, 17y, SS, 
no Hb, 97.3%
PT
T, H
H, dizziness, 
paraesthesia, 
confusion
0 0 N N 3 0 N N
31.M, 18y, SS, 
no Hb, 95.2%
PT
H
TIA + 
headaches
Tx
stopped-
HU
3 0 N •p** 0 0 N N
32.M, 16y, SS, 
no Hb, 92%
PT
H
Collapse + 
transient loss 
o f vision
Tx +
Oxygen
overnight
3 0 F
(DWM)
p*p** 0 1 F
(DWM)
p**
p**
33.F, 15y, SS, 
8.8, 93.5%
PT
H
TIA + 
headaches Tx 3 5
MM
FT
(DWM 
+ BG)
p**p**-p**
0**
3 0 T
(BG)
p**
p**
-p**
O**
(SC)
34.M, 9y, SS, 
7.7, 96%
PT
H, L
Headaches + 
pica + L 0 0 N N 0 0 N 0**
35.F, 6y, SS, 
6.9, 92%
PT,H
H, L
Headaches + 
double vision 
+ MCA veloc 
> 200cm/sec
Tx 0 3 N p**p**
(SC)
2 3 N
p**
p**
(SC)
36.M, 9y, SS, 
5.7, 97.7%
PT
A
Transient L 
hemi & unres­
ponsiveness + 
blurred vision 
episodes
Acute Tx 
Aspirin 0 0 N N 3 0 N N
37.F, 15y, SS, 
11, 97.8%
PT
H, L
TIA + 
headaches 0 0 N N 0 0 N N
38.M, 12y, SS, 
8.1, 95.9%
PT, Sz
Sz, H, L
Blank 
episodes, R 
sided Sz + H
AED 0 0 N •p** 0 0 N N
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No, Sex, Age,
Diagnosis,
Haemoglobin
(g/dl), s Po 2
Problem
Main
Symptoms at 
Onset
Rx
R
TCD
R
MRA
R
MRI
R
Perf.
L
TCD
L
MRA
L
MRI
L
Perf.
39.F,13y, SS, 
6.6, 95.7%
PT, H
T, H, L
Transient hemi 
+ VI nerve 
palsy + H
Tx
stopped 4 0 FP
(DWM)
N 4 1 PTO
(DWM)
N
40.M, 13y, SS, 
9, no Sp02
PT
H, L
Headaches + 
blurred vision 0 2
(PCA)
F
(DWM)
N 3 1
(PCA)
F
(DWM)
N
41.M, 1 ly, SS, 
no Hb, 94.8%
PT, H
T, H
Headaches + 
dizziness 0 1 N N 3 0 N N
42.F, 20y, SS, 
9.8, 98%
Sz
Sz ,L
SCD crisis 
with ?stroke + 
hallucinations 
+ visual 
phenomena
Acute Tx 
on AED
4 0 Mild
atrophy (SC)
3 0 Mild
atrophy
p * *
p * *
■ p * *
(SC)
43.M, 8y, SS, 
11.6, no Sp02
Sz
Sz, L
?blank spells 
+ L 0 0 N 0 0 N p * *
44.F, 20m, SS, 
8.2, 98.7%
Sz
A
Generalised 
tonic- clonic 
seizure
0 1 N
O**
0 1 N
p * *
p * *
• p * *
0**
Cereb
45.M, 12y, 
S/B°thalass, 
no Hb, 97%
Sz
Sz
Staring spells 
(petit mal like) AED 3 0 N 0 0 N N
46.M, 4y, SS, 
9.2, no Sp02
Sz
Sz, L
Autism, ?blank 
spells 0 0 N N 0 0 N N
47.F,17y, 
S/B°thalass, 
no Hb, 92.8%
Sz
H
Seizures in 
infancy + 
occipital 
headaches
0 0 N N 0 0 N N
48.M, 1 ly, 
SS,8.4, 98%
Sz
Sz, H, L
?epilepsy + 
pain crisis 0 0 N N 0 0 N N
49.F,1 ly, SS, 
no Hb, 95%
H
H, L
Headaches
0 0 N N 0 0 N N
50.M, 24y, SS, 
9.9, 97.8%
H
H
Headaches HU 4
?win-
dow
0 N N 3
?win-
dow
0 N N
51.M, 5y, SS, 
no Hb, 93.5%
H
H
Severe
headaches 0 1
(PCA)
P
(DWM) o**
0 2 N
p**
p**
y**
0**
52.M,15y, SS, 
9.5, no S p 0 2
H
H, I
Severe 
headaches + 
chest crisis, 
previous 
MCA veloc 
>200 cm /sec
Tx
stopped 0 1 N p * * y » *
O**
3 1 N y * *
O**
53.M, 22y, SS, 
no Hb, 96%
H, L
//, L
Headaches + L
0 0 N N 0 0 N N
54.F, 16y, SS, 
no Hb, 93.5%
H, L
H, L
Headaches + L 4
?win-
dow
0 N N 4
?win-
dow
0 N N
55.M, 8y, SS, 
9.9, 94.9%
H
H, L
Severe 
headaches + 
previous MCA 
veloc >200 
cm/sec
Tx 0 1 N p * * p * *
(SC)
0 2 N
p * *
p * *
(SC)
56.M, 22y, SS, 
no Hb, 92.9%
H
A
Headaches
0 0 N N 4 0 N N
385
No, Sex, Age,
Diagnosis,
Haemoglobin
(g/dl), s Po 2
Problem
Main
Symptoms at 
Onset
Rx
R
TCD
R
MRA
R
MRI
R
Perf.
L
TCD
L
MRA
L
MRI
L
Perf.
57.M, 1 ly, SS, 
9.1,96.5%
H, L
H, L
Headaches + L 0 1 N N 0 1 N N
58.F, 23y, SS, 
6.9, 88%
H
H, L
Headaches
0 0 FPT
(DWM)
p*p*-p**
o**
3 1 FPTO
(DWM)
p*p+
T**
0**
59.M, 8y, SS, 
no Hb, 95.5%
H
H
Headaches
0 0 N N 0 0 N N
60.F, 9y, SS, 
11.3,97.8%
H, L
H, L
Headaches + L
3 0 N N 3 0 N N
61.F, 14y, SS, 
8.4, 94.3%
H
H
Severe 
headaches + 
chest crisis
Tx
stopped
HU
0 1 N N 0 1
(PCA)
N N
62.F, 1 ly, SS, 
9, 96.7%
H, L
H, L
Severe
headaches + L 3 0 N N 3 0 N N
63.M, 21y, SS, 
no Hb, 96%
H
H
Headaches
0 0 N N 3 0 N N
64.M, 1 ly, SS, 
no Hb, 90.5%
L
L
Learning
difficulty,
priapism,
asthma
Acute Tx 
Broncho- 
dilators
0 0 N p**p**
(SC)
0 0 N p**
p*+
(SC)
65.M, 3y, SS, 
no Hb, no 
Sp02
L
L
Learning 
difficulty, 
severe OSA
Tonsillec
-tomy
CPAP
No
data 2 N Cerebellum
No
data 0 N
■p**
0**
cereb.
66.F, 1 ly, SS, 
7.1, no Sp02
L
L
Learning
difficulty 0 0 N N 0 0 N N
67.M, 12y, SS, 
10.7, 98%
L
L
Learning
difficulty 0 0 N N 0 0 N N
68.F, 7y, SS, 
no Hb, 91%
A
A
None
0 2 N N 0 3 N N
69.F, lOy, SS, 
no Hb, no 
Sp02
A
L
No
neurological, 
recurrent chest 
syndrome
BMT 3 1 N p * * p * * Q * * 0 1 N p * *
o * *
70.F, 7y, SS, 
no Hb, 98%
A
A
None
0 1 F
(DWM)
N 3 1 F
(DWM)
N
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Table 2. Cross-sectional data of 70 patients with sickle cell disease who underwent 
transcranial Doppler ultrasound (TCD), MRI, MRA and perfusion MRI studies.
Column 1\ Hb= haemoglobin level (there is no Hb level for the patients whose 
haematological data is later than a year from the perfusion MRI study) ; Sp02= day- 
oxygen saturation measured by pulse oximetry. Column 2\ neurological manifestations 
at onset and recurrent neurological symptoms (C=coma; S=stroke; PLKE=posterior 
leukoencephalopathy; R=reversible ischaemic neurological deficit; T=TIA [transient 
ischaemic attack]; AT= anterior territory TIA; PA= posterior territory TIA; Sz=seizures; 
H=headaches; L= learning difficulty (cognitive); A=asymptomatic.
Column 3: hemi=hemiparesis; hemianop= hemianopia; R=right; L=left.
Column 4: Rx=treatment; Tx=transfusion; LRV= left-sided revascularisation;
HU=hydroxyurea; SxD= Surgical decompression; BMT= bone marrow transplant; 
AED= antiepilectic drugs; ATB=antibiotics; CPAP= continuous positive airway 
pressure.
Columns 5 (R) and 9 (L): results of the TCD analysis (0= normal; 1= mean maximum 
MCA velocities > 170 < 200 cm/sec; 2= mean maximum MCA velocities > 200 cm/sec; 
3= mean maximum MCA velocities < 70 cm/sec and lowest:highest ipsilateral velocity 
ratio < 0.5 or a ACA:MCA ipsilateral ratio > 1.2; 4= undetectable MCA).
Columns 6 (R) and 10 (L): worst grade of turbulence in any basal vessel on MRA 
(0=normal; 1 = mild turbulence; 2= moderate turbulence; 3= severe turbulence; 4= 
occlusion; 5= occlusion + moyamoya collaterals [MM]; PCA= posterior cerebral artery 
[appears when the vessel with the greatest grade of turbulence is not related to the 
vascular territory of abnormal MRI or perfusion MRI)]).
Columns 7 (R) and 11 (L) have data of T2-weighted MRI; and columns 8 (R) and 12 (L) 
have data of perfusion MRI: N= normal; Perf.= MRI perfusion (DSC-MRI); F=frontal; 
P=parietal; T=temporal; 0=occipital; BG= basal ganglia; DWM= deep white matter 
watershed infarcts; BDZ= borderzone infarcts; SC= subcortical; cereb.= cerebellum; *= 
region of perfusion abnormality beyond the T2- weighted abnormality; **=region of 
perfusion abnormality in a territory with no T2- weighted abnormality (table adapted 
from Kirkham et al 2001).
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Tables 3 and 4: Chapter 5.
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Tables 3 and 4. Association of perfusion abnormality with progression of cerebrovascular disease and central nervous system events in sickle 
cell disease: longitudinal study (Chapter 5)
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Table 3. A ssociation o f perfusion abnorm ality with TCD, M RI and M R A  (longitudinal study)
Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of 
Study 
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
l.M , HbSS
BTx
Coma,
stroke
PLKE,
Headaches
BTx
Coma, stroke
Initial:
30/11/1999
(9y)
No data Normal Multiple are 
o f ischaemia 
in anterior & 
posterior 
watershed 
territories
R. Parietal 
Cortical 
R. parietal 
subcortical 
R. parietal/ 
occipital Bdz 
beyond 
infarcts
No data Normal Multiple are 
of ischaemia 
in anterior & 
posterior 
watershed 
territories
L. parietal 
subcortical, 
beyond 
infarcts
- h -
Final: 
11/07/2002 
(12 y)
Changed
Perfusion
Normal R. 
MCA veloc. 
No US 
signal from 
L.ACA
Normal Unchanged
R.P. C.
R. P. (SC), 
R. P O Bdz, 
more 
extended
W orse 
(C B 1 )
L.MCA 
veloc ratio 
L:H <0.5
Normal
Unchanged, 
new L. 
caudate 
infarct
Worse
L P  SC,
more
extended
W orse 
(( Bl )
2. M, HbSS
BTx
Coma,
stroke
Headaches,
learning
difficulties
Coma, 
bilateral 
stroke w/ 
1CP (needed 
surgical de- 
compresion)
Initial: 
25/08/1999 
(13 y)
No data
R.Terminal 
ICA, MCA 
& ACA 
turbulence 
(2)
Areas of
extensive
cystic
encephalo-
malasia in R.
hemisphere
R. frontal 
(C/SC),
R. parietal
(C/SC),R.
temporal
(C /SQ  R.
temp/Occip
Bdz(C/SC).
Beyond
infarct
No data
L.Terminal 
ICA, MCA 
& ACA 
turbulence 
(2)
L.ACA
territory
infarct
No
abnormality
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of 
Study 
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
2. M, HbSS 
(cont) Final: 
15/08/2001 
(16 y)
Changed
Perfusion
Undectecta- 
ble R MCA 
(?window)
Unchanged Unchanged
Beyond 
infarct. R. F- 
P-T (C/SC), 
R. P (C/SC) 
less
extended. 
Normal R. 
T/O Bdz
C/SC
Better (CBF 
& C BV)
Undectecta- 
ble L. MCA
(?window)
Unchanged Unchanged No
abnormality
3. F, HbSS
BTx stopped
Coma,
posterior
TIA
Headaches
Coma,
posterior
TIA,
seizures
Initial: 
24/03/1999 
(18 y)
Normal Normal Normal No
abnormality L. MCA L:H 
Ratio veloc 
<0.5
1
i Normal Normal : No 
abnormality
Final: 
19/06/2001 
(19 y)
Normal , Normal Normal No
abnormality
Unchanged Normal Normal
: No 
abnormality
Unchanged
Perfusion !
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of 
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
4. F, HbSS
BTx.
Stroke
Seizures,
Learning
difficulties
Right
hemiparesis 
and right 
focal 
seizures
Initial: 
12/09/2002 
(6 y)
Normal R 
MCA veloc
; Normal
Ischaemic 
lesion in 
peritrigonal 
areas
R. Posterior 
Parietal (C) 
R. Superior 
F-P-T (SC) 
beyond P-T 
infarct
L. MCA L:H 
ratio veloc 
<0.5
Unsuccessful
study,
previous
MRA
(2001 )LMC 
A (3).
?Now L. 
MCA (4)
Unsuccessful
study.
Previous
MRI (2001):
L. Precentral
cortex
infarct,
ischaemic
lesion in
peritrigonal
areas. ? New
cerebral
atrophy
L.eft P-F-T 
(C/SC)
L T/O Bdz 
C/SC, 
beyond P-T 
infarct
Final:
12/06/2003
(7y)
Changed
Perfusion
Normal
R.MCA Normal Unchanged
R. Post P. C 
R. Sup F/P/T 
SC
Better 
(MTT )
L. MCA L:H 
ratio veloc 
<0.5
L.MCA (4)
Unchanged
lesions,
?progression
of cortical
atrophy in L
MCA
territory
Worse
L.P-F-T. 
F/P/T 
(C/SC), L 
T/O Bdz
C/SC, less 
extended
Better 
(MTT & 
CBF )
5. F, Hb SS
BTx
Stroke
Headaches,
Learning
difficulty
R
hemiparesis 
+ Headaches
Initial: 
18/12/1998 
(12 y)
No data : r . a i  ( i ) Normal No No data L.M1 (4),
A 1 (3), P I(1), 
PCA collat 
MM
L. F-P-BG 
(caudate n.)
L Frontal (C/
! sc),
Temporal 
1 (C), F/T Bdz 
i (C/SC), 
beyond  
| infarct.
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
5. F, Hb SS 
(cont)
Final: 
12/10/2001  
(16  y)
Changed
Perfusion
R MCA 
Low:High 
Ratio 
Veloc <70 
cm/sec
R. A l (1) Normal No L MCA L:H
V< 70 cm/s
L. Ml (4) 
A l (3->4) 
PI (1), P2 
(1), MM
Worse
L. F-P-BG 
(caudate n.) 
No new inf.
L Frontal
(C/SC)
Temporal
(C)
L F/T Bdz 
(C/SC), 
beyond 
infarct. 
Worse MTT 
& CBF  
(Improved 
CBV)
6.F, HbSS
BTx
Stroke
Anterior
TIA,
seizures,
Headaches,
learning
difficulties
R hemi+ Sz+ 
Aphasia
Initial: 
29 /06 /1999  
(12 y)
R. MCA 
L:H vel 
<0.5
R. A l (1) R.lentiform
nucleus
No
L. MCA 
L:H vel
<0.5
TICA (2), 
Ml (2), 
A l (2)
Large F-P-T 
infarct
L.Frontal 
(C/SC); 
Parietal ( C)
Final:
17 /06/2002  
(16  y)
Changed
Perfusion
R. MCA 
L:H vel
<0.5
R. A l (1) R.lentiform
nucleus
R. Frontal
(C)
Worse
(MTT,CBF,
(B Y )
L. MCA 
L:H vel
<0.5
Ml (2), 
M2 (1)
A2 (4)
Worse
Large F-P-T 
infarct. No 
new infarct. 
F-P-T 
atrophy
Worse
L. Frontal
(C/SC);
Parietal ( C) 
L Temporal 
(C/SC), 
beyond 
infarct. 
W orse 
(MTT,CBF, 
CBV)
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
7. F, HbSS
BTx
Stroke
Anterior
TIA,
Headaches,
Learning
Difficulties
Left hemip.
Initial: 
06/12/2001 
(7 y)
Undectecta- 
ble R. MCA/ 
ACA
tICA (3), Ml 
(3), M2 (1), 
Al (3)
F-P
watershed 
multiple 
infarcts, 
infarct in 
head o f  
caudate, 
mild hemisp. 
atrophy
R. Frontal- 
Parietal [C] 
R. Parietal 
[C/SC] 
R.F/P
Borderzone
[SC]
R.Temporal 
[C/SC], 
beyond 
infarcts
Normal L. 
MCA, 
undetecta­
ble L. ACA.
Al (2) Two frontal 
deep
watershed 
infarcts, no 
atrophy
No
Final:
06 /03 /2003
( 8 y )
Changed
Perfusion
Undectecta- 
ble R. 
MCA/ACA
tICA (2—>l),
Ml (3), M2
O M /
(3^2), 
A2(I), P2 (I)
Better
Unchanged
MRI
Mormalised 
F-P BdZ 
Unchanged 
other regions 
but less 
extended. 
B etter  
(M T T  & 
C B F
L. MCA L:H 
ratio <0.5, 
undectecta- 
bleACA
Worse
Al (2), M l 
(1), PI (1)
Worse
...................
Unchanged
MRI No
8. F,SS
Stopped 
Blood tx 
(autoantib)
Stroke
Stroke, TIAs, 
Headaches, 
Learning d if
Right & left 
hemiparesis 
Dysphasia
Initial: 
18/06/1999 
(21 y) No data
Ml (4), Al 
(3), TICA & 
PI (2), P2 
(1), MM
F-P-T-O,
multiple
AWS/DWS/
PWS
Slight
hemisph.
Atrophy
R. Parietal 
[C/SC]
R. Temporal 
[SC], beyond 
infarct
No data
TICA,
M1,A1 &P1 
(2), P2 (1)
......................
FPT(large
MCA
infarct),
AWS/PWS/
DWS, severe
hemisph
atrophy
L. Temporal 
[SC ]?
394
Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
8. F,SS 
(cont) Final: 
15/11/01 
(24 y)
Changed
Perfusion
Undectecta- 
ble R. MCA/ 
ACA
Ml (4),
M2 (4), 
TICA 
(2—>4),
A1 (3->2), 
MM
Worse & 
Better
FPTO,
multiple
AWS/DWS/
PWS , BG
(new?),
general is.
Atrophy
Worse
R. Parietal 
[C/SC]
R. Temporal 
[SC], beyond 
infarct, new 
Temporal
I Q  
Worse 
MTT, CBF, 
CBV
Undectecta- 
ble L. MCA, 
Mild 
increased 
velocity in L. 
ACA
T/CA(2->3),
M l (2->l),
A1 (2)
Worse & 
Better
FPT infarct, 
BG (new), 
gen era I is. 
Atrophy
Worse
? Extension 
o f p erf abn. 
in T lobe o f 
L. FPT 
infarct.
Worse 
MTT, CBF, 
CBV
9. M, HbSS
BTx
Stroke
Headaches
and
decreased 
vision acuity
Headaches,
collapse
Initial 
17/09/1999 
(14 y)
Normal R.P2 (4), 
PCA collat
R F & P, 
focal atrophy R. Parietal- 
occipital [C]
Normal
L. P2 (4), 
PCA collat
L. DWM, 
BG
L. Occipital 
[C]
Final:
14/03/2002 
(16 y)
Changed
Perfusion
Undectecta- 
ble R. MCA
Worse
R.P2 (4), PI 
(2), PCA 
collat
Worse
Unchanged
Unchanged
L.MCA L:H 
ratio <0.5
Worse
L. P2 (4), PI 
(2)
PCA collat 
Worse
L. DWM, 
BG
?occipital
atrophy
Worse
L. Occipital 
1C]
Worse
(MTT)
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
10. M, 
HbSS
BTx-
Stopped
BMT
Stroke
Anterior TIA
Aphasia and 
right hemip.
Initial: 
02/07/1999 
(10 y)
R. MCA 
veloc, L:H 
ratio < 0.5
TIC A (3), 
Ml (3), 
moyamoya
Deep
watershed
frontal-
parietal
infarcts (two
infarcts)
R. Parietal 
[C/SC], 
R.P/O Bdz 
C/SC,
R.Temporal
[C],
R. T/O Bdz 
[C/SC], 
beyond inf.
L. MCA 
veloc, L:H 
ratio < 0.5
TICA (3), 
Ml (3), 
moyamoya
Infarct F-P
L. Parietal 
[C],
L.P [SC],
L. P/Occip. 
[C]
L.T/O Bdz 
[C], beyond 
infarct
Final: 
20/12/2002 
(13 y)
Changed
Perfusion
Undectecta- 
ble R MCA
Worse
TICA (3), 
Ml (3), 
moyamoya, 
more 
collaterals
Worse
Unchanged
R. PfC/SC], 
R.P/O Bdz
c/sc;
R.TfCJ,
R. T/O Bdz 
IC/SCJ, »  
extended 
Worst MTT. 
CBF. CBV 
Better CBV
Undectecta- 
ble L.MCA
Worse
TICA (3), 
Ml (3), 
moyamoya, 
more 
collaterals
Worse
Unchanged
l .p  [ q .
LPfSCJ  
L. P/O [C.]
L. T/O Bdz 
fCJ, more 
extended 
Worse 
MTT, CBF, 
CBV
11. M. 
HbSS
BTx
Anterior
TIA
Asymptoma­
tic
TIAs Initial: 
13/12/2001 
(15 y)
R. MCA 
veloc L:H 
ratio < 0.5
M2 (1)
___________
No No R. MCA 
veloc L:H 
ratio < 0.5
No
.......................
Small F-P 
subcortical 
white matter 
infarcts
___________
No
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Main
Case, Sex, Symptom at Onset Date of Right TCD Right MRA Right MRI Right Left TCD Left MRA Left MRI Left
Dx presentation Symptoms Study Turbulence Infarct Perfusion Turbulence Infarct Perfusion
Recurrent (age) Abnormal Abnormal
Therapy Symptom(s)
11. M. R. Sup.
HbSS R. MCA Unchanged No Parietal [C], L. MCA Unchanged Unchanged No
(cent.) Final: veloc L:H different veloc L:H
BTx
25/07/2003 ratio < 0.5 slice orien­ ratio < 0.5
(16 y) tation to
compare
Unchanged \v/previous
study
Perfusion
12. F, HbSS Initial: R. MCA Ml (2) Small R Frontal L MCA Small deep L. Parietal
Anterior 'Transient 23/11/1999 veloc L:H anterior deep ('/SC veloc L:H TICA (3), white matter [CJ,
BTx- TIA hemiparesis, (21 y) ratio < 0.5 watershed R. Parietal- ratio < 0.5 Ml (3), M2 infarct and L. Parietal-
stopped
Anterior
h a ,
Headaches,
headaches infarctsn and
basal ganglia 
(F-T)"
Temporal 
[SC (W M )],
beyond
infarct
(2), A1 (3) basal ganglia 
(T)
Temporal 
[SC (WM)],
beyond
infarct
Learning &,
behaviour
problems Final:
07/12'200l 
(25 y)
Unchanged
Perfusion
Undectecta- 
ble R. MCA  
(thick skull)
M l (2), A 1 
(2)
Worse
Unchanged Unchanged Undectecta- 
ble /.. MCA 
(thick skull)
TICA
(3->0),
M l (3-+1), 
M 2 (2—>l), 
A I 0 - X ) )
Better
Unchanged Unchanged
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
13. F, HbSS
BTx,
AED
(Carbama-
zepine)
Anterior
T IA
Anterior
TIA,
Seizures,
Headaches
Transient L 
& R.
heniiparesis,
Focal
seizures,
Headaches
Initial:
30/11/1999
(8y )
Final:
04/01/2002
(11 y)
Changed
Perfusion
R. MCA 
veloc >200 
cm/s
R. Ml (3), 
M2 (1),
A1 (2)
R.T/DWS
(corona
radiata)
R. Frontal-
Parietal
[C/SC];
R. Temporal 
[C]
RT/O Bdz 
C/SC 
R.T. SC, 
beyond 
infarct
L MCA 
normal 
veloc,
L. AI (3), 
Ml (1)
No No
R. MCA 
veloc >200 
cm/s
And R MCA 
vel. L:H 
ratio <0.5 at 
4 cm depth
Worse
R.
M l (3—>4), 
M2 ( l —>2), 
AI (2->0), 
PCA collat
R.T/DWS
(corona
radiata)
Unchanged, 
no new 
infarct
Worse & 
Better
R. F-P 
[C/SCJ 
R. T.[CJ 
RT/O Bdz 
[C/SC]
R.T. [SC] 
Beyond 
infarct, new 
areas o f  
perfusion 
abnormality 
Worse 
(MTT & 
CBF)
Better CBV
L MCA 
veloc L:H 
<0.5
L.
A1 (3—>0), 
Ml (1)
No No
Worse Better
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Main
Case, Sex, Symptom at Onset Date of Right TCD Right MRA Right MRI Right Left TCD Left MRA Left MRI Left
Dx presentation
Recurrent
Symptoms Study
(age)
Turbulence Infarct Perfusion
Abnormal
Turbulence Infarct Perfusion
Abnormal
Therapy Symptom(s)
14. R. PC L. P [SC]
M, HbSS Initial: Undectecta- Multiple R. Parietal Normal Ml (1), M2 Multiple (WM)
Anterior TIA 18/06/1999 ble R. MCA A1 (2) small [SC (WM)] MCA (2), A 1 (1) small L. P[C/SC]
TIA (transient (12 y) ACA/MCA R.P/O Bdz ACA/MCA L. P/O Bdz
right watershed [SC] watershed L. T [SC
BTx-stopped Anterior
TIA,
hemip.),
Headaches
infarcts, mild 
parietal lobe
R. T/O Bdz 
[C/SC]
infarcts, and 
small infarct
(WM)] 
L.T/O Bdz
Left indirect Headaches, atrophy, R.O [C]; in head of [C/SC]
Frontal Learning mild global beyond caudate L. 0  [C],
revasculari­ Difficulties atrophy infarct. nucleus. beyond
sation Mild parietal 
lobe
infarct
Hydroxyurea
___________
atrophy, 
mild global 
atrophy
R. P C r . . . . . . . . . . . . . L. P [SC]
Final: Normal TICA (2), Unchanged R. PSC TICA (1). Unchanged (WM)
27/08/2002 MCA, M l (1), A1 (WM) L. MCA M l (l->0), L. P[C/SCI
(15 y) undectecta- (2) R.P/O Bdz veloc L:H M2 ( 2 —>l), L P/O Bdz
Changed bleACA R. T/O Bdz ratio <0.5, A1 (1) L. T [SC
Perfusion- R.O C; Be­ undetectable (WM)]
Better yond infarct,
less extended
ACA. L.T/O Bdz 
[C/SC]
Worsening Better Worse Worse Better & L . O f C /,
only in one Better
Worse
Beyond
region MTT 
and CBF, and 
another region 
CBV on the
(MTT, CBF 
& CBV)
infarct, less
extended.
Better
left perfusion. MTT,
___________ CBF,CBV
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent 
Symptom (s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
15.
M, HbSS
BTx-stopped
Posterior
TIA
Headaches
Posterior
T1A-
headaches
Initial: 
30/07/1999 
(15 y)
Normal No Normal Normal Normal No Normal Normal
Hydroxyurea
.......................
Final:
04/02/2002 
(19 y)
Changed
Perfusion
R MCA 
veloc L:H 
ratio <0.5
Worse
No Normal
R. Temporal 
fCJ
Worse
(MTT,
slightly
CBF)
Normal No Normal Normal
16. F, HbSS
BTx-stopped
Posterior
TIA
Posterior
TIA,
Headaches,
Learning
Difficulties
Posterior 
TIA (mild 
bilateral 
hemiparesis, 
Vlth nerve 
paresis) and 
headaches
Initial:
30/07/1999
( i i  y)
R MCA 
veloc L:H 
ratio < 0.5
TICA (1), 
Ml (1) No
' '
R Temporal 
[C]
L MCA 
veloc L:H 
ratio < 0.5
___________
TICA (1),
Ml (2), A1 
(1)
___________
No No
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI Left 
Infarct Perfusion 
Abnormal
16. F, HbSS 
(cont)
BTx-stopped
Final: 
12/11/2001 
(13 y)
Changed
Perfusion
Undetecta­
ble R. MCA 
(? window)
?Worse
TICA
(l->0), M l 
O->0)
Better
Three small 
F-P deep 
watershed 
infarcts.
Worse
Normalised 
R Temporal 
IQ
Better
(MTT)
Undetecta­
ble L. MCA 
(? window)
?Worse
TICA
(1 —>0), M l 
(2->l), A1 
(1^ 0)
Better
Small
multiple No 
MCA/PCA 
deepwater- 
shed infarcts.
Mild MCA
territory
atrophy
Worse
17. F, 
HbS/B° 
thalassae- 
mia
Seizures
Headaches
Seizures in 
infancy
Initial: 
01/09/1999 
(16 y)
R.MCA 
veloc L:H 
ratio <0.5
Normal Normal No
Normal Normal Normal No
Final: 
03/07/2001 
(17 y)
Normal Normal Normal No Normal Normal Normal No
Unchanged
Perfusion
Better
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of 
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
18. F, HbSS
Headaches
Headaches,
Learning
difficuties
Headaches
Initial: 
17/06/1999 
(8 y)
Normal R. TICA (1). 
M2 (1)
Normal No Normal M2 (2) Normal No
Chronic
hypoxem ia
Final:
08/03/2002 
(11 y)
Unchanged
Perfusion
N orm al
R. TICA 
(1^0),
M2 (1 —>0)
Better
Normal No Normal M2 (2->0)
Better
Normal No
19. M, 
HbSS
Hydroxyurea
Headaches
Headaches
Headaches Initial: 
24/03/1999 
(22 y)
No data No Normal No No data No Normal No
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
19. M,
HbSS
(cont)
Hydroxyurea
Final: 
11/07/2001 
(24 y)
Unchanged
Perfusion
Undetecta­
ble R MCA 
(thick skull, 
?window))
N o Normal
No L MCA 
veloc L:H 
ratio <0.5 
(thick skull, 
?window)
N o
Normal No
20. M, 
HbSS
BTx-stopped
Headaches
Headaches,
Learning
and
Behaviour
problems
Severe
headaches,
chest
syndrome
Initial: 
24/02/1999 
(12 y)
R. MCA 
veloc >200 
cm/sec
M2 (2), PI 
(2)
.............................
Normal
R. Frontal 
[C/SC],
R.Temporal 
[C/SC],
R.T/ Occip. 
Bdz [C/SC]; 
R.T/O Bdz 
[C]
L. MCA 
veloc L:H , 
0.5
M2 (1)
Normal
L.Temp./Occ 
ipital Bdz; 
L.T-
Occipital
[C].
Final:
29/08/2002 
(15 y)
Changed
Perfusion
Normalised
TCD
Better
TICA (1 or 
2), M2 
(2—>0), PI 
(2—>0)
Better & 
Worse
Normal
R. F [C/SC], 
Normalised 
R.T! C/SC], 
R. T/O Bz 
IC/SC]; 
R.T/O Bdz 
[C]
Better 
(MTT & 
CBF)
L. MCA 
veloc L:H , 
0.5
TICA (1 or 
2), M2 
(1-X))
Better & 
Worse
Normal
L. T/O Bdz 
L. T-O/CJ.
Better 
(M TT & 
CBF) 
Worsening 
of post. T 
region 
(CBV) after 
stopped BTx
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Ons© Sex 
Dx
Therapy
Main 
Symptom at
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
21. M,
HbSS Headaches
Headaches,
Learning
Difficulties
1 leadaches, 
learning
difficulties
Initial:
03/1 1/1999 
(20 y)
No data No Normal No No data No Normal No
Final:
22/10/2001 
(22 y)
N orm al No Normal No Normal
N o
Normal No
Unchanged
Perfusion
22, F, HbSS
Headaches
H eadaches,
learn ing
d ifficu lties
Headaches,
learning
difficulties
Initial:
06/07/1999 
0 3  y)
R
ACA: MCA 
> 1.2
No Normal No
L.MCA 
veloc L;H 
ratio <0.5
No Normal No
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Case, Sex, 
Dx
Therapy
Main 
Symptom at 
presentation
Recurrent
Symptom(s)
Onset
Symptoms
Date of
Study
(age)
Right TCD Right MRA 
Turbulence
Right MRI 
Infarct
Right
Perfusion
Abnormal
Left TCD Left MRA 
Turbulence
Left MRI 
Infarct
Left
Perfusion
Abnormal
22. F, HbSS 
(cont) Final: 
10/10/2001 
(16 y)
Unchanged
Perfusion
Undetecta­
ble R MCA 
(? window)
?\Vorse
No Normal No Undetecta­
ble L MCA 
(? window)
? Worse
No Normal No
23. M, 
HbSS Headaches
Headaches,
Learning
Difficulties
Headaches,
Learning
Difficulties
Initial: 
30/06/1999  
(8 y)
Normal No Normal No Normal No Normal No
Final: 
20/07/2001  
( i i  y)
Unchanged
Perfusion
Norm al
R. A1 (1) 
Worse
Normal No Normal R. M l (1), 
M2 (1)
Worse
Normal No
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Table 3. Association of perfusion abnormality with transcranial Doppler ultrasound (TCD), MRI and MRA. Longitudinal study.
Dx: diagnosis; F: female; M: male, SS : homozygous sickle cell anaemia; TIA: transient ischaemic attack; Diff: difficulties; BTx: transfusion; 
AED: antiepileptic medication; L: left; R: right; hemi: hemiparesis; PLKE: posterior leukoencephalopathy; TICA: terminal internal carotid artery; 
MCA: middle cerebral artery; M l & M2: middle cerebral artery segments 1 & 2; AJ & A2: anterior cerebral artery segments 1 & 2, PI & P2: 
posterior cerebral artery segments 1 & 2; MM: moyamoya collaterals; vel: mean MCA velocity; F: frontal lobe; T: temporal lobe; P: parietal 
lobe; O: occipital lobe; AWS: anterior watershed; PWS: posterior watershed; DWS: deep watershed; DWM: deep white matter; BG: basal ganglia. 
MCA L:H: MCA lowest: highest mean ipsilateral velocity ratio; ACA.MCA: ACA:MCA highest ipsilateral velocities ratio.
MRA turbulence classified as: (I): mild; (2): moderate; (3): severe and (4): occlusion.
MTT: Mean transit time 
CBF: Cerebral Blood Flow 
CBV: Cerebral Blood Volume 
C: Cortical 
SC: Subcortical
Worsening of perfusion MRI parameters (MTT, CBF or CBV) 
Improvement (better) of perfusion MRI parameters (MTT, CBF or CBV)
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Case, Symptom  
at Presentation,
Main Recurrent 
Symptom,
T reatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
1 .HbSS I: 30/11/1999 Right Hemisp. No parameter
(9 y) R.P. C. = Unchanged = - =
Coma, stroke F: 11/07/2002 R. F. SC. ++ Unchanged = +
Coma (Posterior (12 y) R. P.SC. ++ Unchang. :>ext. = +
Leukoencepha- I: SVD R. P/O Bdz = Unchanged = =
lopathy) F: Sum. Param.
TTP similar to MTT Left Hemisp.
BTx MPC similar to CBF L. F. SC ++ Unchanged = +
L. P SC. ++ Unchang: >ext. = +
Worse (CBF)
2. HbSS 1:25/08/1999 Right hemisp.
(13 y) R. F C/SC +++ Unchanged — Unchanged — Unchanged
Coma, stroke F: 15/08/2001 R. P C/SC +++ Unchanged — Unchanged — Unchanged
Headaches (16 y) R. T C/SC = Unchanged ---------- ----------
R. T/O Bdz C/SC = Unchanged — = =
BTx
Better Left Hemisp = = = =
(CBF & CBV)
3.HbSS 1: 24/03/1999 Right Hemisp.
Coma, posterior (18 y) R.T. SC (BWM) +++ +++: >extended = Unchanged = Unchanged
TIA F: 19/06/2001
Headaches (19 y) Left Hemisp.
BTx stopped L.P. SC (BWM) +++ +++: >extended - =/- = Unchanged
Unchanged L.T. SC (BWM) -H-+ +++: >extended - Unchanged = Unchanged
(WM affected?)
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Case, Symptom
at Presentation
Main Recurrent MRI-DSC Date Perfusion MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
Symptom, (age) Abnormality
T reatment
4.HbSS Right hemisp.
1: 12/09/2002 R. Post P. C +++ = Unchanged -/= -
Stroke (6 y ) R. Sup F/P/T SC ++ +++ Unchanged = -
Seizures F: 12/06/2003 
(7 y) Left Hemisp.
L.P. C/SC +++ = — -/= -
L. Sup. F/P/T
BTx.
Better
C/SC +++ Unchanged (less 
extended)
— - Unchanged
(MTT & CBF) L T. C/SC +++ Unchanged (less 
extended)
—
L T/O Bdz C/SC +++ = — = Unchanged
5-
HbSS 1: 18/12/1998 Left Hemisp.
(12 y) L Frontal C /SC ++ +++ — Unchanged =
Stroke F: 12/10/2001 L Temporal C +++ Unchanged — Unchanged — =
Headaches (16 y) L F/T Bdz C/SC = +++ = -------- = =
BTx
Worse
(M TT &CBF)
Improved CBV
R hemisphere = Unchanged
= Unchanged = Unchanged
6. 1:29/06/1999 Left Hemisp.
HbSS (12 y) L.F. C/SC = +++ . _____ . . . .
Stroke F: 17/06/2002 L P. C
++ Unchanged ------- - =
Anterior TIA (16 y) LT. C/SC =
+ = - = -
Worse
(M TT,CBF,CBV)
Right hemisp 
R. F .C
= -H-f = . . . = . . .
Btx
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Case, Symptom  
at Presentation
Main Recurrent 
Symptom,
T reatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
7. HbSS 1:06/12/2001
Right Hemisp. 
R.F.C ++ +++ Unchanged -/- -
(7 y) R.P. C. +++ Unchanged — Unchanged = -
Stroke F: 06/03/2003 R. P. C/SC +++ Unchanged Unchanged = -/- -
Anterior TIA (8 y) R.F/P Bdz SC +++ = — = - =
BTx Better
(MTT & CBF)
R.T C/SC 
Left Hemisp.
+++ Unchanged
Unchanged Unchanged
Unchanged
Unchanged
8. HbSS
I: 18/06/1999
L. Hemisph 
L. T. SC ? (different slice ++ ? (different slice ? (different slice
Stroke
Stroke
(21 y)
F: 15/11/2001 
(24 y)
R. Hemisph
R. P.C.
orientation)
++ +++
orientation)
Unchanged
orientation)
BTx (stopped) R. P. SC. +++ Unchanged ---- Unchanged ---- =
Worse R. T. C. = ++ = = ++
(MTT, CBF & 
CBV) R. T. SC. +++ ++ . . . - - . . . -
9 .HbSS 
Stroke
I: 17/09/1999 
(14 y)
Right Hemisp. 
R. PC. Unchanged Unchanged
Headaches F: 14/03/2002 R. O. C. = Unchanged — —
BTx
(16 y)
W orse (MTT)
Left Hemisp. 
L. O.C. = ++ - - Unchanged - - Unchanged
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Case, Symptom
at Presentation,
Main Recurrent MRI-DSC Date Perfusion MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
Symptom, (age) Abnormality
Treatment
10. HbSS I: 02/07/1999 Right Hemisp.
(10 y) R.P. C = +++ ------- Unchanged — Unchanged
Stroke F: 20/12/2002 R. P SC = +++ = — — _
Anterior TIA (13 y) R.P/O Bdz C/SC = Unchanged ------- — -
R.T C. = + = = -
BTx- Stopped R.T SC. (BWM) +++ Unchanged - = -
BMT
Worse
(MTT & CBF)
Improved CBV
R. T/O Bdz C/SC 
Left Hemisp.
+
L.P C.
= Unchanged . . . Unchanged . . . Unchanged
= +++ — —
L.P SC 
L. P/O C. = Unchanged
= - - = -
L. T/O Bdz C +++
11. HbSS
I: 13/12/2001 Right Hemisp.
Anterior TIA (15 y) R. Sup. P. C ? (difT. slice +/++ ? (difF. slice ? (difF. slice -
Asymptomatic F: 25/07/2003 
(16 y)
orientation) orientation) orientation)
BTx
Unchanged
Left Hemisphere Unchanged Unchanged Unchanged
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Case, Symptom  
at Presentation,
Main Recurrent 
Symptom, 
Treatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
12. HbSS I: 23/11/1999 Right hemisp.
(21 y) R.FC/SC ? ( orientation) ++ ? (orientarion) - ? (orientation) =
Anterior TIA F: 07/12/2001 R.P SC. (BWM) +++ Unchanged ----- Unchanged Unchanged
Anterior TIA (25 y) R.T SC (BWM) ++ +++ =/- - =/- -
BTx- stopped Unchanged Left hemisp.
L. P C +++ ? (orientation) ----- ? (orientation) -/= ? (orientation)
L. P SC (BWM) +++ Unchanged ----- Unchanged
L.TSC (BWM) +++ Unchanged =/- =/- -
1 3 -HbSS I: 30/11/1999 Right Hemisp.
(8 y) R. F. C/SC = ++ ++ - ++ =
Anterior TIA F: 04/01/2002 R. P. C/SC = ++ ++ ++ +
Anterior TIA ( ii y) R. T. C = +++ +++ Unchanged ++ +++
RT/O Bdz C/SC ++ +++ - = +
BTx- AED Worse R.T. SC ++ Unchanged - Unchanged = Unchanged
(MTT & CBF)
Improvement CBV L hemisp. Unchanged Unchanged Unchanged
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Case, Symptom 
at Presentation,
Main Recurrent 
Symptom, 
Treatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
14. HbSS I: 18/06/1999 Right Hemisp
(12 y) R. P C = Unchanged = - /- - =
Anterior TIA F: 27/08/2002 R. P SC (BWM) +++ Unchanged = Unchanged = Unchanged
Anterior TIA (15 y) R. P C/SC = Unchanged = Unchanged = Unchanged
R.P/O Bdz ++ = - = = Unchanged
BTx-stopped R. T/O Bdz + = - = - =
Left indirect Better R.O C + = - = -
frontal (MTT, CBF &
revascularisation CBV) Left Hemisp
Hydroxyurea Worsening only in L. P C DifT. orientation +++ Diff.orientation Unchanged DifT. orientation =/+
one region MTT and L. P SC (BWM) +++ ++ =/- =/-
CBF, and another L  PC/SC = +++ = = —/+
region CBV. L. P/O Bdz ++ = - = Unchanged
L. T SC (WM) +++ ++ -/= =
L.T/O Bdz C/SC ++ ++ Unchanged Unchanged
L . O C ++ = = =
15. HbSS I: 30/07/1999 Right Hemisp.
(15 y) R. T. C = +++ = - = Unchanged
Posterior TIA F: 04/02/2002
Headaches (19 y) L. hemisphere — Unchanged = Unchanged = Unchanged
BTx- stopped Worse
Hydroxyurea (MTT, slightly
CBF)
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Case, Symptom  
at Presentation,
Main Recurrent 
Symptom, 
Treatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
16. HbSS 1:30/07/1999 Right Hemisp.
Posterior TIA
(11 y)
F: 12/11/2001
R.T. C ++ = =/- = - =
Posterior TIA 
BTx- stopped
(13 y)
Better
(MTT)
Left Hemisp.
Unchanged Unchanged Unchanged
17. HbSS I: 01/09/1999 
(16 y)
Right Hemisp = Unchanged = Unchanged = Not done 
(Sum. Param)
Seizures
Headaches
F: 03/07/2001 
(17 y)
I: SVD
F: Sum. Param.
TTP similar to MTT 
MPC similar to CBF
Unchanged
Left Hemisp Unchanged Unchanged
18.HbSS
Headaches
I: 17/06/1999 
(By)
Right Hemisp. = Unchanged — Unchanged = Unchanged
Headaches F: 08/03/2002
( i i  y)
Unchanged
Left Hemisp. Unchanged Unchanged Unchanged
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Case, Symptom  
at Presentation,
Main Recurrent 
Symptom,
T reatment
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
19. HbSS I: 24/03/1999
(22 y) Right Hemisp. = Unchanged = Unchanged = Not done
Headaches F: 11/07/2001 (SumParameters)
Headaches (24 y) Left Hemisp. = Unchanged = Unchanged =
I: SVD
Hydroxyurea F: Sum. Param.
TTP similar to MTT
MPC similar to CBF
Unchanged
20. HbSS I: 24/02/1999 Right Hemisp.
(12 y) R. F C/SC +++ ++ ---- - / - - -
Headaches F: 29/08/2002 R. T C/SC +++ = __ = =
Headaches (15 y) R. T/O Bz C/SC -H-+ = --- = _ -
R.T/O Bdz C +++ Unchanged ---- -
BTx-stopped Better
(MTT & CBF) Left Hemisp
Worsening o f post. L. T/O Bdz +++ ++ ---- - - =
T region (CBV) L.OC. ++ +++ =
after stopped BTx
21. HbSS 1:03/11/1999
(20 y) Right Hemisp. = Unchanged = Unchanged Unchanged
Headaches F: 22/10/2001
Headaches (22 y) Left Hemisp. = Unchanged = Unchanged = Unchanged
Unchanged
Prominent deep WM
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( asc. S \ n ip lom  
ai Presentation,
Main Recurrent 
Symptom,
T reatment
22. HbSS
Headaches
Headaches
23.HbSS
Headaches
Headaches
M RI-DSC Date 
(age)
Perfusion
Vbnormality
I: Ob/07/1999 
(13 y)
f :  10/10/2001 
( I b y)
I i u  hanged
1: 30/06/1999
( N \  I
F: 20/07/2001 
H i y )
I: SVD
F; Sum. Param.
TTP similar to M T 1 
MFC similar to CBF
Right Hemisp. 
1 elt Hemisp.
Right Hemisp. 
1 eft Hemisp.
I ncliaim ed
MTT- Initial MTT- Final
I nehanged 
I nehanged
1 nehanged
I nehanged
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CBF- Initial CBF- Final
1 nehanged
I ai changed
I nehanged 
I 'nehanged
CBV- Initial CBV- Final
I 'nehanged
I  nehanged
Not done 
l Sum. Pat am)
Table 4. Longitudinal changes of perfusion MRI parameters (mean transit time [MTT], cerebral blood flow [CBF] and cerebral blood volume 
[CBV]) in sickle cell patients through time.
Column 1: HbSS= homozygous sickle cell disease (sickle cell anaemia); 7X4= transient ischaemic attack; BTx= blood transfusion; BMT= bone 
marrow transplant; AED= antiepileptic drugs.
Column 3: hemisph = cerebral hemisphere, F= frontal region; P= parietal region; T— temporal region; O= occipital region; C= cortical; SC= 
subcortical; BWM= bright white matter (?abnormal) and Bdz= borderzone.
Column 2,4,5,6,7,8 and 9: The table compared the initial (first perfusion MRI scan) and final (last perfusion MRI scan) changes of every
parameter. DSC-MRI= dynamic susceptibility contrast MRI (perfusion MRI); MTT= mean transit time; CBF= cerebral blood flow; CBV=
cerebral blood volume; SVD= singular value deconvolution (to create MTT,CBF and CBV maps); sum. param: summary Parameters; TTP= 
time-to-peak; MPC= mean peak concentration; unchang.= unchanged; ext.= extended; and diff= different.
MTT and CBF were the main parameters to assess the grade of change in cerebral perfusion (better, unchanged or worse perfusion MRI) of every 
patient longitudinally. Perfusion MRI parameters are assessed following a scale of worsening cerebral blood flow:
=: equal or normal
- (for CBF and CBV): decreased passage of IV Gadolinium (-: mild, — :moderate, —: severe)
+(for MTT): increased the mean transit time of the passage of IV Gd (+: mild, ++: moderate, +++ severe)
+ (for CBF/CBV): increased the passage of IV Gd (increased blow flow; +: mild, ++: moderate, +++: severe)
Based on the equation: MTT= CBV/ CBF. A significant change of the perfusion MRI parameters was defined in the improvement or worsening 
of the parameter (MTT, CBF, CBV) in two grades of the scale (i.e. from ‘= to - or ‘+++ to +*), to avoid bias of perfusion graduation in the 
visual assessment of the perfusion maps of MTT, CBF and CBV by different examiners.
Improvement (better) of perfusion MRI parameters (MTT, CBF, CBV)
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Tables 5 and 6. Effect of Blood transfusion therapy on perfusion abnormality in the short-term.
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Case (No. 
table 3), 
Sex, Age, 
Dx, Hb 
(g /d l)
Problem, 
Therapy, 
BTx Date
Onset
Symptoms
Date of 
Study 
(S p 0 2% ; 
BP mniHg)
Right TCD Right MRA 
Turbulence
Right MRI Right
Abnormal
Perfusion
Left TCD Left MRA 
Turbulence
Left MRI Left
Abnormal
Perfusion
1.(11), M,
15 y, SS, no 
Hb
Anterior 
TIAs 
Blood Tx
TIA,
intracranial
aneurysms
Pre-BTx
13/12/2001
(97; 115/49)
R. MCA vel 
<70 cm/sec & 
L:H ratio <0.5
Normal Normal Normal L. MCA vel 
<70 cm/sec & 
L:H ratio <0.5
Normal F-P (DWM) Normal
Blood Tx 
15/12/2001
Post-BTx:
20/12/2001
(97; 121/67)
Unchanged M2 (0-+1) 
W orse
Normal Unchanged Unchanged Normal Unchanged Unchanged
2. (5), F, 16 
y, SS, no 
Hb
Stroke, H, 
L.
Blood Tx
R hemi + H Pre-BTx
12/10/2001
(98; 108/48)
R MCA vel< 
70 cm/sec & 
L:H ratio <0.5
R. A1 (1) Normal Normal L MCA
vel < 70 cm/s
L. M 1 (4)
A1 (4)
PI (1), P2 (1), 
MM
L. F-P-BG
(caudate
nucleus)
L F (C/ SC) 
T (C); L F-T 
Bdz (C/SC), 
beyond 
infarct.
Blood Tx 
19/10/2001
Post-BTx
25/10/2001
(99; 108/55)
Normal
Improved
Unchanged Normal Normal Unchanged L. Ml (4)
A1 (4)
PI ( I —>4), P2 
(1-M ), MM 
W orse
Unchanged L. frontal 
pole (C), 
unchanged 
rest.
Improved
MTT
3. (2), M, 
16 y, SS, 9.2
Stroke, 
coma, H, L. 
Blood Tx
Bilateral 
Stroke with 
coma, 
increased 
ICP
Pre-BTx
15/08/2001
Undetectable
MCA
TICA (2), 
MCA (2), 
ACA (2)
Extensive cystic 
encephalomalacia 
in the ACA/MCA 
territories
R.Temporal
(C/SC)
Undetectable
MCA
TICA (2), MCA 
(2), ACA (2)
L. ACA 
territory 
infarct
Normal
Blood Tx 
22/06/2001
Post-BTx
(04/07/2001)
Unchanged Unchanged Unchanged R. Temporal
(C/SC)
Improved CBF 
& CBV
Unchanged Unchanged Unchanged Unchanged
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Case (No. 
table 3), 
Sex, Age, 
Dx, Hb 
(g/dL)
Problem, 
Therapy, 
BTx Date
Onset
Symptoms
Date of 
Study 
(SpOz%, 
BP mmHg)
Right TCD Right MRA 
Turbulence
Right MRI Right
Abnormal
Perfusion
Left TCD Left MRA 
Turbulence
Left MRI Left
Abnormal
Perfusion
4. (6), F, 16 
y, SS, no Hb
Stroke 
Blood Tx
R hemi + Sz 
+ Aphasia
Pre-BTx
17/06/2002
(98;112/75)
MCA L:H 
<0.5
R. A1 (1) R. T (BG) R. Frontal (C) L MCA vel
< 70 cm/s
Ml (2), 
M2 (1) 
A1 (4)
Large F-P-T 
infarct.
FPT atrophy
L. F (C/SC);
L. P (C)
L T (C/SC),
beyond
infarct
Blood Tx 
20/06/2002 Post-BTx
24/06/2002
(98; 115/73)
Unchanged Unchanged Unchanged R. fronta l pole 
(C).
Improved CBV
Unchanged Unchanged Unchanged L. frontal 
pole (C) 
Improved 
CBV
5. M, 16y 
SS, no Hb
Posterior 
TIA, H 
Blood Tx
Collapse + 
transient 
loss of 
vision
Pre-BTx
24/03/2003
(92; 85/60)
MCA vel < 70 
cm/sec
Normal Frontal DWS small 
infarcts in 
ACA/MCA 
territory
R. Frontal C/SC Normal A (1) Frontal DWS 
small infarcts 
in ACA/MCA 
territory
Left Frontal
(C/SC)
Blood Tx 
26/03/2003
Post-BTx
27/03/2003
(94; 102/54)
Normal
Improved
Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged Left Frontal 
C/SC  
Improved 
MTT/CBF
6. F, 27 y, 
SS, 9.3
Stroke 
Blood Tx
Blood Tx 
18/03/2002
Blood Tx 
12/04/2002
(Perfusion)
Sz, collapse Pre-BTx
12/03/2002
(96; 105/57)
Post-BTx
22/03/2002
(MRI-MRA-
TCD)
12/04/2002
(Perfusion) 
(97; 110/52)
Normal MCA 
Unchanged
TICA (3), Ml 
(2), M2 (1), 
A1 (2), PI (1)
TICA (3), M l  
(2->l), M2 
( l —>0), A1 
(2->0), PI 
(1->0),P2(1) 
Improved
R. P infarct 
Cerebral atrophy
Unchanged
R. superior P-O 
(C), R .inferior 
P-O (C) beyond 
infarct. R. T (SC).
R. superior P-O 
(C). Unchanged 
other regions
Improved MTT
Normal MCA, 
decreased L. 
PCA velocity
Unchanged
PI (1)
PI (1-^0), P 2 (l)
P infarct
watershed
(MCA/PCA)
Cerebral
atrophy
Unchanged
L.superior P- 
O (C ) 
limited to 
infarct area
L. superior 
P-O (C).
Improved
C B F / CBV
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C ase (No. 
table 3), 
Sex, Age, 
Dx; Hb 
(g/tll )
Problem, 
Therapy, 
BTx Date
Onset
Symptoms
Date of 
Study 
(S p02 ’%, 
BP mniHg)
Might TCD Eight MRA 
Turbulence
Right MRI Right
Abnormal
Perfusion
Left TCD Left MRA 
Turbulence
Left MRI Left
Abnormal
Perfusion
7. (7), F, By,
SS, no Hb
Stroke, 
anterior 
TIAs, H, 1.
Blood Tx
Left hemi Pre-BTx
06/03/2003
(no SpCU/ 
BP)
R. MCA vel.<
70 cm/sec
TIC A (2), M 1 
(3), M2 (1), 
A1 (2), A2 
(1), P2<1)
Large MCA/AC A 
(DWS) infarct + 
head of caudate 
infarct
R. superior F-P 
(C), R. inferior F- 
P -0  (C/SC), R. T 
(C/SC)
L. MCA vel <
70 cm/sec.
M l (1). A1 (2),
PI (1)
Frontal DWS 
infarct
L.T (SC)
Blood Tx
08/03/2003
Post-BTx
13/03/2003 
(no S p 0 2. 
104/49)
Unchanged TIC A (2), M 1 
(3), M2 
(l->3), A 1 
(2—>3), A 2 
(1 —>2), P2 (1) 
Worse
Unchanged Unchanged Unchanged M l (1- MI), A1 
(2), PI (l->0) 
Improved
Unchanged Unchanged
8. (9), M, 17 
y, SS, 10.1
Stioke. 11. 
decreased
visual
acuity.
Blood Tx
II. collapse Pre-BTx
14/03/2002
(97; 121/31)
Undetectable
MCA.
Decreased R. 
PCA velocity
PI (2).
P2 (4). |>C \ 
collat
R. F P infarct.
focal atrophy
R. P -0  [C] 1 MCA L:H
tat'.n • n.5
1 P? (4). PI (2)
PCA collaterals
L. DWM. BC
?oceipi:al
atrophy
I- U (Cl
Blood Tx
16/03/2002 Post-BTx21/03/2002 
(99; 119/46)
Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged Unchanged
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Table 5. Association of perfusion abnormality with transcranial Doppler ultrasound (TCD), MRI and MRA :
Pre- and post-blood transfusion study.
Dx: diagnosis; F: female; M: male, SS: homozygous sickle cell anaemia; S: stroke; 7X4: transient ischaemic attack; H: headaches; L: learning 
difficulties; Sz: seizures; BTx: blood transfusion; Hb: haemoglobin; L: left; R: right; hemi: hemiparesis; TICA: terminal internal carotid artery; 
MCA: middle cerebral artery; M l & M2: middle cerebral artery segments 1 & 2; A1 & A2: anterior cerebral artery segments 1 & 2, PI & P2: 
posterior cerebral artery segments 1 & 2; MM: moyamoya collaterals; vel: mean MCA velocity; F: frontal lobe; T: temporal lobe ; P: parietal 
lobe; O: occipital lobe; AWS: anterior watershed; DWS: deep watershed; DWM: deep white matter; BG: basal ganglia. MCA L:H: MCA lowest: 
highest mean ipsilateral velocity ratio.
MRA turbulence classified as: (1): mild; (2): moderate; (3): severe and (4): occlusion.
MTT: Mean transit time; CBF: Cerebral Blood Flow; CBV: Cerebral Blood Volume; C: Cortical; SC: Subcortical.
|  Worsening of perfusion MRI parameters (MTT, CBF or CBV) 
Improvement (better) of perfusion MRI parameters (MTT, CBF or CBV)
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Case, (No. table M R I-D SC  Date Perfusion 
3), Sex, Age, Dx, Abnormality 
Hb (g/dL),
Problem, BTx 
Date
MTT- Pre-BTx MTT-Post-BTx CBF-Pre-BTx CBF-Post-BTx CBV- Pre-BTx CBV-Post-BTx
1. (11), M, 15 y, Pre-BTx Right Hemisp. 
SS, no Hb 13/12/2001 R.P. SC(BW M)
Anterior TIAs Post-BTx Left Hemisp.
20/12/2001 L.P.SC (BWM)
Blood Tx 
15/12/2001
+++ Unchanged 
+++ Unchanged
= Unchanged 
= Unchanged
= Unchanged 
= Unchanged
2. (5), F, 16 y, Pre-BTx Right Hemisp. 
SS, no Hb 12/10/2001
Left Hemisp.
Stroke, H, L. L.Fpole 
Post-BTx L.F C 
25/10/2001 L.lnferior F.C 
Blood Tx L.P C/SC 
19/10/2001 L.TC/SC
L.inferior T C 
L inf T SC 
(BWM)
L. T/O C Bdz
+++
+++ Unchanged 
+++ Unchanged 
+++ Unchanged 
+++ Unchanged
= ++
+++ ++
++ +++
—  Unchanged
—  Unchanged
—  Unchanged 
Unchanged
=/- Unchanged
=/+ Unchanged
= Unchanged 
= Unchanged 
= Unchanged
= Unchanged
3. (2), M, 16 y, Pre-BTx Right Hemisp. 
SS, 9.2 15/08/2001 R. T. C/SC
R.inf T C/SC
Stroke, coma, H,
L Post-BTx
04/07/2001 Left Hemisp.
Blood Tx 
22/06/2001
= Unchanged 
= Unchanged
=
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Case, (No. table 
3), Sex, Age, Dx, 
Hb (g/dL), 
Problem, BTx 
Date
M R I-D SC  Date Perfusion
Abnormality
MTT- Pre-BTx MTT-Post-BTx CBF-Pre-BTx CBF-Post-BTx CBV- Pre-BTx CBV-Post-BTx
4. (6), F, 16 y, SS, Pre-BTx Right hemisp.
no Hb 17/06/2002 R. F pole +++ ++ ---- ----- -
Stroke Left hemisp.
Post-BTx L.F pole +++ ++ ----- Unchanged ----- -
24/06/2002 L.FC/SCsuperior ++ Unchanged Unchanged - Unchanged
Blood Tx L.FC/SCinferior +++ ++ ----- — ----
20/06/2002 L.F/T Bdz C/SC + +/++ - — -
L.T C/SC + -Hi-
5. M, 16y SS, no Pre-BTx Right hemisp.
Hb 24/03/2003 R. F C/SC ++ Unchanged - /- - - Unchanged
R. P SC (BWM) +++ Unchanged = Unchanged = Unchanged
Posterior TIA, H R.TSC (BWM) +++ (>extended) Unchanged (less = Unchanged = Unchanged
Post-BTx extended)
Blood Tx 27/03/2002 Left hemisp.
26/03/2003 L. F C/SC ++ = = - =
L. P SC (BWM) +++(>extended) Unchanged (less = Unchanged = Unchanged
L. T SC (BWM) +++ Unchanged Unchanged Unchanged
6. F, 27 y, SS, 9.3 Pre-BTx Right hemisp.
12/03/2002 R. Sup P/O C +++ + ------ ------
Stroke R.Inf. P/O C +++ Unchanged ------ Unchanged . . . Unchanged
Blood Tx Post-BTx
18/03/2002 12/04/2002 Left hemisp
(For Pre-BTx) L. Sup P/O. C. + = = =
Blood Tx
12/04/2002
(For Post-BTx
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Case, (No. table 
3), Sex, Age, Dx, 
Hb (g/dL), 
Problem, BTx 
Date
MRI -D SC  Date Perfusion
A bnorm ality
M TT- Pre-BTx MTT-Post-BTx CBF-Pre-BTx CBF-Post-BTx CBV- Pre-BTx CBV-Post-BTx
7. (7), F, 8y, SS, 
no 1 lb
Pre-BTx
06/03/2003
Right hemisp. 
R.Sup F/P C 1 . . .  +. Unchanged
Stroke, anterior
Rinf.F/P/O C/SC 
R.TC/SC
+++
+++ 1 Tehanged
— Unchanged
TIAs, If, I. Post-BTx R.Inf.T C/SC ++ Unchanged Unchanged
13/03/2003 R .in fT C ++ — -
Blood Tx 
08/03/2003
L. Hemisp.
L. T SC (BWM) = = Unchanged
8. (9), M, 17 y, 
SS, 10.1
Pre-BTx
14/03/2002
Right hemisp. 
R.Sup P/O C/SC = Unchanged Unchanged . .
Stroke, H,
R.lnf.P/O C
R.T/O Bdz C/SC 4
Unchanged
Unchanged
- - - Unchanged
Unchanged
—  Unchanged 
Unchanged
decreased visual 
acuity.
Post-BTx
21/03/2002 Left hemisp. ++ + 4 . t . Unchanged Unchanged
Blood Tx 
16/03/2002
L.Sup.P/0 C
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Table 6. Pre- and post-blood transfusion change in perfusion MRI parameters (mean transit time [MTT], cerebral blood flow [CBF] and 
cerebral blood volume [CBV]) in sickle cell patients.
Column 1: HbSS= homozygous sickle cell disease (sickle cell anaemia); H b -  haemoglobin; 7X4= transient ischaemic attack; and BTx= blood 
transfusion.
Column 3: hemisph = cerebral hemisphere, F= frontal region; P= parietal region; T= temporal region; 0=  occipital region; C— cortical; £C= 
subcortical; BWM= bright white matter (unexplained high signal on MTT map) and Bdz= borderzone.
Column 2,4,5,6,7,8 and 9: The table compares the changes in the pre-blood transfusion and post-blood transfusion perfusion MRI scans of 
every perfusion MRI parameter. DSC-MRI= dynamic susceptibility contrast MRI (perfusion MRI); MTT= mean transit time; CBF= cerebral 
blood flow; CBV= cerebral blood volume; unchang. = unchanged; ext.= extended; and diff= different.
MTT and CBF were the main parameters to assess the grade of change in cerebral perfusion of every patient before and after blood transfusion. 
Perfusion MRI parameters were assessed following a scale of worsening perfusion abnormality caharacterised by :
=: normal
- (for CBF and CBV): decreased passage of IV Gadolinium (-: mild, —:moderate, —: severe)
+(for MTT): increased the mean transit time of the passage of IV Gd (+: mild, ++: moderate, +++ severe)
+ (for CBF/CBV): increased the passage of IV Gd (increased blow flow; +: mild, ++: moderate, +++: severe)
Based on the equation: MTT= CBV/ CBF. A significant change of the perfusion MRI parameters was defined as the improvement or worsening 
of the parameter (MTT, CBF, CBV) in two grades of the scale (i.e. from ‘= to - or ‘+++ to +’), to minimise the effects at bias of perfusion 
gradation in the visual assessment of the perfusion maps of MTT, CBF and CBV by different examiners.
Worsening of perfusion MRI parameters (MTT, CBF, CBV) 
Improvement (better) of perfusion MRI parameters (MTT, CBF, CBV)
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Tables 7. Effect of Blood transfusion therapy on perfusion abnormality in the long-term. Patients of this study are also included m the 
longitudinal study (Appendix, table 3).
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Case (Case in table 
3), Symptom 
at Presentation,
Main Recurrent 
Symptom, 
Treatment
MRI-DSC Date 
(age)
Perfusion
Abnormality'
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
1 .(1) 1:30/11/1999 Right Hemisp. No parameter
HbSS (9 y ) R.P. C. = Unchanged = - =
F: 11/07/2002 R. P.SC ++ Unchanged = +
Coma, stroke (12 y) R. P/O Bdz = Unchanged = =
Coma (Posterior I: SVD
Leukoencepha- F: Sum. Param. Left Hemisp.
lopathy) TTP similar to MTT L.PSC. ++ Unchanged = +
MPC similar to CBF
BTx
Worse (CBF)
2.(2) HbSS I: 25/08/1999 Right hemisp.
(13 y) R. F C/SC +++ Unchanged ---------- Unchanged — Unchanged
Coma, stroke F: 15/08/2001 R. P C/SC +++ Unchanged ---------- Unchanged — Unchanged
Headaches (16 y) R. T C/SC = Unchanged — —
R. T/O Bdz C/SC — Unchanged ---------- = =
BTx
Better Left Hemisp
(CBF & CBV)
3 .(3 ) I: 24/03/1999 Right Hemisp.
HbSS (18 y) R.T. SC (WM) +++ +++: >extended = Unchanged = Unchanged
Coma, posterior F: 19/06/2001
TIA (19 y) Left Hemisp.
Headaches L.P. SC (WM) +++ +++: >extended = =/- = Unchanged
BTx stopped Unchanged L.T. SC (WM) +++ +++: >extended = Unchanged = Unchanged
(WM affected?)
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Case (Case in table 
3), Symptom at 
Presentation
Main Recurrent 
Symptom, 
Treatment
MR1-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
4 .(4 )
HbSS
Stroke
Seizures
BTx.
I: 12/09/2002 
(6 y )
F: 12/06/2003 
(7 y)
Better
(MTT & CBF)
Right hemisp.
R. Post P. C 
R. Sup F/P/T SC
Left Hemisp.
L.P. C/SC 
L. Sup. F/P/T 
C/SC
L T. C/SC
L T/O Bdz C/SC
-HH-
++
+++
+++
+++
+-H-
+++
Unchanged (less 
extended) 
Unchanged (less 
extended)
—
Unchanged
Unchanged
-/=
-/=
Unchanged
Unchanged
5-(5)
HbSS
Stroke
Headaches
1: 18/12/1998 
(12 y)
F: 12/10/2001 
(16 y)
Left Hemisp.
L Frontal C /SC  
L Temporal C
L F/T Bdz C/SC
++
+++
+++
Unchanged
+++
- - -
Unchanged
Unchanged
- - =
BTx
Worse
(MTT &CBF)
Improved CBV R hemisphere
= Unchanged = Unchanged = Unchanged
6. (6)
HbSS
Stroke
Anterior TIA
I: 29/06/1999 
(12 y)
F: 17/06/2002 
(16 y)
Left Hemisp. 
L.F. C/SC
L P. C
LT. C/SC
++
+++
Unchanged
+ =
. . .
_
=
Btx
Worse
(M TT,CBF, CBV)
Right hemisp 
R. F. C = +++
= . . . = . . .
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Case (Case in table 
3), Symptom 
at Presentation
Main Recurrent 
Symptom, 
Treatm ent
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
Right Hemisp.
7. (7) 1:06/12/2001 R.F.C ++ +++ — Unchanged - - /- -
HbSS (7 y ) R.P. C. +++ Unchanged — Unchanged = -
F: 06/03/2003 R. P. C/SC +++ Unchanged Unchanged - - /- -
Stroke (8 y) R.F/P Bdz SC +++ = ----- = - =
Anterior TIA R.T C/SC +++ Unchanged =/- Unchanged
Better
BTx (MTT & CBF) Left Hemisp. = Unchanged = Unchanged = Unchanged
8. (8) L. Hemisph
HbSS I: 18/06/1999 L. T. SC ? (different slice ++ ? (different slice ? (different slice -
(21 y) orientation) orientation) orientation)
Stroke F: 15/11/2001 R. Hemisph
Stroke (24 y) R. P. C. ++ +++ — Unchanged ----- =
R. P. SC. +++ Unchanged — Unchanged ---------- =
BTx (stopped) Worse R. T. C. = ++ = = ++
(MTT, CBF & +++ ++ __ __
CBV) R. T. SC.
9. (9)
HbSS I: 17/09/1999 Right Hemisp.
(14 y) R. PC. = Unchanged = — Unchanged
Stroke F: 14/03/2002 R. O. C. = Unchanged — —
Headaches (16 y)
Left Hemisp.
BTx Worse (MTT) L. O.C. ++ Unchanged Unchanged
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Case (Case in table 
3), Symptom 
at Presentation,
Main Recurrent 
Symptom, 
Treatm ent
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
10.(10) I: 02/07/1999 Right Hemisp.
HbSS (10 y) R.P. C = +++ — Unchanged ----- Unchanged
F: 20/12/2002 R. PSC = +++ = ----- ----- -
Stroke (13 y) R.P/O Bdz C/SC = Unchanged — ----- -
Anterior TIA R.T C. = + = - -
R.T SC. (WM?) +++ Unchanged - = -
BTx- Stopped R. T/O Bdz C/SC = + = = -
BMT Worse
(MTT & CBF) Left Hemisp.
Improved CBV L.P C. Unchanged . . . Unchanged ----- Unchanged
L.PSC = +++ = ----- = -
L. P/O C. = Unchanged = - - = -
L  T/O Bdz C = +++ = “ * * =
11.(11)
HbSS I: 13/12/2001 Right Hemisp.
(15 y) R. Sup. P. C ? (diff. slice +/++ ? (diff. slice ? (diff. slice -
Anterior TIA F: 25/07/2003 orientation) orientation) orientation)
Asymptomatic (16 y)
Left Hemisphere = Unchanged = Unchanged = Unchanged
BTx Unchanged
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Case (Case in table 
3), Symptom 
at Presentation,
Main Recurrent 
Symptom, 
Treatm ent
MRI-DSC Date 
(age)
Perfusion
Abnormality
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
12.(12) I: 23/11/1999 Right hemisp.
HbSS (21 y) R.F C/SC ? ( orientation) ++ ? (orientarion) - ? (orientation) =
F: 07/12/2001 R. P SC. (WM) +++ Unchanged — Unchanged Unchanged
Anterior TIA (25 y) R. T SC (WM) ++ +++ =/- - =/- -
Anterior TIA
Unchanged Left hemisp.
BTx- stopped L. PC +++ ? (orientation) — ? (orientation) -/= ? (orientation)
L. P SC (WM) +++ Unchanged . . . Unchanged
L.T SC (WM) -H-+ Unchanged =/- =/- -
13-(13) I: 30/11/1999 Right Hemisp.
HbSS (8 y) R. F. C/SC = ++ ++ - ++ =
F: 04/01/2002 R. P. C/SC = ++ ++ ++ +
Anterior TIA (11 y) R. T. C = +++ +++ Unchanged ++ +++
Anterior TIA RT/O Bdz C/SC ++ +-H- - = +
Worse R.T. SC ++ Unchanged - Unchanged = Unchanged
BTx- AED (MTT & CBF)
Improvement CBV L hemisp. Unchanged Unchanged Unchanged
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Case (Case in table
3), Symptom
at Presentation, MR1-DSC Date Perfusion MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- FinalMain Recurrent 
Symptom, (age) Abnormality
Treatm ent
14.(14) I: 18/06/1999 Right Hemisp
HbSS (12 y) R. P C = Unchanged = - /- - =
F: 27/08/2002 R. P SC (WM) +++ Unchanged = Unchanged = Unchanged
Anterior TIA (15 y) R. P C/SC = Unchanged = Unchanged = Unchanged
Anterior TIA R. P/O Bdz ++ = - = = Unchanged
R. T/O Bdz + = - = - -
BTx-stopped Better R.OC + = - = - =
Left indirect (MTT, CBF &
frontal CBV) Left Hemisp
revascularisation Worsening only in L. P C Diff. orientation +++ Diff.orientation Unchanged Diff. orientation =/+
Hydroxyurea one region MTT and L. P SC (WM) +++ ++ = =/- = =/-
CBF, and another L. PC/SC = +++ = = — /+
region CBV. L. P/O Bdz ++ = - = = Unchanged
L. T SC (WM) +++ ++ -/= =
L.T/O Bdz C/SC ++ ++ Unchanged Unchanged
L . O C ++ = = =
15.(15) I: 30/07/1999 Right Hemisp.
HbSS (15 y)
F: 04/02/2002
R.T. C = +++ = - = Unchanged
Posterior TIA
Headaches
(19 y) 
Worse
L. hemisphere Unchanged Unchanged Unchanged
BTx- stopped (MTT, slightly
Hydroxyurea CBF)
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Case (Case in table 
3), Symptom 
at Presentation,
Main Recurrent 
Symptom, 
T reatm ent
MRI-DSC Date 
(age)
Perfusion
Abnormality'
MTT- Initial MTT- Final CBF- Initial CBF- Final CBV- Initial CBV- Final
Right Hemisp.
16.(16) I: 30/07/1999 R.T. C ++ = =/- = - =
HbSS (ii y)
Posterior TIA
F: 12/11/2001 
(13 y) Left Hemisp.
= Unchanged — Unchanged = Unchanged
Posterior TIA
Better
BTx- stopped (MTT)
17(20). I: 24/02/1999 Right Hemisp.
HbSS (12 y) R. F C/SC +++ ++ — - /- - -
F: 29/08/2002 R. T C/SC +++ = — = - =
Headaches (15 y) R.T/OBz C/SC +++ = — = - =
Headaches R.T/O Bdz C +++ Unchanged — -
Better
BTx-stopped (MTT & CBF) Left Hemisp
Worsening o f  post. L. T/O Bdz +++ ++ __ _ =
T region (CBV) L.OC. ++ +++ =
after stopped BTx
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Table 7. Long-term blood transfusion change in perfusion MRI parameters (mean transit time [MTT], cerebral blood flow [CBF] and cerebral 
blood volume [CBV]) in sickle cell patients.
Column 1: HbSS= homozygous sickle cell disease (sickle cell anaemia); Hb= haemoglobin; 7X4= transient ischaemic attack; and BTx= blood 
transfusion.
Column 3: hemisph = cerebral hemisphere, F= frontal region; P= parietal region; T= temporal region; 0=  occipital region; C— cortical; SC= 
subcortical; BWM= bright white matter (unexplained high signal on MTT map) and Bdz= borderzone.
Column 2,4,5,6,7,8 and 9: The table compares the changes in the pre-blood transfusion and post-blood transfusion perfusion MRI scans of 
every perfusion MRI parameter. DSC-MRI= dynamic susceptibility contrast MRI (perfusion MRI); MTT= mean transit time; CBF= cerebral 
blood flow; CBV= cerebral blood volume; unchang.= unchanged; ext. = extended; and diff= different.
MTT and CBF were the main parameters to assess the grade of change in cerebral perfusion of every patient before and after blood transfusion. 
Perfusion MRI parameters were assessed following a scale of worsening perfusion abnormality caharacterised by :
=: normal
- (for CBF and CBV): decreased passage of IV Gadolinium (-: mild, —:moderate, —: severe)
+(for MTT): increased the mean transit time of the passage of IV Gd (+: mild, ++: moderate, +++ severe)
+ (for CBF/CBV): increased the passage of IV Gd (increased blow flow; +: mild, ++: moderate, +++: severe)
Based on the equation: MTT= CBV/ CBF. A significant change of the perfusion MRI parameters was defined as the improvement or worsening 
of the parameter (MTT, CBF, CBV) in two grades of the scale (i.e. from £= to - -*; or ‘+++ to +’), to minimise the effects at bias of perfusion 
gradation in the visual assessment of the perfusion maps of MTT, CBF and CBV by different examiners.
Improvement (better) of perfusion MRI parameters (MTT, CBF, CBV)
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